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during normal blood cell production the cells differentiate into specific types. 
In a pathological situation the differentiation into specific cells is blocked. This 
disturbance of normal differentiation - so called leukaemia - is a disease sui 
generis. We know the sequelae of this disease, we do not know its origin."
Virchow R. 1856
vil
ABSTRACT
Current therapeutic regimes for the treatment of acute myeloid leukaemia employ 
aggresive cytotoxic strategies which have limited success and are not suitable for 
all patients. Manipulating myeloid leukaemic cells according to their responses 
To pharmacologically tolerable agents rather than employing aggressive non 
specific cell kill would be desirable. Differentiation induction of myeloid 
leukaemic cells as an alternative Therapeutic regime was evaluated.
To elucidate the growth and differentiation abnormalities of myeloid leukaemic 
cells The differentiation induction and growth factor responses of bone marrow 
from Three myeloid leukaemic models (SA2, SA7, SA8) and a leukaemic cell line 
(SA2 CL) were investigated in microtitre suspension cultures and compared with 
normal. The regulators of normal haemopoiesis occupy a key position in attempts 
To understand the nature of the abnormal state existing in myeloid leukaemia and 
could potentially play an important role therapeutically by suppressing myeloid 
leukaemic populations. To evaluate differentiation induction as an alternative 
therapeutic regime for the treatment of myeloid leukaemia both the 
physiological regulators and the differentiation inducer p-all trans retinoic acid 
(PatRA) alone and in combination with ara-C were investigated. The effects of 
these agents directly on the leukaemic clonogenic cell populations in vitro were 
measured following in vivo transplantation.
The proliferative effects of WEHI-3B CM, as a source of IL-3, L929 CM as a source 
of M-CSF, and recombinant murine GM-CSF alone and in combination were 
investigated. Bone marrow cells from the SA7 and SA8 transplanted leukaemias 
were growth factor dependent for proliferation in vitro. The SA2 transplanted 
leukaemia proliferated autonomously at low passage numbers, the dominant 
leukaemic clone changed characteristics with progressive transplantation and 
became growth factor dependent at high passage numbers. A cell line (SA2 CL) 
was derived from leukaemic bone marrow cells of a low passage number of the SA2 
leukaemia and proliferated at a high rate autonomously with minimal 
spontaneous differentiation in culture.
The growth factor dependent leukaemias were induced to proliferate with each of 
the growth factors. No differences were observed in the dose response 
relationships between normal and leukaemic cells. Differences were observed in 
the proliferative rates, the day to which exponential cell growth was sustained 
in culture and the growth factor which induced maximal proliferation. WEHI-3B 
CM induced the maximal proliferative response of normal bone marrow cells and
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two of the leukaemias whereas rGM-CSF induced a maximal response of the third 
leukaemia. Leukaemic cells proliferated at a higher rate than normal cells in 
the first two to three days in culture but were not sustained in culture for as long as 
normal bone marrow cells. It appeared therefore, that in the case of some 
leukaemias the haemopoietic growth factors were effective at inducing a high 
initial but short term proliferative response of leukaemic cells and were more 
effective in sustaining normal bone marrow cells in vitro . L929 CM induced a 
lower proliferative response of both normal and leukaemic cells compared to 
WEHI-3B CM and rGM-CSF. The regulators of normal haemopoiesis have been 
shown to exert stimulating effects upon the same target cells. Different subsets of 
leukaemic cells were observed according to their proliferative response to 
combinations of growth factors. Variable responses were obtained, different 
combinations of factors induced synergistic responses with the different 
leukaemias. A systematic approach of this type of study may be useful for the 
reclassification of the heterogeneous human leukaemic subtypes and may be of 
prognostic value.
The three growth factors studied induced differentiation of the transplanted 
leukaemic cells, L929 CM was the most effective. Higher numbers of immature 
cells combined with a differentiation effect were observed with the other two 
growth factors. A 10 and 100 fold reduction in the number of leukaemic clonogenic 
cells was observed with WEHI-3B and L929 CM cultured cells respectively as 
assessed in the transplantation study. The differentiation effect was not 
enhanced with the combinations of growth factors. Generally higher numbers of 
immature cells were sustained in culture compared to at least one of the growth 
factors used singularly. The addition of growth factors to the autonomously 
proliferating SA2 CL did not alter the proliferative or differentiative responses 
observed in foetal calf serum (FCS) alone.
The addition of (atRA to growth factor stimulated cultures enhanced the 
differentiation response of the transplanted leukaemic cells and induced an 
inhibitory response without evidence of differentiation of the SA2 CL. A 
decrease in the number of clonogenic cells compared to growth factor alone was 
observed with the combination of J3tRA plus L929 CM but not with WEH1-3B CM 
indicating that a combination of differentiation inducers further decreased the 
number of leukaemic clonogenic cells.
It has been postulated that two agents having different modes of action, one of 
DNA synthesis inhibition and a differentiation inducer would enhance the
IX
differentiation and inhibitory effect of these agent on leukaemic cells, allowing 
for the use of lower concentrations of the more toxic agent. We tested this 
hypothesis on the murine myeloid leukaemic models. The combination of PatRA 
and ara-C induced varied proliferative responses on the leukaemic bone marrow 
cells. A stimulatory response was observed with normal bone marrow and the SA7 
leukaemia, a decrease in the proliferative response compared to ara-C alone was 
observed with the SA2 CL and synergistic decreases were observed with the SA2 
and SA8 leukaemias. With the synergistic responses, the proliferative responses 
observed with low doses of ara-C in combination with PatRA were similar to the 
responses observed with 10 or 100 times greater concentration of ara-C alone. The 
concentration of each agent required to induce a synergistic response for each 
leukaemia was observed to be critical.
The murine transplanted myeloid leukaemias were shown to be suitable models 
for the study of myeloid leukaemia. The heterogeneity of responses observed 
were comparable to studies with fresh human leukaemic bone marrow cells. These 
models facilitate the study of the effect of therapeutic agents on leukaemic 
clonogenic cell populations which sustain the leukaemic condition in vivo.
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INTRODUCTION
NORMAL HAEMOPOIESIS
Normal haemopoiesis is a highly dynamic process and is continuous throughout 
life. The number of new blood cells that the haemopnietic tissues must produce to 
replace effete cells is extremely large. In an adult human approximately 10®® red 
cells and 4 x 10® white cells are produced per hour. In normal health, levels of the 
various mature cells in the blood are maintained within quite narrow limits, yet 
in response to emergencies such as blood loss or infection, the haemopoielic tissues 
are able to respond rapidly by increasing production (Metcalf, 1988).
It is now well established that all the functionally diverse mature blood cells 
arise originally from a common pluripnlential stem cell (Sieff, 1988). There is a 
hierarchial and clonal progression from pluripotent stem cells, to transit cells 
(progenitor cells with high proliferative potential, to morphologically 
recognisable proliferative cells) and finally maturation to fully functional non 
proliferative blood cells. Stem cells, under normal conditions are quiescent, 
relatively few in number (10® to 10® cells in the adult) and through a stochastic 
mechanism which is still undefined they are capable of self-renewal and 
producing daughter cells which undergo initial differentiation to progenitor cells 
(for review see Dexter et al, 1987). As proliferation and differentiation continues 
the progenitor cells become more restricted and eventually committed to specific 
cell lineages. Early progenitor cells have a high proliferative potential and can 
generate clones of up to 10® lineage restricted cells which finally mature into 
blood cells and it is from this cell compartment that haemopoiesis is sustained 
under normal conditions. Hence the hierarchial system can be described as a 
clonal progression from a quiescent pluripotent stem cell which is capable of self
1
renewal to progenitor cells which sustain the body's haemopoietic requirements, 
to finally bi~ or uni- potential progenitors which give rise to the specific lineage, 
mature, non proliferative functional blood cells.
This systematic progression of proliferation and differentiation of haemopotettc 
cell is partly regulated by a group of glycoprotein regulators. The development of 
in vitro culture systems for supporting haemopoietic cell growth (Plutznik and 
Sachs,1965; Bradley and Metcalf, 1966) and the discovery of these regulators in 
cell culture supernatents (Lotem and Sachs, 1966; Ichikawa et al, 1966) has led to 
the isolation, identification and molecular cloning of these growth factors. The 
first four regulators to be identified in these systems were the colony stimulating 
factors, (CSF's), a term derived from the in vitro observation that they stimulate 
progenitor cells to form colonies of recognizable maturing cells; prefixes are used to 
denote the cell type in the mature colonies, ie GM-CSF granulocyte and 
macrophage-CSF, M-CSF macrophage-CSF, G-CSF granulocyte-CSF and multi- 
CSF also named interleukin^ (IL-3) which produces a mixture of cell types 
(Metcalf, 1988).
The mode of action of the CSF's is by binding to specific receptors on the cell 
surface. When a stem cell becomes committed to differentiation it produces 
receptors on its surface that respond to specific regulator signals. Those signals in 
turn push the cell further down the pathway toward ultimate specialization 
(Golde and Gasson 1988; Nicola, 1987).
The regulation of normal haemopoiesis is a complex process of which the CSF's 
form part of the total system. The haemopotettc bone marrow mteroenvtroment is 
essential and numerous other regulatory processes are also involved. As well as
2
the CSFs a series of interleukins, 17 to date, various inhibitors (Lord, 1976) and 
other immune modulators such as interferon (Resnitzky.et al, 1986), tumour 
necrosis factor and small peptides are involved.
The Hemopoietic Mtayorevtyomret
The role of the mtaroenviyomeet is not well understood. Sustained in vitro
haemopoiesis requires an adherent stromal layer (Dexter et al, 1977) that consists 
of fibyoblrstoid cells, adipocytes, 'blanket cells', macrophages and possibly 
endothelial cells (Dexter et al, 1984). These cells secrete components of a complex 
extracellular matrix that include ftbroerctin, laminin, collagen and 
glycosamteoglycans (Sieff, 1988). The cellular components have been shown to 
synthesize CSF (Heard et al, 1982) and factors that affect stem cell cycling 
(Toksoz et al, 1980). Furthermore, synthesis of proteins such as fibroeeatie and 
harmonecttn may provide essential substrates to which developing erythroid and 
myeloid progenitors adhere during maturation. (Tsai et al, 1986; Campbell et al,
1987).
THE COLONY STIMULATING FACTORS
Interleukin^ (IL-3)
IL-3 is produced by activated T-lymphocytes (Andreeff and Welte, 1989). Murine 
IL-3 was first purified by Ihte et al (1982) and was consequently shown to support 
the formation of multiftnrage colonies in vitro (Prystowsky et al, 1984). It was 
shown that IL-3 was capable of generating colonies of all three granulocytic cell 
types, neutrophils, eosinophils and basophils, macrophage colonies, 
megakaryocyte colonies and early erythroid colonies in the presence of 
erythropoietin (Epo). Because of its regulatory role in all the mye^oi^c
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lineages IL-3 has also been called multi-CSE The precise role of IL-3 in the
regulation of self renewal, proliferation and differentiation of the pluripotent
stem cell remains obscure.
Gibbon, human (Yang et al, 1986) and murine (Fung et al, 1984) IL-3 have also been 
cloned . IL-3 was found to be a complex glycoprotem, ranging in size from 14 to 28 
kilodaltons (kD). The expected size of the active polypeptide is 14 to 15 kD. The 
sequence homology of gibbon and human IL-3 was found to be 96%, and human and 
murine IL-3 only 49%. The gene encoding human IL-3 is located on the long arm of 
chromosome 5, in close vicinity to the GM-CSF gene (Le Beau et al, 1987).
Recombinant gibbon IL-3 has been tested on enriched populations of human 
progenitors (Leary et al 1987). It supported the formation of various types of 
single lineage, as well as muHilineage colonies in the presence of Epo. In 
addition, IL-3 supported, and more effectively than GM-CSF, the formation of 
blast cell colonies with a high replating capability. These data suggested that 
IL-3 was the least restricted of the CSFs with regard to cell lineage induction and 
had the greatest variety of action with regard to target cells. Also, there is 
evidence that IL-3 supports stem cell self renewal (Testa and Dexter, 1992).
The in vivo action of IL-3 have been investigated in simian studies (Donahue et al 
1987; Krumwieh et al, 1988 ;Mayer et al 1988). It was shown that IL-3 was a poor 
haemopoietic stimulus when given alone, however, it primed the haemopoielic 
system to the effects of GM-CSF. It was suggested that IL-3 is capable of acting on 
an immature population of progenitor cells, which in turn can be stimulated to 
proliferate and terminally differentiate in the presence of a second haemopoietic 
growth factor such as GM-CSF. These studies have also shown that IL-3 is a
4
differentiation factor for eosinophils and basophils.
These in vivo studies have also been supported by in vitro studies using 
fractionated stem and early progenitor cell populations (Iscove et al, 1989; 
NcNiece et al 1987; Saeland et al 1988; Kavnoudias et al, 1992; Williams et al, 
1992). IL-3 was shown to directly induce colony formation and/or proliferation of 
murine and human stem or early progenitor cells and be more effective in 
supporting formation and/or proliferation of early progenitor cells compared to 
other myeiopotette growth factors.
It has been shown that IL-3 binds to high or low affinity binding sites. In the 
murine system, the low affinity receptor gene has been cloned and apparently 
represents one member of a gene family which includes other interleukins (IL-2, - 
4, and -6).(Itoh et al, 1990). More recently, it has been suggested that the specific 
receptors for human IL-3 and GM-CSF share an identical subunit (Park et al, 
1989).
Macrophage-Colony Stimulating Factor (M-CSF)
M-CSF characteristically produces macrophages in vitro. Activated monocytes 
have been shown to contain high levels of mRNA for M-CSF. M-CSF has been 
shown to be a potent stimulator of murine macrophage colony formation, but both 
murine and human forms which have been btosynthesized were less active with 
human target cell (Andreeff and Welte, 1989). This however may be due to 
limitations of human eaemopoietic cell culture techniques.
Murine M-CSF was the first of the CSF's to be identified in the colony assay 
however the cloning of M-CSF was the most complex of all the CSF's. M-CSF was 
found to be a homodimer of two identical subunits connected by an interchain
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disulphide bond and highly glycosylated. The system was complicated because 
at least two differentially spliced messenger ribonucleic acids (mRNA's) were 
expressed from a common gene, and each of these encoded different M-CSF 
precursors. Additional processing and glycosyla^on resulted in at least two forms 
of M-CSF; a 10 to 90 kD glycoprotein comprising a dimer of 35 to 45 kD subunit, and 
a smaller 40 to 50 kD glycoprotein comprising of a dimer of a 20 to 25 kD subunit 
(Kawasaki et al 1985; Wong et al, 1987). The gene of human M-CSF has been 
localized on chromosome 5q23-q31, and the receptor for M-CSF is encoded by the 
fms protooecogree (LeBeau et al, 1986).
M-CSF has been shown to activate mature macrophages, and the larger form of 
recombinant M-CSF strongly potentiates human macrophage cytotoxicity (Clark 
and Karmen, 1987). The responsiveness of M-CSF has been shown to be greatly 
enhanced by GM-CSF and to participate in maintaining a reserve of progenitor 
cells for neutrophils (Rothstein et al, 1988). It has also been shown that GM-CSF 
in very small concentrations enhanced the responsiveness of marrow progenitors to 
M-CSF (Caracciolo et al, 1987). Clinical trials of M-CSF are currently in progress 
(Andreeff and Welte, 1989)
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)
Murine GM-CSF was the first of the CSF's to be purified (Burgess, 1980) and 
cloned (Gough et al, 1984). Compared to IL-3, GM-CSF has been shown to be more 
restricted in its activities. Several cell types have been shown to express mRNA 
for GM-CSF following activation. These include T lymphocytes, and endothelial 
cells and fibroblasts present in the bone marrow stroma (Herrman et al, 1986). 
Vascular endothelial cells produce mRNA and release both G- and GM-CSF upon 
stimulation with tntryleukte-1 (IL-1) (Zsebo et al, 1988).
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Recombinant human GM-CSF (rhGM-CSF) has been shown to be highly variable 
in size with molecular species in the range of 14 to 30 kD. The expected size of the 
mature polypeptide was 14 to 15 kD therefore, the carbohydrate content of the 
molecule can reach 50% of the total mass. The most highly glycosylated GM-CSF 
was less than one tenth as active as the smallest form of the molecule (Clark and
Karmen, 1987).
GM-CSF has been shown to have a wide range of activities. It supports the 
proliferation of neutrophil, macrophage, and eosinophil colonies and affects 
numerous functions in these end cells (Lopez et al, 1986; DePersio et al, 1988). 
rhGM-CSF acts directly or in combination with Epo or IL-3 on erythroid 
progenitors. GM-CSF produces monocyte-macrophage colonies and also controls 
specific monocyte functions through the induction of M-CSF transcripts in 
monocytes (Horiguchi et al, 1987) and the stimulation of Fc-dependent 
phagocytosis of tissue derived macrophages (Coleman et al, 1988). GM-CSF and 
IL-3 induces the production of tumour necrosis factor from monocytes and 
significantly enhances monocyte killing in response to endotoxin (Cannislra et al, 
1988). GM-CSF also has megakaryocyte colony stimulating activity and augments 
the effect of I9-3 on megakaryocyte colony formation (Robinson et al, 1987). GM- 
CSF has been shown to have a direct effect on multipotential progenitor cells from 
S-flurouracil treated mice (Koike et al, 1987), however normal human bone 
marrow cells obtained by fluorescence-activated cell sorting did not proliferate 
after a single pulse stimulation with GM-CSF (Begley et al, 1988).
In vivo studies of the effects of GM-CSF have been studied in simians and
humans. In simian studies rhGM-CSF induces a prompt five fold increase in 
granulocytes, a two to four fold increase in lymphocytes and a three to four fold
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increase in monocytes (Donahue et al, 1986). It also primes circulating 
granulocytes for enhanced oxidative metabolic activity and for knling of E coli 
(Mayer et al, 1987). In another study by Nienhuis et al (1987) GM-CSF was 
administered before and after total body irradiation and autologous bone marrow 
transplantation. GM-CSF shortened the period of neutropenia by 10 days and 
produced accelerated production of platelets. Clinical studies of GM-CSF have 
also been carried out on patients with aplastic anaemia (Vadhan-Raj et al, 1988) 
and aids (Groopman et al, 1987) with favourable results.
Granulocyte-Colony Stimulating Factor (G-CSF)
G-CSF induces bone marrow progenitor cells to form colonies of granulocytes in 
vitro (Ottman et al, 1987). G-CSF has also been shown to have an effect on the 
functional activity of peripheral granulocytes (Platzer et al, 1987). Two G-CSF
cDNA clones were isolated from different tumour cell lines. The first clone
encoded a 207 amino protein., of which 177 amino acids comprised mature G-CSF, 
while 30 hydrophobic amino acid determine the probable leader sequence 
(Nagata et al, 1986). The second clone was identical apart from a deletion of 
three amino acids. The predicted molecular masses of the two proteins have been 
19 and 18.6 kD. Monocytes, endothelial cells, and fibroblasts have been 
identified as G-CSF producers (Herrman et al 1986; Zsebo et al, 1988; Kaushansky 
et al, 1988).
The in vivo affects of G-CSF have been studied in the rhesus monkey. Dose 
dependent increases in the total white blood cell count, mainly of neutrophils 
were observed (Welte et al, 1987). The effects of G-CSF on 
chemotherapeutica^-induced cytopenias were investigated in this study. The 
administration of G-CSF dramatically increased the peripheral white cell count.
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however there was no decrease in the duration of the cytopenia. The effects of G- 
CSF after autologous bone marrow transfusion were also investigated (Bonilla et 
al, 1987). With the administration of G-CSF the white blood cell counts were six 
times greater than the controls. Chemotherapeutic regimes for various 
malignancies result in significant decreases in white blood cell numbers resulting 
in high risks of fatal infections. Cftetcal trials of G-CSF on patients receiving 
chemotherapy for bladder cell carcinoma have shown favourable results with at 
least three fold increases in the number of granulocytes (Gabriiove et al, 1988).
Favourable results have also been obtained with the administration of G-CSF to 
children with severe congenital neutropenia (Welte et al, 1988).
LEUKAEMIA
Leukaemias are a very heterogeneous group of malignant diseases of varying 
aetiology, pathogenesis and prognosis. In most leukaemic cases the aetiology is 
unknown. As with other malignancies, known causative agents are radiation, 
viruses and toxic chemicals. The present most widely used system of classification 
of the leukaemias is the FAB (French, American, British) system. Currently, the 
MIC (Morphologic-Immunologic-Cytogenetic) classification system is also being 
used (Bain, 1988). However, heterogeneity of the disease is observed within 
these classification groups.
The clinical manifestations of the leukaemias are due directly or indirectly to the 
proliferation of leukaemic cells and their infiltration into normal tissues. 
Increased cell proliferation has metabolic consequences and infiltrating cells also 
disturb tissue function. Anaemia, neutropenia and thrombocytopenia are 
important consequences of infiltration of the bone marrow which can lead to
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infection and haemorrhage (Bain, 1988).
Genetic alterations leading to leukaemic transformations of a cell were often 
associated with major alterations of chromosomes which could be detected by
studying cells of the leukaemic clone in mitosis. Particular chromosomal 
aberrations were often associated with a particular leukaemia and have been 
shown to have prognostic value (Bain, 1988). These microscopically detectable 
abnormalities have helped identify the chromosomes where significant 
alterations have occurred at a molecular level in relation to haemopoietic 
regulators (Le Beau et al, 1986; de The et al, 1991).
Clonal Development and Stem Cell Origin of leukaemia
Myeloid leukaemia has been described as a clonal neoplasm involving a 
progressive expansion of proliferative myeloid cells with evidence of a dif­
ferentiation block or abnormal maturation (Sachs, 1978, 1986; Francis et al 1982; 
Metcalf, 1988). There was convincing evidence to show that acute leukaemia 
begins in a single cell that undergoes clonal proliferation to give rise to a 
recognizable population of leukaemic cells. The nature of this change was central 
to theories concerning the pathogenesis of acute leukaemia (Adamson 1984).
Although the etiology of human leukaemia is unknown, it was clear that in 
experimental systems, where leukaemogenesis can be studied, the responsible 
agents were capable of modifying nuclear DNA, and their actions were enhanced 
if certain genetic constitutions were present (Metcalf, 1988). The growing body of 
data showing associations between nonrandom chromosome abnormalities 
particularly translocations and activation, amplification, or mutation of cellular 
proto-oncogenes strengthened the view that leukaemia begins as a somatic
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mutation from which an abnormal clone arises (Fialkow, 1990).
The observation that nonrandom cytogenetic abnormalities characterised 
hacmopoielic neoplasias, prompted the 'clonal' theory. Evidence on the 
clonality of leukaemia was obtained when studies were carried out on cells from 
females who were heterozygous for the enzyme glucose-h-phosphate 
dehydrogenase (G®PD). Tumour cells from these females all contained the same 
allele of the G®FD gene. Normal cells contain either one or the other allele at a 
50% distribution (Fialkow 1970). Another marker system based on X chromosome 
inactivation mosaicism which has provided evidence of the clonality of 
leukaemia was the analysis of DNA polymorphisms of restriction fragment 
length (Vogclttein et al, 1985).
The most widely accepted theory on the development of leukaemia is that 
leukaemias are clonal disorders; however, two arguments arose from this
observation:-
i) that an agent involved in the cause of disease may have specific affinity for 
certain chromosomal regions, therefore a common karyotypic change would not 
necessarily indicate clonal development and
ii) that the chromosomal marker identified an evolved subclone and that cells
lacking the cytogenetic abnormality may have been clonal as well (Dameshek 
and Gunz, 1990)
Target Cells for Lrukarmogrnrsit
The location in the haemopoietic hierarchy of the clonogenic cell that initiates 
what is clinically recognized as myeloid leukaemia can vary. In chronic myeloid 
leukaemia all the cell lineages contain the chromosomal aberrations hence the
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initiating cell was expected to be from the pluripotent stem cell compartment 
(Metcalf, 1988). In acute myeloid leukaemia (AML) there is evidence that the
initiating cell in some cases may be from the pluripotent stem cell compartment 
and in others, from the granulocyte macrophage progenitor cell compartment. In 
one patient with AML it has been shown that B lymphocytes had arisen from the 
leukaemic clone. By contrast, the leukaemic population in younger AML patients 
appeared to arise from a stem cell restricted to granulocyte macrophage 
progenitor cell compartment, as other cell lineages appear to arise from non-clonal 
progenitors.(Fialkow, 1981).
Multistep Pathogenesis
The theory of multistep, rather than single step pathogenesis of leukaemia and 
myelodysplastic syndromes (Raskind et al, 1984) has evolved from studies 
utilising G6PD/X chromosome inactivation mosaicism and cytogenetic studies of 
Epstein-Barr virus (EBV) transformed B lymphoid cell lines. The nonrandom 
cytogenetic abnormalities observed in myeloid leukaemia were more likely to be 
part of the progression or manifestation of the disease rather than the cause. 
This process has been described as a stepwise series of events rather than a single 
genetic alteration (multistep pathogenesis). It has been postulated that, at least, 
a two step process is involved in leukaemogenesis. The first causing growth of a 
leukaemic clone of pluripotent haemopoietic stem cells and the second inducing 
the nonrandom chromosomal aberration in descendants of those progenitors 
(Fialkow, 1985).
Suppression of Normal Haemopoiesis
Failure of normal haemopoiesis is the most serious pathophysiological 
consequence of acute leukaemia. This pathogenesis is poorly understood however,
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a number of observations have been made. It has been shown that normal
haemopoietic progenitors [Colony Forming Units -GM (CFU-GM)] fail to 
proliferate normally if cultured in vitro with leukaemic cells (Morris et al, 1975;
Nara et al., 1984), with leukaemic extracts or medium conditioned by incubation 
with leukaemic cells (Broxmeyer et al, 1978 and 1979; Olofsson and Olsson 1980; 
Olofsson et al, 1984). Two distinctly different inhibitory activities have been 
isolated. Leukemia cell-derived inhibitory factor (LIA) (Broxmeyer et al., 1978) 
and leukemia-associated inhibitor (LAI) (Olofsson and Olsson 1980). The first 
was produced by lymphoid like cells from patients with acute and chronic 
myeloid leukaemia and chronic lymphocytic leukaemia and was attributed to 
being an acidic isoferritin, however other workers regard this as incompatible 
with available information of ferritin biochemistry (Sala et al, 1986). LAI 
differed physically and chemically from LIA but had the same effect of reducing 
the proliferation of CFU-GM. The cells producing LAI were large non-T non-B, Fc 
receptor positive mononuclear cells, different from those producing LIA (Olofsson 
et al., 1984). LIA acted selectively on S-phase cells. Inhibition of normal CFU- 
GM by an inhibitory factor could explain the suppression of normal haemopoiesis
in the leukaemic state.
Other observations involved the haemopoietic microenviroment. Another 
explanation for depression of normal haemopoiesis in AML, based on studies in an 
animal model, was that AML cells specifically localized to the subendosteal 
region of the bone marrow, where the microenviroment is optimal for normal stem 
cell proliferation (Van Bekkum et al, 1981). Hence, there would be displacement 
of normal stem cells from optimal bone marrow sites. Leukaemic cells have also 
been shown to suppress the growth of fibroblast colonies from normal marrow 
(Nagao et al, 1983). It has also been shown that stromal cells in long term culture
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from four of five AML patients studied by Singer et al were derived from the same 
progenitors as the leukemic clone (Singer et al, 1984). In view of the dependence of 
haemopoietic stem cells on an intact functional stromal layer, this might 
contribute to the failure of normal haemopoiesis in acute leukaemia. From 
studies on murine leukaemias in our own laboratory (Michaelis and Riches, 
unpublished data) it was noted in a study on the histology of the marrow that the 
bone marrow becomes progressively necrotic with progression of the disease. Bone 
marrow necrosis has also been observed in leukaemic patients (Maisel et al, 1988)
Normal haemopoietic stem cells are almost certainly present, albeit suppressed, 
in the marrow of many patients when they present with acute leukaemia. AML 
patients in very early remission produced a wave of multipotent stem cells in the 
blood whose presence could be inferred from the successful trilineage engraftment 
when the blood was subsequently reinfused after ablative chemotherapy (Juttner 
et al, 1985) and by greatly increased numbers of circulating CFU-GM which grew 
normally in culture (Tilly et al, 1986). Also, normal stem cells capable of 
engraftment following ablative chemoradiotherapy have been grown from long 
term culture of bone marrow of patients with AML (Chang et al, 1986). By contrast 
however residual leukaemic stem cells have been shown to persist in the blood 
and marrow of patients with AML in chemotherapy induced remission (Consolini 
et al, 1986; Estrov et al, 1986; Jasmin et al 1991).
Possible Theories on Leukaemopoiesis
Central to the discussion of the leukaemogenic event was the fact that the 
majority of normal pluripotent stem cells have been infered to be in a quiescent non 
cycling or Go state. In one hypothesis, it was suggested that damage (i.e. a 
potentially leukaemogenic event) occuring in a Go stem cell produced leukaemia
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only if that cell was subsequently recruited into cell cycle (Killman SA, 1968). An 
alternative hypothesis proposed that the leukaemogenic event altered the 
responsiveness of a Go stem cell to normal control mechanisms, increased its 
cycling rate, and decreased the time in Go (Lajtha, 1981). If Go is a phase during 
which the cell undertakes "genetic housekeeping" to keep the genome error-free, 
shortening the time spent in Go would carry with it risk of accumulating
additional errors.
The extent to which input from a stem cell compartment serves to maintain a 
leukaemic cell population once the disease is established is not known with 
certainty. The relationship between the stem cell in which acute leukaemia 
originates and the putative leukaemic stem cell present at the time the disease 
becomes clinically evident has been vigorously debated.
Most acute leukaemias at presentation show a population of blasts in the marrow 
and blood which is relatively homogeneous, which may show morphologic and 
phenotypic evidence suggestive of maturation (eg promyelocytes in AML-3), and 
which is capable of reentering the cell cycle. Although large numbers of 
leukaemic cells normally die, the fraction reentering division is sufficient to 
ensure that the population continues to expand, and it could be argued that acute 
leukaemia will persist without any continued input from a stem cell compartment. 
This interpretation is strengthened by experience with cell lines such as the 
HL-60, in which a population of mature-looking promyelocytes proliferates 
indefinitely in vitro. On the other hand, predictions based on the response of 
acute leukaemias to chemotherapy and the identification in vitro of small 
subpopulations of leukemic cells with self renewal capacity and high 
proliferative activity suggest that maintenance of the leukaemic process might
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require a continued inflow of cells from a stem cell compartment (Fialkow, 1985).
Cell Surface Markers and Acute Myeloid Leukaemia
The surface phenotype markers of AML have been less well defined than is the
case for ALL, but antigens present on blast and colony forming cells have been 
identified using monoclonal antibodies (Lange et al, 1984; Lowenberg and Bauman,
1985).
Of particular interest is the observation that fucosylglycopeptides, normally 
found only on mature marrow neutrophils, are also found on the surface of blasts in 
AML. These substances are postulated to play a role in the egress of mature 
neutrophils from the marrow into the blood, and their presence on AML could 
account for the premature release of these cells from the marrow (Van Beek et al,
1984).
Oncogenes and Acute Myeloid Leukaemia
In normal cellular systems a balance needs to be maintained between cellular 
proliferation, cellular differentiation, cellular function and cell death. 
Oncogenes have been implicated in malignancy and are involved in all of these 
four areas. Oncogenes are the genes carried by retroviruses which produce cancer 
in experimental animals and which are now known to be normal components of 
human chromosomes (Garson, 1990). Nearly 50 cellular proto-oncogenes have been 
identified and are classified into seven main groups according to their 
involvement in cellular function i) growth factor, ii) cell surface receptors, iii) 
membrane associated tyrosine kinase, iv) G-proteins, v) cytoplasmic 
serine/threonine kinases vi) nuclear proteins and vii) putative or unclassified 
(Demczuk S, 1991). Activation of oncogenes is often a result of structural
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chromosome rearrangement, a common feature of leukaemia, and is involved in 
the development of malignancy (Carson, 1990).
Cellular oncogenes seem to play a role in haemopoietic growth stimulation. Anti­
oncogenes, which have a suppressive effect on oncogene products, may be directly 
linked to terminal differentiation. The maturation arrest in leukaemia may 
result from both constitutive expression of oncogenes and lack of expression of anti­
oncogenes (Olsson et al, 1988).
To date none of the translocations described in human AML have been proven to 
involve oncogene rearrangement although c erts may be altered in the llq 
abnormalities, c mos is close to the breakpoint on Chromosome 8 in the t(8;21), erb 
A on chromosome 17 may be involved in the t(15;17) (Garson, 1990) and the c-fms 
oncogene product is related to the M-CSF receptor (Sherr et al, 1985). Point 
mutations of the gene N-ras in codons 12, 13,61 have been shown to occur in 
preleukaemia and such patients progress to overt leukaemia with the same 
mutation (Carson, 1990).
Classification and the Heterogeneity of Acute
Myeloid Leukaemia
The AML's appear to be heterogeneous in at least two important respects:-
• The pattern of differentiate expression of the involved stem cells and
• The nature of the remission.
The heterogeneity of AML imposes difficult problems for the prognosis and 
treatment of the disease. The FAB classification system classifies the acute 
myeloid leukaemias according to the predominant proliferative morphologically 
recognizable myeloid leukaemic cell. However, heterogeneity within these 
subclasses is observed when conventional chemotherapeutic regimes are employed
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for the treatment of the disease. Immunological classification with cell surface 
markers has been limited with AML and identification of specific chromosomal 
abnormalities within the subgroups has been shown to have some limitations for 
prognosis (Bain, 1988). In in vitro studies of human AML a marked heterogeneity- 
in response to growth factors has also been observed. It has been postulated that 
the pattern of the in vitro proliferative response to growth factors of AML cells 
may be of prognostic significance (Moore et al, 1974).
The purpose of any pathological classification of disease is to bring together cases 
which have fundemental biological similarities and which are likely to share 
features of causation, pathogenesis and natural history. The recognition of more 
homogeneous subgroups of biologically similar cases is important as it permits an 
improved understanding of the leukaemic process and increases the possibility of 
causative factors being recognized. Since such subgroups may differ from one 
another in the cell lineage affected and in their natural history and prognosis, it 
is likely that the identification of biologically different subgroups will lead 
ultimately to a different therapeutic approach in some subgroups and to an 
overall improvement in the prognosis of patients with acute leukaemia.
THE COLONY STIMULATING FACTORS AND
ACUTE MYELOID LEUKAEMIA
The most accepted theoretical postulate on the proliferation and differentiation 
mechanisms in haemopoieis is that of asymmetrical or stochastic events (Metcalf, 
1988). If this is correct, for the understanding and manipulation of leukaemia, it 
becomes fundamentally important to establish whether abnormally high levels 
of self generation characteristic of the disease can be suppressed by manipulating
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extrinsic signals impinging on the cell.
The GSF's are active on normal multipotential and stem cells hence it appeared
obvious that the role of these factors in AML needed to be elucidated. It has been
stated that '-it may be a serious oversimplification to regard the myeloid
leukaemias merely as neoplasms of CSF-dependent populations. How much of the 
information we are generating in our culture techniques is relevant to the 
leukaemic cell is difficult to assess?' (Metcalf, 1988). However, the roles played 
by the GSF's in the progression and maintenance of the disease are fundamental to 
our understanding of the disorder. The proliferative capability of myeloid 
leukaemic cells is not completely understood. What has become evident from 
previous studies is the heterogeneity of the leukaemic response to normal 
haemopoietic regulators (Moore et al, 1974). Also it has become evident that 
leukaemic cell populations can be manipulated to alter their responses in vitro 
with physiological regulators (Lotem and Sachs, 1974, 1977,1980, 1982, 1983).
In view of the current concepts of myeloid leukaemia we have attempted to study 
the responses of myeloid leukaemic cells to three of the GSF's. The first part of 
our study concentrated on documenting in vitro proliferative responses to single 
and combinations of growth factors. With the use of combinations of growth 
factors we attempted to identify possible subgroups of myeloid leukaemia 
according to or lack of synergistic responses to growth factors as compared to
normal bone marrow cells.
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DIFFERENTIATION INDUCTION AS AN ALTERNATIVE 
THERAPEUTIC REGIME FOR THE TREATMENT OF
ACUTE MYELOID LEUKAEMIA
In 1856 Virchow gave the following description of leukaemia:-
Tn a pathological situation the differentiation into specific cells is blocked. This 
disturbance of normal differentiation - so called leukaemia - is a disease 'sui 
generis". We know the sequelae of this disease, we do not know its origin.
During the 1970's Lotem and Sachs gave attention to the concept that a block in 
the differentiation process was inherent to the leukaemic state (Lotem and Sachs, 
1978). Their experimental work with murine myeloid leukaemias and work on 
myeloid leukaemic cell lines showed that the differentiation block in some 
leukaemias could be bypassed with regulators of normal haemopoiesis (CSF's). 
Guimares et al (1984) have described the imbalance between proliferation and 
differentiation in myeloid leukaemia as observed in CSF stimulated cultures as, 
'merely a profound shift in the differentiation probability of one or more cell 
stages rather than a particular stage which cannot be achieved".
Current therapeutic regimes for the treatment of myeloid leukaemia rely upon 
non-specific cytotoxicity and although a number of advances have been made 
towards cure and palliation of the disorder their beneficial effects are usually 
accompanied by significant morbidity. With increasing evidence on the 
differentiability of a number of malignancies including myeloid leukaemia, 
studies on an alternative approach for the treatment of myeloid leukaemia 
utilizing differentiation induction appeared warranted. The assumption with 
this approach is that malignancy is not an irreversible state and that malignant 
cells can be induced to differentiate into mature benign forms with no 
proliferative potential.
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Spontaneous differentiation of leukaemic cells in vitro has been noted since 1960 
(Nowell, 1960). During the 1970's in a series of experiments utilizing a 
spontaneous murine leukaemia in a SL mouse, radiation induced murine 
leukaemias in various mice strains and in murine leukaemic cell lines, including 
WEHI-3B, Sachs and colleagues isolated various 'differentiation positive' 
leukaemic clones. 'Differentiation negative' clones were also isolated. It was 
shown that physiological regulators of haemopoiesis were able to induce 
differentiation in some leukaemic clones (Sachs, 1978a,1978b, 1980, 1982; Lotem
and Sachs, 1985; Shabo and Sachs, 1988; Lotem et al, 1988). The in vitro studies 
were supported with evidence from in vivo studies in murine leukaemic models 
(Lotem and Sachs, 1981, 1984, 1988). Studies using leukaemic cell lines of 
homogeneous undifferentiated populations of leukaemic cells provided strong
evidence that differentiation induction of murine leukaemic cells could be
achieved in vitro. During the early 1980's Collins et al induced differentiation in 
the human promyelocytic cell line HL60 (Collins et al, 1980).
Various physiological and non physiological compounds have been shown to 
induce differentiation in leukaemic cells. These agents can be classified into four
main groups:-
1. The regulators of normal haemopoiesis, CSF's and the CSF's in combination 
with the immunomodulators interferon and tumour necrosis factor-^.
2. Steroids, the vitamin A derivatives retinoic acid, 13-c/s and patRA, and the 
vitamin D3 derivative 1,25 dihydroxycholecalciferol.
3. Low doses of some antimetabolite agents eg ara-C, aclacinomycin A or other 
cytotoxic agents.
4. Polar compounds such as dimethylsulphoxide (DMSO) and hexylmethylbes- 
anthracene or phorbol esters (Chomienne, 1991).
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Of the CSF's G-CSF has been shown to be the most effective in the induction of
differentiation of murine leukaemic cells in vitro (Metcalf and Nicola, 1985). 4
However, the inclusion of the physiological growth factors in therapeutic 
regimes for myeloid leukaemia have been treated with caution because they have |
been shown to have proliferative effects on leukaemic cells in vitro (Jones and ’j
Millar, 1989). The relationship of the CSF's to normal and leukaemic cells in the 
leukaemic state still needs to be elucidated (Jones and Millar, 1989). Current in 
vitro data suggests that the CSF's may be able to play a role in differentiation |
induction regimes for the treatment or maintenance of myeloid leukaemia. We ■'
aim to study the in vitro differentiation effects of WEHI-3B CM (as a source of f
IL-3), L929 CM (as a source of M-CSF) and rGM-CSF, the interrelationships and 4
synergy of the growth factors in relation to differentiation induction on myeloid 4
leukaemic cells and to compare these to the responses of normal bone marrow. • ?
More specifically, we aim to determine the effect of the growth factors on the 4
clonogenic leukaemic cell fraction utilizing an in vivo clonogenic cell assay.
RETINOIC ACID AND DIFFERENTIATION 
INDUCTION OF MYELOID LEUKAEMIA ;
Retinoids are a class of chemical compounds structurally related to Vitamin A 4
• -ip
(Vit A) and are comprised of natural and synthetic analogs. A correlation
between Vit A and cancer was first noted with the classic work of Wolbach and 4
Howe (1925) when experimentally-induced Vit A deficiency was shown to lead to 4
hyperplastic, metaplastic and dysplastic tissue changes. In the forties Abels et f
al (1941) conducted the first studies which associated vitamin A deficiency with |
human malignancy. At this time success rates in clinical trials of Vit A were not
promising as very high concentrations of the vitamin were required to induce a 4
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response resulting in undesirable side effects of hypervitaminosis A. Since the 
mid fifties derivatives were developed in an attempt to produce drugs with an 
improved therapeutic ratio and now over 2000 analogs have been synthesized 
(for reviews see Lippman et al, 1987 part I; Bollag and Holdener, 1992). During 
the fifties and sixties a preventative effect of Vit A on the development of 
chemically induced tumours was demonstrated in animal models (Chu and 
Malmgren,1965) By the seventies the therapeutic effects of Vit A and Vit A acid 
were demonstrated experimentally on epithelial and skin tumours (Bollag 1970,
1971).
Differentiation induction with the use of retinoids was achieved in certain
malignant cell lines in mice and from humans, such as, neuroblastoma (Schubert et 
al, 1971; Sidell 1982), teratocarcinoma (Pierce and Wallace, 1971; Strickland and 
Mahdavi, 1978), squamous cell carcinoma (Pierce and Wallace, 1971), 
adenocarcinomas of the breast (Decosse et al, 1973), embryonal carcinoma (Jetten 
et al, 1979) and on human myeloid leukaemic cell lines HL60 (acute 
promyelocytic), the histiocytic lymphoma U-937 and THP-1 (Metcalf et al, 1969; 
Breitman et al, 1980, 1983; Gootwine et al, 1982). During the early to mid eighties 
numerous observations were made on the differentiation inducing or 
antiproliferative properties of RA on human acute myeloid leukaemic cells (for 
review see Lippman et al, 1987 part II) which warranted further studies on the 
efficacy of RA in the treatment of AML. Differentiation induction was achieved 
only on fresh human promyelocytic leukaemic cells in primary culture (Breitman 
et al, 1981; 1983). Antiproliferative effects have been observed with other AML 
subtypes (Findley et al, 1984; Lawrence et al, 1987). Only the two naturally 
occuring isomers of RA, P-all trans and 13-cis RA with a free carboxyl end group 
(Fig. 1) have been shown to be active inducers of differentiation in human
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Figure I. The basic structure of the retinoid molecule consists of a cyclic end 
group, a polyene side chain and a polar end group. By modifying any part, 
different therapeutic ratios can be achieved. Chemical manipulation of the 
polar end group and the polyene side chain produced retinyl esters, amides, 
aldehydes, ethers, amines and acids. These were the first analogues to be 
developed and were termed first generation retinoids. Second generation 
retinoids were produced by altering the cyclic end group, and cyclization of 
the polyene side chain has produced potent and less toxic third generation 
retinoids. The two naturally occurring isomers of RA, 13-cis RA and 
especially p-all trans RA have been shown to have differentiation inducing 
properties in acute myeloid leukaemias.
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myeloid leukaemic cell lines and on fresh human APL cells. Although other 
synthetic analogues may be more potent some like etretinate have no effect on 
leukemic cell differentiation (Castaigne et al, 1990). Until the late eighties 
studies concentrated on the use of 13-cis RA. The aim of our experiments was to 
evaluate the efficacy of {atRA to differentiate myeloid leukaemic cells. Bone 
marrow cells from three out of the four transplanted murine myeloid leukaemias 
studied were induced to differentiate, an antiproliferative effect was shown with 
the fourth and with a highly proliferative SA2 CL. In recent studies on structure- 
function relationships of RA on APL cells (Chomienne et al,1989; 1990) and in 
clinical trials on patients with APL (Huang Menger et al, 1988; Castagne et al, 
1990) patRA has been shown to be the more effective of the two isomers for
differentiation induction.
It had been postulated that the anti-tumour activity of retinoids was at least 
partially due to either induction of differentiation (Breitman et al 1983; 
Chomienne et al, 1986) and/or inhibition of proliferation (Roberts and Sporn, 
1984). Although the experimental evidence was not directly conclusive the use of 
homogeneous cell lines strongly suggested that the mode of action of retinoids, at 
least in these cell lines, was via differentiation induction. Definitive evidence on 
the differentiation inducing properties of RA has been provided very recently by 
Lo Coco et al (1991). Utilizing molecular evaluations of genetic rearrangements 
characteristic of promyelocytes from APL patients they showed that these 
rearrangements were present in mature granulocytes after patients were treated 
withpatRA.
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RETINOIC ACID IN COMBINATION WITH
PHYSIOLOGICAL REGULATORS OF HAEMOPOIESIS
In 1984 Olsson et al, reported on synergistic differentiation effects on the HL-60 
cell line with RA in combination with T-lymphocyte derived differentiation 
inducing factor. This was followed by a study by Ho (1985) who reported 
synergistic anticellular effects with the combination of RA and P-interferon 
against U-937 cells. In our studies we aimed to evaluate the combination of PatRA 
with regulators of normal haemopoietic proliferation and differentiation for 
synergistic differentiation effects on myeloid leukaemic cells. As a source of IL-3
we evaluated WEHI-3B CM which we showed maintained immature leukaemic
cells in culture, and as a source of M-CSF we evaluated L929 CM which we showed 
predominantly induced differentiation of leukaemic cells in culture. We were not 
able to make comparisons with RA treated cells in growth factor free cultures 
however, we showed that the combination of patRA with L929 CM induced a more 
enhanced differentiation response than with WEHI-3B CM. In the preceeding 
years a number of cytokines which had previously been shown not to have 
differentiation inducing properties on transformed cell lines when used alone, 
were shown to have synergistic effects when used in combination with RA. These 
cytokines include IL-1 a and b, IL-2, IL-4, interferon-a, -p and -% tumour necrosis 
factor-a, G-CSF, epidermal growth factor, transforming growth factor-pl and -P2 
(Hemmi and Breitman, 1987; Kohlhepp et al, 1987; Trinchieri et al, 1987; 
Nakamaki et al, 1989; Santini et al, 1989; Peck and Bollag, 1991)
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THE COMBINATION OF A DNA SYNTHESIS INHIBITOR, 
CYTOSINE ARABINOSIDE, AND A DIFFERENTIATION
INDUCER, p-ALL TRANS RETINOIC ACID, FOR THE 
TREATMENT OF MYELOID LEUKAEMIA
Vigorous chemotherapeutic regimes have been shown to:-
1) be ineffective in some AML patients as they are refractory to such treatment
2) be undesirable as they result in high mortality rates in elderly AML patients 
who cannot tolerate aggressive chemotherapy and in patients with MDS whose 
cytopenias are exacerbated with cytotoxic protocols and
3) following successful initial induction of complete remission,.not to eliminate 
minimal residual disease resulting in relapse and often the emergence of dominant
resistant leukaemic clones.
Less toxic and more effective therapeutic regimes would be desirable for such 
patients.
Combinations of differentiation agents and DNA synthesis inhibitors have been 
shown to have synergistic differentiation effects on bone marrow cells from 
patients with AML and MDS (Francis et al, 1985, 1987; Ho et al, 1987; Hoffman et 
al, 1985; Hassan and Rees, 1988; Hellstrom et al, 1987). The resultant responses 
observed in vitro suggested that with the combination of agents which use 
different modes of action, inhibition or slowing down of proliferation and 
differentiation induction; lower, less toxic doses of each agent can be used to 
achieve decreases in the proliferation of the malignant clones comparable to 
decreases observed with higher doses of single agents (Francis et al, 1985).
Studies on the combination of these agents have been mainly limited to bone 
marrow cells from patients with MDS (Francis et al, 1985; Francis et al, 1987; Ho 
et al, 1987). Studies on bone marrow cells from patients with AML have been 
limited (Hoffman et al, 1985; Hassan and Rees, 1988: Hellstrom et al, 1987) and
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have focused on the use of 13-cfs RA or have not specified which RA was 
employed.
We aimed to evaluate the combination of PatRA and ara-C in the treatment of
myeloid leukaemic cells in vitro. We monitored for synergistic decreases in the 
proliferative response and found that synergistic decreases in proliferative 
response were observed with two myeloid leukaemias tested and an enhanced 
stimulatory response was observed with one. An enhanced stimulatory effect 
with the combination of agents was also observed with normal bone marr^^ cells. 
One of the transplanted leukaemic cell lines, in which a synergistic response was 
observed, was progressively undergoing changes in respect to the dominant 
leukaemic clone. With progressive transplantation the characteristics of the 
dominant leukaemic were observed to change from being growth factor 
independent in vitro to growth factor dependent. We show in these studies that 
with progressive transplantation the leukaemic clones became less sensitive to 
both differentiation induction and to the cytotoxic effects of ara-C.
LOW DOSE CYTOSINE ARABINOSIDE 
AND LEUKAEMIC CELL DIFFERENTIATION
Ara-C is the chemotherapeutic agent of choice for the treatment of acute myeloid 
leukaemia. It is a naturally occuring antimetabolite. A number of other 
antimetabolites are used in conjunction with ara-C for the treatment of AML and 
these have been deliberately designed. Ara-C is a pyrimidine antimetabolite, a 
close structural analogue of the normal nucleoside metabolite, deoxycytidine 
(Capizzi et al, 1991).
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Baccarani and Tura (1983) and Housett et al, (1982) showed that low doses of ara-
C were also effective in the treatment of AML. It was postulated that the mode of 
action of ara-C may be via differentiation of the leukaemic clone. Ara-C was also
shown to induce differentiation in leukaemic cell lines. 100% differentiation was
observed with the monoblastic cell line U-937 and a 40% differentiation effect
was observed with the HL-60 cell line (Griffin et al, 1982; Takeda et al, 1982).
There was disagreement in the literature as to whether low doses of 
chemotherapeutic agents acted principally as cytotoxic agents or differentiation 
inducers. The most widely accepted theory was that they primarily slow down 
DNA synthesis. Studies on differentiation commitment of leukaemic cells using 
chemical induces of differentiation such as butyric acid and phorbol esters 
suggested that there is a decision point in the cell cycle regarding commitment 
late in the cell cycle or in G1 (Boyd and Metcalf 1984). This has been refered to as 
the differentiation responsive "window" (Francis et al, 1985). By slowing DNA 
synthesis with a chemotherapeutic agent this phase of the cell cycle may be 
lengthened and/or the cell may be rendered more responsive to differentiation 
induction. Hence, it has been suggested that the inhibitory effect of 
chemotherapeutic agents on leukaemic cell proliferation was an initiating factor 
for differentiation induction, by maintaining the cells in a cell-cycle phase 
responsive to endogenous or exogenous differentiation agents (Francis et al, 1985).
A MODEL OF LEUKAEMIA: RADIATION-INDUCED
TRANSPLANTED MURINE MYELOID LEUKAEMIAS
The high frequency of acute leukaemia witnessed after the dropping of the atomic
bomb on Hiroshima and in patients treated with ionizing radiation for ankylosing
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spondylitis first established the connection between ionizing radiation and 
leukaemogenesis (Mole, 1990). The myeloid leukaemic models used for these 
studies were radiation induced murine myeloid leukaemias established in our 
laboratory on the criteria established by Major and Mole (1978). CBA/H mice, in 
which no spontaneous leukaemia has been observed, have been used for the 
establishment of these cell lines. Major and Mole (1978) showed that with 300Gy 
total body irradiation approximately 20% of the mice developed myeloid 
leukaemia over their lifetime. This has been the experience in our laboratory 
(Riches, unpublished data). Transplantation and morphological studies of the 
primary and passaged leukaemias have been reported (Hepburn et al, 1987). 
Differing radiation doses induced lymphocytic leukaemias (Major and Mole, 
1978).
It is important in the establishment of leukaemic cell lines that their 
characteristics parallel those of the human form of the disease. The models need 
to reflect the hierarchial organisation of the leukaemic population into stem cell, 
progenitor cell and transit cell compartments (Hepburn et al, 1987). The in vitro 
responses of the myeloid leukaemic cells in this study closely paralleled the 
responses observed with human myeloid leukaemic cells in vitro and are
discussed.
IN VITRO ASSAYS FOR THE STUDY OF NORMAL
AND LEUKAEMIC HAEMOPOIESIS
Currently, two types of culture systems are used for the study of haemopoietic 
cells. Consequent cell growth in these cultures is dependent upon the initial cell 
population cultured and the growth factor used. The colony assay, or semisolid
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culture system, permits the detection of haemopoietic progenitor cells by their
ability to form colonies. Hence, progenitor cell numbers can be enumerated and 
specific growth factors can be assayed (Plutznik and Sachs, 1965; Bradley and 
Metcalf, 1966). Suspension cultures can also be used for the growth of 
haemopoietic cells. Lusis and Koeffler (1980) developed a rapid microtitre 
suspension culture assay for human colony stimulating activity based on 
measurements of growth factor dependent tritiated thymidine (^H-TdR) uptake 
in the human acute myelogenous leukaemia cell line (KG-1). In 1983 Horak et al 
extended this assay for the determination of dose response relationships of 
haemopoietic cells and mouse lung conditioned medium. This assay reflected the 
number of progenitor cells and the proliferative capacity within each colony.
Both these culture techniques have limitations. In the study of leukaemic cells 
the problems are further accentuated as it is not possible to determine directly the 
effects of various stimuli or inhibitors on the leukaemic clonogenic cell. It has 
been reported that malignant proliferation can occur even without the presence of 
the clonogenic cells as defined by the colony assays performed in semisolid media 
(Buick and Pollark, 1984). Both techniques favour the growth and survival of 
leukaemic progenitor cells however the cells and parameters studied may not be 
the same (Chomienne, 1991). We have chosen to use microtitre suspension cultures 
as they were more rapid assays for determining the proliferative responses of 
cultured cells, differentiative induction was easier to assess by preparing 
cytospins and we wanted to quantify the response of the leukaemic bone marrow as
a whole.
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AIMS
The aims of these studies were:-
a) . to investigate the in vitro responses of myeloid leukaemic cell populations to
regulators of normal haemopoiesis and
b) . to evaluate differentiation induction as an alternative therapeutic regime for 
the treatment of acute myeloid leukaemia.
Three radiation induced, serially transplanted murine myeloid leukaemic models 
developed in our laboratory (Riches et al, unpublished data) (SA2, SA7, and SA8) 
and a cell line derived from the SA2 transplanted murine leukaemia (SA2 CL) 
were used for these studies. The physiological characteristics of the transplanted 
leukaemic cell lines are described in Chapter One.
The initial classical in vivo studies on normal haemopoiesis by Till and 
McCulloch (1961), the establishment of in vitro culture systems (Lotem and Sachs, 
1965; Bradley and Metcalf, 1966; Dexter et al, 1977; Lusis and Koeffler, 1980) for 
the study of normal haemopoiesis, the consequent identification of regulators of 
normal haemopoiesis, experimental techniques for maintaining leukaemic cell 
lines in vitro and the establishment of leukaemic models in rodents (Major and 
Mole,1981; Hagenbeek and Van Bekkum, 1977) have provided the foundations 
and tools for the study of acute myeloid leukaemia.
In the first in vitro study (Chapter Two) the proliferative responses of bone 
marrow cells from the leukaemic models were characterised using regulators of 
normal haemopoiesis (growth factors) and compared to normal bone marrow. The 
regulators of normal haemopoiesis occupy a key position in attempts to understand 
the nature of the abnormal state existing in myeloid leukaemic cells and 
potentially could play an important role in therapeutic attempts to suppress
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myeloid leukaemic populations. The growth factors studied were WEHI-3B CM
as a source of interleukin-3 (IL-3), L929 CM as a source of macrophage-colony 
stimulating factor (M-CSF) and recombinant murine granulocyte-macrophage 
colony stimulating factor (rGM-CSF)
The regulators of normal haemopoiesis have been shown to affect overlapping 
stages of the haemopoietic pathways, that is, they exert stimulating effects upon 
the same target cells (Metcalf, 1988). They have also been shown to have 
synergistic proliferative effects on the same target cell when used in combination 
(McNeice et al, 1988 ). To further characterise the various leukaemic populations 
the interactions of the growth factors in controlling myeloid leukaemic cells by 
using combinations of growth factors in vitro were studied. With the use of 
combinations of growth factors we have attempted to identify aberrations of 
synergistic responses compared to normal bone marrow cells and to possibly 
identify specific subsets of myeloid leukaemic cells according to these responses. 
The comparative variations in response between the leukaemias and compared to 
normal myeloid cells may provide indicators of classifying leukaemic cell 
populations with biologically different disease and may prove to be of prognostic
value.
Experimental observations have shown that malignant cells could be induced to 
differentiate with both physiological and non physiological agents (Fibach and 
Sachs, 1976; Boyd and Metcalf,1984). In Chapter Three the differentiation 
inducing properties of WEHI-3B CM, L929 CM and rGM-CSF on the leukaemic cell 
populations were investigated. To determine the effect of the differentiation 
response of the growth factors specifically on the leukaemic clonogenic cell 
fraction we employed an in vivo leukaemic clonogenic cell assay.
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In Chapter Four the differentiation effects of p-all trans retinoic acid (PatRA) on 
leukaemic cell populations was investigated. The acute promyelocytic cell line 
HL60 (Collins et al, 1980) and bone marrow cells from patients with acute 
promyelocytic leukaemic have been shown to differentiate in vivo when treated 
with 13-cis retinoic acid (13-cfs RA) (Flynn et al, 1983). In this study we aimed to 
evaluate the efficacy of PatRA for the differentiation induction of leukaemic cell 
populations. The effects of the combination of patRA and growth factors on 
leukaemia cell differentiation were also investigated. We evaluated the effects 
of PatRA on the leukaemic clonogenic cell fraction using the in vivo leukaemic 
clonogenic cell assay.
It has been postulated that combinations of factors which act with different 
modes of action, inhibition or slowing down of proliferation and differentiation 
induction, lower, less toxic doses of each agent can be used to achieve increases in 
the proliferation of the malignant clones comparable to decreases observed with 
higher doses of single agents (Francis et al, 1985). In Chapter five the effects of 
the combination of the differentiation inducer, PatRA, and the DNA synthesis 
inhibitor, ara-C on the proliferation of myeloid leuakemic cells was 
investigated.
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MATERIALS AND METHODS
Experimental Animals
Syngeneic CBA/H mice, derived from the breeding nucleus at the Medical Research
Council radiobiology unit (Harwell, UK) were used for the murine myeloid leukaemia 
models and normal controls. All mice used for these experiments were bred and housed 
in the Bute animal house, University of St. Andrews. They were fed on R and M No. 1 
food pellets and chlorinated water (15ppm chloride) ad libitum.
Culture Medium, Supplements, Serum and Antibiotics
Fisher's modified medium, Dulbecco's medium and horse serum were obtained from
Gibco Bioculture Ltd.
RPMI1640 and glutamine were obtained from How laboratories Ltd.
Foetal calf serum was obtained from Northumbria Biological Ltd.
Penicillin was obtained from Glaxo and streptomycin from Evans.
For cell culturing RPMI 1640 medium was supplemented with 50 IU penicillin per ml, 
50 mg streptomycin per ml, 2mM glutamine and 10% foetal calf serum. Fisher's 
modified medium and Dulbecco’s medium were supplemented with 50 lU penicillin 
per ml, 50 mg streptomycin per ml, 2 mM glutamine and 20% horse serum.
Murine Radiation Induced Transplanted Myeloid Leukaemia 
Primary murine myeloid leukaemias were induced in CBA/H male mice aged 100 ± 10 
days following exposure to whole body doses of 3 Gray X irradiation. There has been 
no evidence of spontaneous incidence of leukaemia in CBA/H mice.
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The various leukaemias induced after irradiation were characterised and numbered.
Three primary leukaemias, numbers 2, 7 and 8, were maintained by serial 
transplantation of splenic single cell suspensions (see Splenic Single Cell Suspensions) 
from leukaemic animals into syngeneic recipients, injecting either ip or iv, 10^ cells 
were required for 100% leukaemia take in the recipients. The transplanted 
leukaemias used for this study were maintained by serially passaging high doses of 
splenic cells (10^ total cells in 0.5ml unsupplemented medium). With the injection of 
10^ cells leukaemia was manifest by day seven. The transplantation number was 
serially recorded and the cell lines were coded as SA(X)T(Y):-
SA = St. Andrews
X = The number of the primary leukaemia (2, 7 and 8 were used for this study) T(Y) = 
Transplantation Number
These leukaemias had been rederived from frozen stocks of early passages. The
leukaemic bone marrows used from each cell line for these experiments were between 
the following transplantation numbers:-
SA2 - T34 to T77
SA7-T83 toT185
SA8 - T70 to T162
The SA2 leukaemic cells from spleen and bone marrow were found to proliferate in 
liquid culture without the addition of an exogenous source of growth factor. They were 
maintained and passaged in liquid suspension cultures and consequently labelled SA2 
cell line (SA2 CL). Fisher's medium was gassed with 5% CO2 in air for two minutes 
and the supplements were added. 10ml of 10^ cells/ml single cell suspension was
36
seeded in 25 mm plastic culture flasks (Sterilin), gassed for 15 seconds with 5% CO2 in 
air and incubated at 37® C. Cultures were refed with fresh medium every three to four
days.
The HL-60 Cell Line
The HL-60 cell line was used as a control for determining the activity of the 
differentiation inducing agents eg. retinoic acid.
The HL-60 cell line derived from a patient with acute promyelocytic leukaemia 
(Collins et al, 1977) was kindly provided by Dr. Eric Wright (St. Andrews
University).
2 ml aliquots of 2.77 x 10^ cells/ml in 20% PCS RPMI were stored in liquid nitrogen. 
Cells were rederived and passaged in liquid suspension cultures (supplemented RPMI) 
for at least one week prior to experiments and not for longer than four weeks.
Cells were thawed quickly in a 37® C waterbath and transferred to a 30 ml plastic 
universal tube. Approximately 15 ml of medium was added dropwise while the cells 
were continuously mixed. The cell suspension was centrifuged at 1000 rmp for 10 
minutes in a MSE chillspin centrifuge. The supernatant was discarded, the cells were 
resuspended in 20 ml of medium and pipetted into a 75 mm plastic tissue culture flask 
(Sterilin), gassed with 5% CO^ in air for 1 minute and incubated at 37® C. The culture 
was refed by aspirating several times into a 10 ml glass pipette, 10 ml of cell 
suspension removed and replaced with 10 ml of fresh medium.
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Growth Factors
WEHI-3B Conditioned Medium
WEHI-3B CM was used as an unpurified source of IL-3. WEHI-3B cells were kindly 
provided by Professor M. Dexter (Patterson Laboratories Manchester, UK) and were
stored in liquid nitrogen in 1 ml aliquots of 2 to 3 x 10^ cells per ml. The cells were 
thawed quickly in a 37® C waterbath and transfered to a 30 ml plastic universal tube. 
Approximately 10 ml of Dulbecco's medium was added dropwise while the cells were 
continuously mixed. The cell suspension was centrifuged at 1000 rpm for 10 minutes and 
the supernatant discarded. The cells were resuspended in 25 ml of medium and 
pipetted into a 75 mm plastic flask (Sterilin) gased with 5% C02 in air for 30 seconds 
and incubated at 37® C. Every three days 15 ml of cell suspension was removed and 
centrifuged as above. The supernatant (conditioned medium) was progressively 
collected in a two litre bottle and stored at -20® C. 15ml of fresh medium was added to
the original culture flask, it was gassed and reincubated as above. Cultures were 
maintained for up to six weeks. The collected supernatant was thawed, filtered 
through a 0.2 micron millipore filter (MiUipore), aliquoted into 5 ml plastic tubes 
(Titertek) and stored at -20o C. Each batch of conditioned medium (CM) was titrated 
using normal bone marrow in the microtitre and clonogenic assay (see below) to 
determine the specific activity.
L929 Conditioned Medium
L929 CM was used as a source of M-CSF. The cells were kindly provided by Professor 
M. Dexter (Paterson Laboratories Manchester, UK). L cells (C3H lung fibroblasts, 
stain L60T) stored in liquid nitrogen and thawed with the same procedure as the 
WEHI-3B cells. Cells were grown to confluence in supplemented Dulbecco's medium
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(10% PCS, penicillin, streptomycin, glutamine). Cells were trypsinized and seeded at 
3.3 x 106 cells/20ml medium in flat bottomed flasks, incubated at 37o C in a 
humidified atmosphere of 5% CO2 for five to six days. The supernatant (CM) was 
collected and the cells were trypsinized and recultured for two further growth cycles
and then discarded.
Recombinant Murine Granulocyte-Macrophage Colony
Stimulating Factor (rGM-CSF)
Recombinant murine granulocyte-macrophage colony stimulating factor (rGM-CSF) 
was kindly provided by the Immunex Corporation (Seattle, Washington, USA). A 250 
mg lyophilized sample in 24 mg mannitol, 6 mg sucrose in 728 mg tris pH 7.4 buffer was 
diluted in 10 ml Dulbecco's medium plus 10% PCS and lOOpl aliquoted into 1ml 
eppendorf tubes and stored at -20®C. Prior to use rGM-CSF was diluted to the required 
concentration in the appropriate medium.
p-all Trans Retinoic Acid
All handling of P-all trans retinoic acid (PatRA) was carried out in subdued light 
conditions. PatRA (Sigma Chemical Co.) was obtained in 50 mg vials, diluted to 10"2 
molar concentration in aristor alcohol (BDH), aliquoted into small bottles and stored 
at -20® C. Immediately prior to each experiment it was serially diluted in the 
appropriate medium to the required concentration for addition to cultures. The final 
concentration of aristor alcohol in culture was always < 0.1% and control runs on each 
leukaemic cell line and normal marrow showed it had no significant effect on cell 
growth and differentiation at that concentration.
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Cytosine Arabinoside (ara-C)
Cytosine Arabinoside (ara-C) (Sigma Chemical Co.) was preweighed into 5ml plastic 
titertek tubes and stored at 4® C with a dessicant. For use in experiments it was
serially diluted in the appropriate medium to the required concentration and volume
immediately prior to addition to cultures.
Tritiated Thymidine
Methyl - tritiated thymidine (^H-TdR) was obtained from Amersham International 
in 1ml vials at a radioactive concentration of 37.0 MBq/ml, specific activity of 185 
GBq/mmol, purity 98.5% and thymine content of < 0.1 %. This was diluted to 300 
kBq/ml in RPMI, aliquoted into 5ml plastic teklab tubes and stored at 4® C. A final 
concentration of 7.5 kBq in 25ml was added per culture well. This level for the 
addition to cultures had been predetermined in our laboratory. ^H-TdR of the same 
batch number was used within each experimental group. Use and disposal of the 
material was recorded with accordance to the radioactive safety regulations of the 
ICPR and the University of St.Andrews local regulations.
Bone Marrow and Spleen Single Cell Suspensions
Mice were sacrificed with an overdose of ether anaesthesia. The skin was cleansed
with 70% ethanol and using sterile instruments the femurs and/or spleen were 
removed and placed into a sterile petri dish. For the diagnosis of leukaemia , each
animal was observed for splenomegaly, and splenic imprints were prepared, stained 
with Diff-Quik (Merz-Dade) and observed for leukaemic blast cell infiltration.
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Under sterile conditions in a laminar flow hood the femurs were dissected free of fat
and muscle, the proximal end cut off with a scalpel blade and the bone marrow was 
expelled from the diaphysis into a 10ml plastic tube with 1ml of the appropriate 
medium using a 1ml syringe and number 23 gauge needle. The volume in the 10ml tube 
was made up to 5 or 10ml with medium and the bone marrow plugs were dispensed 
gently to a single cell suspension by aspirating several times into a 10ml glass pipette. 
The spleen was dissected free of fat, cut into small pieces with a scalpel blade, placed 
in a 10 ml plastic tube containing approximately 5 ml of appropriate medium and 
aspirated several times into a 1 ml syringe. The large clumps were allowed to settle 
and the supernatant was dispersed gently to a single cell suspension by aspirating 
several times into a 10ml glass pipette.
The cells were counted on a Coulter Cell Counter model B (Coulter Electronics) and 
diluted in the appropriate medium to the required cellular concentration and volume. 
Two cytospins (Shandon) were made of every single cell suspension prepared for 
experimentation, and were stained with Jenner Giemsa (BDH/Gurr) haematological 
stain and differentials on at least 300 cells per slide were counted to further confirm 
the diagnosis of leukaemia.
Preparation of Cytospins
Cells required for the preparation of cytospins were diluted in medium containing 10%
FCS. 100,OX) cells were required per slide in < 500p.l of medium.
Haematological Cytochemical Staining
Sudan Black B Cytospins were prepared allowed to dry and fixed for 10 seconds in 
fixative containing 95% ethanol (BDH) and 40% formaldehyde (BDH), rinsed in
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water and then allowed to dry. They were then stained for 30 minutes in Sudan Black
B solution at 37® C. The solution was drained off the slides and the slides were
counterstained with Jenner/Giemsa (BDH/Gurr). Strong positive staining was 
observed in the phospholipid containing granules of the myeloid cells and blast cells
of the myeloid leukaemias stained blue black.
Myeloperoxidase Cytospins were prepared allowed to dry and fixed for 15 seconds in 
fixative containing 95% ethanol (BDH) and 40% formaldehyde (BDH), and rinsed in 
water. The slides were then stained for 30 seconds at 20® C in a myeloperoxidase 
staining solution [30% ethanol, 100ml, benzidine dihydrochloride 0.3g, zinc sulphate 
(38g/l ZnSO4.7H2O) 1ml, sodium acetate (NaC2H3C>2-3H2O) Ig, N-sodium 
hydroxide 1.5ml, 3% hydrogen peroxide (10 vol) 0.7ml. The slides were then rinsed 
in tap water and counterstained with dilute Giemsa stain for 10 minutes, rinsed and 
allowed to dry. A strong positive reaction was observed in the azurophilic granules of 
developing granulocytes and in the myeloid leukaemic blasts.
The Microtitre Assay
Ninety-six well flat bottomed plastic microtitre (Nunc) were used for these assays. 
Growth factors and bone marrow single cell suspensions were diluted in RPMI. Each 
test condition was carried out in quadruplicate. The cultures were incubated at 37® C 
in a fully humidified atmosphere of 5% CO2 in air for the specified number of days
a). For cell dose studies. 100 pi of the required concentration of bone marrow single
cell suspension was added to 100 pi of RPMI containing optimal concentrations of
WEHI-3B CM (10-15%) and L929 CM (10-15%).
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b) For growth factor titrations. 100 |ll of 7 x 104 cell/ml bone marrow single cell 
suspension was added to 100 pi of the required concentrations of growth factor.
c) For studies on the effects of PatRA and ara-C. 100 pi of 7 x 104 cell/ml bone 
marrow single cell suspension was added to 100 pi of growth factor diluted to optimal 
concentrations for cellular proliferation. A total volume of 50 pi of PatRA and ara-C 
were added either alone or in combination at the required concentrations. 50 pi of
RPMI was added to the control wells.
For proliferation studies On the appropriate day of culture the cells were labelled 
with ^H-TdR for eight hours, collected using a 12 channel cell harvester (Titertek) on 
to glass microfibre filter paper (Titertek) using 9% saline. These were allowed to dry 
for at least 18 hours in a drying oven and the disks were added to plastic tubes 
containing 2 ml of Optiphase Safe scintillation fluid. The radioactivity incorporated 
by the cells was measured as counts per minute (CPM) on a LKB 1214 scintillation
counter.
For determining the total cell count per cell The cells were removed from the 
wells with a pasteur pipette and immediately transfered to 20ml of Isoton (Coulter) 
and the cells were counted on a Coulter Cell Counter model B (Coulter Electronics)
For differential cell counts Concurrently with ^H-TdR uptake, and cell count 
studies, cultures were set up for the preparation of cytospins. Cells were removed from 
the wells with a pasteur pipette placed into a 5ml titretek tube and the total cell
count was determined, at least 3 cytospins were prepared with approximately 100,000
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cells in no more than 5OOpl of medium, stained in Jenner/Giemsa (BDH/Gurr) and 500
cells were counted per slide. Differentials were reported in both percentage and
absolute cell numbers per slide.
For the determination of the percentage of phagocytic cells Cells were cultured 
in the microtitre assay with appropriate growth factors and/or differentiating agents 
as above. On the appropriate day the cultures were incubated with 25 |il of a 0.04% 
solution of polystyrene O.8p particles size (Sigma) for eight hours. Cytospins were 
prepared and stained as above, the percentage of phagocytic cells was determined 
microscopically, at least 1000 cells were counted per slide. Cultures for the 
determination of cell number per well were set up concurrently to determine the 
absolute number of phagocytic cells.
The Colony Assay
A single layer agar technique was used. 3% agar (Bactoagar Difco Laboratories) w/v 
in double distiled water was pre heated and sterilised in boiling water for at least 
half an hour. 8ml aliquots of Dulbecco's medium and single cell suspension of 5 x 10^ 
cells/ml were warmed to 37® C in a water bath just prior to use. 1ml of agar was added 
to the 8mls of medium followed by 1ml of single cell suspension and thorough mixing 
was insured by inversion. For plating 1ml of suspension was added to 35 ml plastic 
petri dishes (Sterilin) containing lOOp of the required growth factor. The cultures 
were mixed gently, the agar was allowed to set at room temperature for 10 minutes, 
and incubated at 37® C in a fully humidified atmosphere of 5% CO2 in air. After a 
seven day incubation period the number of colonies (>50 cells) and clusters (< 50 cells) 
were counted using a Kyowa dissecting microscope set-up for dark field illumination.
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The In Vivo Leukaemic Clonogenic Cell Assay
Single cell suspension of SA7 leukaemic bone marrow was prepared in non 
supplemented RPMI and injected into syngeneic recipients at a total cell dose of 10^, 
10^, 1(P, 10^ and 10 cells in 0.5ml of medium. Five mice were injected per test group 
and leukaemia free survival was monitored over 90 days. A sample of the cells was 
stained with fast green and cytospins were prepared for determining percentage cell 
viability prior to injecting. Microtitre cultures were set up from the same single cell 
suspension in appropriate growth factors and with or without PatRA. On day four of 
culture the cells were harvested from the wells with a pasteur pipette and cell 
number and viability determined. The cultured cells were then injected into syngeneic 
recipients at the same concentrations as above and leukaemia free survival was 
monitored for 90 days to determine whether the in vitro treatment altered the number 
of leukaemic clonogenic cells. The mice were sacrificed when moribund and leukaemia 
confirmed by spleen weight and microscopic examination of splenic imprints.
Statistical Analysis
The Students t-test was used as the statistical analysis.
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CHAPTER ONE
CHARACTERISTICS OF THE MURINE, RADIATION- 
INDUCED, TRANSPLANTED MYELOID LEUKAEMIAS
The myeloid leukaemic models used for these studies were CBA/H murine,
radiation-induced, transplanted myeloid leukaemias developed in our laboratory 
on the criteria established by Major and Mole (1978). Three transplanted 
leukaemias the SA2, SA7 and SA8 and a cell line established from the SA2 
leukaemia (SA2 CL) were studied. The characteristics of the SA2 transplanted 
leukaemia changed with progressive transplantation hence, this leukaemia was 
described at low passage (LP) and high passage (HP) numbers. Experiments for 
this study were carried out on the transplanted cell lines between the 
transplantation numbers listed under Materials and Methods. The physiological 
changes, including blood and bone marrow cellular changes, of the transplanted 
leukaemias will be described and compared to normal. The parameters measured
were:-
1. The gross physiological characteristics of body weight, spleen weight, 
haemoglobin (Hb), haematocrit, the nucleated cell count of the blood and the bone 
marrow nucleated cell count per femur.
2. The peripheral blood leukocyte differentials in percentage and absolute cell
numbers
3. Bone marrow nucleated cell differential counts in percentage and absolute 
number per femur.
4. Cytochemical staining of bone marrow cells
The characteristics of the SA2 CL were also studied with differential cell counts
and cytochemical staining.
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1.1 EXPERIMENTAL PROCEDURE
a) . Six week old mice were used for these studies.
b) . Moribund animals were weighed, blood was taken for blood nucleated cell 
counts, preparation of blood films and haematocrit. Blood films were stained 
with Jenner Giemsa and differentials counted (100 cell counts). Percentage and
absolute numbers of blood cells were determined.
c) . Spleens were removed, weighed and imprints were prepared on glass slides, 
and stained with Diff-Quik to confirm leukaemic cell infiltration.
d) . Bone man^ow single cell suspensions were prepared in RPMI, the number of 
nucleated cells per femur were counted, cytospins were prepared, stained with 
Jenner Giemsa and differentials counted (500 cell counts). Percentage and absolute 
nucleated cell counts per femur were determined.
e) . Cytospins of the bone marrow single cell suspensions were prepared for 
haematological cytochemical staining. Myeloperoxidase and Sudan Black B 
stains were performed in this laboratory, and slides were sent to Cytocolor Inc. 
Laboratories (Ohio, USA) for further staining.
f) . Cytospins of the 5A2 CL were prepared and stained with Jenner Giemsa for 
differential cell counts and with cytochemical stains as described above.
1.2 RESULTS
1.2.1 The Physiological Characteristics of the Leukaemic Models 
Comparative studies were made between normal and leukaemic mice for body 
weight, spleen weight, haemoglobin, haematocrit and on the blood and bone 
marrow nucleated cell counts (Table 1.1). There was evidence of weight loss in the 
leukaemic animals. There was a six to eight fold increase in spleen weight mainly 
due to myeloid cell infiltration, as observed microscopically on splenic imprints and
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NORMAL SA7 SA8 SA2 LP SA2HP
Body Weight (g) 27.00 ± 0.20 20.40 ± 0.31 21.5 ± 0.41 23.63 ± 0.25 22.00 ± 0.29
Spleen Weight (mg) 66.53 ± 5.85 546.23 ± 6.42 576.81 ± 4.32 368.4 ± 5.83 502.5 ± 6.17
Haemoglobin (g/1) 154.3 ±2.1 54.6 ± 3.0 61.3 ±2.8 74.5 ± 2.9 67.3 ± 2.4
Haematocrit (1/1) 0.43 ± 0.01 0.17 ± 0.03 0.18 ± 0.02 0.27 ± 0.01 0.20 ± 0.03
Blood NCC/1 x 109 5.13 ± 0.03 5.13 ±0.03 31.22 ± 1.22 20.31 ± 1.42 28.68 ± 1.18
BM NCC/femur x 10^ 14.21 ± 3.8 14.21 ± 3.8 7.93 ± 2.4 13.96 ± 3.6 9.44 ± 2.3
Table 1.1 The physiological characteristics of six week old CBA/H murine, radiation induced, transplanted leukaemias compared 
to normal.
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cytospins. The leukaemic mice were grossly anaemic. Haemoglobin levels were 
between 54.6 ± 3.0 to 74.5 ± 2.9 g/1; normal levels were 154.3 ± 2.1 g/1. Haematocrits 
ranged between 0.17 ±0.03 to 0.27 ± 0.011/1; normal levels were 0.43 ± 0.01 1/1 The 
total nucleated cell count of the peripheral blood of the leukaemic mice was
increased between four to six fold. The nucleated cell count of the femur was
decreased in the case of the SA7, the SA8 and the SA2 HP leukaemias. The 
nucleated cell count of the femur of the SA2 LP leukaemia was equivalent to that of
normal.
1.2.2 Peripheral Blood Leucocyte Differentials
Leucocyte differentials were determined on the peripheral blood, the results are 
listed as percentages (Table 1.2) and absolute cell numbers (Table 1.3). The 
predominant cells in the normal CBA/H murine peripheral blood leukocyte 
differential were lymphocytes, 73.5%, followed by 16.0% segmented cells, 10.5% 
monocytes and 0.5 % bands.
The four to six fold increase in the nucleated blood cell counts of the leukaemic
mice, as described above, were due to leukaemic myeloid cell infiltration. The 
peripheral bloods of the leukaemic transplanted cell lines were infiltrated with 
numerous immature myeloid cells, and mature myeloid cells monocytes or 
macrophages. Absolute lymphocyte numbers were equivalent to that of normal. 
Without a specific marker it is difficult to determine whether the mature 
myeloid cells observed in the blood of the leukaemic animals were from the 
leukaemic clone or due to a host reaction. The absolute numbers of mature myeloid 
cells were higher in the leukaemic animals than in the normal and the 
differential pattern of the mature cells was not the same with each of the 
leukaemias. Macrophages and monocytes were the predominant mature cells of
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PERCENTAGE CELL NUMBER ± STANDARD ERROR
CELL NBM SA7 HD SA8 HD SA2 HD LP SA2 HD HP
Blasts 0 0 10.3 2.2 14.4 2.8 8.8 2.2 16.8 3.2
Promyel 0 0 13.5 2.5 6.7 1.7 13.8 3.1 15.2 3.5
Myel 0 0 5.2 0.8 2.0 0.7 5.4 1.5 5.4 2.1
Metamyel 0 0 5.7 1.2 1.5 1.0 4.5 1.5 4.1 2.0
Bands 0.5 0.1 7.7 2.6 11.9 3.4 7.2 2.1 6.4 1.5
Grans 15.5 0.5 7.0 2.1 35.3 3.8 26.5 4.1 25.8 4.4
Monoc 10.5 0.5 11.5 1.6 9.0 2.6 11.5 4.0 11.5 3.1
Mf 0 0 21.7 3.6 2.0 1.2 0 0 2.0 1.5
Lymph 73.5 1.0 17.2 4.2 11.3 3.0 22.3 4.5 12.8 3.8
Table 1.2 Differential leukocyte count of normal and leukaemic blood.
ABSOLUTE CELL NUMBER X 10* / L ± STANDARD ERROR
CELL NBM SA7 HD SA8 HD SA2 HD LP SA2 HD HP
Blasts 0 0 2.99 0.16 4.50 0.88 1.78 0.45 4.82 0.92
Promyel 0 0 3.92 0.73 2.09 0.53 2.80 0.63 4.36 1.00
Myel 0 0 1.51 0.23 0.62 0.22 1.10 0.31 1.55 0.60
Metamyel 0 0 1.66 0.35 0.47 0.31 0.91 0.30 1.18 0.58
Bands 0.03 0.01 2.24 0.76 3.72 1.06 1.46 0.43 1.84 0.43
Segs 0.80 0.04 2.03 0.61 11.02 1.19 5.38 0.83 7.40 1.26
Monoc 0.54 0.03 3.34 0.46 2.81 0.81 2.33 0.81 3.30 0.89
Mf 0 0 6.03 1.00 0.62 0.04 0 0 0.57 4.28
Lymph 3.77 0.05 4.99 1.22 3.53 0.94 4.53 0.91 3.67 0.80
Table 1.3 Absolute cell numbers of peripheral blood differentials. Absolute
cell number = total cell number / L x percentage cell number (see 'Table 1.1 for
total peripheral blood nucleated cell count).
Promyel=Promyelocytes, Myel=Myelocytes, Metamyel=Metamyelocytes 
Grans=Granulocytes, Mf=Macrophages, Lymphs=Lymphocytes
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the SA7 leukaemia whereas with the granulocytes were the predominant mature
cells of the SA8 and SA2 leukaemias. It may be predicted from these two
observations that the full range of myeloid cells (immature to mature) observed in
the leukaemic animals were from the leukaemic clones.
Both high numbers of blasts and promyelocytes were observed in the leukaemic 
blood samples. The SA7 leukaemia had a higher absolute number of 
promyelocytes than blast cells and a higher number of macrophages compared to 
the other leukaemias. The SA8 leukaemia had a higher number of blasts than 
promyelocytes, and a higher number of granulocytes compared to the other 
leukaemias. The SA2 LP leukaemia had a higher number of promyelocytes than 
blasts and the SA2 HP leukaemia had equal numbers of blasts and promyelocytes. 
The SA2 HP leukaemia had the greatest number of infiltrating blast cells and 
promyelocytes.
1.2.3 Bone Marrow Differentials
The bone marrow differentials were listed as both cell percentages (Table 1.4) and 
absolute cell number per femur (Table 1.5). Even though the femur cellularity of 
the leukaemic mice was generally less than that of normal, absolute blast cell 
numbers were higher or of the same order as that of normal. The bone marrow 
differential of normal CBA/H mice was 9.5% blasts, 9.0% promyelocytes, 14.4% 
myelocytes, 63.3% metamyelocytes, 20.6% bands, and 0.7% of both segmented cells 
and monocytes.
1.2.3.1 The SA7
Blast cell numbers constituted nearly 50% and promyelocytes 31% of the cells of 
the SA7 bone marrow; intermediate cell (myelocytes, metamyelocyte and band
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PERCENTAGE ± STANDARD ERROR
CELL NBM SA7 HD SA8 HD SA2 HD LP SA2 HD HP
Blasts 9.5 0.2 49.0 2.14 17.2 0.9 36.0 1.7 19.3 0.4
Promyel 9.0 0.4 31.0 0.9 18.5 0.9 7.7 0.1 18.7 0.7
Myel 14.4 0.4 9.5 0.4 8.6 0.3 4.6 1.5 5.5 0.1
Metamyel 63.6 0.4 19.1 1.3 42.9 1.7 49.0 4.5 49.0 1.6
Bands 20.6 0.2 0 0 2.8 0.4 1.3 0.2 2.8 0.1
Grans 0.7 0.4 1.4 0.1 0.8 0.4 1.3 0.2 3.4 0.1
Monoc 0.7 0.4 2.0 0.6 8.6 0.3 0 0 13.0 0.2
Mf 0 0 1.4 0.1 0.8 0.6 0 0 0 0
Table 1.4 Differential nucleated cell count of normal and leukaemic bone 
marrow as percentage.
ABSOLUTE CELL No. PER FEMUR ± STANDARD
ERROR
CELL NBM SA7 HD SA8 HD SA2 HD LP SA2 HD HP
Blasts 1.35 0.42 3.79 1.05 1.36 0.45 5.02 1.20 1.81 0.51
Promyel 1.28 0.40 2.40 0.96 1.47 0.42 1.07 0.85 1.76 0.52
Myel 2.05 0.80 0.74 0.18 0.68 0.22 0.64 0.02 0.52 0.06
Metamyel 9.03 2.12 1.48 0.57 3.41 1.05 6.84 1.55 4.61 0.88
Bands 2.93 0.96 0 0 0.22 0.08 0.18 0.05 0.26 0.03
Grans 0.10 0.06 0.11 0.08 0.06 0.03 0.18 0.03 0.32 0.03
Monoc 0.10 0.06 0.15 0.08 0.68 0.21 0 0 1.22 .036
Mf 0 0 0.11 0.08 0.06 0.03 0 0 0 0
Table 1.5 Differential nucleated cell count of normal and leukaemic marrow 
as absolute cell number per femur. Absolute cell number per femur = total cell 
number per femur x percentage cell number (see Table 1.1 for total number of 
nucleated cells per femur).
Promyel=Promyelocytes, Myel=Myelocytes, Metamyel=Metamyelocytes 
Segs=Segmented cells, Mf=Macrophages, Lymphs=Lymphocytes
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cells) numbers were reduced to one third of normal a level lower than observed
with the other leukaemias; the percentages of granulocytes and macrophages
were mildly higher than normal. The femur cellularity of the SA7 leukaemia 
was half that of normal however, absolute blast cell numbers were three times 
higher, absolute numbers of intermediate cells were significantly decreased and 
mature cell numbers equivalent to normal.
1.2.3.2 The SA8 Leukaemia
An equal percentage of blasts and promyelocytes were observed in the bone 
marrow of the SA8 leukaemia (approximately 18%); intermediate cell numbers 
were reduced to two thirds of normal; a high percentage of monocytes was 
observed and granulocyte numbers were similar to normal.. Tire absolute number of 
blasts and promyelocytes of the SA8 leukaemia were equivalent to that of 
normal, however the absolute numbers of the intermediate cell numbers were 
significantly reduced; granulocyte numbers were equivalent to normal however, 
the absolute number of macrophages was significantly higher than normal.
1.2.3.3 The SA2 LP Leukaemia
High percentage numbers of promyelocytes were not observed with the SA2 LP 
leukaemia; 36% blasts were observed and metamyelocyte and band cell numbers 
were reduced to two thirds of normal; granulocytes and macrophage numbers were
similar to normal. The femur cellularity of the SA2 LP leukaemia was equivalent 
to that of normal however, absolute numbers of blast cell were four times higher 
than normal; absolute numbers of intermediate cells were reduced and absolute
mature cell numbers were similar to normal.
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1.2.3.4 The SA2 HP Leukaemia
The bone marrow differential of the SA2 HP leukaemia was similar to that of the
SA8 leukaemia however, few similarities were observed between these 
leukaemias in relation to their in vitro responses (see Chapters Two to Five). The 
SA2 HP leukaemia had higher percentage and absolute numbers of macrophages
than the SA8.
1.2.4 The SA2 CL
Cytospins were prepared from suspension cultures of the SA2 CL. A fairly 
homogeneous cell population was observed with 99% blasts and 1% blastic cells 
containing a few azurophilic granules; the latter were classified as pro­
myelocytes.
1.2.5 Haematological Cytochemical Staining
The bone marrow cells from the four transplanted leukaemias and the SA2 cell 
line stained strongly positive for myeloperoxidase and Sudan Black B and 
negative for PAS and acid phosphatase which is characteristic of myeloid 
leukaemia. Staining for chloroacetate and naphthol acetate were difficult to 
assess in our laboratory. A full panel of cytochemical staining was done for us by 
Cytocholour Incoporated (Ohio USA) and their results indicated myeloid
leukaemia.
1.3 DISCUSSION
The physiological characteristics of the transplanted cell lines were examined
and found to indicate myeloid leukaemia. The leukaemic animals showed 
evidence of weight loss, splenic enlargement with leukaemic cell infiltration and
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gross anaemia. The blood nucleated cell counts were four to six times greater than 
normal. Abnormally high percentages of immature and mature myeloid cells were
observed in the blood. It could not be infered whether the increased number of
mature myeloid cells observed in the blood of the leukaemic animals were part of
the leukaemic clone or or due to a host reaction.
A decreased femur cellularity was observed with the SA7, SA8 and SA2 HP 
leukaemias; the femur cellularity of the SA2 LP leukaemia was similar to
normal. The absolute numbers of blast cells observed in the leukaemic femurs
however, were greater than or equivalent to normal. Intermediate cell numbers in 
the bone marrow were reduced in each case, indicating abnormal maturation. The 
SA8 and SA2 HP leukaemias had abnormally high numbers of macrophages in 
their femurs, higher than normal and higher than the other two leukaemias. 
Differential counts on the bone marrow confirmed a heterogeneous cellular 
composition of myeloid leukaemic cells with each of the transplanted cell lines 
which is also characteristic of human AML cell populations (Griffin and 
Lowenberg, 1986). The cells of the SA2 CL appeared homogeneous.
Haematological cytochemical staining confirmed that the four transplanted 
leuakemias and the SA2 CL were myeloid.
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CHAPTER TWO
IN VITRO PROLIFERATIVE EFFECTS OF WEHI-3B CM
L929 CM AND rGM-CSF ON LEUKAEMIC AND 
NORMAL BONE MARROW CELLS
The in vitro proliferative responses of the transplanted leukaemic cell lines and 
the SA2 CL to WEHI-3B CM ( as a source of IL-3), L929 CM (as a source of M-CSF) 
and recombinant murine GM-CSF were determined and compared to normal. The 
regulatory processes affecting leukaemic cells are not fully understood. What 
became evident from previous studies was the heterogeneity of the leukaemic 
response to normal haemopoietic regulators (Moore et al, 1974). CSF's are active 
on normal multipotential and stem cells (Metcalf, 1988) hence it appeared obvious 
that the role of these factors in AML needed to be elucidated. The roles played by 
the CSFs in the progression and maintenance of the disease appeared 
fundamental to our understanding of the disorder. The regulators of normal 
haemopoiesis may occupy a key position in attempts to understand the nature of 
the abnormal state existing in myeloid leukaemic cells and potentially could play 
an important role in therapeutic attempts to suppress myeloid leukaemic 
populations either by reducing the leukaemic cell population or by preferentially 
enhancing normal haemopoiesis. In the first study we investigated the dose- 
response relationships between the leukaemic cell populations and the 
individual CSF's. This was followed by a time study of proliferative response of 
the leukaemic populations to optimal concentrations of CSF's and compared to 
normal. The proliferative response of the leukaemic cells to individual CSF's 
were studied daily between day one and day seven.
The regulators of normal haemopoiesis affect overlapping stages of the normal 
haematopoietic pathways, that is, they exert stimulating effects upon the same
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target cells (Metcalf, 1988). They have also been shown to have synergistic 
proliferative effects on the same target cell when used in combination (McNeice et
al, 1988). To further characterise the various leukaemic populations we 
investigated the interactions of the CSFs in controlling myeloid leukaemia cells 
by using combinations of growth factors in vitro. With the use of combinations of 
growth factors we have attempted to identify aberrations of synergistic responses 
observed with normal bone marrow cells and to possibly identify specific subsets 
of myeloid leukaemia cells according to these responses. The comparative 
variations in response between the leukaemias and compared to normal myeloid 
cells may provide indicators of classifying leukaemia cell populations with 
biologically different disease and may prove to be of prognostic value. The 
proliferative responses of the leukaemic cells , to combinations of CSF's were 
studied daily over seven days.
The leukaemia bone marrow cell populations were studied as a whole in microtitre 
suspension cultures over the time periods specified and proliferation was 
measured by utilizing ^H-TdR uptake. Colony assays in semi-solid medias were 
run in parrallel and the results obtained with the two culture techniques were 
compared although, the cells and parameters studied in each system may not be 
the same. The first experiments in this study determined the optimal number of 
cells for the the microtitre assay. Optimal cell numbers for the colony assay were 
determined by others in our laboratory (Briscoe and Riches unpublished data).
2.1 CELL DOSE STUDIES OF LEUKAEMIC AND NORMAL BONE 
MARROW CELLS IN THE MICROTITRE ASSAY
These experiments were designed to determine the optimal cell concentrations 
required for optimal cellular proliferation of normal and leukaemia bone marrow 
cells in the microtitre assay.
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2.1.1 Experimental Procedure
a) Optimal levels of WEHI-3B CM and L929 CM for stimulating normal bone 
marrow murine haemopoietic cells were predetermined in the laboratory using a
standard procedure in the colony assay. Optimal levels were usually found to be 
between 10 and 15% v/v. The rmGM-CSF was also initially titrated in this assay 
and was found to give optimal stimulation between 40 to 100 IU/ml.
b) The predetermined levels for optimal stimulation of normal bone marrow were 
used to determine optimal cell doses for normal and leukaemic bone marrow in the 
microtitre assay. Cells at varying cell concentrations (1 to 10 x 10^ cells per well) 
were cultured for four days in microtitre cultures with optimal levels of WEHI-3B 
or L929 CM and cellular proliferation was determined by measuring ^H-TdR 
uptake.
2.1.2 Results
Optimal cell concentration for normal and leukaemia marrow from the 
transplanted cell lines in the microtitre assay was found to be 7 x 10^ cells per well 
in a total volume of 200ml (Fig. 2.1 and Appendix Table A2.1). The SA2 CL 
differed; proliferation increased exponentially to 10^ cells per well, the upper 
limit tested. For uniformity 7 x 10^ SA2 CL cells per well were used in all 
experiments.
All further batches of conditioned medium were concurrently tested in the
microti ter assay. There was always almost 100% correlation between the
microtiter and colony assay
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2.2 IN VITRO DOSE RESPONSE STUDIES OF WEHI-3B CM,
L929 CM AND rGM-CSF ON LEUKAEMIC AND NORMAL 
BONE MARROW CELLS
The bone marrow cells of the murine myeloid leukaemias were characterised in 
vitro by studying their growth response patterns with and without the 
stimulators of normal bone marrow WEHI-3B CM, L929 CM and rGM-CSF in the 
microtitre assay after four days in culture. Normal and leukaemic bone marrow 
cells from each of the leukaemias were set up with varying doses of each growth 
factor and the dose-response relationship for each leukaemia was determined. 
From these studies the concentration of growth factor which induced optimal 
proliferation of the leukaemia cells was determined. This optimal concentration 
of each growth factor was used to further determine the differences in 
proliferative response between normal and leukaemic cells.
2.2.1 Experimental Procedure
Dose-response studies were set up in the microtitre assay. Single cell suspensions 
of 7 x 10^ normal and leukaemia bone marrow cells were cultured with FCS alone 
and with increasing concentrations of WEHI-3B CM (5 to 20% v/v), L929 CM (5 to 
20% v/v) and rmGM-CSF (10 to 100 IU/ml) for two, four and six days. Cultures 
were set up for ^H-TdR uptake studies and for the determination of total cell 
number per well.
2.2.2 Results
Normal and leukaemia bone marrow cells were cultured in FCS alone and with
increasing doses of WEHI-3B CM, L929 CM and rGM-CSF. Normal bone marrow 
(Fig. 2.2) the SA7 (Fig. 2.3), SA8 (Fig. 2.4) and the SA2 HP (Fig. 2.5) leukaemias 
were growth factor dependent.for proliferation in vitro. The SA2 LP (Fig's. 2.6 
and 2.7) and SA2 CL (Fig. 2.8) were observed to proliferate autonomously in vitro.
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The responses to stimulators of normal and the growth factor dependent
leukaemias were dose dependent. The dose of each growth factor for maximal
stimulation of both normal and leukaemia bone marrow cells was the same with
only one exception. WEHI-3B and L929 CM were both found to be maximal at 15%
v/v. rGM-CSF was found to be maximal from 40 to 100 lU/ml except in the case of 
the SA8 leukaemia where maximal stimulation was observed with 60 lU/ml. 
Maximal proliferation of normal bone marrow (Fig. 2.2), the SA7 (Fig. 2.3) and 
the SA8 (Fig. 2.4) leukaemias was observed when the cells were stimulated with 
WEHI-3B CM. Maximal stimulation of the SA2 HP leukaemia (Fig. 2.5) was
observed when the cells were stimulted with rGM-CSF.
Although the required concentration of each of the growth factors for optimal 
stimulation of normal and leukaemia cells was the same the rate of proliferation 
and the day to which proliferation was sustained differed. The highest 
proliferative responses of normal bone marrow with each of the CSFs were 
observed on day six. With the SA7 leukaemia maximal proliferative responses 
were observed on day six when stimulated with WEHI-3B CM and L929 CM and 
on day two and four when stimulated with rGM-CSF. Maximal proliferation was 
observed with the SA8 leukaemia on day six when stimulated with WEHI-3B 
CM, on day four when stimulated with L929 CM and on day two when stimulated 
with rGM-CSF. The SA2 HD leukaemia proliferated maximally on day four 
when stimulated with WEHI-3B CM and L929 CM and on day two when 
stimulated with rGM-CSF. The time study differences in proliferative response 
to the CSFs are investigated in detail in the next section.
Autonomous cell growth in vitro was observed with the SA2 LP leukaemia (Fig's. 
2.6 and 2.7) and the SA2 CL (Fig 2.7) which was derived from the SA2 LP 
leukaemia (passage number 32). The interesting feature of the SA2 leukaemia 
was that in the early passages studied (passage 34 to 40) the dominant clone was
60
independent of growth factor for proliferation in vitro (Fig. 2.6) however, with 
continuous passaging minimal autonomous proliferation was observed at passage 
number 54 (Fig. 2.7) and by passage number 77 (Fig. 2.5) a subclone was obtained 
which was growth factor dependent for proliferation. The growth factor 
dependent clone was observed to be more highly proliferative than the SA2 LP 
clones. The SA2 transplanted cell line had been rederived from frozen cells of 
passage number 32 and this pattern of change, from independent to growth factor 
dependent cell growth in vitro was observed in two series of transplanted cell
lines established.
A dose response relationship of the CSF's and the SA2 LP leaukaemia was not 
observed (Fig. 2.6). The CSF's did not alter the proliferative response observed
with FCS alone.
The SA2 CL was observed to be highly proliferative however, a dose response 
relationship of the CSF's and the SA2 CL was not observed. With the addition of 
L929 CM a significant decrease in the proliferative reponse was observed on day 
two (Fig 2.7) compared to FCS alone. The inhibitory effect of L929 CM appeared 
not to be sustained and no differences in proliferative response were observed on 
days four and six compared to FCS alone. Minimal decreases in the proliferative 
response of the SA2 CL were observed with the addition of WEHI-3B CM on day 
two and with the addition of rGM-CSF on day four compared to FCS alone. 
Conditioned medium was collected from the SA2 CL and used to stimulate normal 
bone marrow in microtitre and colony assay cultures and no proliferative response 
was observed (results not shown).
Minimal autonomous proliferation was observed with the SA8 and the SA2 HP 
leukaemias to day two but this was not sustained.
The results obtained for the determination of total cell number per well paralled 
the ^H-TdR uptake studies.
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2.3 TIME STUDY OF THE PROLIFERATIVE RESPONSES OF
NORMAL AND LEUKAEMIC BONE MARROW CELLS TO
OPTIMAL CONCENTRATIONS OF WEHI-3B CM, L929 CM
AND rGM-CSF
The main differences in the proliferation responses between normal and the 
growth factor dependent leukaemic bone marrow cells, as observed in section 2.2, 
were the proliferative rates of the cells to each of the CSF's and the day to 
which the cells were sustained in culture. The aim of this study was to 
investigate these differences by studying the proliferative responses of the 
leukaemic cells to the individual CSF's progressively over seven days in the
microtitre culture.
2.3.1 Experimental Procedure
The proliferation characteristics of leukaemic cells in FCS alone and to optimal 
concentrations of WEHI-3B CM, L929 CM and rGM-CSF, used singularly, were 
studied daily over seven days in the microtitre assay. Single cell suspensions of 7 
x 10^ leukaemic and normal bone marrow cells and cells from the SA2 CL were 
incubated with 15% WEHI-3B CM (V/V), 15% L929 CM (V/V) and 60 U/ml rGM- 
CSF. Proliferation was measured utilizing ^H-TdR uptake. The results obtained 
were compared to the responses obtained with normal bone marrow cells.
2.3.2 Results
2.3.2.1 Proliferative responses in FCS
NBM, the SA7, SA8 and the SA2 HP leukaemias were growth factor dependent 
for proliferation (Fig. 2.9 A). Two differences in the proliferative response 
between NBM and these three leukaemias were observed in FCS:-
• Proliferation of normal bone marrow was observed only during the first eight 
hours of culture whereas a proliferative response of the SA7 and SA8 leukaemias 
was observed to day two and of the SA2 HP leukaemia to day three of culture.
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• After eight hours of culture the proliferative response observed with the SA7
and the SA2 HP leukaemia were double and triple the response observed with
normal bone marrow respectively.
The SA2 LP leukaemia used for this study was from passage number 49. A 
minimal autonomous proliferative response was observed with the SA2 LP 
leukaemia to day seven of culture.
An autonomous and highly proliferative response was observed with the SA2 CL 
(Fig. 2.9). The maximal proliferative response was observed on day one. The 
proliferative response decreased on each consecutive day from day one to day
seven.
2.3.2.2 Proliferative responses to WEHI-3B CM
WEHI-3B CM induced a maximal proliferative response compared to the other 
two growth factors of NBM, the SA7, SA8 and SA2 LP leukaemias but not the SA2 
HP (Fig. 2.9 B). rGM-CSF induced a maximal proliferative response of the SA2
HP leukaemia.
Increasing proliferation of normal and leukaemic bone marrow cells was not 
sustained in culture for the same number of days. Increasing proliferation of NBM, 
SA8 and SA2 LP leukaemic cells was sustained to day six, of the SA7 to day five 
and of the SA2 HP only to day four. The maximal proliferation obtained on these 
days by normal bone marrow, the SA7, SA8HD and the SA2 HP leukaemic cells 
was similar (approx. 20,500 CPM). The maximal proliferation of the SA2 LP 
leukaemia as observed on day six was significantly less than that observed with 
normal bone marrow (14,644 CPM).
Another main difference between normal and leukaemic marrow was the 
proliferative rate of the cells at the earlier time points in culture (from day one to 
day four). The proliferative rate of the SA7 leukaemia was marginally higher
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than normal bone marrow, and the proliferative rates of the SA8 and the SA2 HP 
leukaemias were double and triple the rate observed with normal bone marrow 
respectively. The proliferative rate of the SA2 LP leukaemia was significantly
less than the response observed with normal bone marrow at every time point.
An inhibitory effect on the proliferation of the SA2 CL was observed with the 
addition of WEHI-3CM compared to FCS alone between eight hours of culture and 
day one (Fig 2.9). From day two to day seven there was no difference in the 
proliferative response compared to FCS alone.
2.3.2.3 Proliferative responses to L929 CM
L929 CM was not as effective at stimulating the proliferation of normal and 
leukaemic cells as WEHI-3B CM or rmGM-CSF (Fig. 2.9 C). The differences in 
the patterns of proliferative response between normal and leukaemic marrow
were similar to those observed with WEHI-3B CM.
There were differences in the number of days that increasing proliferation was 
sustained. Increasing proliferation of normal bone marrow and the SA2 LP 
leukaemia was sustained to day five, of the SA7 and the SA8 to day four and the 
SA2 HP leukaemia only to day three.
At the early time points, between day one and day four, the SA7, the SA8 and the 
SA2 HP leukaemias had a significantly higher proliferative response than 
normal bone marrow. The SA2 LP had a lower proliferative rate than normal 
bone marrow to day six of culture.
The difference between L929 and WEHI-3B CM was that L929 CM induced a
higher maximal response from the SA7, SA8 and the SA2 HP leukaemia than
normal bone marrow.
An inhibitory effect on the proliferation of the SA2 CL was observed with the 
addition of L929 CM to day two in culture compared to FCS alone. On day three
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the inhibitory effect of L929 CM observed on the earlier days was overidden and 
an increase in the proliferative response was observed on day three. The
proliferative response observed on day three and day four was higher than the
response observed with FCS alone.
2.3.2.4 Prollferative responses to rGIM-CSF
At the early time points in culture (eight hours to day three) an equivalent 
proliferative response was observed when normal bone marrow cells were cultured 
with rmGM-CSF or WEHI-3B CM. However, rGM-CSF induced a higher 
proliferative response at these time points with all the leukaemias studied than 
WEHI-3B CM (Fig. 2.9 D).
rGM-CSF was more effective than WEHI-3B and L929 CM for the proliferation of
the SA2 HP leukaemia.
rGM-CSF did not sustain increasing proliferation of normal and leukaemic cells 
for as long as it was sustained with the other two growth factors. The increasing 
proliferation of NBM, the SA7 and SA2 HP leukaemias was sustained to day 
three and of the SA8 leukaemia to day two. The exception was the SA2 LP 
leukaemia, proliferation was sustained to day six, although this was not 
exponential cell growth.
As with the other two growth factors the SA7, SA8 and the SA2 HP leukaemias 
had higher proliferative responses when stimulated with rGM-CSF at the early 
time points in culture than normal bone marrow. The maximal proliferative 
response observed with the SA7 and the SA8 leukaemias was double the response 
observed with normal bone marrow and the response observed with the SA2 HP 
was four times greater than normal.
The proliferative response of the SA2 CL when stimulated with rGM-CSF was 
greater than the response observed with FCS during the first eight hours of
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culture. From days one to day seven there was no difference in the response
between the two treatments.
2.3.2. Summary of the proliferative responses of leukaemic and normal 
bone marrow cells to WEHI-3B CM, L929 CM and rGM-CSF
Heterogeneous proliferative responses to the growth factors were observed with 
with the different leukaemias (Fig 2.9). There were three main differences:-
1) . The same growth factor did not induce maximal proliferation of each
leukaemia. WEHI-3B CM induced maximal stimulation of NBM. Maximal
stimulation of the different leukaemic cells was achieved with different growth
factors.
2) . Except for the SA2 LP leukaemia, a higher proliferative response was 
observed with the leukaemic cells with each of the growth factor at the earlier 
time points in culture than NBM.
3) . The leukaemic cells were generally sustained in culture for c shorter time
period than NBM
4) Autonomous proliferation was observed with the SA2 LP leukaemia and the 
SA2 CL. Autonomous proliferation was also observed with the other leukaemias 
for the first two to three days in culture
The SA7 leukaemia was maximally stimulated to proliferate with WEHI-3B 
CM. Increasing proliferation was observed to day five with WEH-3B CM, day 
three with L929 CM and rGM-CSF. A higher proliferative response was observed 
with each of the growth factors at ealier time points than NBM. rGM-CSF 
induced a higher maximal proliferative response of the SA7 leukaemia than 
NBM. Autonomous proliferation was double that observed with NBM after eight 
hours of culture and minimal autonomous proliferation was observed to day two of 
culture.
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The SA8 leukaemia was maximally stimulated with WEHI-3B CM. Increasing
proliferation was observed to day six with WEHI-3B CM, day four with L929 CM 
and day three with rGM-CSF. A higher proliferative response was observed 
with each of the growth factors at the earlier time points than NBM. L929 CM 
and rGM-CSF induced a higher maximal proliferative response of the SA8 
leukaemia than NBM. The level of proliferation during the first eight hours in
each of the culture conditionsd was similar to that of NBM and minimal 
autonomous proliferation was observed to day two.
The SA2 HP leukaemia was maximally stimulated with rGM-CSF. Increasing 
proliferation was observed only to day three with all three growth factors. A 
higher proliferative response was observed with each of the growth factors at 
earlier time points than NBM and the other leukaemias. The autonomous 
proliferative response observed after eight hours of culture was three time higher 
than NBM and autonomous proliferation was observed to day three.
The SA2 LP leukaemia differed from the other leukaemias. The overall
proliferative responses observed were lower than the other leukaemias and 
generally lower than NBM. The SA2 LP leukaemia was maximally stimulated 
with WEH1-3B CM. Increasing proliferation was sustained to day six with 
WEHI-3B CM, day five with L929 CM and day four with rGM-CSF. The passage 
number of the SA2 LP leukaemia was number 49 and a minimal autonomous 
proliferative response was observed to day seven in culture.
The SA2 CL was highly proliferative in culture. Maximal stimulation was 
observed with FCS alone. The addition of growth factors induced an inhibitory 
effect on the proliferation of the SA2 CL at early time points in culture. The 
greatest inhibitory effect was observed with L929 CM.
67
2.4 TIME STUDY OF THE PROLIFERATIVE RESPONSES OF 
NORMAL AND LEUKAEMIC BONE MARROW CELLS TO 
COMBINATIONS OF WEHI-3B CM, L929 CM AND rGM-CSF
To further characterise the various leukaemic populations we investigated the 
interactions of WEHI-3B CM, L929 CM and rGM-CSF in controlling myeloid 
leukaemic cells by using combinations of growth factors in vitro. The regulators of 
normal haemopoiesis affect overlapping stages of the haematopoietic pathways, 
that is, they exert stimulating effects upon the same target cells (Metcalf, 1988). 
They have also been shown to have synergistic proliferative effects on the same 
target cell when used in combination. (McNeice et al, 1988 ). The cooperative 
interactions between these molecules in controlling myeloid leukaemic cell growth 
and how they compared to normal were investigated. With the use of 
combinations of growth factors we have attempted to identify aberrations of 
synergistic responses observed with normal bone marrow cells and to possibly 
identify specific subsets of myeloid leukaemic cells according to these responses. 
The comparative variations in response between the leukaemias and compared to 
normal myeloid cells may provide indicators of classifying leukaemic cell 
populations with biologically different disease and may prove to be of prognostic
value.
2.4.1 Exppsimesnal Proccduro
The proliferation characteristics of leukaemic cells to optimal concentrations of 
WEHI-3B CM, L929 CM and rGM-CSF, used in combination, were studied daily 
over seven days in the microtitre assay. Single cell suspensions of 7 x 10^ 
leukaemic and normal bone marrow cells and cells from the SA2 CL were incubated
with 15% WEHI-3B CM (v/v, 15% L929 CM (v/v) and 60 U/ml rGM-CSF in double 
combinations. Proliferation has measured utilizing ^H-TdR uptake. The results 
obtained were compared to the responses obtained with normal bone marrow cells.
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2.4.2 Results
2.4.2.1 Proliferative responses of eeukaemic and normal bone marrow 
cells to the combination of WEHI-3B CM and L929 CM
After the first eight hours of culture the proliferative response of normal bone
marrow was equivalent to the response observed with FCS. From day one to day 
three the response was equivalent to the response with WEHI-3B CM alone (Fig. 
2.11 A). On days four and five the response was additive and on day six 
synergistic.
No synergistic response was observed with the SA7 leukaemia over the time 
period studied and the maximal proliferative response observed with the 
combination of growth factors was less than the maximal response observed with 
WEHI-3B CM alone (Fig. 2.11 B). Over the first two days of culture the response 
was equivalent to the response observed with WEHI-3B CM alone. An additive 
response was observed on day three and a less than additive response was 
observed on day four.
A synergistic and additive responses similar to normal bone marrow were observed 
with the SA8 leukaemia. A synergistic response was observed on day five and an 
additive response was observed on day three and four (Fig. 2.11 C). The difference 
in response as compared to normal was at the early time points, days one and two, 
were the response observed was less than the response observed with WEHI-3B 
CM alone; L929 CM appeared to down regulate the response to WEHI-3B CM.
A synergistic response was also observed with the SA2 LP leukaemia on day five 
(Fig. 2.11 D); an additive response was observed on days four and six. Similar to 
normal bone marrow and the SA7 leukaemia the response observed at the early 
time points in culture were similar to the response with WEHI-3B CM alone.
No synergistic response was observed with the SA2 HP leukaemia (Fig. 2.11 E). A 
less than additive response was observed on day two and an additive response on 
day three. On day one the response observed was less than the response observed
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with WEHI-3B CM alone and as with the SA8 leukaemia L929 CM appeared to 
down regulate the response to WEHI-3B CM.
Summary of the results:-
a) A synergistic response was observed only with normal bone marrow, the SA8
and the SA2 LP leukaemias
b) Additive responses were observed with normal bone marrow and all four of the 
transplanted cell lines.
c) A higher maximal proliferative response was observed with the combination of 
WEHI-3B plus L929 CM with normal bone marrow, the SA8, SA2 LP and SA2 HP 
but not the SA7 leukaemia as compared to either factor alone.
d) L929 CM appeared to down regulate the proliferation response to WEHI-3B CM 
of the SA8 and SA2 HP leukaemias at the early time points.
2.4.2.2 Proliferative responses of leukaemic and normal bone marrow 
cells to the combination of WEHI-3B CM and rGM-CSF
A synergistic response was observed with normal bone marrow cells on days four 
and five of culture (Fig. 2.12 A), an additive response was observed on days three
and six.
With this combination of growth factors a synergistic response was observed with 
the SA7 leukaemia (Fig. 2.12 B); the synergistic response was observed on day 
four and additive proliferative responses were observed on days three five and 
six. An interesting response was observed with the SA7 leukaemia after eight 
hours of culture and on day one. The maximal proliferative responses at these 
time points were observed with the addition of rGM-CSF alone, when WEHI-3B 
CM was added the response observed was equivalent to the response observed 
with WEH1-3B CM alone i.e. it was less than the response observed with
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rGMCSF. Hence, WEHI-3B CM appears to down regulate the relatively high 
proliferative response of these leukaemic cells to rGM-CSF.
Synergistic or additive proliferative responses were not observed with the SA8 
leukaemia (Fig. 2.12 C). The responses were generally equivalent to the maximal 
responses observed with either factor alone, rGM-CSF alone gave the highest 
response on days two and three and WEHI-3B CM from day four to six. Hence, no 
down regulatory effect was observed.
A synergistic response was observed with the SA2 LP leukaemia on day five and 
additive responses were observed on days three and four.(Fig. 2.12 D).
Synergy was not observed with the SA2 HP leukaemia (Fig. 2.12 E). On days two 
and three less than additive responses were observed. After eight hours of culture 
rGM-CSF alone induced a very high proliferative response of this leukaemia. 
This response was down regulated with the addition of WEHI-3B CM and the 
response observed with the combination of growth factors was equivalent to the 
response observed with WEHI-3B CM alone.
In summary:-
a) A synergistic response was observed with normal bone marrow, SA7 and the
SA2 LP leukaemias but not with the SA8 or SA2 HP leukaemias.
b) Additive responses were observed with normal bone marrow, the SA7, SA2 LP
and SA2 HP leukaemias, but not the SA8 leukaemia.
c) WEHI-3B CM down regulated the relatively high proliferative responses 
observed with rGM-CSF alone of the SA7 and SA2 HP leukaemias at early time 
points in culture.
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2.4.2.3 Proliferative responses of leukaemic and normal bone marrow 
cells to the combination of L929 CM and rGM-CSF
No additive or synergistic responses were observed with normal bone marrow
with this combination of growth factors during the first four days in culture when
the cells were in exponential cell growth (Fig. 2.13 A). Additive responses were
observed on days four to six.
A synergistic response was observed on day four with the SA7 leukaemia and 
additive responses were observed on day two and three (Fig. 2.13 B).
An increased but less than additive responses was observed with the SA8 and no 
down regulatory effect was observed by L929 CM on the high proliferative 
response observed with rmGM-CSF (Fig. 2.13 C).
A marked synergistic response was observed with the SA2 LP leukaemia from day 
three to day six (Fig. 2.13 D)
An increased but less than additive response was observed with the SA2 HP 
leukaemia on day three of culture (Fig. 2.13 E). L929 CM did appear to down 
regulate the high proliferative response observed with rmGM-CSF alone after 
eight hours of culture.
It must be noted that significantly higher (p<0.05) proliferative responses were
observed with this factor combination than either factor alone for both normal
and leukamic marrow at the later time points in culture when the cells were no 
longer in exponential cell growth.
In summary:-
a) Synergy was not observed with normal bone marrow and the SA8 and SA2 HP
leukaemias
b) Synergy was observed with the SA7 and SA2 LP leukaemia.
c) Additive responses were observed with the SA7HD, SA8HD and SA2 HP
leukaemic bone marrows.
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d) TTis factorcombination s ustained a higher proliferative response than either 
factor alone at the later time points in culture for normal marrow and all the 
transplanted leukaemic cell lines.
2.4.2.4 Proiirerat■ve of the SA2 CL to the combinations of
growth factors
The combination of any of the growth factors did not significantly alter the 
response of the SA2 CL as compared to FCS or to either one of the growth factors 
alone (Appendix Table A2.10)
2.5 RESPONSES OF LEUKAEMIC AND NORMAL
BONE MARROW CELLS TO OPTIMAL CONCENTRATIONS OF 
WEHI-3B CM, L929 CM AND rMGM-CSF, ALONE AND IN 
COMBINATION, IN THE COLONY ASSAY
The responses of leukaemic cells to single and combinations of growth factors were
also investigated in the colony assay. The colony assay depicts the number of 
progenitor cells able to form colonies in culture in response to a particular growth 
stimulus (Chomirnnr, 1990). Major differences were observed between the
microtitre assay and the colony assay in terms of the growth factor inducing 
maximal stimulation of a particular leukaemic cell population. Differences were 
also observed in the synergistic responses observed with the combinations of 
growth factors in the two methods. The response of the leukaemic cells to growth 
factors in the colony assay and the differences observed between the two methods
are described in this section.
2.5.1 Exxrrimental Prorcduse
Single cell suspensions of normal and leukaemic bone marrow cells and cells from
the SA2 CL were set up in the colony assay with FCS alone and with optimal 
concentrations of WEHI-3B CM (15% V/V), L929 CM (15% V/V) and rGM-CSF (60
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U/ml), alone and in double combinations. Colonies were scored on day seven. The
results obtained were compared to the results of the microtitre assay.
2.5.2 Results
2.5.2.1 Responses to single growth factors
The number of clonogenic cells stimulated to form colonies, from normal and 
leukaemic bone marrows, in response to WEHI-3B CM, L929 CM and rmGM-CSF, 
were assessed (Table 2.1). A number of major differences between the colony and 
microtitre assay were observed:-
• In the microtitre assay, where the proliferative responses of the total bone 
marrow cellular populations were determined utilizing the uptake of 3H-TdR, it 
was observed that rmGM-CSF induced a higher proliferative response than L929 
CM, especially of the leukaemic cell populations. In the colony assay, where a 
specific subset of the total bone marrow population is induced to form colonies in 
culture, L929 CM induced a higher proportion of progenitor cells to form colonies
than rmGM-CSF.
• In the microtitre assay WEHI-3B CM induced a higher proliferative response 
of the SA7 leukaemia than the other two growth factors whereas in the colony 
assay L929 CM induced the greatest number of colonies.
• The SA2 LP leukaemia was growth factor dependent for colony formation 
whereas in the microtitre assay a minimal proliferative response was observed at 
each time point studied. This difference may be due to the lower number of bone 
marrow cell plated in the colony assay.
The main similarities between the two culture systems were;-
• The high proliferative responses observed with the SA2 HP and SA2 CL 
leukaemias in the microtitre assay were paralleled with the high number of 
colony forming cells observed in the colony assay. The number of clonogenic cells
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from the SA2 HP leukaemic bone marrow and the cells from the SA2 CL were 
found to be relatively high, and tersr cells were plated at 104 and 103 cells per 
plate respectively. Normal bone marrow and the other leukaemias were plated 
at 2.5 x 104 cells per plate.
• Normal bone marrow and the transplanted leukaemic cell lines which were 
growth factor dependent in the microtitre assay (the SA7, SA8 and the SA2 HP 
leukaemia) were also growth factor dependent in the colony assay.
2.5.2.2 Responses to combinations of growth factors
Major differences were observed with the combination of growth factors between 
the colony and microtitre assays. The main difference was that no synergistic or 
additive responses were observed with normal bone marrow with any of the 
growth factor combinations. The responses of the leukaemic cells to each of the
combinations is described below.
WEHI-3B CM plus L929 CM
A synergistic or additive response was not observed with the SA7 or SA2 HP 
leukaemias as in the microtitre assay. Synergy was not observed with the SA2 LP 
leukaemia, however it was observed in the colony assay.
An additive response was observed with the SA8 leukaemia, however in the 
microtitre assay both additive and a synergistic responses were observed.
As noted above no synergistic response was observed with the SA2 HP leukaemia.
L929 CM alone induced the greatest number of colonies from this leukaemia and 
the combination with WEHI-3B CM appeared to down regulate this response.
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WEHII-3B CM plus rGMCSF
This combination of growth factors enhanced the number of colonies formed from 
the SA7 and the SA2 HP leukaemic cells as compared to either factor alone,
however the responses was less than additive. These result were similar with 
the microtitre assay.
An additive response was obtained with the SA8 leukaemia in the colony assay 
but not with the microtitre assay. The opposite was observed with the SA2 LP 
leukaemia were additive and synergistic responses were observed in the 
microtitre assay but not in the colony assay.
L929 CM plus rGM-CSF
rmGM-CSF down regulated the number of colonies observed with L929 CM alone 
with the SA7, SA2 LP and the SA2 HP leukaemias. This is opposite to the results 
obtained with the micro titre assay where L929 CM down regulated the response 
to rmGM-CSF at the early time points in culture. Also synergistic responses were 
observed with these three leukaemias in the microtitre assay but not in the colony
assay.
No additive or synergistic response was observed with the SA8 leukaemia 
whereas an enhanced response was observed with the microtitre assay.
2.6 DISCUSSION
The proliferative dose response relationships of the leukaemic cells to three 
growth factors of normal haemopoietic cells,WEHI-3B CM as a source of IL-3,
L929 CM as a source of M-CSF and rGM-CSF were examined in vitro. These three 
growth factors and G-CSF are the only known proliferative stimuli of normal 
haemopoietic cells both in vitro and in vivo and hence it was relevant to consider 
the effects of these growth factors on myeloid leukaemic cells.
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Growth factor dependent and autonomously proliferative responses were observed 
with the leukaemias studied. The SA7, SA8 and SA2 HP leukaemias were
growth factor dependent in vitro. Hence, it appears that some leukaemias can be 
induced to proliferate by the regulators of normal haemopoiesis. The role and 
degree to which in vitro responsive leukaemic cells are sustained in vivo by the 
regulators of normal haemopoiesis cannot be infered from these studies. 
Autonomous proliferation was observed with the SA2 LP leukaemiaand the SA2 
CL. The proliferative response of the SA2 LP leukaemia at passage number 36 
was not affected by the addition of the CSF's on day four of culture. At passage 
number 54 where a minimal autonomous proliferative response was observed the 
addition of growth factors enhanced the proliferative response. A significant 
inhibitory effect on the proliferation of the SA2 CL was observed on day two of
culture with the addition of L929 CM.
The patterns of proliferative response observed with the different leukaemias 
were heterogeneous. No specific "leukaemic^" response could be detected. The CSF
which induced maximal stimulation varied between the leukaemias. WEHI-3B
CM induced a maximal proliferative response of NBM, the SA7 and SA8 
leukaemia, and rGM-CSF stimulated maximal proliferation of the SA2 HP 
leukaemia. The in vitro time course for maximal-proliferative-response differed
between normal and leukaemic cells and between the CSF studied. Maximal 
proliferation of leukaemic cells was often observed at early time points, day two 
or day four and of NBM on day six. These observations promoted further 
proliferative studies whereby normal and leukaemic cells were cultured with 
optimal concentrations of each growth factor and proliferative responses were 
measured daily over seven days in the microtitre assay and in the colony assay.
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There were two main similarities between the proliferative responses observed 
with normal bone marrow and the growth factor dependent leukaemic bone 
marrow cells. All the transplanted leukaemic cell lines were induced to 
proliferate with each of the growth factors studied indicating that leukaemic 
cells may retain some of the proliferative characteristics of normal cells. In 
studies on human myeloid leukaemic cells it has been shown that IL-3 and GM- 
CSF frequently induce the proliferation of AML cells however M-CSF 
infrequently induces proliferation (Delwel et. al. 1988). Hence these transplanted 
leukaemic cell lines may provide a good model for studying M-CSF responsive 
leukaemic cells. Secondly, the same concentration of each growth factor required 
to induce optimal proliferation of normal cells was also required to induce optimal 
proliferation of the leukaemic cells. It has also been documented that for human 
bone marrow cells the same concentrations of growth factors were required for 
optimal proliferation for normal and leukaemic cells (Metcalf 1988).
It was evident from these studies that the growth factor dependent leukaemic 
cells responded differently from normal cells to these growth factors. Although 
the concentration of growth factor required to induce maximal proliferation of 
normal and leukaemic cells was the same, the level of proliferation between 
normal and leukaemic cell differed. The leukaemic cells proliferated in vitro in 
response to regulators of normal haemopoietic cells however, they proliferated at 
a higher rate than normal cells at early time points in culture and they were not 
sustained in culture for as long as normal cells. Further studies are required to 
determine whether the responses observed in vitro are able to be paralleled in 
vivo. The use of physiological growth factors for therapeutic regimes for 
leukaemia should be viewed with caution because of their proliferative effects on 
leukaemic cells in vitro. However, because of the differences in proliferative 
responses obtained between normal cells and leukaemic cells the physiological
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growth factors may be effective in decreasing the leukaemic burden or 
preferentially sustaining the proliferation of suppressed normal progenitor cells.
Studies with human AML cells have shown that specific growth factors arrest 
progenitor cells at specific points in the cell cycle and hence the administration of 
growth factors with therapeutic agents may be beneficial (Bhalla et al, 1991; 
Hassan and Maurer, 1991). However there are studies which are contradictory to 
this possibility. (Koistinen et al, 1991).
Autonomous proliferation was observed with the SA2 CL and the SA2 LP 
leukaemia was observed to undergo changes with serial transplantation from 
being growth factor independent to growth factor dependent. The 
characterization of leukaemic cells which proliferate autonomously in vitro has 
opened major discussions as to whether or not leukaemia arises because of the 
emergence of an autocrinally regulated cell (Metcalf, 1988). Studies on oncogenes, 
cellular proto-oncogenes and specific chromosomal translocations involving these 
genes supports the hypothesis that cancer development is due to abnormalities of 
growth factors or their cell membrane receptors. However, growth factor genes do 
not generally induce leukaemia when inserted into normal aaemnooietic cells, 
although they do so if they are inserted into immortalized haemopoietic stem 
cell lines (Testa and Dexter, 1989). A discussion on leukaemogenesis and the role 
of the harmopnietic growth factors in this process, is beyond the scope of this 
study (for a review of autoa-inal concepts in lrukaemogrnesis see Metcalf, 1988). 
However, the change in the proliferative response observed with the SA2 
leukaemia with continued transplantation and the minimal proliferative 
responses observed with the growth factor dependent leukaemias to day two or 
three in the microtitre cultures readdresses the question as to whether autonomous 
cell growth is a prerequisite of leukaemogenicity. Myeloid leukaemia appears to 
be an "evolving" disease. With the long term progression of the disorder, as is the
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case with continued transplantation, a change in the dominant clone of a highly 
proliferative cell population is probably likely. It appeared that leukaemic
populations undergo varied genetic changes with time. Hypothetically, there 
cos two possibilities:-
• the dominant leukaemic clone progressed from being autocrinal and sustainable 
in the culture system to being autocrinal and unsustainable, supporting the theory 
that autoceinal regulation, whatever the mechanism, is essential for the 
leukaemic process or
• after leukaemogenesis the emergence of an autocrinal dominant population may 
be part of the evolution of a particular leukaemia and with the progression of the 
disorder a dominant clone with different characteristics may evolve. Normal 
haemopoietic cells produce haemopoietic growth factors hence this explanation
is possible.
With progressive improvements in culture techniques for human bone marrow 
cells, most clinical cases of AML have been found to be susceptible to growth factor 
stimulation for colony formation, DNA synthesis, enhanced survival of AML 
progenitors in vitro and for the support of the self renewal of AML precursors 
(Lowenberg et al, 1990). Liquid cultures (Pebusque, 1988) or a liquid phase prior to 
semi-solid culture (Lowenberg et al, 1980) has been shown to improve the in vitro 
responses of human leukaemic cells to growth factors. However, from this data 
and studies by others, the possibility that, once leukaemogenesis has occured, the 
affected cells are no longer dependent upon growth factors and that proliferation 
of these cells is achieved by a novel cytoplasmic or nucleic mechanism cannot be 
excluded. The difficulty arises with the growth factor dependent leukaemias 
where it is difficult to assess with the methodology used for these studies 
whether a small proportion of the cells in culture are autonomous and whether it 
is these cells that constitute the leukaemic clone. These questions will be
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addressed with in vivo clonogenlcity assays in the next section. The cells from 
early transplantations of the SA7 or SA8 were not studied therefore it was not 
possible to assume that the progression from growth factor independent to growth 
factor dependent leukaemic cells is characteristic of these transplanted cell lines.
The haemopoietic growth factors affect overlapping stages of normal 
haemopoietic pathways and the cell membrane receptors for these growth factors 
appear to interact with each other (Nicola,1987). Hence, the haemopoietic 
growth factors exert stimulating effects upon the same target cells. A possible 
reason as to why a particular progenitor is able to be induced to proliferate with a 
range of growth factors may be attributed to haemopoietic cellular cooperation 
requirements in immune responses (Nicola, 1987).
The heterogeneity of AML imposes difficult problems for the prognosis and 
treatment of the disease The varied clinical responses to chemotherapy observed 
in AML patients within the FAB classification system, the marked variation in 
leukaemic cell phenotype (Griffin and Lowenberg, 1986), and the heterogeneity of 
response to growth factors by different leukaemias observed in vitro (Moore et al, 
1974) implies that the acute myeloid leukaemias may need to be reclassified. 
Specific leukaemic progenitor cell subgroups according to growth factor response 
may be identifiable and this possible classification of myeloid leukaemic cells 
may have some prognostic value. Hence, the response of leukaemic progenitor 
cells to multiple growth factors and how they compared to the response of normal 
haemopietic progenitors was assesed.
The leukaemic cells did not show the same proliferative patterns as normal cells 
to the combinations of growth factors and there were also differences in response 
amongst the leukaemias. As expected the combination of growth factors induced 
synergistic and additive responses of normal bone marrow cells indicating that
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different and overlapping subsets of cells have been stimulated to proliferate. 
The combination of WEHI-3B CM and L929 CM induced additive responses with 
normal bner marrow, the SA7 and the SA2 HP leukaemias and synergistic 
responses from the SA8 and SA2 LP leukaemias. The combination of WEHI-3B 
CM plus rmGM-CSF induced synergistic responses of normal bone marrow and the 
SA2 LP leukaemia; additive responses with the SA7 and SA2 HP leukaemia; and 
no additive response of the SA8 leukaemia indicating that these two growth 
factors affect the same cells of the SA8 leukaemia. The combination of L929 CM
plus rmGM-CSF induced an additive response of normal bone marrow cells the 
SA7, SA8HD and SA2 HP and a high synergistic response of the SA2 LP 
leukaemia. The difficulty in assessing additive and synergistic responses with 
the microtitre culture system is that individually, the growth factors sustain 
proliferation of the cells for a different number of days. Different leukaemic 
subgroups according to response to combinations of growth factors were observed. A 
comparative study of in vitro responses of human AML cells to growth factors 
prior to remission induction and the outcome of therapy would be needed to 
determine the prognostic value of this classification system.
Differences in responses of leukaemic cells to growth factor combinations as 
compared to normal were also observed when the colony assay was used. 
Differences in responses however, were also observed with the leukaemic cells 
when the two culture systems were compared. For example in some cases a 
different growth factor was observed to induced maximal responses of the same 
leukaemia in each of the assays; synergistic repOTs^ were observed with the 
combination of growth factors of a particular leukaemia in one assay but not the 
other. In a study on human AML cells by Pebusque et al (1988) it was shown that a 
synergistic response was observed with the combination of IL-3 and G-CSF when 
the cells were cultured in the microtitre assay but only three of five samples
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confirmed this result when studied in the colony assay. In a study by Dewel et al, 
(1987) on human AML cells using colony assays no synergistic responses were 
observed with double combinations of IL-3, GM-CSG and G-CSF. In a study by 
Lemoli et al (1991) of human AML cells in the colony assay in most cases an 
additive response was observed compared to either factor alone by the same 
combinations used in the Dewel study. In studies by Buick et al (1977), Nara and 
McCulloch (1985) and McCulloch et al (1988) it has been shown that:- 
o the colony assay principally measures terminal divisions and minimal self 
renewal can be detected by replating cells recovered from colonies.
o in the suspension assay, clonogenic cells increase with time, a change that 
reflects self renewal.
Responses of leukaemic cells to combinations of growth factors need to be 
investigated further with recombinant growth factors and a standardized 
technique for comparative studies needs to be established if clear patterns of
proliferative responses are to be determined.
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-B-----WEHI-3B CM
L929 CM
Figure 2.1 Cell Dose Study. Normal and leukaemic cells between 1 to 10 x 10^ cells 
were cultured with optimal concentrations of WEHI-3B CM and L929 CM to determine 
the optimal cell number required for proliferation studies in the microtitre culture.
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Figure 2.2 Normal Bone Marrow. Growth Factor Dose Response Study. 
Normal bone marrow cells were cultured in FCS alone and with varied 
concentrations of WEHI-3B CM, L929 CM and rGM-CSF in the miceotfter 
assay for two, four and six days to determine the dose-response relationship. 
Proliferation was measured with 3H-TdR uptake and the results recorded as 
scintillation counts per minute (CPM) and with the measurement of total 
cell count per well.
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Figure 2.3 SA7 leukaemic boer marrow. Growth Factor Dose Response Study. 
SA7 leukaemic bone marrow cells were cultured in FCS alone and with varied 
coecretratioes of WEHI-3B CM, L929 CM and rGM-CSF in the microtitre 
assay for two, four and six days to determine the dose-response relationship. 
Proliferation was measured with 3H-TdR uptake and the results recorded as 
scintillation counts per minute (CPM) and with the measurement of total cell 
count per well.
87
CELLS 
PER 
WELL 
X 10*
25'
20'
-----DAy 2
-------DAY 4
DAY 6
35.00
30.00
2L.00
20.00
15.00
10.00
5.00
0.00
COUNTS ! CELLS
PER
WELL 
x 104
35.00
30.00
25.00
20.00
1 5.00
10.00
5.00
0.00
% WLHI-3B CM
% L929 CM
35.00
30.00;
25.00;CELLS 
PER 20.00:
WELL
104 15.00;
10.00;
5.00
0.00 4 -T—.—I—«—I--- 1--- 1—.
20 40 60 80
lU/ml rmGM-CSF
100
rt**»S?**'
0
Figure 2.4 SA8 leukaemic bone marrow . Growth Factor Dose Response Study. 
SA8 leukaemic bone marrow cells were cultured in FCS alone and with varied 
concentrations of WEHI-3B CM, L929 CM and rGM-CSF in the microtitre 
assay for two, four and six days to determine the dose-response relationship. 
Proliferation was measured with 3H-TdR uptake and the results recorded as 
scintillation counts per minute (CPM) and with the measurement of total cell 
count per well.
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Figure 2.5 SA2 HP (passage number 77) leukaemic bone marrow. Growth 
Factor Dose Response Study. SA2 leukaemic bone marrow cells were cultured 
in FCS alone and with varied concentrations of WEHI-3B CM, L929 CM and 
rGM-CSF in the microtitre assay for two, four and six days to drarrmier the 
dose-response relationship. Proliferation was measured with 3H-TdR uptake 
and the results recorded as scintillation counts per minute (CPM) and with the 
measurement of total cell count per well.
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Figure 2.6 SA2 LP (passage number 36) leukaemic bone marrow. Growth Factor 
Dose Response Study. SA2 leukaemic bone marrow cells were cultured in FCS 
alone and with varied concentrations of WEHI-3B CM, L929 CM and rGM-CSF 
in the miceotfter assay for four to determine the dose-response relationship. 
Proliferation was measured with 3H-TdR uptake and the results recorded as 
scintillation counts per minute (CPM) and with the measurement of total cell 
count per well.
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Figure 2.7 SA2 LP (passage number 54) leukaemic bone marrow. Growth Factor 
Dose Response Study. SA2 leukaemic bone marrow cells were cultured in FCS 
alone and with varied concentrations of WEHI-3B CM, L929 CM and rGM-CSF 
in the microtitre assay for two, four and six days to determine the dose-response 
relationship. Proliferation was measured with 3H-TdR uptake and the results 
recorded as scintillation counts per minute (CPM) and with the measurement of 
total cell count per well.
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Figure 2.8 SA2 CL leukaemic cells. Growth Factor Dose Response Study. 
The SA2 CL was cultured in FCS alone and with varied concentrations of 
WEHI-3B CM, L929 CM and rGM-CSF in the miceotfter assay for two, four 
and six days to determine the dose-response relationship. Proliferation was 
measured with 3H-TdR uptake and the results recorded as scintillation 
counts per minute (CPM) and with the measurement of total cell count per 
well.
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Figure 2.9 Proliferative effects of WEHI-3B, L929 CM, and rGM-CSF on 
normal and leukaemic cells. Cells were cultured in the microtitre assay
gor eight hours to seven days. Proliferation was measured with 3H-TdR
uptake.
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Figure 2.10 Proliferative effects of WEHI-3B, L929 CM, and rGM-CSF on the
SA2 CL. Cells were cultured in the microtitre assay for eight hours to seven
days. Proliferation was measured with 3H-TdR uptake.
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Figure 2.11 Proliferation effects of combinations of growth factors, WEHI-3B CM, 
and L929 CM on normal and leukaemic cells. Cells were cultured in the microtitre 
assay for eight hours to seven days. Proliferation was measured with the uptake of 
3H-TdR.
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Figure 2.12 Proliferation effects of combinations of growth factors, WEHI-3B CM, 
and rGM-CSF on normal and leukaemic cells. Cells were cultured in the microtitre 
assay for eight hours to seven days. Proliferation was measured with the uptake of 
3H-TdR.
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Figure 2.13 Peolieeeation effects of combinations of growth factors, L929 CM and 
and rGM-CSF on normal and leukaemic cells. Cells were cultured in the microtihe 
assay for eight hours to seven days. Peolieeection was measured with the uptake of 
3H-TdR, (* p<0.05, Comparing the proliferative response between combined and 
single factors. A significant increase in the proliferative response was observed with 
the combination of growth factors compared to either factor alone for normal and 
leukaemic bone marrow at the later time points in culture).
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CHAPTER THREE
IN VITRO DIFFERENTIATION EFFECTS OF 
WEHI-3B CM, L929 CM AND rGM-CSF ON LEUKAEMIC 
AND NORMAL BONE MARROW CELLS CELLS
The aim of these experiments was to determine whether the leukaemic bone 
marrow cells had maintained or lost their capacity for differentiation by 
studying their differentiation responses to physiological regulators of normal 
haemopoietic proliferation and differentiation. These types of studies could 
assist in determining the aberrant characteristics of different types of leukaemic 
cells and in determining whether normal physiological growth factors could 
possibly be used therapeutically for controlling the proliferation, via 
differentiation induction, of leukaemic cells in vivo or to be used in purging the 
leukaemic population from bone marrow samples for autologous transfusion or to 
assess the possible use of physiological regulators in conjunction with conventional 
therapeutic regimes. Another important aspect of the usefulness of these types of 
studies would be for the identification of subgroups of acute leukaemia according 
to their differentiability by physiological agents and may assist in the improved 
prognosis and treatment of the disease. The response or lack of response of certain 
leukaemias to normal physiological regulators and possible preferential 
stimulation the regulators may have on the normal suppressed haemopoietic cell 
population as opposed to the leukaemic cell populations, may be able to be 
utilized for subgrouping of leukaemias or for alternative therapeutic regimes.
The current most widely accepted model of the leukaemic cell population is that 
it represents a heterogeneous population of cells. These include a minority of 
blasts with in vitro proliferative potential with abnormally high levels of self 
renewal characteristics (clonogenic cells) and a majority of cells with little or no
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proliferative capability (Buick et al, 1979; Lange et al, 1984; Griffin and 
Lowenberg, 1986). It is not yet clear whether differentiation inducers can force the 
leukaemic clonogenic cell fraction towards differentiation at the expense of self 
renewal or merely induce terminal differentiation of the partially differentiated 
cell population. Another important question which needs to be elucidated is 
whether induction of differentiation of the leukaemic clonogenic cells may be 
compensated by an increase in their proliferation rate. We have aimed to answer 
these questions by examining the in vitro effects of the WEHI-3B CM, L929 CM 
and rGM-CSF in an in vivo leukaemic clonogenic cell assay utilizing the 
transplanted leukaemic cell lines. An effective differentiation inducer should 
ultimately not enhance and preferably decrease clonogenic cell numbers. 
Measuring the number of clonogenic cells is easily facilitated when using 
transplantable leukaemic models in vivo . In this study the in vivo leukaemic 
clonogenic cell assay was used to determine the effectiveness of differentiation 
induction in reducing the number of leukaemic clonogenic cells.
3.1 IN VITRO DIFFERENTIATION EFFECTS OF WEHI-3B CM, 
L929 CM AND rGM-CSF ALONE AND IN COMBINATION ON 
LEUKAEMIC AND NORMAL BONE MARROW CELLS
3.1.1 Experimental procedure
a). Cytospins were prepared and stained with Jenner Giemsa from single cell 
suspensions of normal and leukaemic bone marrow and with cells from the SA2 CL
and differentials counted.
b). Normal and leukaemic bone marrow cells and cells from the SA2 CL were
cultured in the microtitre assay with optimal concentrations of WEHI-3B CM, 
L929 CM and rGM-CSF, both singularly and in combination, for eight hours, two,
four and six days.
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c) . At these time points the total number of cells per well for each treatment was 
counted using the Coulter Counter.
d) . Three cytospins were prepared for each treatment, stained with Jenner Giemsa
and at least 500 cell differentials were counted for each slide. A full differential
was counted with the cell classification being:-
Blasts, promyelocytes, immature macrophages, myelocytes, metamyelocytes, 
bands, segmented cells, monocytes and macrophages. Tables of the differentials of 
the single cell suspensions and the cultured cells are listed in the Appendix. The 
absolute number of each cell type per well was determined using the total number 
of cells per well counted vide supra (c).
e) From the differential data, graphs were prepared depicting the absolute 
number of immature cells (blasts and promyelocytes), intermediate cells 
(myelocytes, metamyelocytes and immature macrophages) and mature cells 
(bands, granulocytes, monocytes and macrophages) per well to determine whether 
partial or complete differentiation had occured with each of the treatments.
f) . The Maturation Index was calculated from the differential data and graphed 
for each treatment. The Maturation Index = The absolute number of mature cells 
per well / The absolute number of immature cells per well; whereby 1 is 
equivalent to an equal number of mature and immature cells, a value of <1 is 
equivalent to a predominance of immature cells and a value >1 is equivalent to a 
predominance of mature cells. The maturation index is a comparative measure 
between the number of immature cells sustained in culture and the effectiveness of
differentiation induction by a particular growth treatment.
g) . Induction of differentiation was also measured determining the number of 
phagocytic cells. Normal and leukaemic bone marrow cells and cells from the SA2 
CL were cultured in the microtitre assay for eight hours, two, four and six days. 
Eight hours prior to the preparation of cytospins 0.8ji latex particles were added
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to the cultures. Three cytospins were prepared and stained as above and the 
percentage and absolute numbers of phagocytic cells per well were determined and
graphed. At least 1000 cells were counted per slide.
3.1.2 Results
The bone marrow of the transplanted leukaemic cell lines contained higher 
percentages of immature cells (blasts and promyelocytes) and lower percentages of 
intermediate cells (myelocytes, metamyelocytes and immature macrophages) 
than normal bone marrow (Table 3.1).
PERCENTAGE No. OF CELLS OF *SCS
CELLS NBM SA7 SA8 SA2 LP SA2 HP SA2 CL
IMMATURE 18.5 66.6 35.7 43.6 38.0 100
INTERMEDIATE 77.8 28.5 51.5 53.3 54.4 0
MATURE 3.5 4.9 13.5 2.9 7.5 0
Table 3.1 Percentage number of immature, intermediate and mature cells of the bone 
marrow single cell suspension *(SCS) from the leukaemic transplanted cell lines and the 
SA2 CL and normal.
The cellular classification of "immature macrophages" was included in the 
differentials of the cultured leukaemic marrows only. These cells were the size of 
macrophages, contained dark grey blue cytoplasm and an immature blastic nucleus 
with numerous nucleoli. They were classified as intermediate cells.
The differentiability of the bone marrow cells from each of the transplanted 
leukaemic cell lines to WEHI-3B CM, L929 CM and rGM-CSF, singularly and in 
combination, as compared to normal bone marrow is discussed below. The effects of 
the growth factors on the autonomously proliferating SA2 CL will be discussed 
separately.
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3.1.2.1 WEHI-3B CM
WEHI-3B CM sustained the proliferation of normal bone marrow cells to day six
with a 3.4 fold increase in the absolute number of cells per well. WEHI-3B CM 
was effective in sustaining immature normal cells in vitro; there was a 13 fold 
increase in the number of immature cells (Fig. 3.1 A) The most significant increase 
was in the number of promyelocytes. The number of intermediate cells decreased 
1.2 fol<i. Differentiation inductton was observed in botth the monocyttc and 
granulocytic series with a 17 fold increase in the absolute number of mature cells 
per well. WEHI-3B CM was more effective in sustaining normal immature cells in 
culture than inducing differentiation. Immature cells constituted 59% of the 
normal bone marrow differential at day six when stimulated with WEHI-3B CM 
(Appendix Table A3.1). These results were depicted with a negative gradient in 
the maturation index (Fig. 3.2 A). The differential data was paralleled with the 
phagocytosis study where a relatively low percentage (Fig.3.3 A) and absolute 
number of phagocytic cells (Fig. 3.4 A) were observed in the normal bone marrow
cultures.
WEHI-3B CM also sustained the proliferation of the SA7 leukaemic bone marrow 
cells to day six, the increase in the absolute number of cells per well was higher 
than that of normal, 4.2 fold (Fig. 3.1 B). WEHI-3B CM was not as effective at 
sustaining immature cells of the SA7 leukaemia as it was of normal bone marrow. 
There was only a 1.5 fold increase in the number of immature cells and immature 
cells only constituted 24% of the SA7 differential on day six (Appendix Table 
A3.4). Hence, WEHI-3B CM appeared to be a more potent stimulator of normal
blast cells than the SA7 leukaemic blast cells. Differentiation induction of the
SA7 leukaemic bone marrow was more effective than that observed with normal.
Intermediate cells increased 3.7 by day six in culture and the number of mature 
cells increased 33 fold, the most significant increase being in the number of
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macrophages. The proportion of mature cells of the SA7 leukaemia increased
with time in culture whereas the proportion of mature cells of normal bone marrow 
decreased. These two major differences between normal and SA7 leukaemic bone 
marrow cells was depicted in the maturation index. A positive gradient was 
observed with the SA7 leukaemia (Fig 3.2 B) and a negative gradient was 
observed with normal bone marrow (Fig.3.2 A). A higher percentage and absolute 
number of phagocytic cells was observed with the SA7 leukaemia than normal 
bone marrow (Fig's. 3.3 B and 3.4 B).
The SA8 leukaemia was also sustained in culture to day six when stimulated with 
WEHI-3B CM (Fig. 3.1 C). The proliferative response was higher than normal on 
day four and equivalent to normal on day six. There was a 3.6 fold increase in the 
total number of cells per well by day six. Unlike the SA7 leukaemia the total 
number of immature cells from the SA8 leukaemia sustained to day six was high 
and only minimally less than the absolute number sustained with normal bone 
marrow. Immature cells constituted 50% of the SA8 differential on day six. 
Differentiation induction was not as prominent as that observed with normal bone
marrow or the SA7 leukaemia. There was a 1.6 fold increase in the number of 
intermediate cells and only a 7.7 fold increase in the number of mature cells by day 
six in culture. The predominantly negative gradient of the maturation index (Fig. 
3.2 C) depictt thedecrease in the proportion of maturecells to immature cells over
time in culture when the SA8 leukaemic bone marrow cells were stimulated with
WEHI-3B CM. The number of macrophages observed in the differential of the 
SA8 leukaemia (Appendix Table A3.8) were higher than that of normal bone 
marrow (Appendix Table A3.2) and this is depicted in the phagocytosis study 
(Fig's 3.3 C and 3.4 C).
The SA2 LP leukaemia was sustained in culture to day six when stimulated with 
WEHI-3B CM however the proliferative response observed was lower than that
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observed with normal bone marrow or the other leukaemias (Fig. 3.1 D). There
was only a 2.2 fold increase in the total number of cells per well by day six.
Immature cells increased 3.8 fold and the absolute number of immature cells was
high; immature cells constituted 75% of the differential on day six (Appendix 
Table A3.10). Differentiation induction was limited. There was a 1.6 fold 
decrease in the number of intermediate cells and only a 7.4 fold increase in the 
number of mature cells. Depicting these results, the maturation index of the SA2 
LP leukaemia decreased over time in culture (Fig. 3.2 D). The lack of a 
differentiation response was observed with the phagocytosis study (Fig's 3.3 D 
and 3.4 D).
A high proliferative response was observed with the SA2 HP leukaemia (Fig. 3.1 
E). There was a 4.9 fold increase in the total number of cells per well. Immature 
cells increased 4.7 fold. Differentiation induction was higher than that of normal 
and similar to that observed with the SA7 leukaemia by day six. There was a
two fold increase in the number of intermediate cells and a 26 fold increase in the
number of mature cells, predominantly the number of macrophages increased. 
Immature cells constituted 37% of the differential by day six (Appendix Table 
A3.13) and a positive gradient was observed with the maturation index 
indicating differentiation induction (Fig. 3.2 E).
In summary:-
• WEHI-3B CM was more effective in sustaining normal blast cells in culture than
the blasts from the SA7, SA8 and SA2 HP leukaemias but not the SA2 LP
leukaemia.
• A progressive increase in the maturation index over time in culture was only
observed with the SA7 and SA2 HP leukaemias. WEHI-3B CM was more
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effective in inducing differentiation than sustaining immature cells from these
two leukaemias than with normal bone marrow.
• Differentiation induction of the SA8 and SA2 LP leukaemias.was minimal and
less than that of normal bone marrow.
• WEHI-3B CM may be effective in preferentially stimulating normal bone 
marrow and reducing the leukaemic burden of the SA7 and SA2 HP leukaemias.
3.1.2.2 L929 CM
L929 CM was not as effective at stimulating the proliferation of normal bone
marrow cells as WEHI-3B CM. There was a 2.2 fold increase in the total number
of cells per well by day six (Fig. 3.5 A). Normal immature cells were not sustained 
in culture. The number of blast cells decreased progressively, none were detected 
in the differential counts by day six. Promyelocyte number increased two fold by 
day 2 and then decreased. Immature cells constituted 20% and 2% of the 
differential ,on day four and six respectively. The number of intermediate cells 
also decreased, 2.7 fold by day six. Differentiation induction was observed; 
absolute numbers of mature cells increased 54 fold, the most significant increase 
being in the number of macrophages. These results are reflected with the steep 
increase observed with the maturation index between day four and day six (Fig. 
3.6 A). The number of macrophages obtained with the differential of normal bone 
marrow cells (66.5%) (Appendix Table A3.1) is depicted in the phagocytosis study 
(Fig's. 3.7 A and 3.8 A).
L292 CM did not sustain the immature cells of the SA7 leukaemia in culture (Fig. 
3.5 B). There was a 30 fold decrease in the number of immature cells by day six 
and they constituted 11% and <1% of the differential on days four and six
respectively. Differentiation was evident. The number of intermediate cells
increased 1.4 fold, the main increase being in the number of ’immature
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msrrrphsgre'. The absolute number of mature cells per well increased 51 fold. 
L929 CM appeared to be an effective inducer of differentiation of the SA7 
leukaemia however, the increase in the maturation index was not as high as that 
of normal (Fig. 3.6 B). This was mainly attributed to the partial differentiation 
to immature macrophages which were classified as immature cells for the 
determination of the maturation index. A higher number of macrophages were 
counted in the differential of the SA7 leukaemia (Appendix Table A3.4) than 
normal bone marrow and this is depicted by a higher number of phagocytic cells 
(Fig's. 3.7 B and 3.8 B).
Increasing cell numbers of the SA8 leukaemic bone marrow were only observed to 
day four in culture when stimulated with L929 CM (Fig. 3.5 C). A possible reason 
for this was that L929 CM appeared to have an "immediate" differentiation
effect on the SA8 leukaemia. Unlike normal bone marrow and the SA7 
leukaemia, proliferation was observed in the first eight hours of culture 
accompanied with a significant drop in the number of immature cells, an increase 
in intermediate cell numbers (intermediate cens of normal bone marrow and the 
SA7 leukaemia decreased at this time point) and a more significant increase in 
the number of mature cells. By day four immature cell numbers were markedly 
reduced . There was an eight fold decrease in the number of immature cells by day 
four and a 23 fold daeressa by day six. Immature cells constituted 2.7% and 1.2% of 
the differential on days four and six respectively. On day four there was a 1.6 
fold ineresee in the number of intermediate cells and by day six they had 
decreased three fold. Mature eells increased 8 fold by day four, the most 
significant increase being in the number of macrophages. The number of mature 
cells dropped minimally by day six. A positive gradient was observed with the 
maturation index from day two to day six and the value of the maturation index 
was higher than that of normal only on day four (Fig. 3.6 C). The relatively high
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differentiation effect observed with the SA8 leukaemia was stimulated with
L929 CM and was also observed with the phagocytosis study where the number of 
phagocytic cells observed with the SA8 leukaemia was higher than normal bone 
marrow and the other leukaemias (Fig's. 3.7 C and 3.8 C).
L929 CM was not an effective stimulator of the SA2 LP leukaemia, there was only 
a 1.3 fold increase in the total number of cells per well by day six (Fig. 3.5 D). 
Higher numbers of immature cells were sustained in culture than normal bone 
marrow. Immature cells constituted 32% and 6% of the differential on day four 
and six respectively. There was a five fold decrease in the number of 
intermediate cells however, differentiation induction was evident with a 36 fold 
increase in the number of mature cells, mainly macrophages. Differentiation 
induction was less than that observed with normal bone marrow. A positive 
gradient was observed with the maturation index between days four and six only 
(Fig.3.6D), however, the values are less than that of normal because more
immature cells were sustained in culture and less differentiation than normal bone 
marrow was observed. The high percentage of macrophages in the differential 
(Appendix Table A3.10) were also observed with the phagocytosis study (Fig. 3.7 
D). The absolute number of phagocytes was less than observed with normal bone 
marrow (Fig. 3.8 D).
Compared to normal bone marrow and to the other leukaemias a relatively high 
proliferative response was observed with the SA2 HP when stimulated with L929 
CM (Fig. 3.5 E). Similar to the SA8 leukaemia, proliferation of the SA2 HP 
leukaemia was only sustained to day four with L929 CM. Unlike the SA8 
leukaemia an ""immediate" differentiation response was not observed. The 
opposite effect was observed whereby there was a relatively high increase in the 
number of immature cells in the first eight hours of culture and no differentiation 
induction was evident. Intermediate and mature cells number actually decreased
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in the first eight hours. A progressive decrease in the number of immature cells 
was then observed to day six. There was a 1.2 fold decrease in the number of 
immature cells by day four and a 3.7 fold decrease by day six. Immature cells 
constituted 11% and 3% of the differential on day four and six respectively.
Differentiation was evident with a 1.2 fold increase in the number of
intermediate cells by day four, this number however, decreased minimally by day 
six. There was a 27 fold increase in the number of mature cells by day four and a 32 
fold increase by day six. There was a higher increase in the number of
intermediate cells and mature cells than normal bone marrow. Differentiation 
induction was reflected in the maturation index with a positive gradient from day 
two to day six (Fig. 3.6 E), however because higher numbers of immature cells were
sustained in culture than normal bone marrow the maturation index was lower 
than that of normal at each time point. The higher numbers of macrophages 
observed in the differential of the SA2 HP leukaemia compared to normal bone 
marrow was depicted in the phagocytosis study (Fig's. 3.7 E and 3.8 E).
In summary:-
• L929 CM did induce differentiation of leukaemic cells and differentiation 
induction in two cases, the SA7 and SA2 HP leukaemias were higher than that of
normal.
• However, L929 CM sustained more immature leukaemic cells in culture with 
every leukaemia studied than normal immature cells.
• The maturation index was higher for normal bone marrow than the leukaemias 
at each time point, except for the SA8 leukaemia on day four. In the case of the 
SA7 HD leukaemia this was due to the partial differentiation of this leukaemia 
to immature macrophages. In the case of the SA2 LP leukaemia this was because
more immature cells were sustained in culture and less differentiation was
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observed than normal; and in the case of the SA2 HP because higher numbers of 
immature cells were sustained in culture even though differentiation induction 
was higher than that of normal.
• L929 CM may be effective in reducing the leukaemic burden of the SA8
leukaemia.
3.1.2.3 rGM-CSF
rGM-CSF sustained increasing cell growth of normal bone marrow cells to day six 
in culture with a 1.2 fold increase in total cell number per well (Fig. 3.9 A). rGM- 
CSF sustained relatively high numbers of immature normal cells in culture to day 
six. Immature cells increased to day two and then derreaeed to numbers minimally 
lower than the SCS. Immature cells constituted 12% and 9% of the differential on 
day four and six respectively (Appendix Table. A3.1) Intermediate cell numbers 
decreased. Differentiation induction was observed with the predominant mature 
cells being monocytes and macrophages. A positive gradient of the maturation 
index was observed from day two to day six (Fig. 3.10 A). 33% macrophages were 
observed with the differential and this result is paralleled in the phagocytosis 
study (Fig's. 3.11 A and 3.12 A),
rGM-CSF only sustained increasing cell growth of the SA7 leukaemic bone marrow 
cells to day four in culture (Fig. 3.9 B). There was a 2 fold increase in the total 
number of cells per well by day four^h^h was higher than that of normal. No 
"immediate" differentiation induction was observed after eight hours of culture. 
rGM-CSF sustained higher numbers of immature cells from the SA7 to day four in 
culture than normal bone marrow. Immature cells constituted 33% and 5% of the
differential on days four and six respectively. Differentiation induction was 
evident but not as complete as that of normal bone marrow. Partial 
differentiation to the intermediate cell stages was more pronounced than that of
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normal bone marrow, there was a 2.2 fold increase in the number of intermediate 
cells. However, full maturation was significantly less (p<0.01) than that
observed with normal bone marrow with only a 9 fold increase in mature cells: 
absolute numbers of mature cells were similar. An equal increase in the number of 
segmented cells and macrophages was observed. A positive gradient was observed 
with the maturation index, however the value at each time point was less than 
that of normal bone marrow (Fig. 3.10 B). The percentage and absolute number of 
macrophages observed with the differentials of the SA7 leukaemia (Appendix 
Table A3.4) were similar to the percentage and absolute number of phagocytic 
cells (Fig's. 3.11 B and 3.12 B). The absolute number of phagocytes observed with 
the SA7 leukaemia was higher than the number observed with normal bone
marrow.
rGM-CSF sustained increasing cell growth of the SA8 leukaemia to day four in 
culture with a 2 fold increase in the total number of cells at this time point (Fig. 
3.9 C). As with L929 CM "immediate" differentiation and a decrease in immature 
cell numbers was observed after the first eight hours of culture. rGM-CSF was not 
effective in sustaining high numbers of immature cell from the SA8 leukaemia in
culture as normal bone marrow. The absolute number of immature cells decreased
progressively over the six days in culture with a 25 fold decrease by day four. 
Immature cells constituted <1% of the differential at day four. On day six 
however, a recovery phase was observed with the absolute number of immature 
cells, mainly promyelocytes increasing in number. Differentiation induction was 
evident. Intermediate cells increased to day two and then decreased to numbers 
similar to that of the single cell suspension. Mature cells, predominantly 
granulocytic cells, increased to numbers higher than that of normal bone marrow 
on day four. The decreasing number of immature cells and the accompanied
differentiation induction of the SA8 leukaemia was reflected in the maturation
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index where there was a steep positive gradient between day two and day four 
(Fig. 3.10 C). The late recovery phase in the number of immature cells was 
reflected with a negative gradient between day four and day six. On day four of 
culture the percentage and absolute number of phagocytic cells observed with the 
SA8 leukaemia were higher than the number observed with normal bone marrow 
(Fig's. 3.11 C and 3.12 C). This was also the case with the number of macrophages 
observed in the differential studies (Appendix Tables. A3.1 and A3.7).
As with normal bone marrow, rGM-CSF sustained increasing cell growth of the 
SA2 LP leukaemia to day six in culture (Fig. 3.9 D). There was a two fold increase 
in the total number of cells per well by day six. However, unlike normal bone 
marrow, rGM-CSF was very effective in increasing the absolute number of 
immature cells of the SA2 LP leukaemia to day six. Immature cells constituted 
42% and 44% of the differential on days four and six respectively. Intermediate 
cells initially decreased and were then sustained at the same level as that of the 
single cell suspension. An increase in the absolute number of mature cells was 
observed, however the increase in mature cells was less than that observed with 
normal bone marrow. Reflecting these results a negative gradient was observed 
with the maturation index (Fig. 3.10 D). rGM-CSF appeared not to be effective in 
reducing immature leukaemic cells from the SA2 LP leukaemia, or inducing 
enhanced differentiation. Relatively low percentage and absolute numbers of 
phagocytic cells were also obtained (Fig's. 3.11 D and 3.12 D).
rGM-CSF sustained increasing cellular growth of the SA2 HP leukaemia to day 
four in culture with a 3.7 fold increase in the total number of cells per well (Fig. 3.9 
E). The proliferative response observed was greater than that of normal bone 
marrow. Absolute numbers but not the percentage numbers of immature cell 
numbers were higher than that observed with normal bone marrow on day four. 
By day six the number of immature cells was significantly lower (p<0.05) than
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that of normal. Immature ralle ronetitutae 7% and 1% of the differential on day 
four and six respectively. As with the SA7 leukaemia there was prominent 
partial differentiation to the intermediate cell stages on day four with a four fold 
increase in the number of teeea cells. Unlike the SA7 leukaemia the predominant 
intermediate cells were the metamyelocytes. Differentiation to intermediate and 
mature cells was more prominent with the SA2 HP leukaemia than normal bone 
marrow. The predominant mature ealle were the macrophages. The maturation 
index reflected these differentiation results with a relatively steep positive 
gradient between day two and day four (Fig. 3.10 E) and higher values on day four 
and day six than normal bone marrow. The higher numbers of mature cells as 
compared to normal bone marrow was also observed with the phagocytosis study 
(Fig's. 3.11 E and 3.12 E).
In summary:-
• rGM-CSF did not sustain immature cells, and enhanced differentiation induction 
of the SA8 leukaemia more effectively than that of normal bone marrow. 
However, a recoeery phase of immature cells was observed on day six of culture.
• rGM-CSF sustained very high numbers of immature cells of the SA2 LP 
leukaemia to day six in culture. Differentiation was observed with this 
leukaemia, however a negative maturation index was observed indicating that 
rGM-CSF was more effective at sustaining immature cells than enhancing
differentiation of this leukaemia.
• Prominent partial differentiation was observed with the SA7 leukaemia. 
Differentiation to fully mature cells was also observed, however this was less
than that observed with normal bone marrow.
• The SA2 HP leukaemia was highly proliferative in culture with relatively 
high numbers of immature cells being sustained to day four. By day six however.
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the number of immature cells were far fewer than that observed with normal bone
marrow. Differentiation induction of this leukaemia was greater than that of
normal.
• The predominant mature cells obtained with normal bone marrow and each of
the leukaemias differed. The predominant mature cells observed with normal 
bone marrow were monocytes and macrophages, with the SA7 leukaemia there 
were equal numbers of granulocytes and macrophages, with the SA8 and SA2 LP 
leukaemia there were greater numbers of granulocytes and with the SA2 HP 
leukaemia a greater number of macrophages.
• It appeared that rGM-CSF preferentially sustained normal immature cells and 
induced a more enhanced differentiation response of the SA8 and SA2 HP 
leukaemias however,a recovery phase was observed with the SA8 leukaemia and 
a very high initial proliferative response was observed with the SA2 HP
leukaemia.
3.1.2.4 WEHI-3B CM + L929 CM
The results obtained with the combination of WEHI-3B CM plus L929 CM with 
normal and leukaemic bone marrows were generally similar to the results 
obtained with WEHI-3B CM alone.
With normal bone marrow there was an enhanced, but less than additive, 
proliferative response with this growth factor combination (Fig. 3.13 A). There 
was a significant increase in the number of immature cells sustained in culture to 
day six compared to WEHI-3B CM alone. Differentiation was not as high as that 
observed with L929 CM alone however the numbers of both intermediate and
mature cells were greater than the number obtained with WEHI-3B CM alone.
The increase in the number of immature cells was reflected in the maturation 
index which had a steeper negative gradient than that of WEHI-3B CM (Fig.
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3.14 A). The percentage and absolute number of phagocytic cells was also less 
than the numbers observed with either factor alone (Fig’s. 3.15 A and 3.16 A).
An enhanced, but less than additive, proliferative response was observed with 
the SA7 leukaemia on day four (Fig. 3.13 B). An increase in cell number was 
observed in all three cell groups on day four. On day six the total number of cells
obtained was similar to that of WEHI-3B CM alone. The number of immature
cells sustained to day six was greater than the number sustained with WEHI-3B
CM alone. The numbers of intermediate and mature cells were similar with the
two treatments. The enhanced survival of immature cells with the combination of 
growth factors as compared to WEHI-3B CM alone was reflected in the 
maturation index (Fig. 3.14 B). The maturation index at day six with the 
combination of growth factors was lower than the maturation index of WEHI-3B 
CM alone. The percentage and absolute number of phagocytic cells were similar to
the numbers observed with WEHI-3B alone and less than the numbers observed 
with L929 CM alone. Hence, the combination of these two growth factors would 
not be as effective in reducing the leukaemic cells as either factor alone.
No enhanced proliferative response was observed with the SA8 leukaemia when 
stimulated with this factor combination. The cellular proliferative response of 
the SA8 leukaemia was similar to that of WEHI-3B CM alone at each time point 
studied (Fig. 3.13 C). On day four there were fewer immature cells than WEHI-3B 
CM alone and there was an enhanced differentiation response with higher 
numbers of intermediate and mature cells than with either factor alone. On day 
six however, there was a sharp increase in the number of immature cells. A 
greater number of immature cells were sustained to day six than with WEHI-3B 
CM alone. There were fewer intermediate cells than with WEHI-3B CM alone 
and fewer mature cells than with either factor alone. A positive gradient was 
observed with the maturation index between day two and day four and a negative
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gradient was observed between day four and day six (Fig. 3.14 C). Hence at early 
time points in culture, this growth factor combination reduced the osOc of 
immature cells produced compared to WEHI-3B CM and increased differentiation 
induction compared to either factor slone. By day six however, a rccoeety of 
immature cell numbers was observed to levels higher than those observed with 
WEHI-3B CM alone and differentiation was reduced compared to either factor 
alone. The number of phagocytic cells was similar to the number observed with 
WEHI-3B alone (Fig's. 3.15 C and 3.16 C).
An additive proliferative response was observed with the SA2 LP leukaemia 
when stimulated with this factor combination (Fig. 3.13 D). Enhanced survival of 
immature cells was observed on days four and six compared to WEHI-3B CM 
alone. Differentiation compared to WEHI-3B CM alone was also enhanced with
an increase in both the number of intermediate and mature cells. The number of
mature cells on day four was similar to the number obtained with L929 CM alone 
and the number obtained on day six was exactly half way between the number 
observed with each of the factors alone. From these results it appeared that two 
different cell types constituted the SA2 LP leukaemia. One which was 
stimulated to proliferate, and differentiate only minimally with WEHI-3B CM 
and the other which was stimulated to proliferate and differentiste by L929 CM. 
A predominantly negative gradient was observed in the msturation index with 
this factor combination, reflecting the sustained proliferation of immature cells 
and limited differentiation induction (Fig. 3.14 D). The number of phagocytic 
cells observed was higher than the number observed with WEHI-3B CM alone 
and less than the number observed with L929 CM alone (Fig's. 3.15 D and 3.16 D). 
Hence, this growth factor combinstion would not be effective in reducing the 
number of cells from this leukaemia compared to either factor alone. 
Differentiation was increased compared to WEHI-3B CM alone but more
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immature cells are sustained in culture. More immature cells are sustained in
culture than L929 CM alone and less differentiation was observed.
No enhanced proliferative response was observed with the SA2 HP leukaemia 
with this growth factor combination. On day four of culture higher numbers of 
immature and mature cells, and fewer intermediate cells were observed than with 
WEHI-3B CM alone (Fig. 3.13 E). The number of mature cells on day four was 
similar to the number observed with L929 CM alone. On day six only half the
number of blasts sustained with WEHI-3B CM alone was sustained with the
growth factor combination. The numbers of intermediate and mature cells were 
equivalent to the numbers obtained with WEHI-3B CM alone. The number of 
mature cells observed on day six was less than the number observed with L929 CM 
alone. The maturation index over time with the growth factor combination was 
similar to that of WEHI-3B CM alone except with the value at day six which 
was higher with the growth factor combination (Fig. 3.14 E). This reflects the 
fewer immature cells sustained to day six compared to WEHI-3B CM alone. The 
number of phagocytic cells was less than the number observed with L929 CM alone 
and greater than the number observed with WEHI-3B CM (Figs3.15 E and 3.16 E). 
The differences in the phagocytic cell numbers were similar to the differences in 
the macrophage numbers observed in the differentials. These results suggest that 
the SA2 HP leukaemia consists of a cell population which is responsive for 
proliferation and differentiation to both WEHI-3B CM. and L929 CM.
In summary:-
• The combination of WEHI-3B CM plus L929 CM sustained higher numbers of 
immature cells in culture than either growth factor alone from normal bone 
marrow, the SA7, SA8 and the SA2 LP leukaemias.
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• With the SA2 HP leukaemia the number of immature cells sustained in culture
was less then the number observed with WEHI-3B CM alone.
• The combination of WEHI-3B CM plus L929 CM induced the enhanced
proliferation of normal bone marrow and the SA7 leukaemia. For both these bone 
marrows, differentiation was greater than that observed with WEHI-3B alone 
but less than the differentiation observed with L929 CM alone.
• Enhanced differentiation induction with the combination of WEHI-3B CM plus 
L929 CM was only observed with the SA8 leukaemia on day four in culture. 
However this effect was overridden by day six as an increase in immature cells
was observed.
• An additive proliferative response was observed with the SA2 LP leukaemia. 
Differentiation was greater than that observed with WEHI-3B CM alone but less
than with L929 CM alone.
3.1.2.5 WEHI-3B CM + rGM-CSF
A synergistic proliferative response was observed with normal bone marrow at 
day six when stimulated with this factor combination. Enhanced numbers of 
immature cells and enhanced differentiation were observed on day four and six 
(Fig. 3.17 A). This factor combination was more effective in sustaining immature 
cells than inducing differentiation and thus the maturation index at each of the 
time points studied was less than that of either factor alone (Fig. 3.18 A). The 
percentage and absolute number of phagocytic cells were less than the numbers 
observed with either factor alone (Fig's 3.19 A and 3.20 A).
An enhanced but less than additive proliferative response was observed on day 
four with the SA7 leukaemia. Enhanced numbers of immature cells were observed 
on days four and six (Fig. 3.17 B). Differentiation, compared to either factor alone 
was reduced. This growth factor combination was more effective at sustaining
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immature ceils and less effective at inducing differentiation of the SA7
leukaemias than either factor alone. As with normal bone marrow the
maturation index was less st etch time than with either factor slone (Fig. 3.18 
B). The percentage and absolute number of phagocytic cells were less than the 
number observed with either factoo alone (Fig's. 3.19 B and 3.20 B).
An enhanced but less than additive proliferative response was observed with the 
SA8 leukaemia on day four and six. The number of immature eelle observed on day 
four was markedly lower than the number observed with WEHI-3B CM alone, but 
higheo than the number observed with rGM-CSF alone (Fig. 3.17 C). By day six 
the number of immature cells was only minimally less than the number of observed 
with WEHI-3B CM alone. Differentiation induction was significantly enhanced 
compared to either factor alone on days four and six. The maturation index was 
higher at each time point than with WEHI-3B CM alone but less than that of 
rGM-CSF (Fig. 3.18 C). The number of phagocytic cells was higher than with 
either factor alone (Fig's 3.19 C and 3.20 C).
An enhanced but less than additive response was observed with the SA2 LP 
leukaemia on days four and six. The number of immature cells sustained in culture 
was less than the number sustained with WEHI-3B CM slone and greater than 
the number sustained with rGM-CSF alone (Fig 3.17 D). Diffeoentiation was 
minimally enhanced on day four and markedly enhanced on day six compared to 
either factor alone. Hence this factor combination enhances the differentiation of
the SA2 LP leukaemia without increasing the number of immature cells sustained 
in culture above the number observed with WEHI-3B CM alone. This response was 
reflected in the maturation index with a positive gradient from day two to day 
six compaoed to a negative gradient observed with either growth factor alone 
(Fig. 3.18 D) The number of phagocytic cells were also higher than with either 
factor alone (Fig's 3.19 D and 3.20 D).
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An enhanced but less than additive response was observed with the SA2 HP
leukaemia with this growth factor combination on day four. On day six the 
proliferative response was less than with WEHI-3B CM alone and greater than 
with rGM-CSF (Fig. 3.17 E). Enhanced numbers of immature cells were observed on 
day four however, by day six the numbers were significantly less than that
observed with WEHI-3B CM alone. Differentiation induction was enhanced on 
day four but not on day six compared to either factor alone. The maturation 
indices were generally lower than with either factor alone (Fig. 3.18 E). The 
number of phagocytic cells were less than the number observed with WEHI-3B CM
alone and similar to the number observed with rGM-CSF alone.
In summary:-
• The combination of WEHI-3B CM plus rGM-CSF enhanced the differentiation 
induction of the SA8 and the SA2 LP leukaemias compared to either factor alone. 
The number of immature cells sustained in culture was not enhanced; the numbers
were similar to those observed with WEHI-3B CM alone..
• Enhanced numbers of immature cells and reduced differentiation were observed
with the SA7 leukaemia compared to either factor alone.
• With the SA2 HP leukaemia immature cell numbers sustained were similar to
the number sustained with WEHI-3B CM alone and enhanced differentiation was
only observed on day four.
3.1.2.6 L929 CM + rGM-CSF
An additive proliferative response was observed with normal bone marrow with 
the combination of L929 CM plus rGM-CSF on day six. Enhanced numbers of 
immature cells were observed on days four and six compared to either factor alone 
(Fig. 3.21 A). Differentiation was enhanced on day four; there were higher
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numbers of intermediate cells and mature cells. By day six higher numbers of 
intermediate cell were observed but the number of mature cells was equivalent to 
the number observed with L929 CM alone The maturation index was lower at
each time than with either factor alone reflecting the increased number of 
immature cells (Fig 3.22 A). The number of phagocytic cells was minimally 
higher than the number observed with rGM-CSF and less than the number 
observed with L929 CM alone (Fig's. 3.23 A and 3,24 A).
An enhanced but less than additive proliferative response was observed with the 
SA7 leukaemia with this growth factor combination. On day six the 
proliferative response was similar to that observed with L929 CM alone and 
greater than that observed with rGM-CSF (Fig. 3.21 B). The number of immature 
cells was greater than the number observed with either either factor alone.
Differentiation induction was less than that observed with L929 CM alone and
greater than rGM-CSF alone. The enhanced numbers of immature cells were
reflected in the maturation index which was lower than with either factor alone 
between day 2 and day six (Fig. 3.22 B). The number of phagocytic cells was less 
than the number observed with L929 CM alone and greater than the number
observed with rGM-CSF alone.
The combination of L929 CM plus rGM-CSF sustained increasing cell proliferation 
of the SA8 leukaemia longer than either factor alone (Fig. 3.21 C). An enhanced 
but less than additive proliferative response was observed on day four and a 
synergistic response was observed on day six. The number of immature cells 
sustained in culture was higher than with either factor alone on days four and six. 
The number of intermediate cells were higher on day four and on day six than
with either factor alone. The number of mature cells was similar to the number
observed with L929 and greater than the number observed with rGM-CSF alone on 
day four. On day six enhanced differentiation was observed with higher numbers
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of both intermediate and mature cells than the number observed with either
factor alone. The increase in the number of immature eclle sustained in culture
with this growth factor combination was reflected in the msturation index which 
was lower than with either factor alone on day six (Fig. 3.22 C). The enhanced
differentiation and increase in immature cells numbers is reflected in the
phagocytosis study. The percentage number of phagocytic cells observed with the 
growth factor combination was less then the percentage observed with L929 CM 
and similar to rGM-CSF slone (Fig. 3.23 C). The absolute number of phagocytic 
cells with the growth factor combination was similar to the number observed with 
L929 CM and goeater than the number observed with rGM-CSF (Fig. 3.34 C).
An additive proliferative response was observed with the SA2 LP leukaemia. 
The number of immature cells was greater than the number observed with L929 CM 
alone and less than the number observed with rGM-CSF alone (Fig. 3.21 D). 
Differentiation was markedly enhanced with increased numbers of intermediate 
and mature cells compared to either factor alone by day six. The maturation index 
st each time point was greater than that of eGM-CSF alone and less than that of 
L929 CM alone (Fig. 3.22 D). Two cell populations appear to constitute the SA2 LP 
leukaemia. The percentage and absolute number of phagocytic cells were greater 
than the numbers observed with oGM-CSF; percentage numbers were less but 
absolute numbers goeater than with L929 CM alone (Fig's. 3.23 D and 3.24 D).
An enhanced but less than additive proliferative response was observed with the 
SA2 HP with this growth factor combination on day four and day six. Increasing 
cell proliferation was only sustained to day four as with each growth factor 
alone. Enhanced numbers of immature cells were sustained to day six in culture 
compared to either growth factor alone (Fig. 3.21 E). Partial differentiation 
induction was increased with higher numbers of intermediate cells being observed 
on day six. Differentiation induction to mature cells was not enhanced with
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numbers being equivalent to those observed with L929 CM alone on day six. The
increase in immature cells was reflected in the maturation index which was lower
than with either growth factor alone on days four and six (Fig. 3.22 E). The
number of phagocytic cells was similar to the number observed with L929 CM
alone (Figs 3.23 E and 3.24 E).
In summary:-
• Enhanced numbers of immature cells without enhanced differentiation were
observed with the SA7 leukaemia.
• Enhanced differentiation was observed with the SA8 leukaemia, however this 
was accompanied by enhanced numbers of immature cells.and the maturation 
index was lower than with either factor alone on day six.
• Enhanced differentiation was observed with the SA2 LP leukaemia. The
number of immature cells of the SA2 LP leukaemia sustained in culture was less
than the number sustained with rGM-CSF alone and greater than the number 
observed with L929 CM. The maturation index was greater than with rGM-CSF
alone but less than with L929 CM alone
• Enhanced numbers of immature cells and intermediate cells but not mature cells
were observed with the SA2 HP leukaemia.
3.1.2. The SA2 CL
The autonomously, high proliferative SA2 CL could not be induced to terminally 
differentiate in culture (Fig 3.25) with and without the addition of growth factor. 
In the initial differential ninety-nine percent of the cells were blasts and one 
percent were blastic cells with azurophilic granules and were classified as 
promyelocytes. In FCS alone partial differentiation was observed to Immature 
macrophages'. This partial differentiation was reduced with the addition of
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single growth factors and no difference compared to either factor alone was 
observed with the combination or WEHI-3B CM plus L929 CM or rGM-CSF. An
enhanced differentiation effect was observed with the combination of L929 CM
plus rGM-CSF compared to FCS and either growth factor alone. The lack of
differentiation to terminal end cells of the SA2 CL was also observed with the
phagocytosis study where less than one percent blasts were observed with every
treatment.
3.2 THE INVITRO EFFECTS OF WEHI-3B CM AND L929 CM
ON THE LEUKAEMIC CLONOGENIC CELLS FRACTION AS
MEASURED IN THE IN VIVO CLONOGENIC CELL ASSAY 
In vivo leukaemic donogenic cell assays wrre carried out to determine the 
effectiveness of the physiological regulators to decrease the clonogenic fraction of 
the leukaemic cell population. Because of limited resources only the SA7
A
leukaemia and two of the growth factors were used for this study. WEHI-3B CM 
was used as it sustained a high percentage of immature cells in culture, and L929 
CM as it did not sustain high numbers of immature cells and was an effective
differentiation inducer.
3.2.1 Experimental procedures
A single cell suspension of SA7 leukaemic bone marrow cells was prepared. A 
proportion of the cells were injected into syngeneic recipients at varying cell 
concentrations (10^, 10^ 10^, 10^ and 10 total cells). The remaining cells were 
cultured in the microtitre assay for four days with either FCS, or optimal 
concentrations of WEHI-3B CM or L929 CM. On day four the cells were harvested, 
washed in non-supplemented RPMI, counted and injected into syngeneic recipients 
at the same varying coeceeieaiioes as above. At least five mice were used per
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treatment and percentage survival was monitored wei' 90 days. The results see 
expressed ss the means of three experiments.
3.2.2 Results
The results obtained with the uncultured SA7 leukaemic bone marrow cells are
well established in this laboratory and form the criteris of maintaining the 
transplanted leukaemic cell lines for study (Riches, unpublished data). Thirty 
percent take was observed with as few as 10 cells being injected and 100% take 
was observed with at least 10^ cells being injected (Table 3.2). A significant 
percentage of the leukaemic clonogenic cell fraction of the SA7 leukaemia was 
maintained in FCS alone to day four in the microtitre assay. Proliferation was not 
observed, however differentiation to the macrophage lineage was observed in 
FCS alone in the previous study (Appendix Table A3.5). Only a minimal decrease 
in the clonogenic fraction was observed, and it was not possible to predict whether 
this was due to spontaneous differentiation or to the lack of growth factor for 
enhanced cell survival in vitro. At least 10^ cells were required for a 100% take, 
the injection of 10^ cells resulted in a 70% take and 100% survival to day 90 was 
observed with the injection of 10 cells. The addition of WEHI-3B CM or L929 CM 
to the cultures resulted in a one log reduction of the leukaemic clonogenic cell 
fraction (Fig. 3.27). The addition of L929 CM to cultures resulted in a higheo 
percentage survival than with WEHI-3B CM. With both treatments 10^ cells 
were required for 100% take of the leukaemia. 90% take was observed when 10^ 
WEH1-3B CM treated cells were injected and 80% take was observed with L929 
CM. With the injection of 10^ cells 30% take and 10% take were observed with 
WEH1-3B CM and L929 CM respectively. The injection of 10^ cells treated with 
eitheo CM resulted in 100% survival to 90 days.
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It was difficult from this study to assess whether the conditioned mediums used 
were unable to sustain the leukaemic clonogenic cells in culture or whether the 
clonogenic cells had been induced to differentiate and to consequently lose their 
self-renewal capacity. From the differential data however the SA7 leukaemia
was shown to have maintained its proliferative and differentiative responses to 
physiological regulators. Both absolute immature and mature cell numbers were
shown to increase with stimulation with WEH1-3B CM and mature cells increased
with stimulation with L929 CM. It would appear therefore that at least part of 
the decrease in leukaemic clonogenic cell numbers observed with the addition of 
growth factors may be due to differentiation induction of these cells.
No. Cells PERCENTAGE TAKE OF LEUKAEMIA
Injected UNCULTURED FCS WEHI-3B CM L929 CM
105 100 by day 7 100 by day 13 100 by day 16 100 by day 13
104 100 by day 11 100 by day 18 90 by day 23 80 by day 16
103 100 by day 13 70 by day 28 30 by day 17 10 by day 18
11)2 70 by day 14 20 by day 23 0 to day 30 0 to day 30
10 30 by day 16 0 to day 30 ND ND
Table 3.2 In vivo Clonogenic Cell Assay. Single cell suspension of the SA7 leukaemic 
bone marrow at varied cell concentrations (10^, 10^, 10^, 102 and 10 total cells) was 
injected into syngeneic recipients. Cells from the same single cell suspension were cultured 
for 4 days in the microtitre assay with FCS, and optimal concentrations of WEH1-3B CM or 
L929 CM. The cells were harvested washed in non-supplemented RPMI and injected into 
syngeneic recipients as above. Percentage survival was monitored over 90 days. Results 
were the means of three experiments.
3.3 DISCUSSION
The leukaemias studied had very heterogeneous responses to the different growth
factors. The leukaemias had not completely lost their capacity for 
differentiation caused by the physiological regulators of normal haemopoiesis
studied. The most effective response for the control of leukaemic cell growth
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would be one where differentiation induction was obtained without immature
leukaemic cells being sustained and consequently allowing the reestablishment of 
a normal dominant harmopoirtic clone. If this type of response was possible, 
physiological growth factors may have a therapeutic role in the treatment of the 
disease. This type of response was observed with at least one of the leukaemias 
with each of the growth factors studied singly. WEH1-3B CM was more effective 
in sustaining normal immature cells than SA7 leukaemic immature cells and the 
differentiation induction of the SA7 leukaemia was greater than that of normal. 
L929 CM was more effective in sustaining immature cells of normal bone marrow
than the SA8 leukaemia and the differentiation induction of this leukaemia was 
greater than that of normal bone. rGM-CSF was more effective in sustaining
immature cells of normal bone marrow than the SA8 and the SA2 HP leukaemias
and differentiation induction of these leukaemias was greater than that of 
normal. However, in the case of rGM-CSF a recovery of immature cells was 
observed on day six with the SA8 leukaemia and the SA2 HP had a very high 
proliferative response to day four in culture compared to normal. If this data can 
be projected to in vivo responses, growth factors which induced differentiation of 
leukaemic cells and preferentially sustained normal immature cells may be useful 
therapeutically for each particular leukaemia.
Relatively high numbers of mature cells were observed with the SA2 HP 
leukaemia with each of the growth factors. The differentiation responsiveness of 
this leukaemia may account for it not being sustained in culture for as long as
normal bone marrow or the other leukaemias.
The SA2 LP was the least proliferative leukaemia in culture with each of the 
growth factors. It was also the leukaemia which did not differentiate in culture 
in response to WEH1-3B CM and rGM-CSF. Differentiation was observed with
L929 CM however this was less than the differentiation observed with normal
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bone marrow and higher numbers of immature cells were sustained in culture than 
with normal bone marrow. It appears theoefore, that growth factors would not be
able to be used as differentiation inducers therapeutically in all cases of
leukaemia.
The combination of growth factors generally did not produce more effective 
responses than when they were used singly. In some cases, where diffeoentiation
induction was enhanced the number of immature cells sustained in culture also 
increased making the matuoation index lower than both oo one of the growth 
factors used. In the case of the SA7 leukaemia the combination of oGM-CSF with
WEH1-3B CM oo L929 CM sustained higheo numbers of immature cells and reduced 
differentiation compared to eitheo factoo alone. In the case of the SA2 LP 
leukaemia differentiation was enhanced with the growth factoo combinations
however the number of immature cells sustained in culture was also increased.
This dsts contoadicts some studies on human AML cells in which improved 
differentiation responses were obseoved with combinations of growth factors 
(Lowenberg et al, 1988; Salem et al, 1989).
The SA2 CL was not induced to differentiate in the growth fsctoos studies. The 
growth factors had adverse effects on the spontaneous diffeoentiation observed 
with this leukaemia when grown in FCS slone. WEH1-3B CM decreased the 
partial differentiation, L929 CM decreased the partial differentiation and 
increased the proliferative response and rGM-CSF appeared to have no effect. 
The combination of growth factoos did not enhance diffeoentiation.
The maturation index was an effective way to represent the relationship between
the number of immature cells sustained in culture and diffeoentiation induction.
The determination of the msturation index to determine the effectiveness of both
physiological and non-physiological growth factors on leukaemic cell growth and
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differentiation could be easily implemented in conjunction with automated total 
cell and differential cell counting.
The phagocytosis assay was used to help confirm the differential data. The use
of this assay alone and the reporting of only the percentage of phagocytic cells
however, would have given misleading results.
No specific pattern for subgrouping the leukaemias became apparent with this 
study, however only a small sample was used. From the heterogeneity of the 
responses obtained it appears that the effects of growth factors on leukaemias
will need to be evaluated on an individual basis.
From the clonogenic cell assay it was evident that the treatment of leukaemic 
cells with physiological growth factors reduced the number of leukaemic 
clonogenic cells. This may have bearing on the possibility of direct use of 
physiological growth factors as part of a therapeutic regime or to purge the 
leukaemic cells from long term bone marrow cultures for autologous transfusion. 
There has been a lot of controversy from numerous studies on the suitability of 
physiological growth factors as therapeutic agents for myeloid leukaemia as the 
haemopoietic growth factors may potentially activate residual leukaemic cells 
expressing CSF receptors and messenger RNA. In numerous studies it was shown 
that GM-CSF stimulated the growth of blast progenitors suggesting that it may be 
contraindicated in the treatment of any condition related to AML or capable of 
progression to that disease (Hoang et al, 1986; Nara and McCulloch, 1985). 
However, in Hoang's study partial differentiation of some of the blasts studied
was obtained. What become evident was that both normal and leukaemic cells 
are stimulated by the normal physiological growth factors, the response by 
leukaemic cells being varied between patients. However, what had not been 
established was whether in some leukaemic conditions the normal cell population 
might be more responsive to growth factor than the leukaemic population and
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therefore the suppressed normal clones may be restored as dominant. This may 
become important as an effective maintenance therapeutic regime, keeping
minimal residual disease in check.
In this study, as far as we were aware, we were the first to identify murine
leukaemic clones which were induced to differentiate with M-CSF. The existence
of such clones has been previously postulated as M-CSF has been shown to increase 
the functional activities of mature myeloid cells (Ziboh et al, 1982; Tushinski and 
Stanley, 1983; Vadas et al, 1983; Chen and Lin, 1984; Gasson et al, 1984) and there 
are myeloid leukaemic cell lines which have M-CSF receptors (Guilbert and 
Stanley, 1980). Therefore it had been predicted that it may also act as a 
physiological differentiation inducing agent. In the study of human AML M-CSF 
stimulated little or no proliferation of AML blasts (Miyauchi et. al, 1988; Suzuki 
et. al, 1988) and its major effect seemed to be the induction of differentiation 
(Lowenberg et al, 1988; Salem et al, 1989). In Miyauchi's study an increase in the 
number of adherent macrophages was observed in suspension cultures of AML 
blasts with the addition of M-CSF. It was proposed that the adherent cells were 
progeny of leukaemic and not normal blasts. Miyauchi et al and Suzuki et al 
showed that M-CSF, in contrast to IL-3, GM-CSF and G-CSF did not stimulate the 
self-renewal of AML blasts and that its major effect on such cells was the • 
stimulation of terminal cell divisions. Our differential data was in keeping with 
these two observations. Mayani in 1991 studied the effects of exogenously added 
M-CSF on human AML blasts in long term bone marrow cultures. They did not 
have direct evidence on the differentiate effects of M-CSF on leukaemic blasts, 
however they showed that the addition of M-CSF resulted in the stimulation of 
putative normal haemopoiesis and inhibition of its putative leukaemic 
counterpart. A significant decrease in the number of blasts in the cultures were 
observed. In a very recent study by Ferrero et al, (1992) it was shown that M-CSF
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reduced the number of leukaemic colony forming units (L-CFU) in some cases of
myelomonocytic leukaemia.
The action of GM-CSF on human myeloid leukaemic cells has been found to be 
primarily proliferative with uncoupling of differentiation (Moore, 1987; 
Lowenberg et al, 1988) however differentiation of the HL-60 cell line with GM- 
CSF has been reported (Moore, 1987).
We show that the radiation induced murine leukaemic models varied in their 
response to differentiation induction with the growth factors used. From our study 
and studies by others it appears to be indicated that most and possibly all the 
physiological regulatory proteins of the normal myeloid haemopoietic system 
have a potential use in differentiation induction therapy in myeloid leukaemia 
and that the leukaemic clonogenic cell fraction can be reduced with the use of 
physiological regulators of normal haemopoiesis.
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Figure 3.1 Differentiation study. Cells were cultured for eight hours, two, four 
and six days with optimal concentration of WEHI-3B CM in the micootitoe assay. 
Cyb^res were prepared and differentials were counted.
Immature cells = blasts, promyelocytes
Intermediate cells = myelocytes, immature monocytic cells and metamyelocytes 
Mature cells = bands, ecgmcntcee, monocytes and macropesgce
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Figure 3.2 Differentiation study. Cells were cultured for eight hours, two, four 
and six days with optimal concentration of WEHI-3B CM in the microtitre assay. 
Cytospins were prepared, differentials were counted and the maturation index 
determined.
Maturation Index = mature cells/immature cells
Mature cells = metamyelcccytes, bands,segmtenteds, moncx^ytes, macrophages
Immature cells = Watts, pcomyelocytes, myelocytes, immature monocyiic cells
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Figure 3.3 Normal and leukaemic cells were cultured for eight hours, two, four 
and six days in the microtitre assay with optimal concentration of WEHOB CM. 
Cells were incubated for eight hours with 0.8|r latex particles prior to cytospins 
being prepared. The percentage number of phagocytic cells was determined.
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Figuee 3.4 Normal and leukaemic rcHe were cultured for eight hours, two, four 
and six days in the micootitre assay with optimal eonecntoatcon of WEHI-3B CM. 
Cells were incubated for eight hours with O.8jj. latex particles prior to cytospins 
being prepared. The absolute number of phagocytic cells was determined.
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Figure 3.5 Differentiation study. Cells were cultured for eight hours, two, four 
and six days with optimal concentration of L929CM in the microtitre assay. 
Cytospins were prepared and differentials were counted.
Immature cells = blasts, promyelocytes
Intermediate cells = myelocytes, immature monocytic cells and metamyelocytes 
Mature cells = bands, segmenteds, monocytes and macrophages
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Figure 3.6 Differentiation study. Cells were cultured for eight hours, two, four 
and six days with optimal concentration of L929 CM in the microtitre assay. 
Cytospins were prepared, differentials were counted and the maturation index 
determined.
Maturation Index = mature cells/mmature cells
Mature cells = metamyelocytes, bands, segmenteds, monocytes, macrophages 
Immature cells = blasts, promyelocytes, myelocytes, immature monocytic cells
DAY DAY
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Figure 3.7 Normal and leukaemic cells were cultured for eight hours, two, four 
and six days in the microtitre assay with optimal concentration of L929CM. 
Cells were incubated for eight hours with O.S|r latex particles prior to cytospins 
being prepared. The percentage number of phagocytic cells was determined.
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Figure 3.8 Normal and leukaemic cells were cultured for eight hours, two, four and 
six days in the microtitre assay with optimal concentration of L929 CM. Cells were 
incubated for eight hours with 0.8x latex particles prior to cytospins being prepared. 
The absolute number of phagocytic cells was determined.
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Figure 3.9 Differentiation study. Cells were cultured for eight hours, two, four and 
six days with optimal concentration of rGM-CSF in the microtitre assay. Cytospins 
were prepared and differentials were counted. (*p<0.01 A singificantly higher percen­
tage number of mature cell were obtained with NBM compared to the SA7 leukaemia. 
•p<0.05 A singificantly lower number of immature cells were observed with the SA2 
HP leukaemia than NBM).
Immature cells = blasts, promyelocytes
Intermediate cells = myelocytes, immature monocytic cells and metamyelocytes 
Mature cells = bands, segmenteds, monocytes and macrophages
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Figure 3.10 Differentiation study. Cells were cultured for eight hours, two, 
four and six days with optimal concentration of rGM-CSF in the microtitre assay. 
Cytospins were prepared, differentials were counted and the maturation index 
determined.
Maturation Index = mature cells/immature cells
Mature cells = metamyelocytes, bands, segmenteds, monocytes, macrophages 
Immature cells = blasts, promyelocytes, myelocytes, immature monocytic cells
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Figure 3.11 Normal and leukaemic cells were cultured for eight hours, two 
four and six days in the microtitre assay with optimal concentration of rGM-CSF. 
Cells were incubated for eight hours with' 0.8n latex particles prior to cytospins 
being prepared. The percentage number of phagocytic cells was determined.
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Figure 3.12 Normal and leukaemic cells were cultured for eight hours, two, 
fours and six days in the microtitre assay with optimal concentration of rGM-CSF. 
Cells were incubated for eight hours with 0.8p latex particles prior to cytospins 
being prepared. The absolute number of phagocytic cells was determined.
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Figure 3.13 Differentiation study. Cells were cultured for eight hours, two, four 
and six days with optimal concentrations of WEHI-3B CM plus L929 CM in the 
microtitre assay. Cytospins were prepared and differentials were counted. 
Immature cells = blasts, promyelocytes
Intermediate cells = myelocytes, immature monocytic cells and metamyelocytes 
Mature cells = bands, segmenteds, monocytes and macrophages
4 6
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Figure 3.14 Differentiation study. Cells were cultured for eight hours, two, four 
and days with optimal concentration of WEHI-3B plus L929 CM in the microtitre 
assay. Cytospins were prepared, differentials were counted and the maturation 
index determined.
Maturation Index = mature cells/mmature cells
Mature cells = metamyelocytes, bands, segmenteds, monocytes, macrophages 
Immature cells = blasts, promyelocytes, myelocytes, immature monocytic cells
DAY DAY
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Figure 3.15 Normal and leukaemic cells were cultured for eight hours, two, four 
and six days in the microtitre assay with optimal concentration of WEHI-3B CM 
plus L929CM. Cells were incubated for eight hours with 0.8p. latex particles 
prior to cytospins being prepared. The percentage number of phagocytic cells 
was determined.
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Figure 3.16 Normal and leukaemic cells were cultured for eight hours, two, four 
and six days in the microtitre assay with optimal concentrations of WEHI-3B CM 
plus L929CM. Cells were incubated for eight hours with 0.8p. latex particles 
prior to cytospins being prepared. The absolute number of phagocytic cells 
was determined.
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Figure 3,17 Differentiation study. Cells were cultured for eight hours, two, four and 
six days with optimal concentration of WBHI-3B CM plus rGM-CSF in the microtitre 
assay. Cytospins were prepared and differentials were counted.
Immature cells = blasts, promyelocytes
Intermediate cells = myelocytes, immature monocytic cells and metamyelocytes 
Mature cells = bands, segmenteds, monocytes and macrophages
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Figure 3.18 Differentiation study. Cells were cultured for eight hours, two, 
four and days with optimal .concentration of WEHI-3B CM plus rGM-CSF 
in the microtitre assay. Cytospins were prepared, differentials were counted 
and the maturation index determined.
Maturation Index = mature cells/immature cells
Mature cells = metamyelocytes, bands, segmenteds, monocytes, macrophages
Immature cells = blasts, promyelocytes, myelocytes, immature monocytic cells
DAY DAY
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Figure 3.19 Normal and leukaemic cells were cultured for eight hours, two, four 
and six days in the microtitre assay with optimal concentration of WEHI-3B CM 
plus rGM-CSF. Ceils were incubated for eight hours with 0.8|i latex particles prior 
to cytospins being prepared. The percentage number of phagocytic cells was 
determined.
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Figure 3.20 Normal and leukaemic cells were cultured for eight hours, two, four and 
six days in the microtitre assay with optimal concentrations of WEHI-3B CM plus 
rGM-CSF. Cells were incubated for eight hours with 0.8p. latex particles prior to cytospins 
being prepared. The absolute number of phagocytic cells was determined.
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Figure 3.21 Differentiation study. Cells were cultured for eight hours, two, four 
and six days with optimal concentration of L929 CM plus rGM-CSF in the microtitre 
assay. Cytospins were prepared and differentials were counted.
Immature cells = blasts, promyelocytes
Intermediate cells = myelocytes, immature monocytic cells and metamyelocytes 
Mature cells = bands, segmenteds, monocytes and macrophages
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Figure 3.22 Differentiation study. Cells were cultured for eight hours, two, 
four and six days with optimal concentration of L929 CM plus rGM-CSF in 
the microtitre assay. Cytospins were prepared, differentials were counted and 
the maturation index determined.
Maturation Index = mature cells/immature cells
Mature cells = metamyelocytes, bands, segmenteds, monocytes, macrophages 
Immature cells = blasts, promyelocytes, myelocytes, immature monocytic cells
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Figure 3.23 Normal and leukaemic cells were cultured for eight hours, two, four 
and six days in the microtitre assay with optimal concentration of L929 CM plus 
rGM-CSF. Cells were incubated for eight hours with 0.8n latex particles prior to 
cytospins being prepared. The percentage number of phagocytic cells was determined.
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Figure 3.24 Normal and leukaemic cells were cultured for eight hours, two, four and 
six days in the microtitre assay with optimal concentration of L929 CM plus rGM-CSF. 
Cells were incubated for eight hours with 0.8p latex particles prior to cytospins being 
prepared. The absolute number of phagocytic ceUs was determined.
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Figure 3.25 Differentiation study. The SA2 CL was cultured for eight hours, 
two, four and six days with optimal concentration of growth factor(s) in the 
microtitre assay. Cytospins were prepared and differentials were counted. 
Immature cells =blasts, promyelocytes
Intermediate cells=myelocytes, immature monocytic cells, metamyelocytes 
Mature cells =bands, segmenteds, monocytes and macrophages
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Figure 3.26 Differentiation study. Cells from the SA2 CL were cultured for eight hours, 
two, four and six days with optimal concentration of growth factor(s) in the microtitre 
assay. Cytospins were prepared and differentials were counted.
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Figure 3.27. In vivo Clonogenic Cell Assay. Uncultured single cell 
suspension and cells cultured for four days in the microtitre assay with 
FCS, and optimal concentrations of WEHI-3B CM or L929CM' from the 
SA7 leukaemic bone marrow were injected into syngeneic recipients at 
varied cell concentrations (10 , lO4, 10^, 102, 10 total cells). Percentage 
leukaemia free survival was monitored for 90 days.
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CHAPTER FOUR
DIFFERENTIATION EFFECTS OF p-ALL TRANS 
RETINOIC ACID ON LEUKAEMIC AND NORMAL
BONE MARROW CELLS
Current therapeutic regimes for the treatment of acute myeloid leukaemia (AML) 
rely upon non-specific cytotoxicity and although a number of advances have been 
made with various combinations and scheduling of chemotherapeutic agents a 
significantly high percentage of patients relapse. Often the leukaemic clones 
present in relapse are aggressive and refractory to treatment (Chomienne, 1991). 
Differentiation induction regimes may be able to provide a maintenance rather 
than cure strategy approach for the treatment of AML. What remains to be 
elucidated is whether long term use of differentiation inducing agents would 
prevent the emergence of refractory leukaemic clones and maintain the patient in 
long term complete remission.
It has been postulated that induction of differentiation of leukaemic cell 
populations may be compensated by an increase in the proliferation of leukaemic 
clonogenic cell fraction (Francis et al 1985). Studies however, have not been 
extended to determine whether differentiation induction with patRA increases or 
decreases the leukaemic clonogenic cell fraction. The role of patRA in the 
maintenance of remission has not been elucidated. These studies are important in 
determining whether complete long term remission is obtainable in PatRA 
responsive patients. The transplanted murine leukaemic cell lines provide a 
useful tool for in vivo studies on leukaemic clonogenic cells.
The aim of this study was three fold:-
1. To stuud the differentiation effect of PatRA on bone marrow cells from the 
myeloid leukaemic models in vitro.
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2. To determine any differences in response to PatRA when growth factors with
different modes of action on normal and leukaemic cells were used in the culture
system. The two growth factors studied were WEHI-3B CM, which was shown to
sustain relatively high numbers of immature leukaemic cells in culture, and L929
CM which was more effective as a differentiation inducer of leukaemic cells than
WEHI-3B CM and sustained fewer immature cells.
3. To determine whether differentiation induction by PatRA decreases the 
clonogenic leukaemic cell fraction in vitro. An in vivo Clonogenic Cell Assay was 
used for this study.
Studies in vitro have shown that RA was a potent inducer of myeloid 
differentiation both in the promyelocytic cell line HL-60 and fresh promyelocytes 
from patients with acute promyelocytic leukaemia (APL) (Lippman et al, 1987; 
Breitman et al, 1981; Douer and Koeffler, 1982a; Fabian et al, 1986; Imaizumi et
al, 1987; Lawrence et al, 1987). RA induced differentiation at concentrations 
which were pharmacologically tolerable to humans and differentiation induction 
has been achieved in vivo in patients with APL (Flynn et al,.1983; Nilsson, 1984; 
Daenen et al, 1986; Fontana et al, 1986). Previous studies have employed 13-cis 
RA, our aim was to evaluate the efficacy of patRA.
4.1 /A VITRO PROLIFERATIVE EFFECTS OF p-ALL TRANS
RETINOIC ACID ON LEUKAEMIC AND NORMAL CELLS.
Preliminary in vitro studies were carried out to determine the concentration of
patRA necessary to reduce the proliferation of normal and leukaemic bone marrow 
cells and cells from the SA2 CL by utilizing the uptake of ^H-TdR in the
microtitre assay.
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4.1.1 Experimental Procedure
Single cell suspensions of normal and leukaemic bone marrow cells and cells from 
the SA2 CL were cultured in the microtitre assay for four days with decreasing 
concentrations of PatRA (10"\ 10-6,10’7, 10“® and 10"^ M total concentration per 
well). For the growth factor dependent cells, WEHI-3B CM was used in culture as 
the growth factor source as it was observed to induce the highest proliferative 
and least differentiative effects of the growth factors used in this study (see 
Chapter 4). On day four the cells were pulsed with ®H-TdR for eight hours, 
harvested and the ®H-TdR uptake measured on the scintillation counter. The 
CPM results were expressed as Tercentage of Untreated Cells' and plotted.
5.1.2 Results
10'^M all-trans patRA had a toxic effect on normal and leukaemic bone marrow 
cells and the proliferative response of the SA2 CL as measured by the uptake of 
3H-TdR was 14% of the untreated control. Concentrations of 10"^M and/or lO'^M 
PatRA were effective in reducing the proliferative response of normal and 
leukaemic bone marrow cells and cells from the SA2 CL.(Fig. 4.1). The SA2 
leukaemias were more susceptible to these two concentrations of patRA than 
normal bone marrow, the SA7 and SA8 leukaemias. lO'^M. PatRA reduced the 
proliferation of normal bone marrow, SA7 and SA8 leukaemic cells to 
approximately 55%, the SA2 LP leukaemia to 8%, the SA2 HP leukaemia to 40% 
and the SA2 CL to 25%. 10“?M PatRA reduced the proliferation of normal and the 
SA7, SA8 and SA2 HP leukaemias approximately 84%, the SA2 LP to 33% and 
the SA2 CL to 64%. Minimal to negligible decreases in proliferation were 
observed with 10'® M and lO'^M PatRA with normal bone marrow and all the 
leukaemias except the SA2 LP which was reduced to 74% with 10"®M and 83% 
with lO'^M.
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For the study of the differentiation effects of patRA on the leukaemic cells.W^M 
and 10"?M total concentration per well were used.
4.2 IN VITRO DIFFERENTIATION EFFECTS OF p-ALL TRANS
RETINOINC ACID ON LEUKAEMIC AND NORMAL CELLS
The differentiation effects of PatRA on normal and leukaemic bone marrow cells 
and cells from the SA2 CL were investigated utilizing the microtitre assay, 
preparation of cytospins and counting differentials. The differences in 
differentiation responses between the combination of PatRA and WEHI-3B CM 
(which induced a high proliferative response and sustained a relatively high 
proportion of immature cells in culture) and L929 CM (which induced a lower 
proliferative response, sustained a relatively low proportion of immature cells 
and enhanced differentiation) were investigated. The addition of growth factors 
was necessary to maintain the growth factor dependent bone marrow cells in 
culture. The growth factors have been shown to have differentiative effects on 
the leukaemic and normal bone marrow cells used in these studies and these may 
augment the responses observed with the addition of patRA. Consequently, the 
responses observed with the patRA treated cells were compared to the responses 
observed with growth factor alone.
4.2.1 Experimental Proccdure
a) Single cell surpentioct oo nonnaa and lenrkemic booe marrow cells and cells; 
from the SA2 CL were cultured for four days in the microtihe assay with two 
concentrations of patRA shown to have an effect on the peolifeentind on normal 
and leukaemic cells as investigated in section 5.1 (10"? M and 10"? M PatRA total 
concentration per well). WEHI-3B CM and L929 CM were used as sources of 
growth factor and the differences in differentiation response between each of the
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two factors and patRA were compared. The cells were cultured in FCS alone as a
control.
b) On day four the total cell count per well was determined, cytospins were
prepared, stained and full differentials counted. At least 500 cells were counted 
per slide. Differentials were determined as both percentage and absolute number 
per well. All experiments were carried out in quadruplicate.
c) The differentials were plotted as 'stack graphs' showing the absolute number of 
immature cells (blast and promyelocytes), intermediate cells (myelocytes, 
metamyelocytes and ’immature macrophages') and mature cells (segmenteds, 
bands, monocytes and macrophages).
d) From the differential data the maturation index was determined.
e) The number of phagocytic cells for each test group was determined. The cells 
were cultured as described above and on day four they were incubated with 0.8p 
latex particles for eight hours. Cytospins were prepared, stained and the 
percentage and absolute number of cells per well containing greater than 10 
particles was determined. At least 1000 cells were counted per slide and the 
results were reported as both percentages and absolute number per well.
4.2.2 Results
4.2.2.1 FCS + P-all trans Retinoic Acid
Decreases in the total cell number per well were observed in cultures containing 
FCS alone with the growth factor dependent leukaemic bone marrow cells and 
normal bone marrow. Cell counts and the percentage of viable cells were low by 
day four and consequently these cultures were not used for comparative studies
(Table 4.1).
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An increase in the total cell number per well of the SA2 CL was observed in FCS 
cultures (Table.4.1). With the addition of PatRA an inhibitory response 
was observed without evidence of differentiation from the morphological studies 
(Fig. 4.2 F). The absolute number of blast cells decreased to half the number 
observed with FCS alone with the addition of both concentrations of patRA. The 
addition of WEHI-3B CM or L929 CM did not alter the response observed with the
FCS cultures.
4.2.2.2 WEHI-3B CM + P-all trans Retinoic Acid
lO’^M PatRA enhanced the differentiation of normal bone marrrow cells (Fig. 4.2 
A). The proportion of immature:intermediate:mature cells of normal bone marrow 
when cultured with WEHI-3B CM alone were 45:25:30 (Appendix Table A4.2). 
With the addition of 10'6m PatRA the proportion of immature cells decreased 
13%, the decrease being in the number of promyelocytes; intermediate cell numbers 
were unchanged and an increase in the number of mature cells, both in the 
granulocytic and monocytic series, was observed. The proportions of the three cell 
groups were 32:22:46. No effect on the proportion of cells was observed with 10'^ 
M PatRA. The total cell count per well of normal bone marrow decreased 
minimally with the addition of I0~6m PatRA and increased mildly with lQ’^M 
PatRA as compared to WEHI-3B CM alone. The differential results were 
reflected in the maturation index; the maturation index for WEHI-3B CM alone 
and with W^M patRA was 0.9 and with IO^M PatRA 1.5 (Table 4.2). The 
percentage and absolute number of phagocytic cells were increased compared to 
WEHI-3B CM alone with the addition of both concentrations of PatRA, lO'^M 
patRA being more effective (Fig's.4.3 A and 4.4 A).
A more enhanced differentiation effect was observed with the SA7 HD 
leukaemia with the addition of 10"6M patRA than with normal bone marrow
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(Fig.4.2 B). The proportion of immature:intermediate:mature cells with WEHI- 
3B CM alone was 34:31:34 whereas with the addition of 1O"6M PatRA the 
proportion was 16:23:61 (Appendix Table A4.4). The immature cells decreased 
18% the intermediate cells decreased 8% and the proportion of mature cells 
almost doubled. Unlike normal bone marrow, with the SA7 HD leukaemia an
enhanced differentiation effect was also observed with the addition of 10“7m 
PatRA although, this concentration was not as effective as the higher 
concentration. The proportion of the three cell types with 10“7 M PatRA was 
20:35:44. The total cell number per well was lower with the addition of 
PatRA.than with WEHI-3B CM alone (Table 4.1). The results were reflected in 
the maturation index whereby the value for WEHI-3B CM alone was 1.0, with 10­
6m PatRA 2.2 and with 10“7M patRA 1.3. The percentage and absolute number of 
phagocytic cells were also higher with the addition of PatRA than with WEHI- 
3B CM alone (Fig's. 4.3 B and4.4 B).
MATURATION INDEX
TREATMENT NBM SA7 SA8 SA2 LP SA2 HP
FCS 25.3 2.3 25.8 0.6 5.5
+ 10"6 m RA 34.4 4.4 4.4 1.4 3.7
+ 10“7 M RA 17.1 2.4 10.3 0.9 6.4
WEHI-3B CM 0.9 1.0 2.0 0.3 1.3
+ 10-6 m RA 1.5 2.2 0.8 1.1 1.6
+ 10-7 M RA 0.8 1.3 2.5 0.8 1.2
L929 CM 3.1 3.1 8.1 1.2 3.0
+ 10-6 m RA 148.3 10.1 69.9 5.2 9.1
+ 10-7 m R 58.4 7.2 151.1 10.2 5.3
Table 4.2 Differentiation study. Cells were cultured for 4 days in the microtitre assay 
with FCS, WEHI-3B CM and L929 CM with and without P—all trans RA. Cytospins were 
prepared, stained and full differentials counted. The maturation index was determined from 
the differential cell counts.
Maturation Index = The number of mature cells / The number of immature cells 
Immature cells = Blasts, promyelocytes, myelocytes and immature macrophages.
Mature cells = Metamyelocytes, bands, segmenteds, monocytes and macrophages
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An enhanced differentiation effect was observed with the SA8 HD leukaemia 
with the addition of 10-7m PatRA but not with lO'^M (Fig. 4.2 C). With the 
addition of 10“6M PatRA partial differentiation was observed as blast cell 
numbers were less than with WEHI-3B CM alone and promyelocyte number was 
greater. Intermediate cell numbers were similar to the number observed with
WEHI-3B CM alone. Mature cell numbers were less than WEHI-3B CM alone.
The total cell number per well was less than the number observed with WEHI-3B 
CM alone as was the proliferative response observed in section 4.1. Maturation in 
the granulocytic series was reduced compared to WEHI-3B CM alone. With the 
addition of lO'7M PatRA there was an increase in the total cell number per well, 
however immature cell numbers were half the number observed with WEHI-3B
CM alone, and intermediate and mature cell numbers were greater. Maturation in 
the granulocytic series and in the monocytic series was observed with this 
concentration of PatRA. The proportions of the three cell types were 28:27:45, 
37:28:36, 14:36:49 with WEHI-3B CM alone, plus lO"6M PatRA and plus lO’7M 
PatRA respectively (Appendix Table A4.6). These results were reflected in the 
maturation index (Table 4.2) with the index being lower with the addition of 
10"6m PatRA and higher with the addition of lO'7M patRA than with WEHI-3B 
CM alone. The results observed with the phagocytosis study also paralleled the 
differential data with fewer phagocytic cells being observed with the addition 
of 10"6M patRA and greater numbers of phagocytic cells being observed with the 
addition of lO'7M patRA compared to WEHI-3B CM alone (Fig's. 4.3 C and 4.4 C). 
The addition of patRA at both concentrations studied enhanced the 
differentiation of the SA2 LP leukaemia, with I0_6m patRA being the more 
effective (Fig. 4.2 D). The proportions of the three cell types were 62:20:19 with 
WEHI-3B CM alone, 32:21:46 with 10^M patRA and 41:22:37 with W7M patRA 
(Appendix Table 4.8). The greatest fold increase in mature cell numbers was
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observed with the SA2 LP leukaemia. These data were supported by the results 
in section 4.1 where the greatest reduction in proliferation was observed with the 
SA2 LP leukaemia. Enhanced differentiation was observed to macrophages but 
not in the granulocytic series. The total cell number per well with the addition of 
10‘6m PatRA was similar to the number observed with WEHI-3B CM alone, and 
minimally less with the addition of lO~?M patRA (Table 4.1). The maturation 
index was 0.3, 1.1 and 0.8 for WEHI-3B CM alone, plus 10‘6m patRA and W^M 
PatRA respectively. The percentage and absolute numbers of phagocytic cells 
were also observed to be significantly higher with the addition of both 
concentrations of patRA than with WEHI-3B CM alone (Fig's-. 4.3 D and 4.4 D). 
The bone marrow cells of the SA2 HP leukaemia have been shown to be highly 
proliferative in culture when stimulated with growth factors (Chapter Three). 
With the addition of 10~6m PatRA a significant decrease in the proliferation of 
the leukaemia was observed with the total cell number per well being decreased 
to almost half the number observed with WEHI-3B CM alone (Table 4.1). A 
decrease was observed predominantly in the absolute number of intermediate cells 
(Fig.4.2 E). The absolute number of immature cells was half the number observed
with WEHI-3B CM alone. The absolute number of mature cells was similar to the
number observed with WEHI-3B CM alone, however because of the decrease in 
total cell number with the addition of 10_6m PatRA, mature cells constituted a 
higher percentage of total cells compared to WEHI-3B CM alone. The addition of 
10"7m PatRA only minimally decreased the total cell number of the SA2 HP 
leukaemia compared to WEHI-3B CM alone (Table 4.1). The percentage of cells in 
each group was similar to the number observed with WEHI-3B CM. There were 
differences in the differentiation pattern between WEHI-3B CM alone and the 
addition of 10'^M PatRA. Fewer blasts and more promyelocytes, and fewer 
metamyelocytes and more bands were observed with the addition of lO'^M patRA
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(Appendix Table A4.11). The absolute number of macrophages observed with the 
addition of both concentrations of patRA was less than with WEHI-3B CM alone 
and the number of granulocytic cells was higher. The proportions of each of the 
cell groups were 28:43:30, 25:23:52, and 30:38:32 for WEHI-3B CM alone, plus 
10"6m PatRA and plus lO'^M patRA respectively (Appendix Table A4.10). The 
maturation index obtained with the addition of lO'^M PatRA was minimally 
higher than with either WEHI-3B CM alone or with the addition of W^M 
PatRA (Table 4.2). In this case, where a decrease in total cell number per well was 
observed, the difference in the maturation index between WEHI-3B CM alone and 
the addition of lO'^M PatRA was not large. The maturation index needs to be 
assessed in conjunction with the proliferation results. As described above the 
absolute number of macrophages observed with the addition of patRA was less 
than the number observed with WEHI-3B CM alone; this was reflected in the 
phagocytosis study where the absolute number of phagocytic cells was less with 
the addition of PatRA than with WEHI-3B CM alone (Fig. 4.4 E), however the 
percentage of phagocytic cells with the addition of l.O"^M PatRA was minimally 
higher than the number observed with WEHI-3B CM alone (Fig. 4.3 E).
4.2.2.3 L929 CM + P-all trans Retinoic Acid
L929 CM was shown to induce a lower proliferative response than WEHI-3B BM 
of normal and leukaemic bone marrow. Generally it did not effectively sustain 
immature cells in culture and induced differentiation mainly to macrophages. The 
addition of both concentrations of PatRA to cultures of normal cells grown in L929 
CM enhanced differentiation markedly (Fig. 4.2 A). The proportions of 
immature:intermediate:mature cells were 21:19:60, 0:4:96 and 1:6:93 with L929 CM 
alone, plus lO'^M patRA and lO’^M PatRA respectively (Appendix Table A4.2). 
The total number of cells per well with the addition of lO'^M PatRA was similar
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to the number observed with L929 CM alone. The total cell number observed with
the addition of lO'^M. PatRA was higher than L929 CM alone however the main
increases were in the number of myelocytes and macrophages (Table 4.1). The
enhanced differentiation was reflected in the maturation index. There was a 
marked increase in the maturation index with the addition of lO'^M PatRA. The 
maturation indices were 3.1,148.3 and 58.4 for L929 CM alone, plus lO'^M patRA 
and lO'^M patRA respectively. The differential results were paralleled with the 
phagocytosis study. The percentage and absolute numbers of phagocytic cells were 
higher with the addition of patRA than with L929 CM alone (Fig’s 4.3 A and 4.4 
A). The combination of L929 CM plus patRA was more effective in inducing the
differentiation of normal bone marrow cells than WEHI-3B CM in combination
with patRA.
L929 CM had a higher proliferative effect on the SA7 leukaemia than normal 
bone marrow. The addition of patRA enhanced differentiation but not to the same 
degree as that of normal marrow (Fig. 4.2 B). The proportions of the three cell 
groups were 11:18:71,4:6:89 and 4:12:84 for L929 CM alone, plus lO'^M PatRA and 
10"7m PatRA respectively (Appendix Table A4.4). The addition of PatRA 
increased the total cell number per well compared to L929 CM alone however, the 
increases observed were in the number of mature macrophages (Appendix Table 
A4.5). The total cell numbers per well observed were 14.93, 15.49 and 22.07 x 10^ 
with L929 CM alone, plus lO"^M PatRA and 10"^M PatRA respectively. The 
maturation index with the addition of PatRA was higher than with L929 CM. 
The values were 3.1 for L929 CM alone , 10.1 with the addition of lO"^M PatRA 
and 7.2 with the addition of 10"^M patRA. The increase in the number of 
macrophages observed with the differential data was paralleled with the 
phagocytosis study with the highest absolute number of phagocytic cells being 
observed with lO'^M PatRA (Fig. 4.4 B). The combination of L929 CM plus patRA
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was more effective in inducing the differentiation of the SA7 leukaemic bone 
marrow cells than WEHI-3B CM in combination with PatRA.
The addition of 1O~7m patRA to L929 stimulated bone marrow cells of the SA8 
leukaemia markedly enhanced differentiation (Fig. 4.2 C). The differentiation
observed was similar to the level observed with normal bone marrow cells 
cultured with L929 CM plus lO^M patRA. The proportions of the three cell groups 
were 3:32:65 with L929 CM alone, 0:9:91 with lO'6M PatRA and 0:4:96 with lO'7M 
PatRA (Appendix Table A4.6). The total numbers of cells per well obtained with 
the two concentrations of PatRA were higher than the number observed with L929 
CM alone, the difference being in the number of macrophages (Appendix Table 
A4.7). The maturation indices with the addition of PatRA were markedly higher
than that of L929 CM alone. The values for the maturation indices were 8.1 for 
L929 CM alone, 69.9 with lO^M PatRA and 151.1 with lO'7M patRA. The numbers 
of phagocytic cells were higher with the addition of PatRA than with L929 CM 
alone (Fig's. 4.3 C and 4.4 C). The combination of L929 CM plus PatRA was more 
effective in inducing the differentiation of the SA8 leukaemic bone marrow cells 
than WEHI-3B CM in combination with PatRA.
Both concentrations of PatRA had an enhanced and similar effect on the 
differentiation of the SA2 LP leukaemia compared to L929 CM alone (Fig. 4.2 D). 
The proportion of the three cell groups were 32:22:46, 2:16:82, and 2:16:82 with 
L929 CM alone, 10"6m PatRA and lO"7M PatRA respectively (Appendix Table 
A4.8). The total cell count per well was higher with the addition of PatRA than 
with L929 CM alone, the increase was in the number of macrophages (Appendix
Table A4.9). The differential results were reflected in the maturation index and 
the phagocytosis studies. The maturation indices were 1.2, 5.2 and 10.2 for L929 
CM, plus 10"6m PatRA and lO"7M PatRA respectively. The absolute numbers of 
phagocytic cells were higher with the addition of PatRA than with L929 CM
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alone (Fig. 4.4 D). The combination of L929 CM plus PatRA was more effective in 
inducing the differentiation of the SA2 LP leukaemic bone marrow cells than 
WEHI-3B CM in combination with PatRA.
There was a major difference in the response of the SA2HP leukaemia when 
cultured with L929 CM plus patRA compared to NBM and the other transplanted
leukaemic cell lines. With the SA2 HP leukaemia a decrease in the total cell
number per well was observed with the addition of PatRA compared to L929 CM 
alone (Table 4.1). With the other leukaemic cells and normal bone marrow an
enhanced differentiation effect was accompanied with an increase in the total 
cell number per well compared to L929 CM alone, the difference being in the 
greater absolute number of mature cells. With the SA2 HP leukaemia, as with 
the other cells, a decrease was observed in the absolute number of immature cells, 
however compared to L929 CM alone a decrease was also observed in the absolute 
number of mature cells. The percentage number of mature cells however, was 
greater than with L929 CM alone (Fig. 4.2 E). The proportion of each of the cell 
groups were 11:22:67 with L929 CM alone, 1:20:79 with lO'^M PatRA and 0:21:79 
with 10“7m PatRA (Appendix Table A4.10). The maturation indices with the 
addition of PatRA were higher than with L929 CM alone (Table 4.2). The 
absolute number of macrophages was reduced with the addition of PatRA 
however the percentage number of macrophages was higher because of the 
decrease in the total cell count and these results are reflected in the phagocytosis 
study (Fig’s. 4.3 E and 4.4 E). With these results it was difficult to assess whether 
the addition of PatRA to L929 CM enhanced the differentiation response or 
whether patRA at these concentrations had a cytotoxic effect on bone marrow cells
from the SA2 HP leukaemia.
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4.2.2.4 Summary of the in vitro all-trans Retinoic Acid Induced 
Differentiation of Normal and Leukaemic Cells
In summary, the addition of PatRA was effective in enhancing the differentiation 
of normal and leukaemic bone marrow cells from the transplanted leukaemic cell 
lines. The results are summarised in Table 4.3. The combination of WEHI-3B CM 
plus PatRA was more effective in enhancing the proliferation of leukaemic bone 
marrow cells from the transplanted leukaemic cell lines than normal bone 
marrow, the most enhanced differentiation being observed with the SA2 LP 
leukaemia. Only partial differentiation with a minimal decrease in total cell 
number per well was observed with the SA8 leukaemia with lO'^M patRA, 
however differentiation induction was observed with 1O'7m patRA. The lower 
concentration of lO'^M PatRA also enhanced the differentiation of the SA7 and 
SA2 LP leukaemia but not normal bone marrow cells or the SA2 HP leukaemia. No
differentiation effect was observed with the SA2 CL.
BM
WEHI-3B CM
RA
L----uni
L929 CM
+ 10’6M ra + lO"7M + lO'^M RA + 10-7M ra
NBM + - ++++ +++
SA7 ++ + +++ ++
SA8 *Partial DiffH ++ +++ •+•+++
SA2 LP +++ +++ ++++ ++++
SA2 HP +/1 Cytotoxic - ? DiffS/Cytotoxic ? Diflfl/Cytotoxic
SA2 CL - - - -
Table 4.3 Summary of the degree of enhanced differentiation with the addition of all-trans 
retinoic acid to cultures of normal and leukaemic bone marrow cells from the transplanted 
leukaemic cell lines and the SA2 CL compared to growth factor alone.
♦Difffi = Differentiation
The combination of L929 CM plus PatRA was effective in enhancing 
differentiation of normal bone marrow cells and leukaemic bone marrow cells from
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the SA7, SA8 and SA2 LP leukaemias. The most enhanced differentiation effect 
was observed in normal bone marrow with W^M patRA and the SA2 LP 
leukaemia with both concentrations of patRA. Where differentiation induction
was observed it was more enhanced than with the combination of WEHI-3B CM
plus patRA. 10"6m as well as 10"7 M PatRA enhanced the differentiation of the 
SA8 leukaemia when cultured with L929 CM. The effect of this combination on
the SA2 HP leukaemia was difficult to assess as a decrease in the total cell
number per well was observed with an increase in the percentage but not the
absolute number of mature cells. No enhanced differentiation was observed with
the SA2 CL although the proliferative response was decreased.
4.3 THE IN VIVO CLONOGENIC CELL ASSAY FOR THE 
DETERMINATION OF THE NUMBER OF CLONOGENIC 
LEUKAEMIC CELLS REMAINING IN CULTURE AFTER 
TREATMENT WITH p-ALL TRANS RETINOIC ACID
For this study the number of clonogenic leukaemic cells remaining in culture 
following differentiation induction with lO'^M patRA was measured by injecting 
known numbers of treated and untreated cells into syngeneic recipients and 
recording the difference in percentage survival over time between the two groups. 
Only the SA7 leukaemia was used for this study. Single cell suspension of 
leukaemic cells were cultured for four days with FCS ± lO'^M patRA as control, 
WEHI-3B CM ± 10"6m patRA and L929 CM ± lO'^'M patRA. In the previous study 
10"6m patRA was found to enhance the differentiation of SA7 leukaemic cells 
compared to growth factor alone. Differentiation induction was more enhanced 
with the combination of lO'^M patRA plus L929 CM than with WEHI-3B CM.
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4.3.1 Experimental Procedure
Single cell suspension of SA7 leukaemic bone marrow cells were cultured in the 
microtitre assay for four days with either FCS, or optimal concentrations of 
WEHI-3B CM or L929 CM ± 10’6 M PatRA. On day four the cells were harvested, 
washed in non-supplemented RPMI, counted and injected into syngeneic recepients 
at varying cell concentrations (10^, 10^ 10^, 10^ and 10 total cells in 0.5ml non 
supplemented RPMI). At least five mice were used per treatment and percentage 
survival was monitored over 90 days. The results were the means of three 
experiments.
For controls:-
• the initial single cell suspension was injected into syngeneic recipients at the
same concentrations listed above.
• differentials were counted for each treatment of the cultured cells and compared 
to the experiments in section 5.2.
4.3.2 Results
The results obtained of the single cell suspension of uncultured SA7 leukaemic bone 
marrow cells are well established in this laboratory and form the criteria of 
maintaining the transplanted leukaemic cell lines for study (Riches, unpublished 
data). The results of the survival studies using the uncultured single cell 
suspension were as expected (see section 3.2.2). Leukaemic clonogenic cells were 
sustained in FCS only cultures to day four. The addition of lO'^M PatRA did not 
significantly decrease the leukaemic clonogenic cell number. With 10^ FCS 
cultured cells being injected into syngeneic recipients no leukaemia free survival 
was observed by day 13; with the addition of patRA 20% survival was observed to 
day 90 (Fig. 4.5 A). No difference in percentage survival was observed when 10^ 
and 10-3 FCS ± PatRA cultured cells were injected (Fig's 4.5 B and 4.5 C). When 10^
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cells were injected 100% survival was observed with PatRA treated cells and 80%
survival was observed with FCS only treated cells.
WEHI-3B CM was shown to sustain immature leukaemic cells to day four in 
culture as described in Chapter Three. Enhanced differentiation induction was 
observed when PatRA was added to WEHI-3B CM stimulated cells as observed in 
the morphological studies described in section 5.2. However, no difference in the 
number of clonogenic leukaemic cells being sustained in culture was observed with 
the Clonogenic Cell Assay. There was no difference in percentage survival 
between groups being injected with WEHI-3B CM treated cells and WEHI-3B CM 
plus patRA treated cells (Fig. 4.6).
L929 CM was more effective in inducing differentiation of leukaemic cells and 
sustained fewer immature cells in culture than WEHI-3B CM. The combination of
L929 CM plus PatRA was more effective in inducing differentiation than the 
combination of WEHI-3B CM plus patRA (Section 5.2). With the Clonogenic Cell 
Assay it was found that there was an improvement in percentage survival when 
10^ L929 CM plus PatRA treated cells were injected compared to L929 CM treated 
cells. The percentage of leukaemia free survival with the former was 60% and 
20% by day 90 (Fig. 4.7).
4.4 DISCUSSION
From the proliferation studies utilizing the uptake of 3H-TdR it was noted that 
10"5 M PatRA had a toxic effect on normal and leukaemic bone marrow cells in 
vitro. At concentrations of lO'^M and 10"7 M PatRA a reduction in proliferation 
was observed in all the cell groups. Minimal or no effects on proliferation were 
observed with concentrations of lO'^M or less. Consequently concentrations of 
lO'^M and lO'^M' PatRA were used for the differentiation studies. Retinoids have
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been shown to to enhance clonal proliferation of normal human erythroid (CFU-E) 
and normal myeloid (CFU-GM) precursors in the colony assay (Douer and 
Koeffler, 1982b), however in our study of normal murine progenitors in the 
microtitre assay proliferation of myeloid progenitors decreased with the 
addition of lO“’M and lO’M patRA.
In vitro studies of fresh human bone marrow cells from patients with acute 
prolmyelocytic leukaemia (APL) have been carried out in suspension cultures 
without the addition of growth factor (Flynn et al, 1983; Huang Meng-er et al, 
1988; Chomienne et al, 1990). In our study, suspension cultures in the microtitre 
assay were used with the addition of growth factor as it was found that cell 
numbers and viability in cultures with FCS alone were too low to provide 
acceptable and statistically significant comparative results. Good correlation 
however, was found between our studies and both in vitro and in vivo studies on
human APL and is discussed below.
PatRA was found to enhance the differentiation of both normal and leukaemic 
bone marrow cells but not the SA2 CL. The SA2 LP, which has been shown to be a 
slow proliferating leukaemia in Chapter Two, was more responsive to 
differentiation induction by patRA than the other leukaemias. Unlike human 
acute myeloid leukaemias where only the partially differentiated APL cells 
have been induced to differentiate with PatRA (Breitman et al, 1981) no 
relationship was found between the bone marrow and blood differentials of the 
transplanted leukaemic cell lines and their response to patRA. Cytogenetic 
studies of the transplanted myeloid leukaemic cell lines would be useful in 
identifying any similarity of genetic abnormalities to human myeloid
leukaemias.
Differentiation induction of the transplanted leukaemic cell lines depended on 
the concentration of patRA, and on the growth factor used in the culture system.
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The concentration of PatRA required for a maximal differentiation response
varied with the leukaemia studied and the growth factor used in the culture 
system. When WEHI-3B CM was used as the growth factor source the addition of
PatRA was more effective at inducing the differentiation of the leukaemic bone
k
cells than normal bone marrow cells. lO'6M but not lO'^M patRA induced the 
differentiation of bone marrow cells and the SA2 HP leukaemia; lO'^M patRA 
was more effective than lO_?M with the SA7 leukaemia; lO'^M patRA induced 
the differentiation of the SA8 leukaemia, lO'^M patRA only induced partial 
differentiation; and equivalent differentiation induction of the SA2 LP
leukaemia was observed with both concentrations. When L929 CM was used as
the growth factor source the addition of PatRA was most effective at inducing the 
differentiation of NBM and the SA2 LP leukaemia. Again 10'^M patRA was more 
effective at inducing the differentiation of the SA7 leukaemia than W^M. 
Equivalent differentiation induction was observed with both concentrations with
the SA8 and the SA2 LP leukaemia. These results were consistent with results
obtained by in vitro studies on human leukaemic cells from patients with acute 
promyelocytic leukaemia whereby maximal differentiation induction was 
observed with both lO'^M and lO'^M PatRA (Chomienne et al, 1990).
Increases in total cell count with the addition of PatRA compared to untreated 
controls were observed in conjunction with differentiation induction: these 
increases were in the absolute number of mature cells. The percentages of mature 
cells in PatRA treated samples were also higher than controls. In the study by 
Chomienne et al (1990), using suspension cultures without the addition of growth 
factor a 'trend' in the increase of cell concentration in patRA-treated samples was 
noted and the total cell number in their study was also higher in PatRA treated 
samples than in the controls. They did not specify in which cell population the 
increases were observed; however, they reported that there was no decrease in
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the percentage of differentiated cells. From this evidence they suggested that
PatRA may play a role in the proliferation and survival of some APL clones. In 
clinical trials of patients with APL treated with PatRA increases in the 
peripheral white blood cell count were observed with maturation of the 
leukaemic promyelocytes (Huang Meng-er et al, 1988; Chen et al, 1991). It may be 
argued that the addition of growth factor may mask or enhance the specific effect 
of PatRA; however, suspension cultures with growth factor reflected the results 
obtained in the in vivo studies.
The second aspect of this study was to determine the differences in response of 
leukaemic cells to combinations of PatRA with growth factors having different 
modes of action on normal and leukaemic cells. Except in the case of the SA2 HP 
leukaemia, it was found that the combination of patRA with L929 CM was more 
effective for inducing differentiation than with WEHI-3B CM. L929 CM has been
shown to be a more effective inducer of differentiation and sustains fewer 
immature cells in cultures of the leukaemic cells than WEHI-3B CM (Chapter 
Three). The bone marrow cells from the transplanted leukaemic cell lines used in 
this study were growth factor dependent therefore, comparison of the results could 
not be made to cultures containing PatRA without growth factor. It may be 
concluded however, that a synergistic differentiation response was observed with 
the combination of the two differentiation inducers, PatRA and L929 CM. The 
differentiation inducing factor, G-CSF, which is involved in the terminal 
differentiation of myeloid cells to granulocytes has been shown to co-operatively 
induce granulocyte differentiation of APL cells in vitro with the addition of 
PatRA (Nakamaki et al, 1989). In another study G-CSF but not GM-CSF co­
operated with PatRA on the induction of differentiation of HL60 cells as 
measured by the induction of functional N-formyl-methionyl-phenylalanine 
receptors (Sakashita et al, 1991). The results obtained for the highly
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proliferative SA2 HP leukaemia differed from those of the other leukaemias and
were difficult to assess. Differentiation induction was observed with the 
combination of W^M but not lO'^M PatRA plus WEHI-3B CM and a decrease in 
proliferation without direct evidence of differentiation was observed with the 
combination of both concentrations of patRA and L929 CM.. With the addition of 
PatRA the percentage numbers of mature cells were greater than the percentage 
observed with L929 CM alone however, the absolute numbers of mature cells were 
less. With the methodology used and the data obtained it was not possible to 
determine whether the reduction in proliferation with the addition of PatRA was 
due to differentiation induction, cytotoxicity alone or a combination of both. In a 
study on human AML cells it was found that 13-c/s RA inhibited the in vitro 
colony growth of 17/35 non APL bone marrow samples and that there was no 
evidence of differentiation induction in these samples (Lawrence et al, 1987). In 
the light of these current studies, by us and others, the re-evaluation of patRA in 
combination with physiological regulators of proliferation and differentiation of 
normal haemopoiesis in the treatment of AML is warranted.
The third part of this study was to determine the effects of PatRA on the 
leukaemic clonogenic cell fraction. The SA7 leukaemia which was induced to 
differentiate with PatRA in combination with both growth factors was used for 
this study. Differentiation induction by patRA did not appear to significantly 
decrease the leukaemic clonogenic cell fraction compared to untreated controls as 
assessed by the in vivo Clonogenic Cell Assay. Although PatRA enhanced the 
differentiation induction as observed by the morphological studies, it did not 
significantly reduce the proportion of cells required to induce leukaemia in 
syngeneic recipients. The difference in percentage survival at 10^ cells injected 
between treated and untreated cells was minimally better with the combination 
of patRA and L929 CM than with PatRA and WEHI-3B CM, which supported the
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in vitro morphological data. However, no increase and a minimal decrease in the 
leukaemic clonogenic cell fraction was observed with differentiation induction. 
This evidence, although not conclusive as the cell culture technique used may not 
have adequately supported the leukaemic clonogenic cells, suggests that the 
differentiation induction of the leukaemic clone is not necessarily compensated by 
an increase in the leukaemic 'stem' or clonogenic cell compartment.
In clinical trials of RA relapse was a common occurrence with patients treated 
with patRA and 13-czs RA for APL and other tumours, (Lippman et al, 1987; 
Daenan et al,1986; Fontana et al, 1986; Huang Meng-er et al, 1988; Castaigne et al, 
1990; Chen et al, 1991). Two cases of APL treated with 13-cfs RA reported by 
Daenan et al (1986) and Fontana et al (1986) relapsed in six and twelve months 
respectively. The high percentage of APL patients who successfully achieved 
complete remission (CR) in the clinical trials of PatRA all relapsed between two 
to ten months even with continuous use of PatRA. (Huang Meng-er et al, 1988; 
Castaigne et al, 1990; Chen et al, 1991). Huang Meng-er et al, (1988) observed the 
persistence of abnormal clones with cytogenetic studies and suggested that 
intensive chemotherapy following CR induction with PatRA would be beneficial. 
In the study by Huang Meng-er et al it was shown using bone marrow samples from 
patients with APL in the in vitro colony assay that normal haemopoiesis was 
restored during patRA induced CR. Prior to treatment leukaemic-colony forming 
unit (L-CFU) growth was predominant and normal GM-CFU growth was 
suppressed (<1 colony). During CR GM-CFU reached normal levels and little or no 
growth of L-CFU was observed. On bone marrow samples from patients with APL 
in the clinical trial by Castaigne et al (1990) proliferation studies were carried 
out on PatRA treated cells and controls (Chomienne et al, 1990). Bone marrow cells 
were grown without growth factor in suspension cultures for five days. After one 
hour, on day three and on day five, treated and untreated cells were removed,
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plated in microtitre wells and pulsed with 3H-TdR for one hour. A marked 
reduction in the uptake of 3H-TdR was observed with PatRA treated cells as 
compared to controls from day three and day five samples (78% reduction). It was 
concluded from these studies that PatRA treated cells showed a decrease or 
absence of self-renewal as compared to controls. In our study we attempted to 
quantify the effect of PatRA on clonogenic leukaemic cells and found that they 
persisted, could be minimally reduced and were not increased with differentiation 
induction. Restoration of normal haemopoiesis with the use of patRA has been 
observed in APL patients (Huang Meng-er et al, 1989); however relapse was a 
common occurrence in patients achieving CR. The reason for this may have been 
provided by a pharmacological study by Muindi et al, (1992). It has been shown 
in these studies that oral administration of PatRA was assaciated with a 
significant decrease in plasma peak levels and a significant decrease in the area
under the concentration time curve when measured two to six weeks after
treatment. These decreases highly correlated with clinical relapse and were 
attributed to the induction of accelerated catabolism of patRA with continuous 
administration by an unspecified cytochrome enzyme. It was suggested in this 
study that treatment may be improved by discontinuous dosing schedules. With 
further understanding of the pharmacology of PatRA, a maintanance rather than 
a cell kill strategy therapy for APL , using this differentiation inducing agent 
still appears as a possibility.
The methods used in this study of cell culture of whole leukaemic bone marrow 
samples stimulated with growth factor and the reliance on changes in 
differential cell counts to quantitate differentiation do not provide direct 
evidence on the differentiation effect of patRA. Similar methodology in studies 
using growth factor independent human leukaemic cell lines such as HL60, K-562, 
U-937 and THP-1 which are relatively homogeneous provide more conclusive
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evidence on differentiation induction. Indirect evidence of the differentiation
properties of PatRA in vitro was also reported in conjunction with the in vivo 
clinical trials of patRA in patients with APL (Huang Meng-er et al, 1988; 
Chomienne et al, 1990). In the study by Huang Meng-er et al, (1988) decreases in 
the number of promyelocytes and increases in the number of mature cells were 
observed and the rate of nitroblue tetrazoleum (NBT) reduction was higher with 
PatRA treated samples as compared to controls. They observed the progression of 
cellular differentiation (from promyelocytes to myelocytes to mature 
granulocytes) with morphological studies on the cultured cells over consecutive 
days from days one to eight. Cytochemical analysis and transmission 
electronmicroscopic examination showed evidence of differentiation in PatRA 
treated cells. Chomienne et al, (1990) also employed morphological and 
functional criteria including NBT reduction and granulocyte respiratory burst 
function. With the morphological studies they observed asynchrony of 
maturation between the nucleus and cytoplasm with the persistence of Auer Rods 
in differentiated cells. With PatRA treated cells, as compared to control, they 
also reported an increase in the CDI5 differentiation cell surface antigen and a 
decrease in cellular proliferation. Direct evidence of the differentiation 
induction of cells can be provided only when chromosomal abnormalities 
characteristic of the leukaemic cell population can be detected in mature cells. 
However, the preparation of karyotypes of non dividing mature cells is very 
difficult to achieve. Recently, Lo Coco et al (1991) were able to definitively show 
the differentiation effects of PatRA on human APL cell. They presented a 
molecular evaluation of response to PatRA in patients with APL by analysing the 
RA receptor a (RARa) locus in the patients' cells during treatme^. The gene for 
the RARa has been shown to be rearranged in all cases of APL (de The et al, 1990). 
Le Coco et al showed that the RARa rearrangement persisted in the APL samples
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containing maturing myeloid cells two to three weeks after the start of treatment
but disappeared after five to eight weeks when patients achieved CR.
The differentiation induction properties of RA have been studied on a variety of
tumours including myeloid leukaemias. A variety of tumour types have been
induced to differentiate, including teratocarcinomas (Pierce and Wallace, 1971),
neuroblastomas (Schubert et al, 1971), squamous cell carcinoma (Pierce and
Wallace, 1971), adenocarcinomas of the breast (Decosse et al, 1973) leukaemias
(Metcalf et al, 1969, Paran et al, 1970, Gootwine et al, 1982). Several in vitro
studies have shown that retinoids, especially those with a free carboxyl group
such as 13-c/s RA and PatRA have potent haematopoietic activity (Lippman et
al, 1987). These reports showed that RA induced terminal differentiation and
cessation of growth of several human leukaemic cell lines and marrow cultures
from certain patients with MDS and AML (Lippman et al, 1987; Breitman et al,
1981; Douer and Koeffler, 1982a; Fabian et al, 1986; Imaizumi et al, 1987;
Lawrence et al, 1987). Breitman et al (1981) were the first to study the effects of
PatRA on human AML cells in vitro. Bone marrow cells from 21 patients with
AML were cultured with 10'^M PatRA in suspensions cultures not stimulated with
growth factor. .Differentiation induction was monitored morphologically and
with reduction of NBT Only cells from patients with acute promyelocytic
leukaemia were shown to differentiate in vitro. During the early eighties
attention focused on 13-cis RA. Flynn et al (1983) described the first case of APL
treated with 13-c/s RA. This patient was refractory to conventional
chemotherapy. Bone marrow cells from this patient were shown to differentiate
with the addition of 13-cis RA in vitro and following oral administration a
significant increase in peripheral blood maturing myeloid cells was observed >
after two weeks of treatment. Favourable results were also obtained with other
patients with APL treated with 13-cis RA (Nilsson, 1984; Daenen et al, 1986;
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Fontana et al, 1986). In a study by Lawrence et al (1987) on bone marrow cells from 
35 patients with AML in the colony assay, and stimulated by growth factor, it 
was shown that only cells from the two patients with acute promyelocytic 
leukaemia were induced to differentiate with 13-cis RA. The six FAB subgroups 
of AML were represented in the study. In 17/35 cases inhibition of leukaemic cell 
growth was observed however, in 10/35 cases an enhanced stimulatory response
was observed.
It was not till the late eighties that the first clinical trial of patRA was 
conducted on 24 patients with APL (Huang Meng-er et al, 1988). The results were 
exceptionally promising. 23/24 patients attained CR with PatRA treatment 
alone. Bone marrow samples from these patients were initially treated with 
PatRA in vitro (suspension cultures without the addition of growth factor) and 
these studies were found to be good predictors of the in vivo response. In studies 
by Chomienne et al (1989, 1990) it was shown that PatRA was more effective for
differentiation induction of APL cells both in vitro and in vivo than 13-c/s RA. It
was also shown that both isomers induced maximal differentiation at 10'^M 
however, maximal differentiation was maintained at lO'^M with PatRA but not 
13-cis RA. A second clinical trial of PatRA on patients with APL was conducted 
by Castaigne et al (1990). The high percentage of complete remissions obtained 
with the first study were also obtained with the second. The induction of CR 
with PatRA on patients with APL had a duel impact. Firstly, the theoretical 
notion that differentiation inducers may play a role in the treatment of myeloid 
leukaemia (Sachs, 1978a, 1978b) was realised. Secondly, PatRA induced CR in a 
high percentage of APL patients and avoided the aggravation of disseminated 
intravascular coagulation, which was often the cause of death, than conventional 
induction chemotherapy (Avvisati et al, 1992).
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The mechanism through which RA induces leukaemic cell differentiation has not 
been elucidated although many effects subsequent to RA action have been 
observed at different levels of the cell and activity has been reported to be 
mediated by binding to specific receptors (Chomienne et al, 1990). The action of 
retinoid and RA on cellular differentiation and development might be attributed 
to the induction of protein kinase activity which in turn triggers multiple cellular 
mechanisms to achieve differentiation. (Sporn and Roberts, 1983; Piet and Evain,
1982)
The characteristic chromosomal abnormality of APL is the t(15;17) translocation. 
(Colomb et al, 1976). Recently, the breakpoint on chromosome 17 has been 
localized within the RARa locus while the breakpoint on the chromosome 15 has 
been localized within a new gene named MYL (de The et al, 1990). As a 
consequence of the translocation a new chimeric gene with residual RARa/MYL 
sequences is produced and actively transcribed in APL (de The et al, 1990; Borrow 
et al, 1990; Longo et al, 1990 Alcalay et al 1991). It has been suggested that the 
MYL gene may represent a novel transcription factor and the pertubation by the 
aberrant RARa-MYL fusion product of the MYL transcriptional pathway may 
contribute to APL (Kakizuka et al, 1991). Another explanation put forward is 
that the RARa-MYL fusion product may generate an RARa mutant that 
contributes to acute promyelocytic leukaemogenesis through interference with 
promyelocytic differentiation, (de The et al, 1991). However, it has also been 
shown that the biological effect of RA on APL cells was not related to the level of 
expression of RARa nor to its modulation by RA (Gallagher et al, 1989). It would 
be of interest to determine whether the genetic abnormalities of the transplanted 
myeloid leukaemias which were induced to differentiate with PatRA, eg the SA2 
LP leukaemia, shared any of the genetic abnormalities observed in APL.
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The results obtained with the in vitro studies of RA on bone marrow cells from
radiation induced murine myeloid leukaemia models have paralleled both the in 
vitro and in vivo studies of human myeloid leukaemia. Our studies have shown 
that PatRA could induce the differentiation of myeloid leukaemic cells but could 
not significantly decrease the leukaemic clonogenic cell fraction. Clinical trials 
have shown PatRA to induce but not sustain CR. This may however, be due to the 
pharmacology of RA. The myeloid leukaemic models provided a useful and 
sensitive tool for the determination of the effects of proliferation and 
differentiation inducing agents on leukaemic cells.
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Figure 4,1 Preliminary study on the effect of p-all trans retinoic acid on the 
proliferation of normal and leukaemic bone marrow cells and leukaemic cells from 
the SA2 CL. Single cell suspensions were cultured in the micro titre assay for four 
days with varying concentrations of PatRA. Proliferation was measured utilising 
the uptake of 3H-TdR. For growth factor dependent cells WEHI-3B CM was used 
to stimulate proliferation and growth factor independent cells were cultured in FCS 
alone. The scintillation CPM were converted to "Percentage of Control". Control 
cells were not treated with RA. 10"^ M and HP? M RA were consequently used for 
the differentiation studies.
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□ MATURE CELLS 
E3 INTERMEDIATE CELLS 
■1 IMMATURE CELLS
Figure 4.2 Differentiation Study: Cells were cultured for four days in the microtitre assay with 
FCS, WEHI-3B CM or L929 CM with and without the addition of patRA. Cytospins were prepared 
stained and differentials counted. At least 500 cells were counted per slide.
Mature cells = bands, segmenteds, monocytes and macrophages 
Intermediate cells = myelocytes, immature monocytic cells and metamyelocytes 
Immature cells = blasts, promyelocytes
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Figure 4.3 Differentiation study. Cells were cultured for four days in the 
microtitre assay with FCS, WEHI-3B CM and L929 CM with and without 
PatRA. Two concentrations of patRA were used, 10"? M and Iff? M.
On day four cells were incubated with 8|i latex particles for eight hours. 
Cytospins were prepared, stained and the number of cells containing 
greater than 10 particles was determined. The results depict the percentage 
number of phagocytic cells per well.
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Figure 4.4 Differentiation study. Cells were cultured for four days in the 
microtitre assay with FCS, WEHI-3B CM and L929 CM with and without 
PatRA. Two concentrations of patRA were used, 10"? M and 1(T? M.
On day four cells were incubated with 8} latex particles for eight hours. 
Cytospins were prepared, stained and the number of cells containing 
greater than 10 particles was determined. The results depict the absolute 
number of phagocytic cells per well.
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Figure 4.5 In Vivo Clonogenic Cell Assay.
Single cell suspension of SA7 leukaemic bone marrow cells were cultured in the 
microtitre assay with FCS ± IC"" M PatRA. On day four of culture the cells 
were harvested with a pasteur pipette, the number of viable cells counted and 
varied concentrations of cells were injected into syngeneic recipients to determine 
the number of clonogenic leukaemic cells remaining in culture after each treatment. 
in vitro. Five mice were injected per test group and the percentage survival was 
monitored for 90 days. The results were the means of three experiments and the 
standard error was not greater than 5% for each treatment.
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Figure 4.6 In Vivo Clonogenic CeU Assay.
Single cell suspension of SA7 leukaemic bone marrow cells were cultured in the 
microtitre assay with WEHI-3B CM ± 10^ M (attRA. On day four of culture the 
cells were harvested with a pasteur pipette, the number of viable cells counted and 
varied concentrations of cells were injected into syngeneic recipients to determine 
the number of clonogenic leukaemic cells remaining in culture after each treatment. 
in vitro. Five mice were injected per test group and the percentage survival was 
monitored for 90 days. The results were the means of three experiments and the 
standard error was not greater than 5% for each treatment.
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L929 CM
L929 CM + lO'6M patRA
A. 106 CELLS INJECTED
DAYS
Figure 4.7 In Vivo Clonogenic Cell Assay.
Single cell suspension of SA7 leukaemic bone marrow cells were cultured in 
the microtitre assay with L929CM ± 10"6 M PatRA. On da y four of culture the 
cells were harvested with a pasteur pipette, the number of viable cells counted and 
varied concentrations of cells were injected into syngeneic recipients to determine 
the number of clonogenic leukaemic cells remaining in culture after each treatment. 
in vitro. Five mice were injected per test group and the percentage survival was 
monitored for 90 days. The results were the means of three experiments and the 
standard error was not greater than 5% for each treatment.
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CHAPTER FIVE
AN IN VITRO STUDY OF THE COMBINATION OF A 
DIFFERENTIATION INDUCER, p-ALL TRANS RETINOIC 
ACID, AND A DNA SYNTHESIS INHIBITOR, ARA-C, ON
MURINE MYELOID LEUKAEMIAS.
Combinations of differentiation inducing agents and DNA synthesis inhibitors 
have been shown to have synergistic differentiation effects on bone marrow cells 
from patients with acute myeloid leukaemia (AML) and myelodysplastic 
syndromes (MDS) (Francis et al, 1985, 1987; Ho et al, 1987; Hoffman et al, 1985; 
Hassan and Rees, 1988; Hellstrom et al, 1987). The resultant responses observed in 
vitro suggested that, with the combination of agents which used different modes 
of action, inhibition of proliferation and induction of differentiation, lower, less 
toxic doses of each agent could be used to achieve decreases in the proliferation of 
the malignant clones comparable to high doses of single agents (Francis et al, 
1985). Such therapeutic regimes have been suggested for patients with AML who 
are refractory to conventional chemotherapy, in elderly patients with AML who 
are unfit for aggressive chemotherapeutic protocols and with MDS patients 
whose cytopenias are exacerbated resulting in increased mortality rates with the 
use of conventional chemotherapy. Studies on the combination of these agents 
have been mainly limited to bone marrow cells from patients with MDS (Francis 
et al, 1985; Francis et al, 1987; Ho et al, 1987). Studies on bone marrow cells from 
patients with AML have been limited (Hoffman et al, 1985; Hassan and Rees, 
1988: Hellstrom et al, 1987) and have focused on the use of 13-cfs RA or have not 
specified which RA was employed. Most in vitro studies on the combination of 
differentiation inducing agents and DNA synthesis inhibitors have been 
primarily concerned with enhanced or synergistic increases in the differentiation 
response. In Chapter Four we have shown that all the transplanted leukaemic 
cell lines were induced to differentiate with patRA in WEHI-3B CM stimulated
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cultures. In this study we were primarily concerned with the enhanced or 
synergistic decreases in the proliferative response of leukaemic cells with the use 
of the combination of agents. We aimed to evaluate the combination of patRA 
with cytosine arabinoside (ara-C) for the treatment of myeloid leukaemia by 
monitoring for synergistic decreases in the proliferative response. Normal bone 
marrow, bone marrow cells from the transplanted murine myeloid leukaemias and 
the SA2 CL were studied in vitro. The SA2 transplanted leukaemia was studied 
progressively on consecutive transplantations. The dominant leukaemic clone of 
the SA2 leukaemia has been shown to alter from growth factor independent to 
growth factor dependent in vitro (Chapter Two) and we aimed to monitor changes 
in the response to the combination of agents following serial transplantation.
5.1 EXPERIMENTAL PROCEDURE
a) .Single cell suspensions of normal and leukaemic bone marrow cells and cells 
from the SA2 CL were cultured in the micro titre assay with varying 
concentrations of patRA and ara-C alone and in combination (patRA - IO"'/ loA, 
10"', 10“® and 10"9M: ara-C - 10"' 10"'/10‘®'10“9 and 10"1Qm total concentration 
per well). WEHI-3B CM was used as the growth factor source for the growth 
factor dependent bone marrow cells. It must be noted here that growth factor 
sources provide an intrinsic differentiation stimulus in the culture system and this
will be reflected in the results. WEHI-3B CM was used as it induced a lower
differentiation response and maintained relatively higher numbers of immature 
leukaemic cells in culture than L929 CM or rGM-CSF, as reported in Chapter 
Three. Growth factor independent cells were cultured in FCS alone.
b) The SA2 transplanted leukaemic cell line which has been shown to undergo a 
change from being growth factor independent to growth factor dependent with 
serial transplantation was rederived using frozen cells from passage number 32.
195
The effects of the combination of patRA and ara-C on the SA2 transplanted
leukaemic cell line were investigated progressively on transplantation numbers 36 
to 59 to monitor the differences in response as the leukaemic population altered. 
Four representative studies were documented, transplantation numbers 36 and 39 
which were growth factor independent and transplantation numbers 55 and 59 
which were growth factor dependent.
5.2 RESULTS
5.2.1 The in proliferative effects olf the combination
of PatRA and ara-C on leukaemic and normal bone 
marrow cells
10’® M PatRA and 10"6m ara-C were found to be cytotoxic on normal and leukaemic 
cells. Increases but not decreases in the proliferative response of the normal bone 
marrow cells were observed with the combination of patRA and ara-C compared 
to either agent alone. With the addition of 1O'6m patRA to each of the 
concentrations of ara-C studied the proliferative responses observed were equal to 
the responses observed with ara-C alone (Fig. 5.1 A). With the combination of 
10’6m PatRA and 10"6m ara-C an increase in the proliferative response was 
observed compared to either factor alone (Fig. 5.1 B). With the addition of 1O'6m 
PatRA to 10"®M or 10"0m ara-C the proliferative responses observed were 
equivalent to the responses observed with ara-C alone. With the addition of 
10’® M patRA no differences in response were observed compared to ara-C alone 
(Fig. 5.1 C).
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5.2.2 The in vitro proliferative effects of the combination 
of PatRA and ara-C on the SA7 leukaemia
The pattern of response observed with the SA7 leukaemia was similar to that of
normal bone marrow. Increases but not decreases in the proliferative response of
the SA7 leukaemia were observed with the combination of patRA and ara-C
compared to either agent alone. With the addition of 10"®M patRA to each
concentration of ara-C studied no differences in the proliferative response were
observed compared to ara-C alone (Fig. 5.2 A ). With the combination of 10"7M
PatRA and W^M ara-C an increase in the proliferative response was observed
compared to either agent alone (Fig. 5.2 B). With the addition of 10"7M patRA to
10"®M or 10“7M ara-C the proliferative responses observed were equivalent to the
responses observed with ara-C alone. With the addition of 10"®M PatRA no
differences in response were observed compared to ara-C alone (Fig. 5.2 C).
5.2.3 The in vitro proliferative effects of the combination 
of patRA and ara-C on the SA8 leukaemia
The combination of PatRA and ara-C to bone marrow cultures of the SA8
leukaemia resulted in 1) decreases in the proliferative response compared to ara-
C alone and 2) synergistic decreases in proliferation compared to either agent
alone. Decreases in the proliferative response compared to ara-C alone were
observed with the combination of 10"®M patRA plus 10~^M or 10'®M ara-C; the
responses observed with these combinations were equivalent to the response
observed with 10"®M PatRA alone (Fig. 5.3 A). The proliferative responses
observed with 10"®M PatRA, 10“7M ara-C and their combination were equivalent.
Synergistic decreases in proliferative response were observed with the
combinations of either lO'7M or 10"®M PatRA with 10"®M or 10‘^M ara-C (Figs.
5.3 B and C). The resultant proliferative responses obtained with these lower 
concentrations of ara-C (10"® and 10’^M) in combination with lower concentrations
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of PatRA (10“7 and 10"®M) were equivalent to the proliferative response obtained 
with the higher concentration of ara-C (10"7M) alone and equivalent to the
higher concentration of PatRA (lO"7M). Hence, with the combination of agents a 
comparable decrease in proliferation was obtained with a 10 fold decrease in the 
concentration of patRA and a 10 and 100 fold decrease in the concentration of the 
more toxic agent ara-C.
5.2.4 The in vitro proliferative effects of the combination 
of patRA and ara-C on the SA2 leukaemia
5.2-.4.1 Transplantation number 36
The SA2 LP passage number 36 (SA2 p36) leukaemic bone marrow cells were 
growth factor independent in vitro and the cells from this study were cultured in 
FCS alone. The proliferative response of the SA2 p36 leukaemia was inhibited 
by both PatRA and ara-C to a greater extent than the other leukaemias described 
(Fig's. 5.4 and 5.5). 10-®M patRA and concentrations as low as 10"®M ara-C had a 
toxic effects on this leukaemia. An inhibitory response (43±7% of control) was 
observed with 10“^^M ara-C the lowest concentration tested whereas no 
inhibitory response was observed with this concentration on normal bone marrow 
or the SA7 or SA8 leukaemias. A synergistic decrease in the proliferative 
response was observed with the combination of patRA plus 10"^M ara-C
(Fig's. 5.6 C). With the combination of 10"7M patRA plus 10"^M ara-C a marked 
decrease in the proliferative response was observed compared to ara-C alone; the 
response was also less but comparable to the response observed with PatRA alone 
(Fig. 5.6 B).
5.2.4.2 Transplantation number 39
The SA2 p39 leukaemic bone marrow cells were growth factor independent in vitro 
and the cells from this study were cultured in FCS alone. The proliferative
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responses of the leukaemic bone marrow cells from the SA2 p39 to decreasing 
concentrations of ara-C alone and in combination with PatRA differed from 
passage number 36. The response to ara-C alone was similar to that of the SA8 
leukaemia. lO'^M ara-C was toxic and the proliferative responses observed with 
10“^M and 10"®M ara-C were 26±13% and 88±9% of the control respectively (Fig
5.4). The responses observed with decreasing concentrations of PatRA alone 
however, were similar to the responses observed with the bone marrow cells from 
passage number 36 (Fig 5.5). This was consistent with the study in Chapter 4 
where the SA2 LP leukaemia was observed to be more responsive to 
differentiation induction with PatRA than the SA7 or SA8 leukaemias. Unlike 
the SA2 p36 leukaemia no statistically significant synergistic decrease (p>0.2) in 
the proliferative response was observed with the combination of agents; however, 
with the combination of lO^M or 10"®M patRA and lO_^M ara-C the trend 
observed was a decrease in the proliferative response compared to either factor 
alone (Figs. 5.7 B and C). The responses observed with the combinations of agents 
were similar to the responses observed with patRA alone and less than the 
responses observed with ara-C alone (Fig 5.7).
5.2.4.3 Transplantation number 55
Leukaemic bone marrow cells from the SA2 p55 leukaemia were growth factor 
dependent in vitro and cells were cultured with WEHI-3B CM which has been
shown to have a more limited effect on differentiation induction of the SA2 HP
leukaemias than L929 CM. The SA2 p55 leukaemia was more sensitive to ara-C 
than normal bone marrow, the SA7, SA8 and SA2 p39 leukaemia. A 50% 
inhibitory response was observed with 10"^M ara-C (Fig. 5.4). The response 
observed with PatRA was similar to that observed with the SA7 and SA8 
leukaemia (Fig. 5.5). Synergistic decreases in the proliferative response with the
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combination of patRA and ara-C were observed. The synergistic decreases in the 
proliferative response were observed with 10"7M PatRA plus lO'^M ara-C (Fig. 
5.8 B), and 10"®M PatRA plus lO'^M or 10"®M ara-C.(Fig. 5.8 C). These responses 
were similar to the response observed with lO'7M ara-C alone, a 10 and 100 fold 
decrease in the concentration of ara-C
5.2.4.4 Transplantation number 59
Leukaemic bone marrow cells from the SA2 p59 leukaemia were growth factor 
dependent in vitro and cells were grown in WEHI-3B CM which has been shown to
have a more limited effect on differentiation induction of the SA2 HP leukaemias
than L929 CM. The SA2 p59 leukaemia was more sensitive to ara-C than the SA7 
and SA8 leukaemias (Fig 5.4). The proliferative response with lO'^M ara-C was 
61±8% of the control. The response observed with PatRA was similar to the SA7, 
SA8, and SA2 p55 leukaemias (Fig. 5.5). A synergistic decrease in the 
proliferative response was observed with the combination of 10“®M patRA and 
10~^M ara-C (Fig 5.9 C). This response was similar to the response observed with 
10"®M ara-C alone.
5.2.5 The in vitro pprliferrtivv effects of the combinatioo 
of patRA and ara-C on the SA2 CL
The SA2 CL was growth factor independent in vitro and the cells for this study
were cultured in FCS alone. The SA2 CL was the least sensitive of the leukaemias
studied to ara-C. The proliferative response observed with 10"7M ara-C was
37+9% of control and no inhibition of growth was observed with 10"®M. ara-C (Fig.
5.4). In the differentiation study in Chapter Four it was shown that PatRA
induced an inhibitory response of the SA2 CL without evidence of differentiation.
The inhibitory response observed with 10’^M patRA was 30+13% of control, with
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lO"'M 64±8% and no inhibitory response was observed with 10‘®jM PatRA (Fig.
5.5). With the combination of PatRA and ara-C only decreases in proliferative 
response were observed compared to ara-C alone (Fig. 5.10). The proliferative 
responses observed with 10_®M patRA in combination with decreasing 
concentrations of ara-C were equivalent to the responses observed with patRA 
alone and less than the response observed with ara-C alone (Fig. 5.10 A). This 
was also the case with 10““M PatRA and 10"^M ara-C (Fig. 5.10 B). The 
proliferative responses observed with all other combinations of 10'^M and 10'®M 
PatRA with decreasing concentrations of ara-C were equivalent to the responses 
observed with ara-C alone (Figs 5.10 B and C).
5.2.6 Summary
In summary (Table 5.1), of the leukaemias tested an adverse stimulatory response 
with the combination of agents was only observed with the SA7 leukaemia. 
Favourable responses were observed with the other leukaemias. An enhanced 
inhibitory effect compared with ara-C alone was observed with the SA8, SA2 
p39, SA2 p55, SA2 p59 and the SA2 CL. Synergistic decreases in the proliferative 
response with the combination of agents was observed with the SA8, SA2 p36, 
SA2 p55 and the SA2 p59 leukaemias. The low dose of 10“^M ara-C in 
combination with 10"^M or 10'®M PatRA produced the synergistic responses 
observed and these responses were similar to the responses observed with a 10 or 
100 times greater concentration of ara-C alone.. From the progressive study on the 
SA2 leukaemia it was observed that the leukaemic bone marrow cells became less 
sensitive to PatRA and ara-C when used alone with serial transplantation. 
However, the enhanced inhibitory responses and synergistic decreases in 
proliferation were observed at each transplantation.
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PROLIFERATIVE RESPONSE WITH COMBINATION OF patPA & ARA-C
STIMULATORY < ARA-C ALONE SYNERGISTIC DECREASE
NBM + - -
SA7 + - -
SA8 - + +
SA2 p36 - +
SA2 p39 - + ?
SA2 p55 - + +
SA2 p59 - + +
SA2 CL - + -
Table 5.1 The proliferative responses of leukaemic and normal cells to the 
combination of patRA and ara-C. Stimulatory responses were observed with the 
combination of agents compared to either agent alone, or decreases in the 
proliferative responses were observed compared to ara-C alone and/or decreases 
in the proliferative response were observed compared to both agents alone 
(synergistic decreases).
5.3 DISCUSSION
With the combination of patRA and ara-C synergistic decreases and enhanced 
decreases in the proliferative response compared to ara-C alone, were observed 
with two out of the four leukaemias studied. The responses observed were 
dependent upon the concentration of agents used. Different concentration 
combinations of the two agents induced synergistic decreases in the different 
leukaemias. An adverse stimulatory effect was observed with one of the 
leukaemias. A stimulatory response was observed with normal bone marrow 
indicating that, comparatively, the combination of agents preferentially inhibits 
some leukaemic cells rather than normal bone marrow cells. It appears therefore, 
that this combination of agents may be effective for the treatment of some 
leukaemias. Screening of patients would be essential for both susceptibility and 
dosage.
The reasoning behind using the combinations of differentiation inducing agents
and DNA synthesis inhibitors for the treatment of AML stems from the concept 
that by using a differentiation inducing agent the resultant reduction in the
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amplification of the system might be compensated by an increase in the leukaemic
stem cell (clonogenic cell) proliferation rate. This possible increase in the 
proliferation of the stem cell pool would then be curbed by the use of a DNA 
synthesis inhibitor (Francis et al, 1985). As far as we are aware however, there is 
no experimental evidence suggesting that an increase in the proliferative rate of 
the leukaemic stem cell pool would result from the differentiation induction of 
the leukaemic clone (Fig. 5.11). From studies utilizing the leukaemic Clonogenic 
Cell Assay in Chapters Three and Four it was observed that there was no increase 
in the leukaemic clonogenic cell fraction when leukaemic cells were induced to 
differentiate in vitro with growth factors or PatRA. When L929 CM was used 
with patRA, which were both shown to be effective inducers of differentiation of 
the leukaemia studied in vitro, a decrease in the leukaemic clonogenic cell
fraction was observed.
It has also been argued that the leukaemic state is not simply due to a maturation 
arrest or blockage but rather that there is a profound shift in the differentiation 
probability (Guimaraes et al, 1984). Consequently, two modes of intervention 
should be possible. One, with the use of agents which slow proliferation and two, 
with the use of agents that speed up differentiation.
There was disagreement in the literature as to whether low doses of 
chemotherapeutic agents acted principally as cytotoxic agents or differentiation 
inducers. The most widely accepted theory was that they primarily slow down 
DNA synthesis. Studies on differentiation commitment of leukaemic cells using 
chemical inducers of differentiation such as butyric acid and phorbol esters 
suggested that the decision point in the cell cycle regarding commitment may be at 
the late stage of the cell cycle or near the S phase (Boyd and Metcalf 1984). This 
has been referred to as the differentiation responsive "window" (Francis et al, 
1985). By slowing DNA synthesis this phase of the cell cycle may be lengthened
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Figure 5.11 The possible effects of differentiation induction on the leukaemic 
clonogenic cell fraction
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and/or the cell may be rendered more responsive to differentiation induction. The
effect of low concentrations of chemotherapeutic agents have been shown to be 
more potent when arrest of proliferation is immediate and if the leukaemic clone 
is arrested in a late stage of differentiation (eg HL60, acute promyelocytic cells) 
(Chomienne, 1991). It has therefore, also been suggested that the inhibitory- 
effect on leukaemic cell proliferation is an initiating factor for differentiation 
induction: by synchronizing the cells in a cell-cycle phase responsive to 
endogenous or exogenous differentiation agents, by controlling the transcription of 
oncogenes implicated in cell proliferation (c-myc, c-fos or with a tyrosine kinase 
action) or by directly modulating the activation of differentiation target genes 
(for review see Chomienne et al, 1991).
Most but not all of the initial in vitro data on the effectiveness of combinations of 
differentiation inducers and DNA synthesis were generally promising (Francis et 
al 1985; Clark et al, 1987; Ho et al, 1987; Hellstrom et al, 1988; Ganser et al, 1989). 
In a study by Waxman and Schreiber (1983) a low proportion of AML and MDS 
samples responded (4/28). However, in that study three patients with MDS were 
successfully treated with the combination of RA and hydroxyurea; one patient 
being relapse free for over two years. Very few combination therapy trials have 
been reported, most of these were on patients with MDS and unfortunately the 
results were not as promising as the in vitro data would suggest (Chomienne,
1991). Previous in vitro data on human AML cells has focussed on the use of 13-c/s 
RA (Hoffman et al, 1985; Francis et al, 1987), and in another study the RA in 
combination with ara-C used was not specified (Hassan and Rees, 1988), and 
results have been variable. With evidence of the higher efficacy of PatRA 
compared to 13-c/s RA (Chomienne et al 1986, 1990) further trials on fresh human 
AML cells with PatRA and ara-C were warranted. In a recent study by Hassan et 
al (1991) the double and triple combinations of PatRA, ara-C and hexamethylene
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bisacetamide (HMBA) were evaluated in bone marrow cells from AML patients. 
A novel statistical analysis was used to assess the significance of synergy and 
antagonism in the studies of drug combinations. They studied AML bone marrow 
cells from each of the FAB classification subtypes (M1-M5) and they reported, but 
not specifically, successfully induced differentiation of bone marrow cells from 
AML patients with either single agents or with a combination of agents. 
Synergistic differentiation responses were observed with the combination of 
agents, PatRA plus ara-C being the most effective of the double combinations
tested.
Further studies are also needed to elucidate whether the use of differentiation
agents exacerbates the emergence of resistant leukaemic clones and whether mild 
long term maintenance of AML is possible and/or preferential over cytotoxic 
regimes. In a study of the long term treatment of Ml cells with the differentiation 
inducer Vit D3 Kasukabe et al (1987) concluded that the combination of Vit D3 
with either daunomyocin or ara-C was more effective in reducing cell numbers of 
the Ml leukaemic cell line in vitro than Vit D3 alone. They also found that after 
20 days of continuous treatment with Vit D3 alone a significant decrease in the 
proliferation of Ml cells was observed, however after 25 days proliferative 
resistant clones emerged in culture. It was not clear however if the treatment was 
ceased between day 20 and 25. They found that resistant cells did not appear 
with the combination therapy. They argued that the continuous treatment of 
myeloid cells with low doses of differentiation agents and low doses of cytotoxic 
agents was effective in inducing terminal differentiation of leukaemic cells and 
that the appearance of differentiation-resistant cells may be suppressed or 
retarded. In the clinical trial on patients with APL by Chen et al (1991) however, 
when patRA was used in combination with chemotherapeutic agents as 
maintenance therapy after CR induction with PatRA, there was a high incidence
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of relapse and emergence of leukaemic clones resistant to differentiation induction 
by PatRA. When chemotherapeutic agents were used alone for maintenance 
therapy the emergence of resistant leukaemic clones were not observed at least at 
first relapse.
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Figure 5.1 Normal bone marrow single cell suspension was cultured in the micro titre 
assay with varying concentrations of PatRA and ara-C both alone and in combination, 
WEHI-3B CM was used as the growth factor source. On day four of culture the cells 
were pulsed with 3H-TdR for eight hours to measure the effects on proliferation. The 
results as scintillation CPM were converted to 'Percentage of Untreated Control'.
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Figure 5.2 SA7 leukaemic bone marrow single cell suspension was cultured in the 
microtitre assay with varying conrentrations of patRA and ara-C both alone and in 
combination. WEHI-3B CM was used as the growth factor source. On day four of 
culture the cells were pulsed with 3H-TdR for eight hours to measure the effects on 
proliferation. The results as scintillation CPM were converted to ’Percentage of 
Untreated Control'.
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Figure 5.3 SA8 leukaemic bone marrow single cell suspension was cultured in the 
microtitre assay with varying concentrations of patRA and ara-C both alone and in 
combination. WEHI-3B CM was used as the growth factor source. On day four of 
culture the cells were pulsed with 3H-TdR for eight hours to measure the effects on 
proliferation. The results as scintillation CPM were converted to 'Percentage of 
Untreated Control'.
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Figure 5.4 The proliferatieve responses of leukaemic and normal cells to varyin; 
concentrations of ara-C. The cells were cultured in the microtitre assay for foui 
days and pulsed with 3H-TdR to measure the effects on proliferation. The results 
as scintillation CPM were converted to 'Percentage of Untreated Control'.
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Figure 5.5 The proliferatieve responses of leukaemic and normal cells to varying 
concentrations of PatRA. The cells were cultured in the microtitre assay for fotu 
days and pulsed with 3H-TdR to measure the effects on proliferation. The results 
as scintillation CPM were converted to 'Percentage of Untreated Control'.
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Figure 5.6 SA2 p36 leukaemic bone marrow single cell suspension was cultured in 
the microtitre assay with varying concentrations of PatRA and ara-C both alone and 
in combination. The cells were cultured in FCS alone. On day four of culture the 
cells were pulsed with 3H-TdR for eight hours to measure the effects on proliferation. 
The results as scintillation CFM were converted to 'Percentage of Untreated Control'.
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Figure 5.7 SA2 p39 leukaemic bone Marrow single cell suspension was cultured in 
the Microtitre assay with varying concentrations of PatRA and ara-C both alone and 
in combination. The cells were cultured in PCS alone. On day four of culture the 
cells were pulsed with 3H-TdR for eight hours to measure the effects on proliferation. 
The results as scintillation CPM were converted to 'Percentage of Untreated Control'. 
(*p>0.2 No synergistic decrease was observed with the combination of 106 M PatRA 
plus ara-C compared to PatRA alone).
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Figure 5.8 SA2 p55 leukaemic bone marrow single cell suspension was cultured in 
the microtitre assay with varying concentrations of patRA and ara-C both alone 
and in combination. WEHI-3B CM was used as the growth factor source. On day 
four of culture the cells were pulsed with 3H-TdR for eight hours to measure the 
effects on proliferation. The results as scintillation CPM were converted to 'Percentage 
of Untreated Control'.
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Figure 5.9 SA2 p59 leukaemic bone marrow single cell suspension was cultured in 
the micro titre assay with varying concentrations of PatRA and ara-C both alone 
and in combination. WEH1-3B CM was used as the growth factor source. On day 
four of culture the cells were pulsed with 3H-TdR for eight hours to measure the 
effects on proliferation. The results as scintillation CPM were converted to 'Percentage 
of Untreated Control'.
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Figure 5.10 The SA2 CL was cultured in the microtitre assay with varying concentrations 
of PatRA and ara-C both alone and in combination. The cells were cultured in FCS alone. 
On day four of culture the cells were pulsed with 3H-TdR for eight hours to measure the 
effects on proliferation. The results as scintillation CFM were converted to 'Percentage of 
Untreated Control'.
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DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC COUNTS PER MINUTE ± SE
MEDIUM 0 . 850 101 333 87 255 59
5% 2463 378 2569 337 5648 489
WEHI-3B 10 5894 356 4998 566 11954 869
CM 15 7046 230 8600 741 21488 999
20 4988 426 6111 657 10256 898
5% 750 79 1689 165 2689 451
L929 CM 10 1659 225 2946 335 5002 358
15 2502 365 4897 227 8569 784
20 1203 114 1783 268 2600 247
lOIU/ml 1187 198 1488 154 1024 115
20 2470 256 3222 226 2648 358
rGM-CSF 40 4991 361 6400 678 5187 266
60 5029 605 6332 564 5216 200
80 5111 666 6236 711 5289 289
100 5214 311 6274 523 5218 458
DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC CELL COUNT PER WELL x 104 ± SE
MEDIUM 0 4.35 0.32 2.00 0.15 1.80- 0.05
5% 4.99 0.28 5.89 0.23 9.69 0.36
WEHI-3B 10 6.01 0.44 7.59 0.56 18.09 0.29
CM 15 6.54 0.51 9.80 0.33 22.60 0.41
20 6.41 0.22 9.65 0.46 22.4 0,50
5% 4.69 0.16 4.89 0.25 6.00 0.19
L929 CM 10 5.01 0.18 4.99 0.29 8.56 0.18
15 5.33 0.14 6.52 0.31 11.87 0,24
20 5.30 0.14 6.45 0.14 11.76 0.3
lOIU/ml 4.63 0.24 4.40 0.20 5.20 0.20
20 4.98 0.29 5.60 0.31 6.80 0.17
rGM-CSF 40 5.21 0.15 7.90 0.18 8.91 0.35
60 5.22 0.17 7.98 0.18 8.88 0.19
80 5.18 0.08 7.91 0.24 8.80 0.26
100 5.14 0.16 7.85 0.27 8.76 0.34
Appendix Table A2.2 Normal Bone Marrow. Growth Factor Dose Response Study. 
Normal bone marrow cells were cultured in PCS alone and with varied concentrations of 
WEHI-3B CM, L929 CM and rGM-CSF in the microtitre assay for two, four and six days 
to determine the dose-response relationship. Proliferation was measured with 3H-TdR 
uptake and results recorded as scintilation counts per minute (CPM) and with the 
measurement of total cell count per well.
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DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC COUNTS PER MINUTE ± SE
MEDIUM 0 1105 150 203 15 159 24
5% 4199 332 6214 654 7216 751
WEHI-3B 10 6029 796 9052 1012 10900 896
CM 15 8426 987 12674 978 15006 1024
20 6013 537 8777 954 7562 874
5% 1257 159 3900 223 781 169
L929 CM 10 2401 553 8201 556 1255 259
15 3010 112 10237 873 2005 333
20 1999 226 6664 751 1553 227
lOIU/ml 2789 266 2198 457 299 66
20 5474 449 4369 541 710 201
rGM-CSF 40 10570 954 8829 786 1464 221
60 10963 897 8811 963 1498 158
80 11236 1032 8619 741 1445 165
100 11147 852 8514 962 1389 412
DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC CELL COUNT PER WELL x 104 ± SE
MEDIUM 0 5.63 0.16 2.44 0.09 1.62 0.25
5% 6.52 0.15 7.56 0.21 14.68 0.16
WEHI-3B 10 7.66 0.12 11.52 0.16 23.97 0.29
CM 15 8.90 0.09 14.41 0.18 26.20 0.21
20 8.82 0.14 14.42 0.14 25.68 0.18
5% 5.77 0.11 7.96 0.16 11.52 0.09
L929 CM 10 5.89 0.09 10.77 0.18 15.04 0.21
15 6.00 0.07 13.42 0.16 18.40 0.24
20 6.02 0.25 13.40 0.27 18.24 0.21
lO IU/ml 5.00 0.15 7.10 0.12 6.54 0.14
20 6.30 0.12 9.94 0.04 8.52 0.18
rGM-CSF 40 7.70 0.21 13.72 0.40 12.00 0.11
60 7.78 0.2 13.71 0.14 12.11 0.16
80 7.71 0.17 13.65 0.12 12.00 0.25
100 7.67 0.26 13.54 0.17 11.78 0.19
Appendix Table A2.3 SA7 leukaemic bone marrow. Growth Factor Dose Response 
Study. SA7 leukaemic bone marrow cells were cultured in FCS alone and with varied 
concentrations of WEHI-3B CM, L929 CM and rGM-CSF in the microtitre assay for 
two,four and six days to determine the dose-response relationship. Proliferation was 
measured with 3H-TdR uptake and results recorded as scintilation counts per minute 
(CPM) and with the measurement of total cell count per well.
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DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC COUNTS PER MINUTE ± SE
MEDIUM .. 0 1458 165 512 79 666 52
5% 4569 260 4896 247 6837 456
WEHI-3B 10 7543 569 8964 169 12359 160
CM 15 13502 699 15696 578 19521 782
20 8963 332 10598 789 12966 334
5% 1596 66 3999 568 789 60
L929 CM 10 2999 158 7254 349 803 101
15 6180 299 13126 561 880 189
20 3325 410 9633 288 598 57
lOIU/ml 3179 336 888 116 561 154
20 6459 459 1727 241 698 59
rGM-CSF 40 12889 579 3226 369 712 70
60 16879 224 5002 188 723 26
80 13986 116 4875 268 699 112
100 12789 472 3926 297 685 106
DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC CELL COUNT PER WELL x 104 ± SE
MEDIUM 0 5.97 0.14 2.26 0.14 1.94 0.06
5% 6.90 0.18 9.60 0.15 13.50 0.28
WEHI-3B 10 8.76 0.11 12.56 0.24 21.50 0.17
CM 15 10.05 0.23 15.35 0.27 24.00 0.16
20 10.10 0.29 15.21 0.20 23.84 0.25
5% 5.71 0.20 6.81 0.30 3.56 3.56
L929 CM 10 5.41 0.08 8.88 0.14 5.48 5.48
15 5.31 0.14 11.20 0.07 8.15 8.15
20 5.24 0.06 11.03 0.25 8.00 8.00
lOIU/ml 6.84 0.13 8.53 0.30 6.45 0.22
20 7.76 0.11 11.02 0.24 7.80 0.23
rGM-CSF 40 9.18 0.18 12.98 0.15 9.12 0.06
60 9.22 0.24 12.97 0.07 9.00 0.19
80 9.20 0.27 12.84 0.14 8.94 0.14
100 9.09 0.17 12.80 0.24 8.84 0.21
Appendix Table A2.4 SA8 leukaemic bone marrow. Growth Factor Dose Response 
Study. SA8 leukaemic bone marrow cells were cultured in FCS alone and with varied 
concentrations of WEHI-3B CM, L929 CM and rGM-CSF in the microtitre assay for two, 
four and six days to determine the dose-response relationship. Proliferation was 
measured with 3H-TdR uptake and results recorded as scintilation counts per minute 
(CPM) and with the measurement of total cell count per well.
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DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC COUNTS PER MINUTE ± SE
MEDIUM 0 2589 188 370 55 300 59
5% 7897 547 8746 854 1876 98
WEHI-3B 10 12889 1024 17984 879 4003 363
CM 15 17590 987 22689 1134 7598 678
20 15786 693 18965 985 5896 645
5% 4789 366 2996 288 355 69
L929 CM 10 6355 784 7570 821 499 30
15 9258 875 12590 985 545 101
20 7985 742 9845 864 366 47
lOIU/ml 7832 652 1786 197 355 59
20 14736 1035 3358 359 478 89
rGM-CSF 40 25456 972 6007 902 566 55
60 25873 853 6147 853 590 108
80 24987 956 6045 784 600 68
100 24541 1215 5982 658 532 71
DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC CELL COUNT PER WELL x 104 ± SE
MEDIUM 0 6.62 0.13 3.94 0.26 2.70 0.15
5% 8.73 0.16 14.56 0.15 21.36 0.12
WEHI-3B 10 10.97 0.22 18.79 0.18 31.40 0.17
CM 15 12.79 0.18 21.50 0.24 35.60 0.27
20 12.82 0.15 21.20 0.30 34.02 0.25
5% 7.05 0.15 10.05 0.17 9.60 0.15
L929 CM 10 7.32 0.17 15.62 0.19 14.82 0.14
15 7.69 0.16 22.30 0.34 21.50 0.19
20 7.52 0.22 21.96 0.26 21.00 0.21
lOIU/ml 8.91 0.18 12.56 0.21 6.23 0.15
20 10.96 0.13 19.55 0.14 9.12 0.16
rGM-CSF 40 12.88 0.24 27.15 0.18 12.90 0.18
60 12.99 0.30 27.10 0.11 12.98 0.29
80 12.80 0.22 27.00 0.28 12.90 0.28
100 12.62 0.32 26.82 0.27 12.78 0.25
Appendix Table A2.5 SA2 HP leukaemic bone marrow. Growth Factor Dose Response 
Study. SA2 HP leukaemic bone marrow cells were cultured in FCS alone and with varied 
concentrations of WEHI-3B CM, L929 CM and rGM-CSF in the microtitre assay for two, 
four and six days to determine the dose-response relationship. Proliferation was 
measured with 3H-TdR uptake and results recorded as scintilation counts per minute 
(CPM) and with the measurement of total cell count per well.
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DAYS CELLS CULTURED DAY 4 DAY 4
CC/WELL X 104 ±GF GF CONC CPM ± SE
MEDIUM 0 9552 875 13.32 0.19
5% 11112 952 13.95 0.36
WEHI-3B 10 10951 568 13.85 0.28
CM 15 9623 963 10.42 0.27
20 9424 644 10.16 0.26
5% 10056 912 13.65 0.15
L929 CM 10 10587 863 13.98 0.30
15 9835 759 11.76 0.24
20 9372 1043 11.06 0.15
lOIU/ml 10432 782 13.86 0.31
20 10241 654 13.00 0.16
rGM-CSF 40 10562 1132 14.20 0.18
60 8692 982 9.20 0.17
80 8341 964 8.64 0.19
100 8222 754 8.10 0.32
Appendix Table A2.6 SA2 LP (passage number 36) leukaemic bone marrow. Growth 
Factor Dose Response Study. SA2 LP bone marrow cells were cultured in FCS alone and 
with varied concentrations of WEHI-3B CM, L929 CM and rGM-CSF in the microtitre 
assay for four days to determine the dose-response relationship. Proliferation was 
measured with 3H-TdR uptake and results recorded as scintilation counts per minute 
(CPM) and with the measurement of total cell count per well.
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DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC COUNTS PER MINUTE ± SE
MEDIUM 0 1579 60 1700 68 2241 167
5% 1790 101 2256 58 2988 204
WEHI-3B 10 3158 290 3783 206 8973 687
CM 15 4121 533 4898 554 12564 651
20 3876 412 4479 321 9013 455
5% 1566 25 2000 147 2746 344
L929 CM 10 1463 154 2659 168 3192 247
15 1490 97 3258 126 3411 289
20 1400 88 2987 188 2987 262
lOIU/ml 2471 158 2874 301 3556 458
20 3328 457 3752 387 4365 547
rGM-CSF 40 6478 587 7005 852 8148 987
60 6587 748 7146 845 8145 784
80 6523 589 7256 678 8006 984
100 6421 874 7122 874 7985 854
DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC CELL COUNT PER WELL x lO4 ± SE
MEDIUM 0 5.12 0.26 3.45 0.12 3.67 0.22
5% 5.86 0.25 6.15 0.16 8.52 0.18
WEHI-3B 10 6.34 0.12 7.85 0.18 12.22 0.26
CM 15 6.51 0.08 9.00 0.07 15.01 0.17
20 6.45 0.07 8.87 0.26 14.90 0.30
5% 5.03 0.26 5.24 0.15 6.47 0.14
L929 CM 10 4.86 0.15 5.50 0.18 7.99 0.16
15 4.74 0.16 5.73 0.22 9.10 0.09
20 4.65 0.18 5.68 0.24 8.79 0.21
lOIU/ml 5.78 0.26 6.43 0.13 7.86 0.30
20 6.41 0.18 7.01 0.16 10.60 0.14
rGM-CSF 40 7.05 0.14 8.99 0.24 14.39 0.18
60 7.10 0.16 9.05 0.19 14.5 0.26
80 7.11 0.22 9.04 0.24 14.43 0.18
100 7.02 0.25 9.00 0.24 14.32 0.21
Appendix Table A2.7 SA2 LP (passage number 54) leukaemic bone marrow. Growth 
Factor Dose Response Study. SA2 LP bone marrow cells were cultured in FCS alone and 
with varied concentrations of WEHI-3B CM, L929 CM and rGM-CSF in the microtitre 
assay for two, four and six days to determine the dose-response relationship. 
Proliferation was measured with 3H-TdR uptake and results recorded as scintilation 
counts per minute (CPM) and with the measurement of total cell count per well.
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DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC COUNTS PER MINUTE ± SE
MEDIUM 0 42398 787 25896 548 17889 735
5% 43025 589 27894 654 22758 894
WEHI-3B 10 38257 412 25879 942 20225 745
CM 15 37859 658 25478 875 21548 785
20 37655 514 24895 547 17758 854
5% 35897 625 26894 741 19785 583
L929 CM 10 28800 941 28489 829 20999 852
15 25894 825 31258 845 23569 748
20 26297 569 30959 647 22569 896
lOIU/ml 42979 936 24763 947 17805 821
20 42479 964 22148 786 17698 997
rGM-CSF 40 43457 893 21458 1048 17489 896
60 43457 759 21237 964 17223 1054
80 42478 1024 21523 863 17589 518
100 42356 978 21402 872 17454 748
DAYS CELLS CULTURED DAY 2 DAY 4 DAY 6
GF GF CONC CELL COUNT PER WELL x IP4 ± SE
MEDIUM 0 38.02 0.34 57.11 0.71 66.59 0.84
5% 38.18 0.91 56.68 0.82 66.00 0.67
WEHI-3B 10 38.27 0.68 56.55 0.84 59.98 0.69
CM 15 38.26 0.48 56.60 0.54 66.11 0.58
20 38.09 0.56 56.00 0.61 59.88 0.84
5% 37.88 0.82 58,90 0.67 69.80 0.75
L929 CM 10 36.97 0,57 61.00 0.81 72.80 0.92
15 36.52 0.68 63.20 0.58 74.50 0.65
20 36.48 0.64 62.99 0.66 74.45 0.87
lOIU/ml 37.98 0.86 57.21 0.72 66.10 0.82
20 38.10 0.77 57.25 0.83 65.78 0.97
rmGM-CSF 40 38.04 0.68 57.17 0.88 65.78 0.75
60 38.12 0.75 57.20 0.85 65.00 0.58
80 37.85 0.98 57.01 0.79 64.45 0.96
100 37.56 0.47 57.11 0.87 64.10 0.87
Appendix Table A2.8 SA2 CL leukaemic cells. Growth Factor Dose Response Study. 
SA2 LP bone marrow cells were cultured in FCS alone and with varied conrentrations of 
WEHI-3B CM, L929 CM and rGM-CSF in the microtitre assay for two, four and six days 
to determine the dose-response relationship. Proliferation was measured with 3H-TdR 
uptake and results recorded as scintilation counts per minute (CPM) and with the 
measurement of total reil count per well.
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COUNTS PER MINUTE ±STANPARP ERROR
BM DAYI MEDIUM WEHI-3B CM L929 CM rmGM-CSF
0.3 "W l&l 2935' ^530 54 3983 122
1 962 60 3492 104 1533 66 4550 383
2 880 77 6696 219 2369 138 5892 204
NBM 3 534 29 7786 73 3367 216 8938 982
4 313 21 8150 735 4411 291 6181 778
5 212 36 17081 641 8607 909 7062 547
6 279 71 20933 204 8349 422 5319 831
7 270 115 16585 214 2029 247 3203 253
0.3 5662 240 3956 81 4654 110 7418 510
1 1170 10 4214 168 1444 149 6952 615
2 1205 390 8625 236 3412 641 11362 298
3 591 10 9332 474 7918 935 14369 719
SA7 HD 4 208 14 11504 1016 9887 900 7898 543
5 178 21 20172 818 7097 954 5011 453
6 113 17 14508 586 1680 231 1037 172
7 146 13 7163 266 299 97 264 16
0.3 2843 156 2028 281 2201 182 3084 209
1 2175 128 7706 306 4180 263 8175 494
2 1365 115 12995 134 5887 124 17261 600
3 907 49 12772 535 8597 552 15641 239
SA8 HD 4 427 49 14562 349 12600 391 5768 204
5 281 20 15652 793 4072 492 2147 166
6 634 54 19230 623 617 71 657 23
7 317 69 8922 100 269 64 269 18
0.3 2783 224 2751 118 2781 285 2884 241
1 1386 127 2535 381 1002 107 4754 557
2 1193 139 3645 445 1042 264 6448 798
3 1196 168 4252 800 1405 133 6566 656
SA2 HD LP 4 1237 122 4864 314 2408 328 7056 235
5 1755 126 8365 941 4218 108 7771 836
6 1787 38 14644 1116 2685 164 8437 1000
7 1991 140 8050 996 3512 449 7535 854
0.3 10768 511 7675 413 6648 589 14149 164
1 4283 146 12802 738 5964 289 15385 978
2 2436 168 18223 1223 8673 264 27830 1124
3 1411 343 20626 770 15548 843 30398 751
SA2 HD HP 4 431 47 21700 165 11619 931 6754 785
5 222 24 13429 502 3103 428 1078 164
6 318 27 7027 658 390 46 407 33
7 220 97 2983 247 128 29 197 54
0.3 41132 103 45920 476 37538 506 50792 417
1 57467 116 45065 341 41923 111 57278 151
2 44118 115 39593 209 28958 185 43275 157
3 33837 454 36132 862 41083 140 32010 380
SA2 CL 4 25153 876 24973 451 30901 102 21725 945
5 20109 993 21781 475 21540 234 17910 789
6 19669 391 23405 276 25666 856 19253 100
7 16043 211 17650 156 21433 855 16689 112
Appendix Table 2.9 Proliferative effects of WEHI-3B CM, L929 CM and rGM-CSF
on normal and leukaemic cells. Cells were cultured in the microtitre assay for 8 hours
to seven days. Proliferation was measured with uptake of 3H-TdR,
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COUNTS PER ...MINUTELY STANDARD.. ERROR 
GROWTH FACTORS WEHI-3B WHH3-3B CM L929 CM
BM DAY I + L929 CM + rmGM-CSF + rmGM-CSF
"03" "^705 70 "71-----—2225 "91“
1 3171 94 4241 376 3678 106
2 4035 225 8323 712 7373 133
3 8228 209 14781 500 8786 233
NBM 4 13299 168 18038 212 10686 502
5 27847 594 26354 345 16712 419
6 32568 855 26368 100 12747 172
7 12960 209 12594 142 8903 135
0.3 4012 479 4123 399 5455 653
1 3356 278 4079 460 4211 561
2 8514 983 14478 964 12267 893
3 15978 1028 21687 1171 21189 936
SA7 HD 4 17143 893 22257 943 22003 1045
5 17002 981 23079 1041 16999 879
6 8245 639 16571 921 11089 999
7 3071 276 7075 832 3248 412
0.3 1646 21 2119 78 1850 104
1 5370 178 8560 327 7384 191
2 10613 326 18506 621 16858 334
3 20753 703 13899 353 21060 342
SA8 HD 4 23595 187 12544 512 15196 605
5 27741 645 14889 173 16451 740
6 12936 738 15349 1000 10312 683
7 7737 319 5588 657 2806 216
0.3 2243 134 2114 102 1810 114
1 2493 143 2911 192 2611 268
2 3725 272 6063. 61 5363 577
3 5242 90 8803 434 10345 719
SA2 HD LP 4 7711 358 11455 799 12650 835
5 19175 151 23385 242 21871 701
6 19782 152 12856 152 24140 945
7 8486 196 11035 161 8673 772
0.3 7706 422 8667 605 10658 850
1 8671 980 15098 627 14116 580
2 21788 858 37291 1441 27319 524
3 35669 1229 33462 771 39333 1091
SA2 HD HP 4 19978 857 14666 717 25157 917
5 6947 513 6890 696 9545 392
6 2820 178 4699 293 4200 250
7 1020 193 4024 659 2344 404
0.3 40898 834 51236 587 37147 1053
1 53865 512 60005 953 57154 693
2 35091 714 46076 1003 49677 876
3 37786 1143 34985 843 37246 592
SA2 CL 4 26247 767 23587 752 28976 927
5 20476 689 20074 819 19174 840
6 25543 924 22265 691 22975 421
7 24327 853 21869 514 23875 746
Appendix Table A2.10 Proliferative effects of combinations of growth factors, 
WEHI-3B CM, L929 CM and rGM-CSS on normal and leukaemic cells. Cells were 
cultured in the microtitre assay for 8 hours to seven days. Proliferation was measured 
with uptake of 3H-TdR.
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APPENDIX TABLES
TO
CHAPTER THREE
PERCENTAGE OF TOTAL CELLS ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
~~Bl~~“95■WTT13“------ 0'"TO~- -----
P 9.0 0.7 16.3 1.4 2.8 0.1 0 0 17.9 2.0
M 14.2 1.5 11.7 1.4 11.5 0.2 4.0 0.4 2.6 0.1
FCS MM 63.6 5.1 58.1 5.0 62.9 5.2 31.2 3.3 11.5 0.8
B 2.1 0.2 2.9 0.2 1.3 0.1 13.9 1.5 0.6 0.1
S 0.7 0.1 4.4 0.3 11.5 0.9 16.8 1.3 0 0
Mo 0.7 0.1 0 0 0 0 0 0 4.5 3.9
Mf 0.0 0.0 2.3 0.1 10.0 0.9 34.2 2.9 62.8 6.6
B1 3.8 0.3 2.2 0.2 1.3 0.1 4.0 0.3
P 14.5 1.1 39.7 4.1 40.8 3.5 55.1 5.1
15% M 6.1 0.7 7.1 0.8 8.5 0.7 10.7 0.9
WEHI-3B MM 12.2 1.4 21.2 1.9 14.8 1.1 8.0 0.7
CM B 51.8 4.5 2.9 0.3 6.7 0.5 0 0
S 3.8 0.2 9.9 0.7 11.6 0.8 5.3 0.4
Mo 2.3 0.2 6.4 0.4 6.5 0.6 6.7 0.8
Mf 5.4 0.6 10.8 0.8 9.7 0.9 6.0 0.7
B1 4.2 0.3 0 0 3.3 0.2 0 0
P 11.4 0.9 34.6 3.0 16.2 1.3 2.1 0.2
M 5.0 0.6 5.1 0.4 3.3 0.4 1.4 0.1
15% MM 62.2 6.5 24.7 2.6 14.2 1.6 11.8 0.9
L929 CM B 2.2 0.2 2.7 0.2 6.9 0.8 1.4 0.1
S 5.6 0.6 15.0 1.2 8.5 0.8 5.6 0.6
Mo 4.2 0.3 2.1 0.2 14.2 1.2 11.2 1.2
Mf 5.3 0.4 15.8 1.4 33.6 2.9 66.5 6.3
BI 5.4 0.6 10.1 0.8 0.7 0.1 2.2 0.1
P 16.9 2.0 20.2 1.7 11.6 0.8 7.2 0.6
M 16.9 1.5 15.9 1.2 24.7 1.9 4.3 0.5
60 U/ml MM 47.6 4.0 17.3 1.3 19.8 0.9 16.1 1.4
rGM-CSF B 1.5 0.1 4.2 0.3 1.3 0.1 0 0
S 7.5 0.4 14.4 1.6 19.0 0.8 20.7 1.8
Mo 0 0 8.8 1.0 8.9 0.6 16.4 1.4
Mf 3.9 0.2 8.7 0.7 13.7 0.9 33.0 2.9
HI 5.3 0.4 4.0 0.3 5.4 0.4 4.1 0.4
P 14.2 0.9 20.6 1.9 40.8 3.7 59.3 6.0
WEHI-3B M 6.1 0.5 11.4 1.3 6.8 0.7 11.1 0.8
CM MM 54.3 5.2 14.2 1.3 19.1 2.0 7.5 0.5
+ B 0.8 0.1 4.6 0.4 3.4 0.2 2.1 0.2
L929 CM. S 8.3 0.8 20.6 1.8 8.1 0.7 8.3 0.6
Mo 3.0 0.3 0 0 2.1 0.2 4.1 0.3
Mf 8.1 0.7 24.7 2.2 14.2 1.3 3.5 0.3
BI 2.2 0.2 2.2 0.2 6.9 0.6 4.2 0.3
P 11.0 0.8 46.3 4.4 42.4 4.0 57.4 5.8
WEHI-3B M 12 4 1.0 8.0 0.6 5.5 0.6 8.4 0.8
CM MM 58.3 5.1 9.6 0.8 8.3 0.8 8.5 0.8
+ B 2.9 0.3 7.1 0.8 0.8 0.8 1.4 0.1
rGM-CSF S 9.6 1.0 15.3 1.4 14.6 1.5 11.1 0.9
Mo 2.9 0.3 5.7 0.5 13.2 1.3 6.3 0.5
Mf 0.7 0.1 5.8 0.5 8.3 0.7 2.8 0.2
BI 2.9 0.2 10.8 0.9 4.2 0.4 0 0
P 10.0 0.8 30.9 2.9 13.2 0.9 10.3 0.9
L929 CM M 24.5 2.1 15.8 1.4 9.8 0.9 9.7 0.9
+ MM 48.1 5.0 8.3 0.7 18.0 1.5 14.5 1.6
rGM-CSF B 0.8 0.8 3.4 0.2 2.0 0.2 0 0
S 8.6 0.8 19.4 1.5 10.4 1.1 26.2 2.8
Mo 0.8 0.8 7.2 0.7 11.1 0.9 16.5 1.7
Mf 4.3 0.3 4.3 0.3 31.2 2.9 22.7 2.0
Appendix Table A3.1 Normal bone marrow differential cell counts. Normal bone 
marrow cells were cultured in FCS and optimcd concentrations of WEHI-3B CM, 
L929 CM and rGM-CSF alone and in combination in the microtitre assay for eight 
hours, two, four and six days. Cytospins were prepared stained and the differentials 
counted.
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS S HOUR DAY 2 DAY 4 DAY 6
BI "oThT"or 039-004“ ... "9“6------.... 0 <3. . ------0
P 0.61 0.07 1.08 0.15 0.11 0.01 0 0 0.28 0.05
M 0.98 0.13 0.78 0.13 0.45 0.03 0.08 0.01 0.04 0.01
FCS MM' 4.33 0.48 3.86 0.54 2.46 0.24 0.63 0.09 0.18 0.03
B 0.14 0.02 0.19 0.02 0.05 0 0.28 0.04 0.01 0
S 0.05 0.01 0.29 0.04 0.45 0.04 0.34 0,04 0 0
Mo 0.05 0.01 0 0 0 0 0 0 0.07 0.06
Mf 0 0 0.15 0.02 0.39 0.04 0.69 0.08 0.98 0.16
Total cells 6.61 ■05F 6.64 "0.74 " 3.9l 6.21 2.02 “0T8” 1.56 -0iO
BI 0.25 0.03 0.13 0.02 0.14 0.02 0.92 0.08
P 0.95 0.13 2.36 0.35 4.23 0.54 12.70 1.29
15% M 0.80 0.13 0.42 0.06 0.88 0.11 2.45 0.23
WEHI MM 3.39 0.54 1.26 0.17 1.54 0.19 1.83 0.18
3B B 0.25 0.03 0.17 0.03 0.70 0.08 0 0
CM S 0.15 0.02 0.59 0.08 1.20 0.14 1.21 0.10
Mo 0.40 0.06 0.38 0.05 0.67 0.09 1.53 0.19
MF 0.35 0.05 0.64 0.08 1.01 0.13 1.37 0.17
Total cells 6.54 0.71 5.95 0.63 10.4 0.98 22.01 0.98
Bi 0.29 0.03 0 0 0.20 0.02 0 0
P 0.79 0.09 1.29 0.18 0.99 0.12 0.32 0.04
15% M 0.35 0.05 0.19 0.03 0.20 0.03 0.21 0.02
L929 MM 4.33 0.56 0.92 0.14 0.87 0.13 1.79 0.18
CM B 0.15 0.02 0.10 0.01 0.42 0.06 0.22 0.02
S 0.39 0.05 0.56 0.08 0.52 0.07 0.86 0.11
Mo 0.29 0.03 0.08 0.01 0.87 0.11 1.70 0.21
Mf 0.37 0.04 0.59 0.08 2.06 0.26 10.10 1.17
Total cells 6.96 0.54 3.73 0.41 6.13 -058“ 15.20 T0
BI 0.38 0.05 0.52 0.08 0.06 0.01 0.18 0.02
P 1.19 0.18 1.04 0.15 0.89 0.08 0.6 0.07
60 M 1.19 0.15 0.82 0.12 1.89 0.18 0.36 0.05
U/ml MM 3.35 0.42 0.89 0.13 1.52 0.11 1.34 0.16
rGM- B 0.11 0.01 0.22 0.03 0.10 0.01 0 0
CSF S 0.53 0.06 0.74 0.12 1.46 0.10 1.72 0.21
Mo 0 0 0.45 0.08 0.68 0.06 1.36 0.17
Mf 0.28 0.03 0.45 0.07 1.05 0.09 2.74 0.34
Total cells 7.03 0.65 5.l3 0.63 7.65 0.43 8.30 0.72
Appendix Table A3.2 Normal bone marrow differential cell counts in absolute number
of cells per well. Cells were cultured for eight hours, two, four and six days with optimal
concentrations of WEHI-3B CM, L929 CM or rGM-CSF in the microtitre assay. The total
cell number per well was determined and cytospins were prepared, stained and differentials
counted. -
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
B1 ■065"~00T000 0.05 00T 0.58 000”100"000
P 0.61 0.07 0.91 0.12 1.49 0.21 4.36 0.64 17.80 2.58
WEHI-3B M 0.98 0.13 0.39 0.06 0.83 0.13 0.73 0.11 3.32 0.42
CM MM 4.33 0.48 3.48 0.53 1.03 0.15 2.04 0.32 2.26 0.28
+ B 0.14 0.02 0.05 0.01 0.33 0.05 0.36 0.05 0.62 0.09
L929 CM S 0.05 0.01 0.53 0.08 1.49 0.21 0.87 0.13 2.48 0.31
Mo 0.05 0.01 0.19 0.03 0 0 0.22 0.03 1.24 0.16
Mf 0 0 0.52 0.08 1.79 0.25 1.52 0.22 105 0.14
Total cells 6.81 051“ 6741 0.75 7.26 070" 10.68 123“ 50.01 302.
B1 0.15 0.02 0.14 0.02 0.82 0.10 1.38 0.18
P 0.76 0.08 2.94 0.37 5.01 0.63 18.90 2.84
WEHI-3B M 0.86 0.10 0.51 0.06 0.65 0.09 2.77 0.41
CM MM 4.03 0.48 0.61 0.07 0.98 0.12 2.80 0.41
+ B 0.20 0.03 0.45 0.06 0.09 0.09 0.45 0.06
rGM-CSF S 0.66 0.09 0.97 0.12 1.72 0.23 3.67 0.50
Mo 0.20 0.03 0.36 0.04 1.56 0.20 2.07 0.28
Mf 0.05 0.01 0.37 0.04 0.98 0.12 0.93 0.12
Total cells 6.91 0.56 6.35 0.54 11.81 0.98 32.99 3.66
B1 0.22 0.03 0.60 0.08 0.33 0.04 0 0
P 0.75 0.09 1.72 0.23 1.03 0.11 2.17 0.28
L929 CM M 1.84 0.24 0.88 0.12 0.77 0.10 2.04 0.27
+ MM 3.62 0.51 0.46 0.06 1.41 0.17 3.04 0.44
rGM-CSF B 0.06 0.06 0.19 0.02 0.16 0.02 0 0
S 0.65 0.09 1.08 0.14 0.81 0.11 5.51 0.79
Mo 0.06 0.06 0.40 0.06 0.87 0.10 3.47 0.49
Mf 0.32 0.04 0.24 0.03 2.44 0.31 4.77 0.62
Total cells 7.52 0.72 7.57 0.75 7.82 0.69 21.00 2.00
Appendix Table A33 Normal bone marrow differential cell counts in absolute number 
of cells per well. Cells were cultured for eight hours, two, four and six days with optimal 
concentrations of WEHI-3BCM, L929CM or rGM-CSF in combination in the microtitre 
assay. The total cell number per well was determined and cytospins were prepared, stained 
and differentials counted.
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PERCENTAGE OF TOTAL CELLS ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
"T5T"“30"77T '33.7 3.1 " TTTTT- rrTTT-—
P 17.7 1.6 23.1 2.0 11.9 1.0 4.7 0.4 0.7 0.1
Imf 0.0 0.0 4.7 0.4 5.0 0.4 8.6 0.7 10.7 0.9
M 9.4 0.8 10.2 0.9 19.6 2.0 14.2 1.2 0.7 0.1
FCS MM 19.1 1.7 23.9 2.0 25.1 2.3 14.2 1.2 5.7 0.6
B 0.0 0.0 1.3 0.1 4.3 0.4 4.7 0.4 0.7 0.1
S 1.4 0.1 0.7 0.1 3.4 0.3 2.1 0.2 0.7 0.1
Mo 2.1 0.2 0 0 0 0 0 0 0 0
Mf 1.4 0.1 1.3 0.1 26.5 2.7 48.9 4.7 80.7 8.2
BI 47.5 5.0 6.8 0.5 5.0 0.5 7.8 0.7
P 10.0 0.9 27.3 2.4 29.5 3.0 16.6 1.5
15% Imf 3.6 0.3 2.7 0.2 3.4 0.3 1.0 0.1
WEHI-3B M 4.4 0.4 9.6 0.8 12.3 1.0 14.9 1.3
CM MM 28.8 3.0 20.0 1.8 15.5 1.4 21.8 2.0
B 2.9 0.2 2.7 0.3 1.8 0.1 1.7 0.1
S 2.1 0.2 6.2 0.6 3.4 0.3 6.1 0.6
Mf 0.7 0.1 24.7 2.6 29.1 3.0 30.0 3.2
BI 37.1 3.8 13.0 1.2 2.3 0.2 0.7 0.1
P 28.4 2.5 13.7 1.2 8.6 0.7 0 0
Imf 5.8 0.5 11.0 0.9 10.6 0.9 12.7 1.3
15% M 8.9 0.8 4.1 0.4 3.1 0.3 0.7 0.1
L929 CM MM 12.4 1.1 23.2 2.4 4.5 0.5 6.0 0.5
B 0.8 0.7 5.6 0.5 0.3 0.1 0.7 0.1
S 2.9 0.2 15.0 1.4 1.7 0.1 0.7 0.1
Mf 3.7 0.4 14.3 1.4 68.9 6.5 78.3 7.7
BI 42.0 4.0 8.2 0.7 2.1 0.2 0.7 0.1
P 20.3 2.0 37.8 3.5 30.8 2.9 4.2 0.4
Imf 6.3 0.6 2.1 0.2 13.6 1.4 4.8 0.4
60 U/ml M 12.6 1.0 7.5 0.8 13.1 1.4 9.0 0.8
rGM-CSF MM 9.2 0.9 9.5 1.0 19.9 1.8 26.1 2.5
B 3.5 0.4 2.1 0.2 0 0 5.6 0.6
S 2.1 0.2 6.8 0.7 10.3 1.1 15.8 1.4
Mf 4.2 0.5 26.0 2.5 10.3 0.8 33.7 3.5
BI 34.0 3.5 7.8 0.6 3.0 0.3 4.8 0.5
P 13.3 1.2 24.2 2.5 30.2 3.0 24.6 2.3
WEHI-3B Imf 4.2 0.4 4.3 0.4 4.0 0.4 15.7 1.4
CM M 7.8 0.6 5.6 0.4 17.1 1.5 7.5 0.7
+ MM 32.6 3.0 12.8 1.0 13.1 1.4 11.6 0.9
L929 CM B 1.3 0.1 2.1 0.2 3.5 0.4 2.8 0.2
S 2.7 0.2 19.2 1.8 7.0 0.6 11.7 0.9
Mo 0 0 0 0 0 0 0 0
Mf 4.2 0.4 23.9 2.0 22.1 2.0 21.3 1.9
BI 34.6 3.3 10.4 0.9 6.1 0.6 4.8 0.5
P 17.3 1.5 22.8 2.0 45.1 4.4 25.2 2.4
WEHI-3B Imf 11.6 1.0 15.3 1.4 8.9 0.8 3.4 0.3
CM M 17.3 1.5 13.2 1.4 8.9 0.8 4.8 0.5
+ MM 14.3 1.5 10.4 0.8 17.8 1.6 40.0 3.8
rGM-CSF B 2.1 0.2 4.9 0.4 0.7 0.6 0.7 0.1
S 1.4 0.1 9.1 0.8 2.1 0.2 10.2 0.8
Mf 1.4 0.1 13.8 1.2 10.3 0.8 10.9 0.8
BI 28.6 2.6 15.1 1.4 6.1 0.6 3.4 0.3
P 12.6 1.1 28.2 2.9 33.7 3.0 2.1 0.2
L929 CM Imf 1.4 1.3 7.5 0.8 13.5 1.4 17.3 1.6
+ M 12.6 1.3 10.9 0.8 7.5 0.8 10.4 0.8
rGM-CSF MM 33.0 2.9 5.4 0.5 5.4 0.6 14.5 1.2
B 4.9 0.4 1.5 0.1 0 0 4.1 0.4
S 2.1 0.2 10.2 0.9 6.8 0.7 17.9 1.8
Mf 4.8 0.5 21.2 2.0 27.1 2.6 30.3 3.1
Appendix Table A3.4 SA7 leukaemic differential cell counts. SA7 bone marrow i
cells were cultured in FCS and optimal concentrations of WEHI-3B CM, L929 1
CM and rGM-CSF alone and in combination in the microtitre assay for eight ss
hours, two, four and six days. Cytospins were prepared stained and the differentials 
counted.
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
Bl T26"142“T34~13T~”124"103"1055101 n 101
P 1.18 0.14 1.56 0.20 0.67 0.09 0.11 0.02 0.01 0.00
Imf 0.00 0.00 0.32 0.04 0.28 0.04 0.20 0.03 0.15 0.02
M 0.63 0.07 0.69 0.09 1.10 0.17 0.33 0.05 0.01 0.00
FCS MM 1.27 0.15 1.61 0.21 1.41 0.20 0.33 0.05 0.08 0.01
B 0.00 0.00 0.09 0.01 0.24 0.03 0.11 0.02 0.01 0.00
S 0.09 0.01 0.05 0.01 0.19 0.03 0.05 0.01 0.01 0.00
Mo 0.14 0.02 0 0 0 0 0 0 0 0
Mf 0.09 0.01 0.09 0.01 1.49 0.22 1.13 0.17 1.13 0.18
Total cells 6.66 0.53 6.76 0.65 5.42 160” 2.31 H 130 0.17
Bl 3.15 0.47 0.60 0.07 0.69 0.10 2.20 0.29
P 0.66 0.09 2.39 0.29 4.11 0.60 4.66 0.61
15% Imf 0.24 0.03 0.24 0.03 0.48 0.07 0.29 0.04
WEHI M 0.29 0.04 0.84 0.10 1.72 0.23 4.20 0.54
3B MM 1.91 0.29 1.75 0.22 2.16 0.30 6.15 0.81
CM B 0.19 0.02 0.24 0.03 0.25 0.03 0.49 0.05
S 0.14 0.02 0.54 0.07 0.48 0.07 1.72 0.23
Mf 0.05 0.01 2.16 0.29 4.06 0.60 8.44 1.20
Total cells 6.63 0.71 8.76 0.75 13.95 1.45 28.15 2.63
Bl 2.42 0.36 0.79 0.11 0.31 0.04 0.15 0.03
P 1.85 0.26 0.83 0.11 1.13 0.16 0 0
15% Imf 0.38 0.05 0.67 0.09 1.40 0.20 293 0.40
L929 M 0.58 0.08 0.25 0.04 0.41 0.06 0.15 0.03
CM MM 0.81 0.11 1.41 0.21 0.59 0.09 1.24 0.17
B 0.05 0.04 0.34 0.05 0.04 0.01 0.15 0.03
S 0.19 0.02 0.91 0.13 0.23 0.03 0.15 0.03
Mf 0.24 0.04 0.87 0.13 9.09 1.36 16.16 1.89
Total cells 132170” 6.07 0.64 13.20 1.51 20.63 2.31
Bl 2.79 0.38 0.64 0.09 0.28 0.04 0.09 0.02
P 1.35 0.19 2.94 0.42 4.20 0.62 0.50 0.07
60.00 Imf 0.42 0.06 0.16 0.02 1.86 0.29 0.58 0.08
U/ml M 0.84 0.11 0.58 0.09 1.78 0.28 1.08 0.15
rGM- MM 0.61 0.08 0.74 0.11 2.71 0.40 3.13 0.46
CSF B 0.23 0.03 0.16 0.02 0 0 0.67 0.10
S 0.14 0.02 0.53 0.08 1.40 0.22 1.90 0.27
Mf 0.28 0.04 2.02 0.29 1.40 0.19 4.04 0.62
Total cells 136 0.75 7.77 "0784" 13.63 1.56 11"99 1.35
Appendix Table A3.5 SA7 leukaemic bone marrow differential cell counts in absolute 
number of cells per well. Cells were cultured for eight hours, two, four and six days with
optimal concentrations of WEH1-3B CM,L929 CM or rGM-CSF in the microtitre assay. 
The total cell number per well was determine and cytospins were prepared, stained and 
differentials counted.
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
Bl 3726"0.42“"236 ■034““"0760“3.07””075^“0.07 1.37 3723
P 1.18 0.14 0.92 0.13 1.85 0.26 5.79 0.74 6.97 1.00
WEHI-3B Imf 0.00 0.00 0.29 0.04 0.33 0.04 0.77 0.10 4.45 0.63
CM M 0.63 0.07 0.54 0.07 0.43 0.05 3.28 0.39 2.12 0.31
+ MM 1.27 0.15 2.26 0.31 0.98 0.12 2.51 0.34 3.28 0.44
L929 CM B 0 0 0.09 0.01 0.16 0.02 0.68 0.09 0.78 0.10
S 0.09 0.01 0.19 0.02 1.47 0.19 1.35 0.16 3.31 0.44
Mo 0.14 0.02 0 0 0 0 0 0 0 0
Mf 0.09 0.01 0.29 0.04 1.83 0.23 4.24 0.51 6.02 0.85
Total cell 6.66 "0753"" *6“94 0.71 7.60 371“ 19.20 1.54 28.30 3.10"
Bl 0.44 0.06 0.91 0.11 1.34 0.19 1.14 0.16
P 1.22 0.15 1.99 0.24 9.86 1.39 5.97 0.80
WEHI-3B Imf 0.82 0.10 1.33 0.17 1.95 0.26 0.80 0.10
CM M 1.22 0.15 1.15 0.16 1.95 0.26 1.14 0.16
+ MM 1.01 0.14 0.91 0.10 3.90 0.53 9.50 1.27
rGM-CSF B 0.15 0.02 0.43 0.05 0.16 0.14 0.17 0.03
S 0.10 0.01 0.79 0.10 0.45 0.06 2.42 0.30
Mf 0.10 0.01 1.20 0.15 2.24 0.29 2.59 0.31
Total cells 7.06 0.62 8.71 0.74 21.85 2.22 23.73 2.24
Bl 2.04 0.28 1.11 0.15 1.15 0.17 0.74 0.10
P 0.90 0.12 2.07 0.30 6.36 0.89 0.45 0.06
L929 CM Imf 0.10 0.09 0.55 0.08 2,54 0.38 3.73 0.52
+ M 0.90 0.13 0.80 0.10 1.41 0.21 2.24 0.29
rGM-CSF MM 2.35 0.31 0.40 0.06 1.01 0.16 3.13 0.41
B 0.35 0.05 0.11 0.01 0 0 0.89 0.13
S 0.15 0.02 0.75 0.10 1.28 0.19 3.87 0.56
Mf 0.34 0.05 1.56 0.22 5.10 0.74 6.55 0.95
Total cells 7.13 0.72 7.35 "5.75 18.85 KT 21.60 2.23
Appendix Table A3.6 SA7 leukaemic bone marrow differential cell counts in absolute number 
of cells per well. Cells were cultured for eight hours, two, four and six days with optimal 
concentrations of WEHI-3B CM, L929 CM or rGM-CSF in combination in the microtitre assay, 
the total cell number per well was determined and cytospins were prepared, stained and 
differentials counted.
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PERCENTAGE OF TOTAL CELLS ± STANDARD ERROR
GF CELL ses 8 HOUR DAY 2 DAY 4 DAY 6
B1 17.2 1.6 13.8 1.4 0 0 3.5 0.4 0 0
P 18.5 1.6 17.1 1.8 11.7 0.9 7.0 0.7 2.9 0.3
Imf 0 0 7.2 0.7 7.5 0.8 3.5 0.3 0.0 0.0
FCS M 8.6 0.9 21.3 2.0 7.5 0.8 10.1 0.8 8.2 0.8
MM 42.9 4.4 34.8 3.3 37.1 3.6 15.6 1.5 13.5 1.4
B 2.8 0.3 5.1 0.5 8.3 0.8 1.0 0.1 0 0
S 0.8 0.1 0.7 0.1 2.9 0.3 2.0 0.2 8.2 0.9
Mo 8.6 0.9 0 0 0 0 0 0 0 0
Mf 0.8 0.1 0 0 25.0 2.6 57.3 5.6 67.3 6.8
Bl 13.1 1.4 5.4 0.5 4.0 0.4 2.7 0.3
P 20.8 1.9 20.5 1.9 38.5 3.5 47.0 4.5
15% Imf 23.6 2.4 25.4 2.4 3.4 0.4 0 0
WEHI-3B M 4.9 0.4 9.5 0.8 3.4 0.4 4.7 0.5
CM MM 27.7 2.5 6.2 0.6 10.2 0.8 18.0 1.9
B 4.9 0.5 2.8 0.3 0.7 0.1 2.0 0.2
S 2.1 0.2 5.4 0.4 7.4 0.7 6.0 0.5
Mf 2.8 0.2 24.7 2.3 32.4 3.3 19.5 1.8
Bl 7.8 0.6 6.4 0.6 0.7 0.1 0.6 0.1
P 6.9 0.6 20.9 1.8 2.0 0.2 0.6 0.1
15% Imf 35.9 3.3 8.4 0.7 12.5 1.0 0.6 0.1
L929 CM M 14.8 1.1 1.4 0.1 2.5 0.3 3.3 0.2
MM 24.0 2.3 6.4 0.5 32.3 3.4 10.4 0.8
B 6.4 0.6 1.4 0.1 2.5 0.3 3.3 0.3
S 2.9 0.2 11.9 0.7 3.3 0.3 2.6 0.3
Mf 1.4 0.1 43.2 3.5 44.2 4.2 78.6 8.0
Bl 0.7 0.1 0 0 0 0 0 0
P 18.3 1.4 13.0 1.5 0.7 0.1 6.8 0.6
Inf 6.4 0.6 10.3 0.8 2.7 0.3 0.7 0.1
60 U/ml M 8.4 0.9 34.2 3.2 0.7 0.1 12.9 0.9
rGM-CSF MM 35.2 3.4 10.3 0.8 21.5 2.0 23.8 2.1
B 2.9 0.3 4.1 0.4 6.7 0.7 4.8 0.4
S 0.7 0.1 18.0 1.5 39.5 4.1 18.3 1.6
Mf 27.4 2.5 10.3 0.8 28.2 3.1 32.6 3.4
Bl 6.4 0.6 20.1 1.9 3.5 0.4 8.0 0.8
P 11.9 0.9 22.2 1.9 13.9 1.2 52.7 4.8
WEHI-3B fail 23.3 2.4 14.1 1.5 1.2 0.1 4.7 0.4
CM M 19.8 1.7 5.4 0.5 10.2 0.9 2.6 0.3
+ MM 31.0 3.2 2.1 0.2 9.2 0.9 7.4 0.8
L929 CM B 1.3 0.1 0 0 0.8 0.1 0.7 0.1
S 0.7 0.1 11.4 1.0 3.6 0.4 8.0 0.9
Mo 0 0 0 0 0 0 0 0
mi 5.7 0.4 24.8 2.5 57.6 5.9 16.0 1.4
Bl 2.5 0.2 7.4 0.8 1.4 0.1 2.1 0.2
P 3.5 0.3 9.5 0.8 7.5 0.8 37.7 4.0
WEHI-3B Iaif 5.0 0.4 25.0 2.6 0.7 0.1 3.4 0.3
CM M 14.7 1.5 12.9 1.1 6.2 0.5 2.8 0.2
+ MM 32.3 3.0 10.9 0.8 31.5 2.9 15.7 1.1
rGM-CSF B 2.8 0.3 4.1 0.4 3.4 0.3 0.7 0.1
S 4.3 0.2 15.6 1.4 11.0 0.9 11.6 0.8
Mf 35.0 3.2 14.8 1.4 38.3 4.0 26.0 1.9
Bl 2.1 0.1 10.0 0.6 4.7 0.3 6.7 0.5
P 11.0 0.7 10.0 0.6 2.0 0.1 11.3 0.7
L929 CM Imf 10.3 1.2 16.2 1.2 0 0 17.3 1.4
+ M 16.1 1.2 10.0 0.8 10.9 0.9 2.7 0.1
rGM-CSF MM 26.5 2.0 8.0 0.8 42.2 3.7 19.3 1.5
B 4.4 0.2 0.0 0.0 2.1 0.1 0 0
S 5.2 0.3 22.2 1.8 8.9 0.7 12.7 1.4
MI 24.2 2.6 23.6 1.9 29.2 2.5 30.0 2.5
Appendix Table A3.7 SA8 leukaemic differential cell counts. SA8 bone man^o^ 
cells were cultured in FCS and optimal concentrations of WEHI-3B CM, L929 
CM and rGM-CSF alone and in combination in the microtitre assay for eight 
hours, two, four and six days. Cytospins were prepared stained and the differentials 
counted.
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
Bl Tl2""0TTK 0.15 ”000 000 0.07 0(1 .. 0
P 1.21 0.15 1.24 0.19 0.65 0.07 0.14 0.02 0.05 0.01
Imf 0.00 0.00 0.52 0.08 0.42 0.06 0.07 0.01 0.00 0.00
M 0.56 0.08 1.55 0.22 0.42 0.06 0.20 0.03 0.14 0.02
FCS MM 2.80 0.38 2.53 0.36 2.07 0.26 0.31 0.05 0.23 0.04
B 0.18 0.03 0.37 0.05 0.46 0.06 0.02 0.00 0.00 0.00
S 0.05 0.01 0.05 0.01 0.16 0.02 0.04 0.01 0.14 0.02
Mo 0.56 0.08 0 0 0 0 0 0 0 0
Mf 0.05 0.01 0 0 1.39 0.18 1.14 0.17 1.15 0.19
Total cells 6.53 "054“-7.26 0.78 5.57 044“ 1.99 0^ 1.71 "0222”
Bl 0.98 0.15 0.52 0.07 0.60 0.09 0.64 0.09
P 1.56 0.22 1.96 0.28 5.72 0.79 11.08 1.46
15% Imf 1.77 0.26 2.43 0.35 0.50 0.08 0 0
WEHI M 0.37 0.05 0.91 0.13 0.50 0.08 1.11 0.15
3B MM 2.08 0.29 0.59 0.09 1.51 0.20 4.25 0.59
CM B 0.37 0.05 0.27 0.04 0.11 0.02 0.47 0.06
S 0.16 0.02 0.52 0.07 1.10 0.15 1.42 0.17
Mf 0.21 0.03 2.36 0.34 4.82 0.70 4.60 0.59
Total cells 7.50 0.81 9.56 1.05 14.86 1.54 23.57 243
Bl 0.56 0.07 0.31 0.04 0.08 0.01 0.05 0.01
P 0.50 0.07 1.02 0.14 0.22 0.03 0.05 0.01
15% Imf 2.59 0.36 0.41 0.06 1.38 0.19 0.05 0.01
L929 M 1.07 0.14 0.07 0.01 0.28 0.05 0.26 0.03
CM MM 1.73 0.25 0.31 0.04 3.56 0.55 0.83 0.11
B 0.46 0.07 0.07 0.01 0.28 0.05 0.26 0.04
S 0.21 0.03 0.58 0.07 0.36 0.05 0.21 0.03
Mf 0.10 0.01 2.11 0.29 4.87 0.72 6.27 0.95
Total cells T22" (77 T88" 0.54 10.92 1.25 7.77 ■087"
Bl 0.05 0.01 0 0 0 0 0 0
P 1.32 0.18 1.15 0.17 0.09 0.02 0.59 0.08
60 Imf 0.46 0.07 0.91 0.11 0.34 0.05 0.06 0.01
U/ml M 0.61 0.09 3.03 0.40 0.09 0.02 1.12 0.14
rGM- MM 2.54 0.38 0.91 0.11 2.73 0.40 2.06 0.28
CSF B 0.21 0.03 0.36 0.05 0.85 0.13 0.42 0.06
S 0.05 0.01 1.60 0.20 5.02 0.77 1.59 0.22
Mf 1.98 0.29 0.91 0.1 1 3.58 0.56 2.83 0.42
Total cells T22~ 0.81 8.87 084“ l2.70 1.42 8.67 042-
Appendix Table A3.8 SA8 leukaemic bone marrow differential cell counts in absolute
number of cells per well. Cells were cultured for eight hours, two, four and six days with 
optimal concentrations of WEHI-3B CM, L929 CM or rGM-CSF in the microtitre assay.
The total cell number per well was determined and cytospins were prepared, stained and
differentials counted.
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
Bl 1,12 "0115""~~034~"06“ 1.76 "035“""0.54 "039"“187""025"
P 1.21 0.15 0.82 0.10 1.94 0.27 2.13 0.30 12.3 1.58
WEHI-3B Imf 0 0 1.60 023 1.23 0.19 0.18 0.03 1.10 0.14
CM M 0.56 0.08 1.36 0.18 0.47 0.07 1.56 0.22 0.61 0.09
+ MM 2.80 0.38 2.13 0.31 0.18 0.03 1.42 0.21 1.73 0.24
L929 CM B 0.18 0.03 0.09 0.01 0 0 0.13 0.02 0.16 0.03
S 0.05 0.01 0.05 0.01 1.00 0.14 0.55 0,09 1.87 0.27
Mo 0.56 0.08 0 0 0 0 0 0 0 0
Mf 0.05 0.01 0.39 0.05 2.17 0.32 8.85 1.35 3.74 0.47
Total cells "638""034“"638 0.71 8.75 "034“ 15.36 1.74 25.5i TTO
Bl 0.17 0.02 0.74 0.12 0.27 0.03 0.52 0.08
P 0,24 0.03 0.95 0.14 1.46 0.21 9.49 1.53
WEHI-3B Imf 0.34 0.04 2.51 0.40 0.13 0.02 0.85 0.13
CM M 1.00 0.14 1.29 0.19 1.20 0.15 0.67 0.10
+ MM 2.20 0.29 1.09 0.16 6.12 0.82 3.96 0.55
rGM-CSF B 0.19 0.03 0.41 0.06 0.67 0.09 0.18 0.03
S 0.29 0.03 1.56 0.24 2.13 0.27 2.92 0.41
Mf 2.39 0.32 1.48 0.23 7.45 1.06 6.54 0.92
Total cells 6.82 0.65 10.03 1.23 19.43 1.87 25.16 3.04
Bl 0.14 0.02 0.85 0.11 0.76 0.10 1.28 0.18
P 0.72 0.09 0.85 0.11 0.32 0.04 2.16 0.29
L929 CM Imf 0.67 0.11 1.37 0.19 0.00 0.00 3.31 0.48
+ M 1.05 0.14 0.85 0.12 1.75 0.25 0.52 0.07
rGM-CSF MM 1.73 0.24 0.68 0.10 6.77 0.98 3.69 0.53
B 0.29 0.04 0 0 0.33 0.04 0 0
S 0.34 0.04 1.88 0.26 1.42 0.20 2.43 0.40
Mf 1.58 0.25 2.00 0.28 4.69 0.67 5.73 0.84
Total cells 6.52 0.75 8.48 0.97 16.04 1.8^5 19.12 2.31
Appendix Table A3.9 SA8 leukaemic bone marrow differential cell counts in absolute number 
of cells per well. Cells were cultured for eight hours, two, four and six days with optimal 
concentrations of WEH1-3B CM, L929 CM or rGM-CSF in combination in the microtitre assay. 
The total cell number per well was determined and cytospins were prepared, stained and 
differentials counted.
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PERCENTAGE OF TOTAL CELLS ± STANDARD ERROR
GF CELL ses 8 HOUR DAY 2 DAY 4 DAY 6
“BT“ ~WT"nr"T8T "77■nr” 28.1 TT
P 7.7 0.6 8.5 0.9 18.1 1.5 42.2 3.9 31.0 3.0
Imf 0 0 0.7 0.1 5.6 0.5 3.4 0.2 2.9 0.2
M 4.5 0.5 7.1 0.6 2.1 0.2 11.1 0.9 2.9 0.3
FCS MM 48.8 4.5 51.7 4.9 41.3 3.6 12.5 0.9 1.3 0.1
B 1.3 0.1 0.0 0.0 4.3 0.3 2.7 0.3 0.0 0.0
S 1.3 0.1 2.1 0.1 8.4 0.7 3.4 0.4 4.2 0.3
Mo 0.3 0.1 0.3 0.1 0 0 0 0 0 0
Mf 0 0 0 0 15.4 1.2 17.6 1.6 29.7 2.6
Bl 13.6 1.5 7.9 0.7 14.7 1.6 8.1 0.8
P 22.8 2.3 33.8 3.0 46.9 4.8 66.9 5.9
15% Imf 2.2 0.1 4.3 0.4 4.2 0.3 4.0 0.3
WEHI-3B M 17.1 1.4 8.7 0.7 12.5 1.4 5.4 0.5
CM MM 37.1 3.2 20.1 1.8 2.8 0.1 5.4 0.5
B 4.3 0.4 3.7 0.3 0 0 0 0
S 1.4 0.1 5.7 0.5 9.0 0.8 2.0 0.1
Mf 1.4 0.1 15.9 1.4 9.8 0.8 8.1 0.7
Bl 5.2 0.4 10.0 0.7 13.4 1.0 4.8 0.3
P 20.8 1.8 24.3 1.9 18.8 1.5 0.7 0.1
Imf 4.5 0.5 2.9 0.2 8.0 0.7 4.1 0.5
15% M 11.1 0.7 2.2 0.2 6.1 0.7 0.7 0.1
L929 CM MM 42.9 3.9 17.9 1.4 7.4 0.7 4.1 0.5
B 3.8 0.4 3.5 0.4 0 0 1.4 0.1
S 2.9 0.3 13.6 1.2 2.0 0.1 1.5 0.1
Mf 8.9 0.7 25.7 2.0 44.2 4.0 82.9 6.5
Bl 13.0 1.2 18.2 1.4 15.9 1.3 44.1 4.0
P 23.2 1.9 36.4 3.7 25.7 2.6 10.2 1.0
Imf 3.0 0.2 0.7 0.1 11.7 0.7 7.5 0.7
60 U/ml M 10.9 0.8 7.7 0.8 4.9 0.3 4.8 0.5
rGM-CSF MM 34.0 2.8 4.3 0.3 11.9 0.9 11.6 1.0
B 0.7 0.1 3.5 0.3 1.4 0.1 0 0
S 9.3 0.8 20.2 1.6 18.7 2.0 13.6 1.2
Mf 5.9 0.5 9.0 0.6 9.8 0.8 8.2 0.9
Bl 12.8 1.0 6.4 0.5 31.3 2.6 39.3 4.0
P 17.8 1.5 42.6 4.0 29.3 2.6 31.3 3.0
WEHI-3B Imf 1.4 0.1 1.4 0.1 3.3 0.3 3.3 0.3
CM M 5.7 0.6 6.4 0.5 6.2 0.7 1.3 0.1
+ MM 51.0 5.2 12.8 1.0 6.9 0.7 2.7 0.3
L929 CM B 2.9 0.3 2.9 0.1 0 0 0 0
S 4.9 0.5 9.9 0.7 8.1 0.7 2.7 0.2
Mo 0 0 0 0 0 0 0 0
Mf 3.5 0.3 17.8 1.3 14.9 1.6 19.4 1.6
Bl 12.5 0.9 15.1 1.4 9.1 0.8 20.5 1.7
P 17.9 1.8 31.6 3.2 34.2 3.1 23.3 1.9
WEHI-3B Imf 3.2 0.3 2.1 0.2 10.5 0.8 6.2 0.6
CM M 13.3 1.2 13.7 0.9 9.1 0.8 3.5 0.3
4 MM 34.3 3.0 9.6 0.9 4.2 0.4 4.7 0.2
rGM-CSF B 4.7 0.5 2.1 0.1 4.3 0.5 0.7 0.5
S 5.6 0.5 13.7 1.5 13.9 1.5 9.6 0.7
Mf 8.6 0.5 12.3 1.4 14.8 1.5 31.5 3.3
Bl 6.9 0.5 12.3 1.1 11.1 0.6 14.1 1.2
P 22.0 1.9 29.2 2.4 24.1 1.7 3.3 0.3
L929 CM Imf 2.3 0.1 8.0 0.7 5.4 0.5 13.4 1.2
M 10.7 0.8 13.1 0.8 8.3 0.9 1.4 0.1
rGM-CSF MM 37.4 3.5 7.3 0.7 5.4 0.6 3.4 0.2
B 2.3 0.2 2.2 0.2 2.1 0.2 2.0 0.2
S 12.9 0.9 19.8 2.0 26.3 2.0 18.1 1.6
Mf 5.4 0.3 8.0 0.5 17.2 0.5 44.3 4.0
Appendix Table A3.10 SA2 LP leukaemic differential cell counts. SA2 LP bone 
marrow cells were cultured in FCS and optimal concentrations of WEHI-3B CM, 
L929 CM and rGM-CSF alone and in combination in the microtitre assay for 
eight hours, two, four and six days. Cytospins were prepared stained and the 
differentials counted.
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
Bl 135"■00T "030”“030"000“”021 ~003 0.80"010”
P 0.54 0.07 0.61 0.09 1.14 0.15 1.25 0.18 0.97 0.14
Imf 0 0 0.05 0.01 0.35 0.05 0.10 0.01 0.09 0.01
M 0.32 0.05 0.51 0.06 0.13 0.02 0.33 0.04 0.09 0.01
FCS MM 3.43 0.46 3.72 0.50 2.60 0.35 0.37 0.05 0.04 0.01
B 0.09 0.01 0.00 0.00 0.27 0.03 0.08 0.01 0.00 0.00
S 0.09 0.01 0.15 0.02 0.53 0.07 0.10 0.02 0.13 0.02
Mo 0.03 0.01 0.02 0.01 0 0 0 0 0 0
Mf 0 0 0 0 0.97 0.12 0.52 0.07 0.93 0.13
Total cells 10!"069”000 0.68 6.29 0.84 "1.96 0.32 5.15 032
Bl 0.94 0.15 0.92 0.14 1.25 0.19 1.25 0,19
P 1.58 0.23 3.94 0.59 4.00 0.60 10.31 1.48
15% Imf 0.15 0.02 0.50 0.08 0.36 0.05 0,62 0.08
WEHI M 1.18 0.16 1.01 0.15 1.07 0.17 0.83 0.12
3B MM 2.57 0.36 2.35 0.36 0.24 0.03 0.83 0.12
CM B 0.30 0.04 0.43 0.06 0 0 0 0
S 0.10 0.01 0.67 0.10 0.77 0.11 0.31 0.04
Mf 0.10 0.01 1.85 0.28 0.84 0.12 1.25 0.18
Total cells 6.92 0.75 11.7 1.42 8.53 0.94 15.40 1.74
Bl 0.37 0.05 0.83 0.10 0.72 0.10 0.42 0.05
P 1.49 0.20 2.02 0.26 1.01 0.14 0.06 0.01
15% Imf 0.32 0.05 0.24 0.03 0.43 0.06 0.36 0.06
L929 M 0.80 0.10 0.18 0.02 0.33 0.05 0.06 0.01
CM MM 3.08 0.42 1.49 0.19 0.40 0.06 0.36 0.06
B 0.27 0.04 0.29 0.04 0.00 0.00 0.12 0.02
S 0.21 0.03 1.13 0.15 0.11 0.01 0.13 0.02
Mf 0.64 0.08 2.14 0.27 2.38 0.35 7.31 0.97
Total cells 7.18 0.74 T52 0.84 5.38 0.62 8.82 0.95
Bl 0.92 0.13 2.20 0.30 1.37 0.18 6.15 0.85
P 1.64 0.22 4.41 0.66 2.21 0.33 1.42 0.20
60 Imf 0.21 0.03 0.09 0.02 1.01 0.12 1.04 0.15
U/ml M 0.77 0.10 0.93 0.14 0.42 0.05 0.67 0.10
rGM- MM 2.41 0.32 0.52 0.07 1.02 0.13 1.62 0.22
CSF B 0.05 0.01 0.42 0.06 0,12 0.02 0 0
S 0.66 0.09 2.45 0.33 1.61 0.24 1.89 0.26
Mf 0.42 0.06 1.09 0.14 0.84 0.11 1.14 0.17
Total cells 010 075 12.1 134 8.60 0.92 15.95 1.45
Appendix Table A3.11 SA2 LP leukaemic bone marrow differential cell counts in absolute 
number of cells per well. Cells were cultured for eight hours, two, four and six days with 
optimal concentrations of WEHI-3B CM, L929 CM or rGM-CSF in the microtitre assay. The
total cell number per well was determined and cytospins were prepared, stained and
differentials counted.
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
Bl 33T“05” “032"““035"030"” 0.41 7.87 1.21
P 0.54 0.07 1.28 0.17 5.01 0.71 2.81 0.40 6.27 0.94
WEHI-3B Imf 0 0 0 0 0.16 0.02 0.32 0.05 0.66 0.10
CM M 0.32 0.05 0.41 0.06 0.75 0.10 0.59 0.09 0.26 0.04
+ MM 3.43 0.46 3.67 0.54 1.50 0.20 0.66 0.10 0.54 0.09
L929 CM B 0.09 0.01 0.21 0.03 0.34 0.04 0 0 0 0
S 0.09 0.01 0.35 0.05 1.16 0.15 0.78 0.11 0.54 0.07
Mo 0.03 0.01 0.10 0 0 0 0 0 0 0
Mf 0 0 0.25 0.03 2.09 0.27 1.43 0.22 3.89 0.55
Total cells T05“W"“739 0.75 11.76 1.26 ""959 1.06 20.03 2.50
Bl 0.83 0.11 2.02 0.29 1.00 0.14 4.68 0.65
P 1.19 0.17 4.23 0.63 3.78 0.55 5.32 0.74
WEHI-3B Imf 0.21 0.03 0.28 0.04 1.16 0.16 1.41 0.21
CM M 0.88 0.12 1.83 0.23 1.00 0.14 0.80 0.11
+ MM 2.28 0.31 1.28 0.18 0.46 0.07 1.08 0.13
rGM-CSF B 0.31 0.05 0.28 0.03 0.47 0.08 0.16 0.12
S 0.37 0.05 1.83 0.28 1.54 0.24 2.18 0.29
Mf 0.57 0.07 1.65 0 36 1.63 0.25 7.19 1.10
Total cells 6.64 0.71 13.40 1.45 11.04 1.26 22.82 2.56
Bl 0.56 0.07 1.40 0.20 1.08 0.15 3.42 0.45
P 1.79 0.23 3.31 0.45 2.35 0.34 0.71 0.11
L929 CM Imf 0.19 0.02 0.91 0.13 0.53 0.08 2.87 0.44
+ M 0.87 0.11 1.49 0.19 0.81 0.13 0.30 0.04
rGM-CSF MM 3.04 0.41 0.83 0.12 0.53 0.09 0.73 0.10
B 0.19 0.02 0.25 0.04 0.20 0.03 0.43 0.07
S 1.05 0.12 235 0.33 2.56 0.38 3.88 0.59
Mf 0.44 0.05 0.91 0.11 1.68 0.22 9.50 1.45
Total cells 8.15 0.78 11.58 1.25 9.74 1.23 31.44 3.64
Appendix Table A3.12 SA2 LP leukaemic bone marrow differential cell counts in absolute 
number of cells per well. Cells were cultured for eight hours, two, four and six days with 
optimal concentrations of WEHI-3B CM, L929 CM or iGM-CSF in combination in the microtitre 
assay. The total cell number per well was determined and cytospins were prepared, stained 
and differentials counted.
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PERCENTAGE OF TOTAL CELLS ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
"BT“ 19.3 T7T“3TT ~6T 0 0 0.9 0.1
P 18.7 2.0 17.1 2.0 29.9 2.5 0 0 3.3 0.2
Imf 0 0 10.3 0.8 4.0 0.3 1.5 0.1 1.4 0.1
M 5.4 0.6 6.9 0.5 4.0 0.2 13.6 1.1 8.8 0.6
FCS MM 49.0 4.5 28.9 3.0 28.0 3.0 21.4 1.7 10.2 0.7
B 2.8 0.3 0.7 0.1 4.0 0.2 1.5 0.1 0 0
S 3.4 0.4 0.0 0.0 0.8 0.5 6.8 0.4 0 0
Mo 1.3 0.1 0.5 0.1 0.2 0.1 0 0 0 0
Mf 0 0 0.7 0.1 22.4 1.9 55.1 5.0 75.3 4.1
Bl 45.9 3.8 5.5 0.3 5.4 0.4 3.5 0.2
P 21.0 1.7 27.4 1.7 22.6 1.9 33.5 2.7
15% Imf 6.0 0.4 15.1 1.8 4.8 0.3 1.4 0.1
WEHI-3B M 12.2 0.9 9.6 1.2 10.3 0.7 3.6 0.4
CM MM 10.8 0.9 13.6 1.2 27.4 2.1 17.5 1.5
B 1.4 0.1 1.3 0.1 0 0 0.7 0.1
S 0.7 0.1 2.8 0.1 6.9 0.8 7.7 0.5
Mf 2.1 0.1 24.8 1.8 22.7 2.6 32.2 2.4
Bl 53.0 5.0 1.4 0.1 4.1 0.3 2.7 0.3
P 17.1 1.0 34.0 2.6 6.7 0.3 0.7 0.1
Imf 3.3 0.4 4.2 0.3 12.3 0.6 4.7 0.3
15% M 9.5 1.1 4.2 0.3 2.0 0.1 1.3 0.1
L929 CM MM 13.7 1.1 13.8 1.5 7.4 0.9 10.1 0.5
B 1.3 0.1 1.4 0.1 0.7 0.1 0 0
S 0 0 5.5 0.4 1.4 0.1 2.0 0.1
Mf 2.1 0.1 35.4 3.4 65.3 4.3 78.5 5.4
Bl 56.8 4.8 4.2 0.3 1.3 0.1 0 0
P 14.2 1.5 37.5 3.2 6.9 0.5 1.3 0.1
Imf 3.3 0.3 10.4 0.9 3.4 0.2 0 0
60 U/ml M 6.1 0.7 10.4 0.9 18.6 2.0 2.8 0.2
rGM-CSF MM 14.9 1.3 4.8 0.3 35.9 3.0 17.0 1.5
B 2.8 0.3 4.2 0.3 2.1 0.2 0.7 0.1
S 2.0 0.1 6.2 0.5 4.1 0.3 8.8 1.0
Mf 0 0 22.3 2.4 27.6 3.0 69.3 5.6
Bl 50.3 4.3 3.3 0.2 4.8 0.3 1.4 0.1
P 22.4 3.0 37.3 4.1 23.6 1.8 22.7 2.4
WEHI-3B Imf 2.0 0.1 7.4 0.5 8.8 0.8 5.0 0.3
CM M 7.5 0.5 4.8 0.3 6.8 0.8 10.7 0.8
+ MM 10.3 0.6 2.7 0.3 10.1 0.8 10.6 0.8
L929 CM B 2.0 0.1 3.3 0.3 0 0 3.5 0.2
S 0.7 0.1 11.4 0.9 8.1 0.8 4.2 0.2
Mo 0 0 0 0 0 0 0 0
Mf 4.8 0.6 29.8 3.1 37.9 4.0 41.9 4.3
Bl 39.8 3.2 8.4 0.7 3.4 0.2 3.4 0.2
P 19.6 2.0 43.2 3.6 27.0 2.0 27.6 3.0
WEHI-3B Imf 11.5 1.0 11.8 1.3 5.4 0.5 0.7 0.1
CM M 10.8 0.9 2.8 0.1 10.1 0.7 6.8 0.5
+ MM 13.6 0.9 4.2 0.3 15.6 1.2 21.3 1.5
rGM-CSF _ B 4.2 0.3 2.8 0.3 0 0 2.8 0.3
S 0.7 0.1 12.1 1.0 8.8 1.0 9.6 0.5
Mf 0 0 14.7 1.5 29.7 3.0 27.6 1.5
Bl 48.9 4.5 4.2 0.4 0 0 0.7 0.1
P 25.5 2.5 44.8 4.2 25.5 2.2 7.7 0.6
L929 CM Imf 5.8 0.5 12.4 1.4 5.8 0.4 1.4 0.1
M 8.7 0.5 9.6 1.0 15.3 1.2 5.7 0.6
rGM-CSF MM 8.1 0.5 2.8 0.1 11.0 1.2 18.4 1.5
B 0.8 0.6 1.4 0.1 2.2 0.2 3.6 0.2
S 2.2 0.2 13.2 1.0 34.4 2.9 8.5 0.6
Mf 0 0 11.7 1.0 5.8 0.6 53.8 4.5
Appendix Table A3.13 SA2 HP leukaemic differential cell counts. SA2 HP bone 
marrow cells were cultured in FCS and optimal concentrations of WEHI-3B CM, 
L929 CM and rGM-CSF alone and in combination in the microtitre assay for 
eight hours, two, four and six days. Cytospins were prepared stained and the 
differentials counted.
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
Bl i.3i 0.17 “15$~0"40“~0OT"$$T 0 -“$52- <5------
P 1.27 0.16 1.27 0.20 1.93 0.27 0 0 0.07 0.01
Imf 0.00 0.00 0.76 0.10 0.26 0.03 0.05 0.01 0.03 0.00
M 0.37 0.05 0.5 1 0.07 0.26 0.03 0.44 0.05 0.19 0.03
FCS MM 3.33 0.39 2.14 0.32 1.81 0.28 0.69 0.08 0.22 0.03
B 0.19 0.02 0.05 0.01 0.26 0.03 0.05 0.01 0.00 0.00
S 0.23 0.03 0.00 0.00 0.05 0.03 0.22 0.02 0.00 0.00
Mo 0.09 0.01 0.04 0.01 0.01 0.01 0 0 0 0
Mf 0 0 0.05 0.01 1.45 0.20 1.78 0.22 1.62 0.21
Total cells 6.79 "O$" 7.41 "$78“ 6.46 $.71 3.23 0.26 2.15 0.25
Bl 3.35 0.45 0.67 0.09 1.40 0.20 1.14 0.14
P 1.53 0.21 3.35 0.47 5.80 0.86 11.08 1.52
15% Imf 0.44 0.06 1.85 0.32 1.24 0.17 0.45 0.06
WEHI M 0.89 0.12 1.17 0.21 2.64 0.37 1.18 0.19
3B MM 0.79 0.11 1.67 0.26 7.04 1.01 5.78 0.81
CM B 0.10 0.01 0.16 0.02 0 0 0.24 0.04
S 0.05 0.01 0.34 0.05 1.77 0.30 2.53 0.32
Mf 0.15 0.02 3.03 0.44 5.83 0.97 10.63 1.42
Total cells 7.30 0.78 12.24 1.56 25.72 3.12 33.03 3.66
Bl 4.13 0.53 0.12 0.01 0.84 0.12 0.55 0.09
P 1.33 0.14 2.91 0.34 1.38 0.18 0.14 0.03
15% Imf 0.26 0.04 0.36 0.04 2.52 0.33 0.96 0.14
L929 M 0.74 0.11 0.36 0.04 0.42 0.06 0.27 0.04
CM MM 1.07 0.13 1.18 0.17 1.53 0.27 2.05 0.28
B 0.10 0.01 0.12 0.01 0.15 0.03 0 0
S 0.00 0.00 0.47 0.05 0.29 0.04 0.41 0.06
Mf 0.16 0.02 3.03 0.40 13.41 1.88 16.01 2.34
Total cells 7.77 $60 8.55 "$76“ 20.54 2.54 20.39 2.63
Bl 4.31 0.59 0.51 0.07 0.34 0.04 0 0
P 1.08 0.16 4.57 0.63 1.76 0.21 0.16 0.02
60 Imf 0.25 0.04 1.27 0.18 0.87 0.10 0 0
U/ml M 0.46 0.07 1.27 0.18 4.73 0.68 0.34 0.05
rGM- MM 1.13 0.16 0.58 0.07 9.13 1.15 2.10 0.31
CSF B 0.21 0.03 0.51 0.07 0.53 0.07 0.09 0.02
S 0.15 0.02 0.76 0.10 1.05 0.13 1.09 0.18
Mf 0.00 0.00 2.72 0.42 7.02 1.01 8.55 1.22
Total cells ”73$W 12.19 ~OT~ 25.43 2.41 12.33 1.45
Appendix Table A3.14 SA2 HP leukaemic bone marrow differential cell counts in absolute
number of cells per well. Cells were cultured for eight hours, two, four and six days with 
optimal concentrations of WEHI-3B CM, L929 CM or rGM-CSF in the microtitre assay. 
The total cell number per well was determined and cytospins were prepared, stained and 
differentials counted.
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
Bl 1.31 6.17 631 “64T"66T 1.38 6.18 3807"665"
P 1.27 0.16 1.68 0.29 4.39 0.76 6.83 0.92 6.36 0.99
WEHI-3B Imf 0 0 0.13 0.02 0.91 0.13 2.36 0.37 1.40 0.18
CM M 0.37 0.03 0.36 0.07 0.39 0.08 1,97 0.32 2.99 0.41
+ MM 3.33 0.39 0.77 0.09 0.33 0.03 2.94 0.40 2.96 0.41
L929 CM B 0.19 0.02 0.13 0.02 0.41 0.06 0 0 0.99 0.13
S 0.23 0.03 0.03 0.01 1.41 0.21 243 0.33 1.19 0.13
Mo 0.09 0.01 0 0 0.03 0 0 0 0 0
Mf 0 0 0.36 0.06 3.67 0.39 11.00 1.68 11.74 1.81
Total cells 6.70 "0.40““7.40'"aTS- l2.32 1.32 29.03 28.02 T2T
Bl 3.03 0.40 1.10 0.13 1.13 0.13 1.11 0.12
P 1.30 0.22 3.69 0.78 9.10 1.14 9.00 1.30
WEHI-3B Imf O.88 0.12 1.36 0.24 1.81 0.23 0.24 0.04
CM M 0.83 0.11 0.37 0.04 3.41 0.42 2.22 0.27
+ MM 1.04 0.13 0.33 0.07 3.23 0.67 6.94 0.83
rGM-CSF B 0.32 0.04 0.37 0.06 0 0 0.91 0.13
S 0.03 0.01 1.60 0.22 2.97 0.43 3.14 0.34
Mf 0 0 1.93 0.29 9.99 1.43 9.00 0.99
Total cells 7.67 0.79 13.17 1.42 33.66 3.41 32.36 3.12
Bl 4.16 0.36 0.30 0.07 0.00 0.00 0.18 0.03
P 2.17 0.30 3.37 0.78 7.61 1.03 1.89 0.23
L929 CM Imf 0.49 0.06 1.49 0.23 1.73 0.22 0.34 0.04
+ M 0.74 0.08 1.13 0.17 4.37 0.61 1.40 0.21
rGM-CSF MM 0.69 0.08 0.34 0.04 3.27 0.30 4.49 0.61
B 0.07 0.03 0.17 0.02 0.63 0.09 0.88 0.11
S 0.19 0.03 1.38 0.21 10.26 1.40 2.08 0.27
Mf 0 0 1.40 0.20 1.73 0.26 13.13 1.79
Total cells 8.51 0.84 12.CO 1.32 29.82 3.21 24.39 2.63
Appendix Table A3.13 SA2 HP leukaemic bone marrow differential cell counts in absolute 
number of cells per well. Cells were cultured for eight hours, two, four and six days with 
optimal concentrations of WEHI-3B CM, L929 CM or rGM-CSF in combination in the microtitre 
assay. The total cell number per well was determined and cytospins were prepared, stained and 
differentials counted.
244
PERCENTAGE OF TOTAL CELLS ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
6i 99.0 0.5 70.4 1.8 50.0 2.5 ~ 84.4 ' 36.5 2.1 ’
P 1.0 0.3 20.4 1.8 12.5 0.9 7.3 1.7 14.1 1.2
Imf 0 0 0 0 36.5 1.7 8.3 0.9 49.4 1.0
FCS M 0 0 0 0 0 0 0 0 0 0
MM 0 0 0 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0 0 0
Mf 0 0 0 0 1.1 0.1 0 0 0 0
Bl 46.8 1.4 88.9 3.0 90.8 3.3 70.6 2.4
P 53.2 1.4 10.1 3.0 5.1 1.5 14.1 1.2
15% Imf 0 0 1.0 0.1 4.1 2.0 15.3 1.2
WEHI-3B M 0 0 0 0 0 0 0 0
CM MM 0 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
Mf 0 0 0 0 0 0 0 0
Bl 64.5 1.3 72.7 1.9 82.0 2.2 66.3 2.5
P 34.8 1.3 27.3 1.9 12.0 1.2 23.9 1.3
Lnf 0.8 0.1 0 0 6.0 1.0 9.8 1.3
15% M 0 0 0 0 0 0 0 0
L929 CM MM 0 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
Mf 0 0 0 0 0 0 0 0
Bl 46.9 1.7 76.0 3.4 79.5 2.6 48.3 3.3
P 53.1 1.7 16.7 2.0 3.4 0.9 13.8 1.4
Imf 0 0 5.2 1.6 17.1 1.8 37.9 2.0
60 U/ml M 0 0 0 0 0 0 0 0
rGM-CSF MM 0 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
Mf 0 0 2.1 0.1 0 0 0 0
Bl 58.6 2.8 93.8 1.4 75.5 3.4 75.8 2.7
P 40.4 2.7 5.2 1.2 13.3 1.6 11.0 1.6
WEHI-3B Imf 0 0 1.0 0.3 11.2 1.9 13.2 1.2
CM M 0 0 0 0 0 0 0 0
+ MM 0 0 0 0 0 0 0 0
L929 CM B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
Mf 1.0 0.3 0 0 0 0 0 0
Bl 58.7 1.4 86.7 3.3 89.0 2.1 61.5 3.7
P 38.1 1.1 7.2 2.1 1.1 0.3 16.7 1.3
WEHI-3B Imf 3.2 0.4 6.1 1.2 9.9 1.9 21.9 2.7
CM M 0 0 0 0 0 0 0 0
+ MM 0 0 0 0 0 0 0 0
rGM-CSF B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
Mf 0 0 0 0 0 0 0 0
Bl 45.6 2.6 62.6 1.3 92.5 1.7 30.1 2.4
P 51.1 2.8 33.3 1.3 4.3 1.3 5.5 0.6
L929 CM Imf 0 0 4.0 0.3 3.2 0.7 64.4 1.9
+ M 0 0 0 0 0 0 0 0
rGM-CSF MM 0 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
Mf 3.3 0.4 0 0 0 0 0 0
Appendix Table A3.16 SA2 CL leukaemic differential cell counts. The SA2 CL 
was cultured in FCS and optimal concentrations of WEHI-3B CM, L929 CM 
and rGM-CSF alone and in combination in the microtitre assay for eight hours, 
two, four and six days. Cytospins were prepared stained and the differentials 
counted.
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ABSOLUTE CELL NO./ WELL X 104 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
Bl TT"0WT4T"078“ 18.57 46.58 5.04 21700 ■2750-
P 0.64 0.20 2.16 0.27 4.64 0.60 4.03 1.03 8.15 1.10
Imf 0 0 0 0 13.54 1.60 4.60 0.50 28.51 3.03
FCS M 0 0 0 0 0 0 0 0 0 0
MM 0 0 0 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0 0 0
mf 0 0 0 0 0.39 0.06 0 0 0 0
Total cells TTT 6.44 10.58 "05" 37.14 T02~ 55.21 "5706" 57.66 002“
Bl 4.46 0.50 34.17 3.93 51.60 5.63 40.21 4.06
P 5.08 0.56 3.88 1.23 2.90 0.90 8.04 1.03
15% Imf 0 0 0.39 0.04 2.32 1.16 8.71 1.07
WEHI M 0 0 0 0 0 0 0 0
3B MM 0 0 0 0 0 0 0 0
CM B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
mf 0 0 0 0 0 0 0 0
Total cells 9.54 1.03 38.44 4.23 56.82 5.84 56.96 5.42
Bl 5.84 0.73 26.45 2.98 51.41 5.43 46.01 4.66
P 3.15 0.40 9.92 1.29 7.52 1.08 16.59 1.80
15% Imf 0.07 0.01 0 0 3.76 0.74 6.79 1.10
L929 M 0 0 0 0 0 0 0 0
CM MM 0 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
mf 0 0 0 0 0 0 0 0
Total cells TTW 1.11 36.37 3.98 62.69 6.41 69.39 6.52
Bl 4.77 0.62 28.19 2,78 41.28 4.65 27.38 3.45
P 5.39 0.69 6.18 0.92 1.77 0.51 742 1.15
60 Imf 0 0 1.93 0.62 8.85 1.33 21.52 2.54
IU/ml M 0 0 0 0 0 0 0 0
rGM- MM 0 0 0 0 0 0 0 0
CSF B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
mf 0 0 0 0 0 0 0 0
Total cells 10.16 0726”‘"37.07"0726“ 51.90 "3730“ 56.72 "6700“
Appendix Table A3.17 The SA2 CL differential cell counts in absolute number of cells
per well. Cells were cultured for eight hours, two, four and six days with optimal 
concentrations of WEH1-3B CM, L929CM or rGM-CSF in the m.icrotitre assay. The 
total cell number per well was determined and cytospins were prepared, stained and
differentials counted.
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ABSOLUTE CELL NO./ WELL X lO4 ± STANDARD ERROR
GF CELL SCS 8 HOUR DAY 2 DAY 4 DAY 6
Bl W“OtT“0^333T330““44.07" 5.01“ 47.60 3.20“
P 0.64 0.20 3.97 0.49 1.85 0.47 7.74 1.23 6.91 1.23
WEHI-3B Imf 0 0 0 0 0.37 0.12 6.55 1.30 8.29 1.14
CM M 0 0 0 0 0 0 0 0 0 0
+ MM 0 0 0 0 0 0 0 0 0 0
L929 CM B 0 0 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0 0 0
Mf 0 0 0 0 0 0 0 0 0 0
Total cells 6.85 0.44 "3782"“TOT" 35.55 T60“ 58.36 6.09 62.80 "OT
Bl 5.83 0.46 31.65 2.84 47.55 4.19 38.77 4.64
P 3.78 0.31 2.61 0.79 0.59 0.17 10.51 1.36
WEHI-3B Imf 0.32 0.05 2.23 0.47 5.28 1.11 13.80 2.22
CM M 0 0 0 0 0 0 0 0
+ MM 0 0 0 0 0 0 0 0
rGM-CSF B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
Mf 0 0 0 0 0 0 0 0
Total cells 9.93 0.75 36.49 2.96 53.42 4.53 63.08 6.52
Bl 4.32 0.45 2.3.78 2.63 54.71 4.93 16.16 1.97
P 4.84 0.50 12.65 1.46 2.52 0.79 2.94 0.42
L929 CM Imf 0 0 1.53 0.20 1.89 0.45 34.52 3.33
+ M 0 0 0 0 0 0 0 0
rGM-CSF MM 0 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0 0
S 0 0 0 0 0 0 0 0
Mf 0.31 0.03 0 0 0 0 0 0
Total cells ’ 9.47 0.82 37.96 4.l3 50.l2 5.21 53.62 4.93
Appendix Table A3.18 The SA2 CL leukaemic cell counts in absolute number of cells per well. 
Cells were cultured for eight hours, two, four and six days with optimal concentrations of WEHI- 
3B CM, L929 CM or rGM-CSF in combination in the microtitre assay. The total cell number per 
well was determined and cytospins were prepared, stained and differentials counted.
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MATURATION INDEX
GF's DAY NBM SA7 SA8 SA2 LP SA2 HP
ses 2.0 0.3 1.3 0.9 1.3
8 HRS 2.1 0.4 0.7 1.2 0.4
FCS DAY 2 6.0 1.5 2.7 2.3 1.2
DAY 4 24.3 2.3 1.0 0.6 5.6
DAY 6 3.9 7.2 8.0 0.5 5.9
8 HRS 2.3 0.5 0.6 0.8 0.2
WEHI-3B CM DAY 2 1.0 1.1 0.6 0.8 0.7
DAY 4 1.0 1.0 1.0 0.3 1.3
DAY 6 0.4 1.5 0.8 0.2 1.4
8 HRS 3.9 0.2 0.5 1.4 0.2
L929 CM DAY 2 1.5 1.4 1.7 1.5 0.2
DAY 4 3.4 3.0 4.6 1.1 3.0
DAY 6 27.7 5.8 18.0 8.8 9.6
8 HRS 1.5 0.2 2.0 1.0 0.2
rGM-CSF DAY 2 1.2 0.8 0.7 0.6 0.6
DAY 4 1.7 0.7 23.4 0.7 2.3
DAY 6 6.3 4.3 3.9 0.5 23.7
WEHI-3B CM 8 HRS 2.9 0.7 0.6 1.8 0.2
+ DAY 2 1.8 1.4 0.6 0.7 0.9
L929 CM DAY 4 0.9 0.8 2.5 0.4 1.3
DAY 6 0.3 0.9 0.5 0.3 1.5
WEHI-3B CM 8 HRS 2.9 0.9 2.9 1.1 0.2
+ DAY 2 0.8 0.6 0.8 0.6 0.5
rGM-CSF DAY 4 0.8 0.4 5.3 0.6 1.2
DAY 6 0.4 1.6 1.2 0.9 1.6
L929 CM 8 HRS 1.7 0.8 1.5 1.4 0.1
+ DAY 2 0.7 0.6 1.2 0.6 0.4
rGM-CSF DAY 4 2.7 0.6 4.7 1.0 1.1
DAY 6 4.0 2.0 1.6 2.1 5.4
Appendix Table A3.19 Differentiation study - Maturation Index. Cells were cultured 
for eight hours, two, four and six days with optimal concentrations of growth factor both 
singularly and in combination in the microtitre assay. The total number, of cells per well 
were counted, cytospins were prepared and differentials counted. The maturation index 
(MI) was determined from the differentials.
MI = Absolute number of mature cells / Absolute number of immature cells
Mature cells = metamyelocytes,bands, segmenteds, monocytes and macrophages 
Immature cells = blasts, promyelocytes, myelocytes and immature monocytic cells
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PERCENTAGE No. OF PHAGOCYTIC CELLS ± SE
GF’s DAY NBM SA7 SA8 sa;I LP SA2 HP SA2 CL
8 HRS 5.3 0.4 2.1 0.2 0 0 0 0 0.5 0.1 0 0
FCS 2 13.3 1.1 29.0 3.1 24.2 2.2 16.9 1.2 25.9 1.9 1.1 0.1
4 32.0 3.3 47.6 3.5 35.2 3.2 20.6 1.5 58.8 4.6 0 0
6 50.7 4.2 82.1 2.2 84.8 5.1 31.0 2.6 66.5 5.9 0 0
8 HRS 7.3 0.8 0.8 0.1 0.8 0.1 3.5 0.2 2.1 0.2 0 0
WEHI 2 12.0 1.0 21.2 1.9 22.6 1.6 20.0 1.8 28.2 2.4 0 0
4 13.3 1.0 23.3 1.8 31.6 1.9 11.3 0.9 25.3 2.4 0 0
6 14.7 1.2 35.1 2.5 26.3 2.6 10.8 0.8 33.6 2.7 0 0
8 HRS 7.3 0.1 2.9 0.3 1.4 0.1 11.1 0.9 2.1 0.2 0 0
L929 2 18.0 2.0 25.4 2.1 35.5 2.3 30.7 2.7 33.3 2.6 0 0
4 36.0 3.2 60.1 5.4 50.0 4,7 43.7 3.4 56.5 5.2 0 0
6 53.3 4.8 77.8 5.6 87.4 5.6 77.6 6.7 73.9 6.1 0 0
8 HRS 7.4 0.8 3.7 0.4 34.5 2.9 8.1 0.7 0.7 0.1 0 0
rGM 2 16.0 1.5 19.3 2.1 17.8 1.2 18.8 1.5 25.8 1.9 2.1 0.1
4 14.7 1.5 15.8 1.0 36.2 2.6 16.6 1.5 26.3 2.4 0 0
6 33.4 3.5 43.3 3.9 39.3 3.4 19.5 5.6 69.3 5.8 0 0
8 HRS 12.6 1.0 6.9 0.5 5.7 0.4 6.3 0.5 4.8 0.3 1.0 0.1
WEHI 2 15.4 1.2 23.0 1.8 23.5 2.0 19.1 1.6 33.1 2.9 0 0
L929 4 16.0 1.3 21.1 1.9 27.2 2.0 9.5 0.8 42.5 3.8 0 0
6 8.0 0.7 37.7 2.5 20.0 2.0 20.0 1.7 42.5 3.6 0 0
8 HRS 7.3 0.8 3.0 0.3 44.9 3.5 12.4 1.1 0.7 0.1 0 0
WEHI 2 9.4 1.0 16.7 1.7 20.9 1.7 19.1 1.7 22.4 1.6 0 0
rGM 4 8.7 0.7 12.4 0.9 41.1 3.6 19.0 1.6 29.7 1.8 0 0
6 6.0 0.5 25.2 1.5 34.8 2.6 37.7 3.2 27.6 2.5 0 0
8 HRS 14.7 1.5 4.9 0.3 49.1 5.0 12.3 0.9 0.8 0.1 3.3 0.1
L929 2 12.8 1.0 24.8 1.9 33.0 2.1 23.4 1.4 15.9 1.3 0 0
rGM 4 33.3 2.8 27.6 2.6 34.0 2.8 32.4 2.6 41.6 3.4 0 0
6 26.1 2.7 44.8 4.2 45.3 3.6 60.4 5.2 62.4 5.1 0 0
Appendix Table 3.20 Differentiation study - Absolute number of phagocytic cells. 
Normal and leukaemic bone marrow cells were cultured for eight hours, two, four and 
six days with optimal concentrations of growth factor singularly and in combination. 
0.8|i latex particles were added to the cultures for eight hours prior to preparing 
cytospins and determining the absolute cell number per well. The cytospins were 
stained with Jenner Giemsa and the percentage number of cells containing >10 latex 
particles was determined. At least 1000 cells were counted per slide.
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ABSOLUTE No. OF PHAGOCYTIC CELLS / WELL ± SE 
GF's DAY NBM SA7 SA8 SA2 LP SA2 HP SA2 CL
8 HRS 0.39 0.02 0.14 0.01 0 0 0 0 0.04 0 0 0
FCS 2 0.56 0.03 1.57 0.09 1.35 0.10 1.06 0.09 1.67 0.09 0.39 0.02
4 0.67 0.03 1.10 0.08 0.70 0.04 0.61 0.03 1.90 0.01 0 0
6 0.92 0.05 1.15 0.08 1.45 0.10 0.97 0.09 1.43 0.10 0 0
8 HRS 0.55 0.02 0.05 0 0.06 0 0.24 0.01 0.15 0.01 0 0
WEHI 2 0.76 0.04 1.86 0.10 2.16 0.16 2.34 0.18 3.45 0.21 0 0
4 1.34 0.09 3.20 0.21 4.70 0.31 0.96 0.04 6.51 0.52 0 0
6 3.36 0.20 9.87 0.84 6.19 0.56 1.66 0.11 11.10 0.96 0 0
8 HRS 0.54 0.02 0.19 0.05 0.10 0 0.80 0.04 0.16 0.01 0 0
L929 2 0.72 0.04 1.54 0.09 1.73 0.11 2.55 0.19 2.85 0.21 0 0
4 2.14 0.12 7.82 0.52 5.46 0.40 2.35 0.14 11.60 0.91 0 0
6 8.46 0.51 16.00 1.00 6.79 0.55 3.84 0.51 15.10 1.12 0 0
8 HRS 0.60 0.05 0.28 0.01 2.49 0.15 0.57 0.02 0.05 0 0 0
rGM 2 0.89 0.08 1.50 0.09 1.58 0.11 2.27 0.18 3.15 0.25 0.77 0.03
4 1.16 0.09 2.15 0.15 4.60 0.40 1.43 0.09 6.68 0.56 0 0
6 2.98 0.27 5.19 0.48 3.41 0.25 8.70 0.75 8.55 0.74 0 0
8 HRS 0.90 0.09 0.48 0.03 0.39 0.02 0.45 0.02 0.36 0.02 0.10 0.01
WEHI 2 0.96 0.09 1.75 0.09 2.06 0.19 2.25 0.19 4.08 0.31 0 0
L929 4 1.75 0.18 4.05 0.35 4.18 0.35 0.91 0.04 12.4 0.96 0 0
6 2.48 0.22 10.70 0.89 4.68 0.39 4.01 0.29 11.9 0.85 0 0
8 HRS 0.55 0.02 0.21 0.01 3.06 0.28 0.82 0.04 0.05 0.01 0 0
WEHI 2 0.65 0.03 1.45 0.08 2.10 0.16 2.56 0.20 2.95 0.22 0 0
rGM 4 1.07 0.59 2.71 0.20 7.98 0.68 2.10 0.16 10.00 0.89 0 0
6 2.07 0.17 5.97 0.41 8.76 0.81 8.60 0.72 9.00 0.83 0 0
8 HRS 1.19 0.10 0.35 0.01 3.20 0.26 1.00 0.45 0.07 0.01 0.31 0.01
L929 2 0.77 0.05 1.82 0.10 2.80 0.24 2.66 0.19 1.91 0.10 0 0
rGM 4 2.71 0.22 5.21 0.42 5.46 0.46 3.16 0.21 12.4 0.87 0 0
6 5.66 0.49 9.68 0.84 8.66 0.82 13.00 0.98 15.2 1.15 0 0
Appendix Table A3.21 Differentiation study - Absolute number of phagocytic cells. 
Normal and leukaemic bone marrow cells were cultured for eight hours, two, four and six 
days with optimal concentrations of growth factor singularly and in combination. 0.8m
latex particles were added to the cultures for eight hours prior to preparing cytospins and 
determining the absolute cell number per well. The cytospins were stained with Jenner 
Giemsa and the percentage number of cells containing >10 latex particles was determined.
At least 1000 cells were counted per slide.
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APPENDIX TABLES 
TO
CHAPTER FOUR
PERCENTAGE QF CONTROL..± STANDARD.. ERROR
SCS
Concentration of RA (M)
10-9 10-8 10’7 10-6 10-5
NBM 101 9 86 10 80 8 64 8 5 20
SA7 98 5 87 9 80 9 46 6 7 33
SA8 83 11 79 7 86 9 54 8 4 25
SA2 LP 83 6 74 17 33 6 8 13 5 19
SA2 HP 94 8 92 8 91 9 40 8 4 22
SA2 CL 98 7 89 8 64 8 25 19 14 25
Appendix Table A4.1. Single cell suspensions (SCS) of leukaemic and normal 
bone marrow cells and cells from the SA2 CL were cultured with varied 
concentrations of PatRA for four days in the microtitre assay to determine the 
concentration of patRA required to decrease cellular proliferation. The growth 
factor dependent cells (NBM, SA7 HD, SA8 HD and the SA2 HD HP) were 
stimulated to proliferate with WEHI-3B CM and the growth factor independent 
cells (SA2 LP and the SA2 CL) were cultured with FCS alone. Proliferation was 
determined utilizing the uptake of 3H-TdR on day four of culture. The results 
from the scintillation CPM were expressed as 'Percentage of Control'.
Percentage of Control = CPM of RA treated cells / CPM of WEHI-3B or FCS 
treated cells.
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PERCENTAGE CELL COUNT / WELL ± SE
FCS + 10“<M RA + 10’77M RA
Bl 0 0 0 0 0 0
P 0 0 0 0 0.8 0.1
M 4.2 0.3 0 0 4.8 0.3
MM 31.3 0.9 059.5 4.2 50.0 3.2
B 13.9 1.2 4.8 0.3 2.4 0.1
S 16.7 1.4 0 0 0 0
Mo 0 0 0 0 0 0
Mf 34.1 3.6 35.7 2.12 42.0 3.1
WEHI-3B CM + 10-6M RA + lO“7M RA
Bl 1.4 0.1 2.1 0.1 3.5 0.2
P 43.4 3.4 30.3 2.4 41.3 3.6
M 9.0 0.7 7.7 0.6 9.9 0.8
MM 15.8 1.3 14.1 1.1 11.8 0.9
B 0.7 0.1 2.1 0.2 1.4 0.1
S 12.3 0.9 17.5 1.4 10.5 0.9
Mo 6.9 0.5 7.1 0.6 2.8 0.2
Mf 10.3 0.8 19.0 2.0 18.9 1.3
L929 CM + 10"7m RA + io-7m4 ra
Bl 3.4 0.2 0 0 0 0
P 17.3 1.2 0 0 0.8 0.1
M 3.5 0.3 0.7 0.1 0.8 0.1
MM 15.2 1.3 3.6 0.3 5.0 0.4
B 0.7 0.1 0 0 0.8 0.1
S 9.0 0.8 7.9 0.6 7.2 0.7
Mo 15.2 1.0 2.1 0.2 10.8 0.9
Mf 35.7 2.8 85.6 6.1 74.8 5.2
Appendix Table A4.2 Normal bone marrow differentiation study with 
PatRA. Cells were cultured in the microtitre assay with or without PatRA. 
Two concentrations of PatRA were used, 10‘7m and 10“^M total concentration 
per well. Cells were stimulated to proliferate with WEHI-3B or L929 CM 
both. As a control cells were also cultured in FCS alone. On day four cytospins 
were prepared, stained and differentials counted. At least 500 cells were 
counted per slide.
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ABSOLUTE CELL COUNT x 104 / WELL ± SE
FCS  + 10‘6M RA + 1O'4m RA
Bl 0 0 0 0 0 0
P 0 0 0 0 0.01 0
M 0.08 0.01 0 0 0.09 0.01
MM 0.66 0.05 1.03 0.09 0.91 0.10
B 0.29 0.03 0.08 0.01 0.04 0
S 0.35 0.04 0 0 0 0
Mo 0 0 0 0 0 0
Mf 0.72 0.09 0.62 0.05 0.76 0.08
Total Cells 2.10 0.15 1.73 0.10 1.81 0.15
WEHI-3B CM + lO^M ra + 1O'4m RA
Bl 0.14 0.02 0.20 0.02 0.37 0.04
P 4.37 0.51 2.92 0.35 4.44 0.60
M 0.92 0.11 0.74 0.09 1.06 0.14
MM 1.59 0.19 1.36 0.16 1.27 0.16
B 0.07 0.01 0.20 0.03 0.15 0.02
S 1.24 0.14 1.69 0.20 1.13 0.15
Mo 0.70 0.08 0.69 0.08 0.30 0.04
Mf 1.04 0.12 1.83 0.25 1.94 0.24
Total Cells 10.08 0.88 9.65 0.85 10.76 1.10
L929 CM + 10-4M RA + 1O’4m RA
Bl 0.20 0.02 0 0 0 0
P 1.02 0.1 0 0 0.08 0.01
M 0.21 0.02 0.04 0.01 1.02 0.17
MM 0.90 0.10 0.21 0.03 0.08 0.01
B 0.42 0.07 0 0 0.47 0.08
S 0.53 0.06 0.47 0.06 0.08 0.01
Mo 0.90 0.09 0.13 0.02 0.68 0.09
Mf 2.12 0.23 5.11 0.64 7.08 0.90
Total Cells 5.94 0.43 5.97 0.61 9.49 1.02
Appendix Table A4.3 Normal bone marrow differentiation study with 
PatRA, Cells were cultured in the microtitre assay with or without patRA. 
Two concentrations of patRA were used, 1O"4m and 10"4m total concentration 
per well. Cells were stimulated to proliferate with WEHI-3B or L929 CM. As 
a control cells were also cultured in FCS alone. On day four cytospins were 
prepared, stained and differentials counted. At least 500 cells were counted 
per slide. The results were expressed as absolute cell numbers per well. 
Absolute cell number = Total Cell No. per Well x Percentage Cell No. per well.
254
PERCENTAGE CELL COUNT / WELL ± SE
FCS+ 10‘<M RA+ 10-7M RA
Bl 2.3 0.2 0.9 0.1 0 0
P 4.6 0.3 0 0 5.0 0.3
Imf 8.6 0.6 8.9 0.7 6.4 0.5
M 14.4 1.5 8.4 0.6 18.5 1.6
MM 14.4 1.5 27.1 2.0 38.6 3.2
B 4.5 0.3 1.7 0.1 0 0
S 2.3 0.2 3.4 0.3 2.9 0.3
Mf 48.9 4.3 49.6 5.2 28.5 1.9
WEHI-3B CM + 10"<M RA + 10’7M RA
Bl 4.9 0.4 3.1 0.2 3.5 0.4
P 29.4 2.3 13.1 1.1 16.8 1.3
Imf 3.5 0.3 8.2 0.6 16.8 1.3
M 12.3 1.0 7.1 0.6 7.0 0.6
MM 15.5 1.0 7.2 0.6 11.5 0.9
B 1.8 0.2 0.8 0.1 2.1 0.1
S 3.5 0.2 5.0 0.4 5.6 0.3
Mf 29.1 3.1 55.5 4.5 36.7 2.4
L929 CM + 10"6M RA + 10‘7M RA
Bl 2.4 0.1 1.4 0.1 2.3 0.2
P 8.6 0.7 3.0 0.2 1.5 0.2
Imf 10.6 0.8 2.5 0.3 6.8 0.4
M 3.1 0.2 2.1 0.3 1.6 0.1
MM 4.4 0.3 1.7 0.1 3.7 0.2
B 0.3 0.1 0.3 0.1 0 0
S 1.8 0.1 1.8 0.2 3.1 0.2
Mf 68.8 0.5 87.2 8.2 81.1 0.7
Appendix Table A4.4 SA7 leukaemic bone marrow differentiation study 
with PatRA. Cells were cultured in the microtitre assay with or without 
PatRA. Two concentrations of patRA were used, 10'^M and lO'7M total 
concentration per well. Cells were stimulated to proliferate with WEHI-3B or 
L929 CM. As a control cells were also cultured in FCS alone. On day four 
cytospins were prepared, stained and differentials counted. At least 500 cells 
were counted per slide.
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ABSOLUTE CELL COUNT x 104 / WELL ± SE
FCS+ 10‘<M RA + 10-7m RA
Bl 0.06 0.01 0.02 0 0 0
P 0.12 0.01 0 0 0.10 0.01
IMf 0.23 0.02 0.19 0.02 0.13 0.01
M 0.38 0.05 0.18 0.02 0.37 0.04
MM 0.38 0.05 0.50 0.05 0.78 0.09
B 0.12 0.01 0.05 0 0 0
S 0.06 0.01 0.07 0.01 0.06 0.01
MI L22 0.13 1.05 0.13 0.57 0.06
Total Cells 2.65 0.15 2.12 0.14 2.01 0.16
WEHI-3B CM + 10-6M RA + io*7m ra
Bl 0.73 0.09 0.38 0.04 0.50 0.07
P 4.32 0.52 1.61 0.2 2.38 0.26
IMf 0.51 0.06 1.00 0.12 2.38 0.26
M 1.80 0.22 0.88 0,11 1.00 0.12
MM 2.27 0.25 0.89 0.11 1.63 0.18
B 0.26 0.04 0.10 0.02 0.30 0.03
S 0.51 0.05 0.62 0.08 0.79 0.08
MI 4,27 0.6 6.85 0.84 121 0.53
Total Cells 14.67 1.32 12.33 1.14 14.19 1.12
L929 CM + 10-7m RA + io 7m ra
Bl 0.35 0.03 0.22 0.02 0.50 0.06
P 1.28 0.15 0.46 0.05 0.33 0.05
IMf 1.58 0.18 0.39 0.06 1.50 0.15
M 0.46 0.05 0.32 0.05 0.35 0.04
MM 0.65 0.07 0.26 0.03 0.82 0.08
B 0.04 0.01 0.05 0.02 0 ###
S 0.21 0.02 0.28 0.04 0.68 0.07
MI 9,75 0.87 1351 1.69 17,78 1.49
Total Cells 14.93 1.33 15.49 1.28 22.07 1.84
Appendix Table A4.5 SA7 leukaemic bone marrow differentiation study 
with patRA. Cells were cultured in the microtitre assay with or without 
patRA. Two concentrations of patRA were used, 1O'7m and 10"7m total 
concentration per well. Cells were stimulated to proliferate with WEHI-3B or 
L929 CM. As a control cells were also cultured in FCS alone. On day four 
cytospins were prepared, stained and differentials counted. At least 500 cells 
were counted per slide. The results were expressed as absolute cell numbers per 
well.
Absolute cell number = Total Cell No. per Well x Percentage Cell No. per well.
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PERCENTAGE CELL COUNT / WELL ± SE
FCS + 10*<M RA + 10* 7M RA
Bi 0.9 0.1 0 0 2.2 0.1
P 0 0 10.2 0.8 0 0
Imf 0 0 2.3 0.1 0 0
M 2.8 0.2 6.2 0.4 6.7 0.4
MM 37.9 2.5 2.8 0.1 12.2 0.6
B 1.9 0.1 0 0 0 0
S 9.3 0.6 2.8 0.1 1.1 0.1
Mf 47.2 3.2 75.7 1.0 77.8 1.3
WEHI-3B CM + 10- 7m RA + 1O-7m RA
Bl 4.7 0.3 1.4 0.1 0.6 0.2
P 23.7 1.3 35.2 1.5 13.7 0.6
Imf 4.5 0.2 1.4 0.1 0 0
M 1.0 0.5 18.6 0.8 14.4 0.6
MM 21.1 1.3 8.3 0.8 21.9 1.7
B 4.0 0.2 1.4 0.1 4.8 0.2
S 5.0 0.3 0 0 4.1 0.2
Mf 36.1 2.1 33.8 2.5 40.4 2.3
L929 CM + 10"<M RA + 10"7M RA
Bl 3.0 0.2 0 0 0 0
P 0 0 0 0 0 0
Imf 0 0 0 0 0.7 0.1
M 8.0 0.5 1.4 0.2 0 0
MM 24.0 1.2 7.6 0.8 3.5 0.4
B 0 0 0.7 0.1 0 0
S 2.0 0.2 0 0 0 0
Mf 63.0 2,3 90.3 2.1 95.8 2.4
Appendix Table A4.6 SA8 leukaemic bone marrow differentiation study 
with PatRA. Cells were cultured in the microtitre assay with or without 
patRA. Two concentrations of patRA were used, 10"7m and 1O"7m total 
concentration per well. Cells were stimulated to proliferate with WEHI-3B or 
L929 CM. As a control cells were also cultured in PCS alone. On day four 
cytospins were prepared, stained and differentials counted. At least 500 cells 
were counted per slide.
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ABSOLUTE CELL COUNT x 104 / WELL ± SE
FCS + RA+1 7 " RA
Bl 0.02 0 0 0 0.04 0
P 0 0 0.18 0.02 0 0
Imf 0 0 0.04 0 0 0
M 0.06 0.01 0.11 0.01 0.12 0.01
MM 0.81 0.07 0.05 0 0.22 0.02
B 0.04 0 0 0 0 0
S 0.20 0.02 0.05 0 0.02 0
Mf Ml 0.09 LM Q.ll 1.40 0.12
Total Cells 2.14 0.18 1.77 0.14 1.80 0.15
WEHI-3B CM + 10'<M RA + IQ‘7M RA
BI 0.70 0.08 0.20 0.03 0.11 0.04
P 3.57 0.38 5.10 0.59 2.33 0.25
Imf 0.68 0.07 0.20 0.03 0 0
M 0.15 0.08 2.70 0.31 2.45 0.26
MM 3.17 0.34 1.20 0.17 3.73 0.46
B 0.60 0.06 0.20 0.03 0.81 0.08
S 0.75 0.08 0 0 0.70 0.08
Ml M3 0.58 4.90 0.64 601 6J1
Total Cells 15.05 1.35 14.50 1.55 17.00 1.63
L929 CM + 10’<M RA + lO-7M RA
Bl 0.33 0.04 0 0 0 0
P 0 0 0 0 0 0
Imf 0 0 0 0 0.08 0
M 0.87 0.12 0.17 0.02 0 0
MM 2.62 0.26 0.92 0.11 0.43 0.05
B 0 0 0.08 0.01 0 0
S 0.22 0.02 0 0 0 0
Ml 600 0.68 M 1.43 1166 1.29
Total Cells 10.93 0.98 12.06 1.31 12.17 1.15
Appendix Table A4.7 SA8 leukaemic bone marrow differentiation study 
with PatRA. Cells were cultured in the microtitre assay with or without 
PatRA. Two concentrations of PatRA were used, 10'^M and W7M total 
concentration per well. Cells were stimulated to proliferate with WEHI-3B or 
L929 CM. As a control cells were also cultured in FCS alone. On day four 
cytospins were prepared, stained and differentials counted. At least 500 cells 
were counted per slide. The results were expressed as absolute cell numbers per 
well.
Absolute cell number = Total Cell No. per Well x Percentage Cell No. per well.
258
PERCENTAGE CELL COUNT I WELL ± SE
FCS + lO"6M RA + lO-7]^ RA
Bl 7.0 0.5 10.8 1.2 25.7 2.4
P 41.9 4.2 14.1 1.2 18.0 1.5
Imf 3.5 0.4 7.0 0.5 5.5 0.3
M 11.2 0.8 9.7 0.5 2.8 0.3
MM 12.6 0.8 10.8 0.8 24.3 1.5
B 2.8 0.1 0.5 0.1 2.8 1.5
S 3.5 0.2 13.5 0.8 4.9 0.5
Mf 17.5 1.3 33.5 2.5 15.9 0.9
WEHI-3B CM + 10 "<M RA + 10-7M RA
Bl 14.7 1.5 5.6 0.3 11.1 0.7
P 46.9 3.5 26.7 2.3 29.9 2.5
Imf 4.2 0.3 7.7 0.5 5.5 0.5
M 12.6 0.8 7.1 0.5 8.3 0.5
MM 2.8 0.2 6.3 0.5 8.3 0.5
B 0 0 1.4 0.1 0 0
S 9.0 0.5 8.5 0.7 7.0 0.5
Mf 9.9 0.5 36.7 3.5 29.9 3.0
L929 CM + 10’6M ra .+ 1O“7M ra
Bl 13.4 0.9 2.3 0.2 1.4 0.1
P 18.8 1.9 0 0 0 0
IMf 8.0 0.7 13.8 0.7 6.7 0.7
M 6.0 0.5 0 0 0.8 0.1
MM 7.4 0.5 2.3 0.2 8.9 0.7
B 0 0 0 0 0 0
S 2 0.2 6.9 0.5 2.0 0.2
Mf 44.3 3.5 74.6 5.3 80.0 6.5
Appendix Table A4.8 SA2 LP leukaemic bone marrow differentiation study 
with PatRA. Cells were cultured in the microtitre assay with or without 
PatRA. Two concentrations of patRA were used, 10“^M and 10"7M total 
concentration per well. Cells were stimulated to proliferate with WEHI-3B or 
L929 CM. As a control cells were also cultured in FCS alone. On day four 
cytospins were prepared, stained and differentials counted. At least 500 cells 
were counted per slide.
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ABSOLUTE CELL COUNT x 104 / WELL ± SE
fcs+ iq-6m ra+ io~'7m ra
Bl 0.22 0.02 0.20 0.03 0.75 0.08
P 1.32 0.15 0.26 0.04 0.52 0.05
IMf 0.11 0.01 0.13 0.02 0.16 0.01
M 0.35 0.03 0.18 0.02 0.08 0.01
MM 0.39 0.03 0.20 0.03 0.70 0.06
B 0.08 0.01 0.01 0 0.08 0.04
S 0.11 0.01 0.25 0.03 0.14 0.02
Mf 0.53 &05 M2 0.08 0.46 0.04
Total CeUs 3.12 0.22 1.85 0.20 2.90 0.15
WEHI-3B CM + 10"6M ra + 10- "m ra
Bl 1.31 0.16 0.49 0.04 0.92 0.12
P 4.19 0.44 2.36 0.25 2.49 0.34
IMf 0.38 0.04 0.68 0.06 0.46 0.07
M 1.13 0.11 0.63 0.06 0.69 0.09
MM 0.25 0.03 0.56 0.06 0.69 0.09
B 0 0 0.12 0.01 0 0
S 0.81 0.07 0.75 0.08 0.58 0.08
Mf 0.88 0.00 1.23 M2 209 M7
Total Cells 8.95 0.65 8.83 0.55 8.32 0.91
L929 CM + 10-6M ra + lO"7M RA
Bl 0.73 0.10 0.19 0.03 0.12 0.01
P 1.02 0.16 0 0 0 0
IMf 0.44 0.06 1.13 0.13 0.54 0.08
M 0.33 0.05 0 0 0.06 0.01
MM 0.40 0.05 0.19 0.03 0.72 0.09
B 0 0 0 0 0 0
S 0.11 0.02 0.56 0.07 0.18 0.02
Mf 200 M3 6.0 0Jl 606 M
Total Cells 5.42 0.62 8.16 0.85 8.08 0.76
Appendix Table A4.9 SA2 LP leukaemic bone marrow differentiation study 
with patRA. Cells were cultured in the microtitre assay with or without 
PatRA. Two concentrations of PatRA were used, 10'^M and 10'^M total 
concentration per well. Cells were stimulated to proliferate with WEHI-3B or 
L929 CM. As a control cells were also cultured in FCS alone. On day four 
cytospins were prepared, stained and differentials counted. At least 500 cells 
were counted per slide. The results were expressed as absolute cell numbers per 
well.
Absolute cell number = Total Cell No. per Well x Percentage Cell No. per well.
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PERCENTAGE CELL COUNT / WELL ± SE
FCS + lO6M RA + 10"7M RA
Bl 0 0 ‘ 0 0 0 0
P 0 0 0 0 1.4 0.1
IMf 1.5 0.1 3.5 0.4 3.6 0.4
M 13.7 0.9 17.9 0.7 8.7 0.4
MM 21.4 1.7 7.7 0.7 21.00 1.6
B 1.6 0.1 1.7 0.2 2.9 0.3
S 6.9 0.5 5.1 0.2 1.4 0.1
Mf 54.9 3.5 64.1 5.6 60.9 5.3
WEHI-3B CM + 10'<*M RA + lO"7M RA
Bl 5.4 0.5 3.5 0.3 1.3 0.1
P 22.6 1.8 21.1 1.8 28.5 1.7
IMf 4.8 0.5 9.8 0.8 4.1 0.3
M 10.3 0.5 4.2 0.3 11.5 0.7
MM 27.4 2.8 9.2 0.5 22.4 1.8
B 0 0 0.7 0.1 5.5 0.5
S 6.9 0.5 14.1 0.8 6.8 0.5
Mf 22.7 1.8 37.3 3.5 19.8 2.3
L929 CM + 10- 6M RA + io-7m ra
Bl 4.1 0.2 0 0 0 0
P 6.7 0.5 0.7 0.1 0 0
IMf 12.2 0.9 7.8 0.6 12.3 1.3
M 2.0 0.1 1.4 0.1 3.5 0.3
MM 7.4 0.6 10.7 0.8 5.4 0.5
B 0.8 0.6 0.7 0.1 0 0
S 1.4 0.1 5.0 0.4 2.1 0.2
Mf 65.4 5.4 73.6 6.3 76.7 6.3
Appendix Table A4.10 SA2 HP leukaemic bone marrow differentiation 
study with PatRA. Cells were cultured in the microtitre assay with or without 
PatRA. Two concentrations of PatRA were used, 10‘7m and W"7M total 
concentration per well. Cells were stimulated to proliferate with WEHI-3B or 
L929 CM. As a control cells were also cultured in FCS alone. On day four 
cytospins were prepared, stained and differentials counted. At least 500 cells 
were counted per slide.
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ABSOLUTE CELL COUNT x 104 / WELL ± SE
FCS + lO*6M RA + 10-7M RA
Bl 0 0 0 0 0 0
P 0 0 0 0 0.06 0.01
IMf 0.06 0.01 0.12 0.02 0.14 0.02
M 0.51 0.05 0.63 0.08 0.33 0.03
MM 0.79 0.08 0.27 0.04 0.82 0.1
B 0.06 0.01 0.06 0.01 0.11 0.02
S 0.25 0.02 0.18 0.02 0.06 0.01
Mf 2M M2 2,24 M2 2.38 M
Total Cells 3.70 0.25 3.50 0.40 3.90 0.35
WEHI-3B CM + 10"4m RA + 1O-4m RA
Bl 1.05 0.17 0.36 0.06 0.25 0.1
P 4.39 0.51 2.18 0.3 5.44 0.25
IMf 0.94 0.05 1.01 0.08 0.78 0.05
M 1.99 0.12 0.44 0.07 2.20 0.07
MM 5.33 0.03 0.95 0.06 4.27 0.08
B 0 0 0.08 0.02 1.05 0
S 1.34 0.09 1.46 0.08 1.30 0.06
Mf 4.41 Ml 3.84 0.43 1.77 Ml
Total Cells 19.44 1.76 10.31 0.97 19.06 1.53
L929 CM + 10‘4m RA + 1O’4m RA
Bl 0.63 0.07 0 0 0 0
P 1.04 0.12 0.05 0 0 0
IMf 1.89 0.05 0.49 0.13 1.09 0.08
M 0.32 0.03 0.09 0 0.31 0.01
MM 1.15 0.05 0.68 0.02 0.48 0.1
B 0.11 0 0.05 0 0 0
S 0.22 0.01 0.32 0.06 0.18 0.03
Mf 1002 M2 4,45 M3 6,79 0M
Total Cells 15.45 1.33 6.32 0.53 8.85 0.93
Appendix Table A4.11 SA2 HP leukaemic bone marrow differentiation 
study with PatRA. Cells were cultured in the microtitre assay with or without 
PatRA. Two concentrations of PatRA were used, 10'4m and 1O'4m total 
concentration per well. Cells were stimulated to proliferate with WEHI-3B or 
L929 CM. As a control cells were also cultured in FCS alone. On day four 
cytospins were prepared, stained and differentials counted. At least 500 cells 
were counted per slide. The results were expressed as absolute cell numbers per 
well.
Absolute cell number = Total Cell No. per Well x Percentage Cell No. per well.
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PERCENTAGE CELL COUNT I WELL ± SE
FCS + 10-6M RA+ HPM RA
Bl 84.4 5.4 79.8 6.5 74.8 3.6
P 7.3 0.5 9.1 0.3 13.1 0.3
Imf 8.3 0.5 11.1 0.3 12.1 0.3
WEHI-3B CM + 10'7'm ra + lO“7M ra
Bl 90.8 7.6 82.3 8.3 82.7 8.0
P 5.1 1.3 6.3 0.3 11.2 1.7
Imf 4.1 0.3 11.4 0.3 6.1 1.7
L929 CM + 10'6M ra + 10-7M RA
Bl 82 7.5 79.6 6.4 63.6 5.6
P 12 1.5 10.7 0.6 12.3 1.3
Imf 6 1.5 9.7 0.6 23.2 1.7
ABSOLUTE CELL COUNT x 104 I WELL ± SE
FCS + 10'6M ra + 1O"7m RA
Bl 18.48 2.42 8.64 1.03 8.82 0.76
P 1.60 0.21 0.98 0.09 1.53 0.12
Imf 1.83 &24 L2Q Ml L41 Ml
Total Cells 21.90 2.50 10.83 0.95 11.80 0.85
WEHI-3B CM + 1O'7m RA + 10-7 M RA
Bl 22.63 2.72 9.03 1.37 10.63 1.52
P 1.27 0.34 0.68 0.08 1.44 0.27
Imf 1.02 M2 18 MS MS M3
Total Cells 24.92 2.15 10.98 1.25 12.85 1.35
L929 CM + 10"6M ra + 10-7M RA
Bl 14.46 1.83 8.63 1 7.84 1.09
P 2.12 0.32 1.17 0.12 1.62 0.24
Imf 18 0,28 1.05 Ml 2.86 M2
Total Cells 17.63 1.55 10.85 0.90 12.33 1.32
Appendix Table A4.12 The SA2 CL differentiation study with PatRA. 
Cells were cultured in the micro titre assay with or without patRA. Two 
concentrations of PatRA were used, lO"^M and 1O“7m total concentration per 
well. Cells were stimulated to proliferate with WEHI-3B or L929 CM. As a 
control cells were also cultured in FCS alone. On day four cytospins were 
prepared, stained and differentials counted. At least 500 cells were counted 
per slide. The results were expressed as absolute cell numbers per well. 
Absolute cell number - Total Cell No. per Well x Percentage Cell No. per well.
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PERCENTAGE PHAGOCYTIC CELLS I WELL ± SE
NBM SA7 SA8 SA2 LP SA2 HP
FCS 33.3 2.6 49.4 3.6 61.2 4.3 20.4 1.4 58.8 4.3
+ 10”6 M RA 33.3 1.3 39.8 1.5 75.7 5.6 33.3 1.5 57.3 2.6
+ 10-7 M RA 39.6 1.3 22.5 1.5 67.2 4.6 14.6 1.5 56.5 3.3
WEHI-3 B CM 13.8 0.9 20.6 1.6 31.3 2.3 11.2 0.9 25.4 1.4
+ 10-4 M RA 19.8 1.7 45.1 2.7 22.7 2.3 33.1 1.6 29.6 1.3
+ 10-7 M RA 18.1 1.7 34.4 2.7 34 2.6 30.6 2.6 19.2 2.3
L929 C M 37.2 1.5 47.2 5.0 50.0 3.6 43.7 3.3 56.5 4.6
+ 10-4 M RA 85.7 4.3 50.4 3.5 63.3 4.8 54.6 2.6 69.3 5.3
+ 10-7 M R 70.7 4.3 53.8 2.6 53.3 4.8 55.6 3.6 69.3 4.5
ABS No. PHAGOCYTIC CELLS I WELL x 104 ± SE 
NBM SA7 SA8 SA2 LP SA2 HP
FCS 0.70 0.07 1.31 0.12 1.31 0.14 0.64 0.06 2.17 0.22
+ 10-4 M RA 0.60 0.04 0.84 0.06 1.34 0.15 0.61 0.07 2.00 0.25
+ 107 M RA 0.70 0.06 0.45 0.05 1.21 0.13 0.42 0.05 2.20 0.24
WEHI-3B CM 1.39 0.15 3.03 0.36 4.71 0.55 1.00 0.11 4.93 0.52
+ 10-4 M RA 1.91 0.23 5.56 0.61 3.29 0.48 2.92 0.23 3.05 0.32
+ 10-7 M RA 1.95 0.27 4.88 0.54 5.78 0.71 2.55 0.35 3.66 0.53
L929 CM 2.22 0.18 7.04 0.97 5.47 0.63 2.37 0.32 8.73 1.03
+ 10-4 M RA 5.09 0.58 7.81 0.84 7.64 1.01 4.46 0.51 4.38 0.5
+ 10-7 M R 6.71 0.83 11.86 1.14 6.49 0.85 4.49 0.51 6.13 0.76
Appendix Table A4.13 Differentiation study. Leukaemic and normal cells 
were cultured for four days in the microtitre assay. On day four the cells were 
incubated with 8p latex particles for eight hours. Cytospins were prepared, 
stained and the percentage and absolute number of cells containing greater 
than 10 particles were determined.
Absolute number = Total Cell No. per Well x Percentage Phagocytic Cells per 
well.
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PERC ENTAGE__ -SURVIVAL
FCS FCS + 10*4 m RA
pf.. Ceils Injected
DAY 105 104 1(P 102 10 105 104 103 102
1 to 10 100 100 100 100 100 100 100 100 100
11 70 100 100 100 100 20 100 100 100
12 10 70 100 100 100 20 80 100 100
13 0 70 90 100 100 20 0 100 100
14 30 70 90 100 20 100 100
15 20 60 90 100 20 80 100
16 10 50 90 100 20 20 100
17 6 50 90 100 20 20 100
18 0 50 90 100 20 20 100
19 50 90 100 20 20 100
20 40 90 100 20 20 100
21 40 90 100 20 20 100
22 40 90 100 20 20 100
23 40 80 100 20 20 100
24 40 80 100 20 20 100
25 40 80 100 20 20 100
26 40 80 100 20 20 100
27 40 80 100 20 20 100
28 to 90 30 80 100 20 20 100
Appendix Table A4.14 In Vivo Clonogenic Cell Assay. Single cell suspension of 
SA7 HD leukaemic bone marrow cells were cultured in the microtitre assay with FCS 
± 10"4 M PatRA. On day four of culture the cells were harvested with a pasteur 
pipette, the number of viable cells counted and cells at varied concentrations were 
injected into syngeneic recipients to determine the number of clonogenic leukaemic 
cells remaining in culture after each treatment. Five mice were injected per test group 
and percentage survival was monitored for 90 days. Results are the means of three 
experiments and the standard errors were not greater than 5% for each treatment.
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PERCENTAGE___SURVIVAL
WEHI-3B CM WEHI-3B CM + 10'6 M RA
Number__oL_ Cells__Injected
DAY lOS 104 103 102 loS 104 103 102
1 to 11 100 100 100 100 100 1(00 100 100
12 70 100 100 100 50 100 100 100
13 30 100 100 100 10 100 100 100
14 30 60 90 100 0 90 80 90
15 20 60 80 100 50 80 90
16 0 50 80 100 50 80 90
17 50 80 100 50 80 90
18 50 70 100 50 80 90
19 50 70 100 50 80 90
20 30 70 100 50 70 90
21 30 70 100 50 70 90
22 20 70 100 40 70 90
23 10 70 100 40 70 90
24 10 70 100 40 70 90
25 10 70 100 40 70 90
26 to 90 10 70 100 30 70 90
L92.9 CM L929 CM + 10-4_ m RA
Number of Cells Injected
DAY 105 104 103 102 105 104 103 102
1 to 11 100 100 100 100 100 100 100 100
12 60 100 100 100 100 100 100 100
13 0 100 100 100 50 100 100 100
14 50 90 100 40 100 100 100
15 40 90 100 40 70 90 100
16 20 90 100 10 70 90 100
17 20 90 100 10 70 90 100
18 20 90 100 10 70 90 100
19 20 90 90 10 70 90 100
20 20 90 90 10 70 90 100
21 20 90 90 0 70 90 100
22 20 90 90 70 90 100
23 20 90 90 70 90 100
24 20 90 90 70 90 100
25 20 90 90 70 90 100
26 20 90 90 70 90 100
27 20 90 90 70 90 100
28 20 90 90 70 90 100
29 to 90 20 90 90 60 90 100
Appendix Table A4.15 In Vivo Clonogenic Cell Assay. Single cell suspension of SA7 HD 
leukaemic bone marrow cells were cultured in the microtitre assay with WEHI-3B CM ± 10"4 
M PatRA and L929 CM ± 10'4 M PatRA. On day four of culture the cells were harvested with 
a pasteur pipette, the number of viable cells counted and cells at varied concentrations were 
injected into syngeneic recipients to determine the number of clonogenic leukaemic cells 
remaining in culture after each treatment. Five mice were injected per test group and 
percentage survival was monitored for 90 days. Results were the means of three experiments 
and the standard errors were not greater than 5% for each treatment.
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APPENDIX TABLES
TO
CHAPTER FIVE
PERCENTAGE OF CONTROL ± STANDARD ERROR 
CONC CONCENTRATION ARA-C (M)
RA (M) I 0 10-10 10 -9 10-8 10-7 10- 6
0 1.2 "8---- 114 13“ 89 11 —86""8----- 61 ---- 1.4 16
N 10-9 101 9 94 9 83 7 74 9 57 11 0.9 15
B 10-8 86 10 92 10 118 8 110 8 55 12 1.5 24
M 10-7 80 8 130 8 120 10 111 13 62 10 1.8 13
10-6 64 8 78 14 70 10 75 8 47 11 1.4 18
10-5 5 20 4 24 5 28 6 26 5 14 0.9 22
0 0.7 15 113 9 88 13 87 11 62 10 0.9 25
S 10-9 98 5 85 13 76 12 75 9 59 13 1.2 32
A 10-8 87 9 92 11 119 9 109 9 54 11 1.4 24
7 10-7 80 9 121 15 123 12 112 13 63 10 0.8 14
10-6 46 6 82 12 72 7 75 9 47 11 0.9 18
10-5 7 5 6 10 5 7 4 8 7 8 7 6
0 1.2 33 104 10 99 9 97 10 48 11 3 24
S 10-9 83 11 55 6 36 10 34 6 31 12 1.5 21
A 10-8 79 7 51 11 37 9 41 9 30 9 2.4 33
8 10-7 86 9 44 14 34 12 54 10 39 7 1.7 16
10-6 54 8 74 7 44 5 52 8 36 10 2.2 33
10-5 4 25 4 8 3 17 4 8 5 12 4 9
S 0 100 5 43 7 52 5 3 2 0.5 18 1.3 16
A 10-9 42 7 19 2 16 5 15 8 2 2 0.7 12
2 10-8 43 2 19 6 17 4 19 15 3 19 0.6 18
P 10-7 29 5 17 3 13 6 11 6 3 6 0.5 15
3 10-6 12 12 6 3 5 8 5 10 1.5 2 0.7 10
6 10-5 3 5 3 13 2 5 3 26 1 4 1 23
S 0 100 8 113 11 78 8 88 9 26 13 1.3 17
A 10-9 56 13 66 12 58 11 40 7 10 9 1.5 19
2 10-8 47 10 59 15 33 8 40 15 11 9 1.6 20
P 10-7 35 12 17 9 23 12 22 14 6 8 1.5 8
3 10-6 6 11 8 9 8 5 8 13 4 7 1 14
9 10-5 2 9 3 24 2 20 3 9 2 14 2 11
S 0 3 6 84 8 49 6 46 7 22 9 0.6 7
A 10-9 35 12 25 15 9 11 9 7 16 6 0.8 19
2 10-8 39 9 26 12 9 10 9 7 5 10 1.1 26
P 10-7 50 9 25 8 11 13 15 16 7 2 3 21
5 10-6 39 6 32 9 28 8 30 8 11 9 0.6 8
5 10-5 3 5 4 8 5 3 3 9 4 6 3 5
S 0 2 15 109 8 61 8 63 7 26 9 1 8
A 10-9 63 8 89 8 21 8 32 8 11 9 1 8
2 10-8 72 8 106 9 29 9 37 8 22 8 3 20
P 10-7 64 8 86 8 55 8 55 8 23 9 4 16
5 10-6 40 8 47 8 33 8 33 8 13 8 1 11
9 10-5 5 9 5 4 3 7 6 11 7 14 8 5
S 0 100 9 84 9 97 8 92 8 37 9 2 25
A 10-9 98 7 103 6 102 8 94 7 44 6 2 25
2 10-8 89 8 89 8 100 8 98 6 34 6 1 24
10-7 64 8 85 6 70 8 76 8 24 6 1 33
C 10-6 30 13 34 6 30 6 36 6 12 7 2 10
L 10-5 14 9 7 14 6 14 9 8 4 7 2 11
Appendix Table A5.1. Single cell suspensions of normal and leukaemic bone marrow and cells 
from the SA2 CL were cultured in the microtitre assay with combinations of patRA and ara-C at 
varying concentrations. Growth factor dependent cells were stimulated to proliferate with 
WEH1-3B CM and growth factor independent cells were cultured with FCS alone. On day four 
of culture the cells were pulsed for eight hours with 3H-TdR. The scintillation CPM were 
converted to 'Percentage of Untreated Control'.
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LIST OF ABBREVIATIONS
AML
APL
ara-C
C
CM
OR
CSF's
DMSO
DNA
EBV
eg
FAB
g
GBq
G-CSF
GM-CSF
GM-CFU
G6PD
Gy
iL-a
3H-TdR
ip
iv
kBq
kD
i
L-CFU
LAI
LIA
MDS
ml
ml
mmol
M-
NBM
NBT
PPm
rGM-CSF
PatRA 
ia-d‘s RA 
rpm
scs
Vit
v/v
w/v
acute myeloid leukaemia
acute promyelocytic leukaemia
cytosine arabinoside
Celsius (degrees)
conditioned medium
complete remission
colony stimulating factors
dimethylsulphoxide
deoxyribonucleic acid
Epstein Barr virus
example
French American British collaborative for the 
classification of leukaemia
gram
giga Bequeral
granulocyte-colony stimulating factor
granulocyte macrophage-colony stimulating factor 
granulocyte macrophage colony forming unit 
glucose-6-phosphate dehydrogenase 
Gray (Dose of radiation)
interleukin-3
tritiated thymidine
intraperitoneal
intravenous
kilo Bequeral
kilo daltons
litre
leukaemic-colony forming unit
leukaemia associated inhibitor
leukaemia inhibitory activity
myelodysplatic syndrome
microlitre
millilitre
millimolar
micron
normal bone marrow
nitroblue tetrazoleum
parts per minute
recombinant granulocyte macrophage-
colony stimulating factor 
P-all trans retinoic acid 
ia-^ds retinoic acid 
rotations per minute 
single cell suspension 
vitamin
volume per volume
weight per volume
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